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Abstract 
 
Arenaviruses cause an estimated 300,000 – 500,000 infections annually. Currently 
there is no arenavirus-specific antiviral drug available to treat these infections. This 
study sought to use the non-pathogenic New World arenavirus Tacaribe virus (TCRV) 
as a model for the pathogenic Junin virus (JUNV) and Machupo virus (MACV) that 
cause haemorrhagic fevers in South America. TCRV was used to explore three 
different approaches in the search for an antiviral drug against arenavirus infection 
targeted specifically against the viral nucleoprotein (NP). Of the four expressed 
arenaviral proteins, NP is the most abundant and is thought to be of multifunctional 
nature involved in viral replication, suppression of the innate immune system and 
viral egress. The approaches to find targets for broad-spectrum anti-arenaviral drugs 
were high throughput screens (HTS) with purified NP using thermal shift assays, 
exploring the virus interactions with the innate immune system and identifying virus-
host protein-protein interactions. HTS resulted in the identification of two small-
molecule compounds, [5-(2-Furyl)thien-2-yl]methanol and cyclosporine A (CsA), 
showing broad-spectrum activity against arenaviruses. Interferon-stimulated genes 
(ISGs), such as IFIT3, were identified to reduce viral titres and potential 202 protein-
interactions between NP and host cell proteins were identified, of which the 
interaction with apoptosis-inducing factor 1 (AIF1) was described further. To 
characterise the importance of these interactions as potential drug targets further, a 
TCRV reverse genetics system was constructed.  
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TRAF tumour necrosis factor receptor-associated factor 
TRIF TIR-domain-containing adaptor-inducing IFN 
tRNA Transfer RNA 
Tsg101 Tumour susceptibility gene 101 
Tyk2 Tyrosine kinase 2 
UTR Untranslated region 
V Paramyxovirus V protein 
VACV Vaccinia virus 
VHF Venezuelan haemorrhagic fever 
VLP Virus-like particle 
VP24 Viral protein 24 kDa 
VP35 Viral protein 35 kDa 
vRNP Viral ribonucleoprotein 
VSV Vesicular stomatitis virus 
WB Western blot 
WNV West Nile virus 
WWAV Whitewater Arroyo virus 
Z Zinc-finger protein 
Z-VAD-fmk N-Benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone 
α-DG Α-dystroclycan 
ΔTm Change in melting temperature µm Micrometre 
µM Micromolar 
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1.1 Arenaviridae 
The first arenavirus identified was Lymphocytic Choriomeningitis virus (LCMV) 
during an outbreak in St. Louis (USA) in 1933 (Armstrong, 1934). Upon the 
discovery of Tacaribe virus (TCRV) in the 1950’s (Downs et al., 1963) and its 
subsequent characterisation, it became apparent that these viruses shared features 
unique to a new group of viruses. After the discovery of further viruses that displayed 
similarities to LCMV and TCRV, the Arenaviridae family was established with the 
initial characterisation of new family members based on serological similarities as 
well as the occurrence of the individual species.  Currently the International 
Committee for the Taxonomy of viruses has characterised 25 virus species (Table 
1.1) as arenaviruses (Salvato et al., 2011) with several newly discovered viruses 
(Cajimat et al., 2007, Cajimata et al., 2013, Cajimat et al., 2012) awaiting 
classification as potential arenavirus species. Two such novel viruses are Golden Gate 
Bridge virus and Californian Academy of Science virus. Interestingly, although these 
viruses share certain features with members of the Arenaviridae family, their 
glycoproteins seem to more closely resemble those of viruses within the Filoviridae 
family (Stenglein et al., 2012). Furthermore, unlike all classified arenaviruses, these 
two viruses were isolated from snakes. Therefore it remains to be seen whether these 
novel virus species will form a new clade within the Arenaviridae or are grouped as a 
new virus family. 
 
 
1.1.1 Distribution 
The Arenaviridae are divided into New World Arenaviruses (NWA; isolated in the 
Americas) and Old World Arenaviruses (OWA; isolated in Africa). Although the 
individual viruses can be assigned into one of these two groups based on geographic 
location (Figure 1.1) or serological evidence, it is now known that they can also be 
separated based on host cell receptor usage (Murphy et al., 1970, Rowe et al., 1970). 
Thus, New World Arenaviruses use transferrin receptor I (TfR1), while Old World 
Arenaviruses used α-dystroglycan as their main receptor, with the exception of Clade 
C New World Arenaviruses that also use α-dystroglycan (Cao et al., 1998, 
Spiropoulou et al., 2002b, Radoshitzky et al., 2007). 
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: Arenaviruses.  
List of characterised (by International Committee of Viruses; ICTV) arenavirus 
species and their name, year of isolation, geographic distribution, reservoir hosts, 
associated human diseases and the source reference of the virus. The arenaviruses are 
divided into two serocomplexes: Old World and New World and based on the viral 
nucleocapsid protein gene sequences the NW viruses are divided into three 
phylogenetic groups. Modified from Zapata and Salvato, 2013. 
 	  
Virus Species Origen of 
name 
Year Distribution Host Associated 
Disease 
Reference 
Old World arenavirus or LASV-LCVM serocomplex 
Lymphocytic 
choriomeningitis 
virus (LCMV) 
Disease 1933 Worldwide House mouse (Mus 
musculus) and (Mus 
domesticus) and 
Syrian hamster 
(Mesocricetus auratus) 
Flu like symptoms, 
meningitis, 
enecephalitis, 
congenital 
abnormalities/abort
ion, multisystem 
organ failure in 
transplanted 
patients 
Armstrong et 
al., 1934 
Lassa (LASV) Town, Nigeria 1969 West Africa  Multimammate mouse 
(Mastomys sp.) 
Haemorrhagic 
fever 
Frame et al., 
1970 
Mopeia (MOPV) Town, 
Mozambique 
1977 Southern Africa Multimammate mouse 
(Mastomys natalensis) 
Not associated with 
human disease 
Wulff et al., 
1977 
Mobala (MOBV) Region, DR of 
Congo 
1983 Central African 
Republic 
Soft-furred rat 
(Praomys sp.) 
Not associated with 
human disease 
Gonzalez et 
al., 1983 
IPPY (IPPYV) Town, Central 
African 
Republic 
1985 Central Africa Nile grass rat 
(Arvicanthis sp.) 
Not associated with 
human disease 
Swanepoel 
et al., 1985 
Lujo (LUJV) Lusaka, 
Zambia 
Johannesburg, 
South Africa 
2009 Southern Africa Unknown Haemorrhagic 
fever 
Paweska et 
al., 2009 
Luna (LUNV) Lusaka-
Namwala, 
Zambia 
2009 Sourthern 
Africa 
Zambia 
Multimammate mouse 
(Mastymus natalensis) 
Unknown 
pathogenicity for 
humans 
Ishii et al., 
2011 
New World arenavirus or Tacaribe serocomplex South American group 
Group A 
Pichindé (PICV) Valley, 
Colombia 
1965 South America 
Colombia 
Tome’s rice rat 
(Oryzomys 
albigularis) 
Not associated with 
human disease 
Trapido et 
al., 1971 
Paraná (PARV) River, 
Paraguay, 
Brazil, 
Argentina 
1965 South America 
Paraguay 
Paraguayan rice rat 
(Oryzomys buccinatus, 
Oryzomys angouya) 
Not associated with 
human disease 
Webb et al., 
1970 
Flexal (FLEV) Brazil 1975 South America 
Brazil 
Tome’s rice rat 
(Oryzomys albigularis, 
Nephelomys 
albigularis), 
Paraguayan rice rat 
(Oryzomys angouya), 
Oryzomys buccinatus) 
Febrile illness 
associated with 
nonfatal 
laboratory-acquired 
infection 
Carlton et 
al., 2012 
Pirital (PIRV) Community, 
Venezuela 
1995 South America 
Venezuela 
Alston’s cotton rat 
(Sigmodon alstoni) 
Not associated with 
human disease 
Fulhorst et 
al., 1997 
Allpahuayo 
(ALLV) 
National 
reserve, Peru 
1997 South America 
Peru 
Arboreal rice rats 
(Oecomys bicolor and 
Oecomys paricola) 
Unknown 
pathogenicity for 
humans 
Moncayo et 
al., 2001 
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Group B 
Tacaribe (TCRV) Beach, 
Trinidad 
1956 Caribbean Sea 
Trinidad 
Fruit-eating bat 
(Artibeus sp.) 
Associated only 
with single, 
nonfatal, 
laboratory-acquired 
infection 
Downs et al., 
1963 
Junin (JUNV) Town, 
Argentina 
1958 South America 
Argentina 
Corn mouse, drylands 
vesper mouse 
(Calomys masculinus), 
grass field mouse 
(Akodon azarae), dark 
field mouse (Bolomys 
obscurus) 
Haemorrhagic 
fever 
Parodi et al., 
1959 
Machupo 
(MACV) 
River, Bolivia 1962 South America 
Bolivia 
Large vesper mouse 
(Calomys callosus) 
Haemorrhagic 
fever 
Johnson et 
al., 1965 
Amapari 
(AMAV) 
Amapá region, 
Brazil 
1964 South America 
Brazil 
Rice rat (Oryzomys 
goeldii), bristly mouse 
(Neacomys guianae) 
Not associated with 
human disease 
Pinheiro et 
al., 1966 
Cupixi (CPXV) Town, Brazil 1970 South America 
Brazil 
Large-headed Rice Rat 
(Oryzomys capito) 
Not associated with 
human disease 
CHarrel et 
al., 2002 
Guanarito 
(GTOV) 
Region, 
Venezuela 
1989 South America 
Venezuela 
Cane mouse 
(Zygodontomys 
brevicauda) 
Haemorrhagic 
fever 
Salas et al., 
1991 
Sabiá (SABV) Town, Brazil 1990 South America 
Brazil 
Unknown (Suspected 
rodent) 
Haemorrhagic 
fever, associated 
with nonfatal 
laboratory-acquired 
infection 
Lisieux et 
al., 1994 
Chapare (CHPV) Town, Bolivia 2005 South America 
Bolivia 
Unknown Haemorrhagic 
fever 
Delgado et 
al., 2008 
Group C 
Latino (LATV) Bolivia 1965 South America 
Bolivia, Brazil 
Large vesper mouse 
(Calomys callosus) 
Unknown 
pathogenicity for 
humans 
Rowe et al., 
1970 
Oliveros (OLVV) Town, 
Argentina 
1990 South America 
Argentina 
Dark bolo mouse 
(Bolomys obscurus) 
Unknown 
pathogenicity for 
humans 
Bowen et al., 
1996 
North American group 
Group A 
Tamiami 
(TAMV) 
Everglades, 
USA 
1964 North America 
Florida 
Hispid cotton rat 
(Sigmodon hispidus) 
Unknown 
pathogenicity for 
humans 
Calisher et 
al, 1970 
Whitewater 
Arroyo (WWAV) 
Whitewater 
Creek 
1993 North America 
New Mexico 
White-throated wood 
rat (Neotoma albigula) 
Febrile infection, 
respiratory distress 
syndrome 
Fulhorst et 
al., 1996 
Bear Canyon 
(BCNV) 
Trailhead, 
USA 
2002 North America  
California 
California mouse 
(Peromyscus 
californico), 
Large-eared woodrat 
(Neotoma macrotis) 
Unknown 
pathogenicity for 
humans 
Fulhorst et 
al., 2002 
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With advanced genetic analysis methods the phylogeny of viruses can be 
characterised in more detail. Analysis of the phylogenetic relationship between the 
individual species (Figure 1.2) is based on the amino acid sequences of the viral 
nucleoproteins (NPs) and the glycoprotein precursor complex (GPC) (Salvato et al., 
2011). This method indicated that OWAs are located within a monophyletic group, 
whereas NWAs can be divided into four distinct clades (A, B, C and A/B Rec). This 
type of analysis has shown that Clade A/B Rec was likely formed by recombination 
events between viruses from Clades A and B respectively (Charrel et al., 2008).  
 
Each species of arenavirus is highly specific for a particular rodent host and as such 
the distribution of these viruses is dictated by the host (see Section 1.1.2). The only 
exception to this limited distribution is LCMV due to its association with the common 
house mouse (Mus musculus). As this rodent is found worldwide LCMV has the 
potential to spread globally (Childs, 1992, Lehmann-Grube, 1971, Emonet et al., 
2007). 
 
 
1.1.2 Hosts 
 
Arenaviruses are zoonotic viruses that cause asymptomatic, persistent infections in 
their natural host but can cause severe disease in other host species. The viruses infect 
rodents with an individual narrow host range (Table 1.1). Rodents of the Murinae 
subfamily serve as reservoirs for NWA, while OWA species infect members of the 
Sigmodontinae subfamily (Gonzalez et al., 1986, Charrel et al., 2001, Charrel et al., 
2008). Currently the only exception to having a rodent host is TCRV, for which fruit 
bats of the Artibeus spp. have been described as the natural hosts (Downs et al., 
1963). However, this observation is under re-examination (personal correspondence 
with Christine Carrington, University of the West Indies, Trinidad) as a potential 
contamination of animal samples cannot be excluded from the original 1963 samples 
(personal conversation with Colin Howard, University of Birmingham; Michael 
Buchmeier, University of California, Irvine). For a small subset of arenaviruses, such  
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: Worldwide occurrence of characterised Arenavirus 
species.  
 
The map indicates the world-wide distribution of the 25 characterised 
Arenaviruses over the Americas (New World Arenaviruses) and in Africa (Old 
World Arenaviruses). The phylogenetic clades are indicated as follows; Old World 
Arenaviruses = red, clade A New World Arenaviruses = green, clade B New 
World Arenaviruses = blue, clade C New World Arenaviruses = grey and clade 
A/B Rec New World Arenaviruses = purple.  
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as Chapare virus (CHPV) or Sabia virus (SABV), the natural host remains unknown 
(Delgado et al., 2008, Lisieux et al., 1994). All arenavirus rodent hosts are distributed 
with regional habitats, and only individual groups within the overall population carry 
the viruses. The various rodent hosts cover a large variety of different habitats that 
range from desert to subtropical climates. The only exception to this is the global 
distribution of Mus musculus and Mus domesticus, the natural rodent hosts of LCMV 
(Childs, 1992, Lehmann-Grube, 1971). Natural habitats (Figure 1.3) dictate the 
adaptation of the individual hosts to the conditions of living and food sources, such as 
living at riverbanks, forests or agriculturally utilised land (Buchmeier et al., 2013, 
Wilson, 2005, Childs and Peters, 1993).  
 
It has been postulated that arenaviruses have coexisted with their rodent hosts for 
millions of years and this virus-host adaptation is responsible for the lack of virulence 
within the individual hosts (Bowen et al., 1997, Charrel et al., 2003, Gonzalez et al., 
2007b). An indication of the adaptation is the lack of antibody production by the host 
against the virus. Most of the information that is known about the arenavirus-host 
relationship has been uncovered through studying LCMV. Depending on the virus 
strain host to host transmission can occur either horizontally (often between juvenile 
animals) or vertically (mother to offspring). Some strains can be entirely 
asymptomatic in their rodent host, while others strains affect the host by reducing 
fertility or causing minor episodes of mild disease (Skinner and Knight, 1973, 
Hotchin and Weigand, 1961, Vitullo et al., 1987).  
 
 
1.1.3 Human Disease 
 
A number of species within the Arenaviridae family are able to infect and cause 
disease in humans (Table 1.1). While infections of the natural hosts are typically 
asymptomatic, infections in humans can develop into severe disease that can result in 
death. Infected animals can develop either chronic or sporadic episodes of viraemia, 
but also viruria that cause the productive shedding of viruses (Childs and Peters, 
1993). The exact route of animal-human transmission is unknown, however, it is 
thought to occur either directly by scratches or bites from infected rodents or 
indirectly by aerosols or food contaminated with faeces or urine. Infections appear to  
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: Phylogenetic analysis of arenaviruses.  
 
Analysis of individual species is based on the amino acid sequences of the viral 
nucleoprotein (NP; left panels) and the glycoprotein precursor complex (GPC; right 
panels). The individual clades are as follows: Old World Arenaviruses = red, and 
within the New World Arenaviruses clade A = green, clade B = blue, clade C = grey  
and clade A/B Rec = purple. A) Phylograms using neighbor-joining, poisson and 
bootstrapping (200 pseudoreplications) algorithms using the MEGA 2 software 
package. Phylograms adapted from Charrel and de Lamballerie, 2009.  
* = arenavirus species as yet uncharacterised by the ICTV. B) Baysian models 
analysis in the MrBayes software package. See Methods Section 2.1 for details of 
modeling. Scale bars indicate amino acid substitutions. 
 
 1. INTRODUCTION  	  
	  	  	  	  	   9	  	  
 
 
 
 
 
 
A'
B'
* 
* * 
et al., 2008), and indicated that these two viruses under-
went the same evolutionary mechanism (Fig. 1).
Phylogenetic analyses were progressively updated with
the availability of complete sequences for the L RNA
segment. The most comprehensive study, based on the
comparative analysis of complete sequences of the four
genes for the largest set of viruses, was published recently
(Charrel et al., 2008). The delineation into an Old World
group and a New World group, which was subsequently
divided into three clades corresponding to the antigenic
findings, was confirmed. Comparative analysis of the NP
and GPC sequences showed that the discrepant position
observed in the two genomic regions respectively for the
viruses indigenous to North America (Tamiami, White-
water Arroyo, Bear Canyon, and the more recently
discovered Skinner Tank, Catarina, Tonto Creek and Big
Brushy Tank viruses is due to the recombinant nature of
the S RNA segment of these viruses, as reported previously
(Charrel et al., 2001). No recombination was observed in
the L RNA segment. From this dataset and analysis, it
appeared that no arenavirus genome was the result of a
reassortment (also known as intersegmental recombina-
tion) mechanism.
5. Disease in animals and man, therapy and diagnostic
Humans may become infected by arenaviruses through
direct contact with infected rodents, including bites, or
through inhalation of infectious rodent excreta and
secreta. The domestic and peridomestic behavior of several
species of rodent reservoir hosts is a major contributing
factor facilitating viral transmission from rodent to human.
However, in most cases, transmission of arenaviruses to
humans occurs following recreational or agricultural
incursions into environments providing critical habitat
for rodent hosts. Additionally, professionals handling
infected rodents in the field or laboratory are at increased
risk of infection (Sewell, 1995). Mostly, modifications of
the environment due either to human activities (modern
farming practices), or natural ecological changes (flooding,
storms) have been implicated in the emergence of human
disease caused by arenaviruses resulting from changes in
behaviour of the reservoir host.
To date, eight arenaviruses are associated with human
disease with different clinical pictures. Lassa, Junin,
Machupo, Guanarito, Sabia and Chapare viruses are known
to cause a severe hemorrhagic fever, in western Africa,
Argentina, Bolivia, Venezuela, Brazil, and Bolivia respec-
tively (Peters et al., 1996; Delgado et al., 2008; Briese et al.,
2009). Infection by LCM virus can result in acute central
nervous system disease and congenital malformations
(Barton and Hyndman, 2000; Barton et al., 1993); it has
recently been described as an important cause of fatal
infection in organ transplantation recipients, and immu-
nocompetent patients (CDC, 2005; Fischer et al., 2006;
Amman et al., 2007; Charrel et al., 2006; Emonet et al.,
2007; Palacios et al., 2008). Very little is known about the
health consequences of infection with the other arena-
Fig. 1. Phylogenetic relationships between arenaviruses within evolutionary lineages. Red, Old world viruses; Green, lineage A new world viruses, Blue,
lineage B new world viruses; Grey, lineage C new world viruses; Purple, recombinant new world viruses. Left panel, phylogram based on nucleoprotein
amino acid sequences, right panel, phylogram based on concatenated signal peptide and glycoprotein two amino acid sequences. The neighbor-joining,
poisson and bootstrapping (200 pseudoreplications) algorithms were computed by MEGA 2 software package.
R.N. Charrel, X. de Lamballerie / Veterinary Microbiology 140 (2010) 213–220216
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occur seasonally and are generally a result of increased encounters between infected 
rodents and humans. For example, human cases of infection in Argentina are 
generally associated with the harvest season, while infections in Bolivia coincide with 
the rainy season (Childs and Peters, 1993, Mills et al., 1994). Of the 25 characterised 
arenavirus species eleven are reported to be able to infect humans. Pichinde virus 
(PICV) is capable of asymptomatically infecting humans as a previous study 
documented the seroconversion of laboratory workers, however no disease symptoms 
were observed (Buchmeier et al., 1974, Gonzalez et al., 2007a). One case of febrile 
illness is known to have occurred after infection with TCRV, but the infected 
laboratory worker was exposed to a large dose of virus and further underlying health 
conditions were presumed for the case (1980, Buchmeier et al., 2013); personal 
conversation Michael Buchmeier, University of California, Irvine). There are two 
documented lab-acquired cases of Flexal virus (FLEV) infection, indicating that this 
virus has the potential to be infectious for humans (1980). The globally prevalent 
LCMV is also able to cause human disease, although this usually does not result in 
haemorrhagic fever (Adair et al., 1953, Ferencz et al., 1979, Meyer et al., 1960, 
Walker et al., 1982a, Warkel et al., 1973). The pathogenicity of the virus is especially 
underestimated for congenitial infections that can cause hydrocephalus, mental 
retardation or chorioretinitis in affected infants (Hirsch et al., 1974, Larsen et al., 
1993, Tindall and Gladstone, 1957). In adults LCMV infections can cause febrile 
illness with neurological symptoms, including meningitis and lymphocytic 
pleocytosis. It is thought that lymphocytic pleocytosis and the associated damage to 
the central nervous system is triggered by antibodies in the spinal fluid and thus, it is 
damage caused by an immune response and not directly by the virus. Studies have 
shown that about 5% of adults have antibodies against LCMV and it is believed that 
infections with LCMV are underestimated due to mild symptoms (Barton and 
Hyndman, 2000, Barton, 1996, Childs et al., 1991, Enria et al., 1999). The risk of 
LCMV infection is higher than that of other arenaviruses as the virus can be carried 
not only by the common house mouse, but also by pet hamsters (Anonymous, 2005, 
CDC, 2005, Hirsch et al., 1974). Additionally LCMV was shown to be transmitted 
during organ transplants (Palacios et al., 2008, Anonymous, 2005, Fischer et al., 
2006, Peters, 2006, CDC, 2005, MacNeil et al., 2011). Cases reported after organ 
transplantation indicate the importance of the patient’s immune system in the defence  
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: Human pathogenic New World arenaviruses that cause 
severe human disease in relation to host habitats.   
 
Reports of human arenavirus infections when compared to the reported habitats of 
the individual rodent hosts indicate that the virus is only carried by a subset of the 
overall rodent population. Reported endemic areas or outbreaks for Guanarito virus 
(GTOV), Junin virus (JUNV), Machupo virus (MACV), Sabia virus (SABV) and 
Whitewater-Arroyo virus (WWAV) are marked in red and Chapare virus (CHPV) is 
marked in black as reported cases overlap with MACV. The rodent host habitats are 
indicated for Neotoma albigula (WWAV; green), Zygodontomys brevicanda 
(GTOV; purple), Calomys callosus (MACV; grey) and Calomys musculinus 
(JUNV; blue). Hosts for CHPV and SABV are currently unknown.  
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against arenavirus infections and that a compromised immune system can result in an 
opportunistic and potential devastating spread of LCMV with fatal results. 
The remaining eight species of arenavirus known to cause human disease (Figure 1.3) 
that can manifest as febrile illness or haemorrhagic fever are CHPV, Guanarito virus 
(GTOV), Junin virus (JUNV) Lassa virus (LASV), Lujo virus (LUJV), Machupo 
virus (MACV), SABV and Whitewater Arroyo virus (WWAV) (Byrd et al., 2000a, de 
Manzione et al., 1998, Frame, 1975, Frame et al., 1970, Frame et al., 1984, Makenzie, 
1965, McCormick and Fisher-Hoch, 2002, Stinebaugh et al., 1966). Of these 
pathogens LASV is the most clinically important as it is responsible for the majority 
of human infections. LASV is endemic in Western Africa with hotspot areas in 
Nigeria and Sierra Leone, where the majority of infections and larger outbreaks occur. 
During the past 20 years there has been an increase in LASV infections in travellers 
that, through worldwide travel, carry the disease back to their home countries, such as 
the USA, Germany or Japan (Freedman and Woodall, 1999, Holmes et al., 1990, 
Isaacson, 2001). . Serological tests, however, showed that these viruses do not 
necessarily cause haemorrhagic fever, but infections can remain subclinical with only 
minor signs of disease. With this observation it is difficult to estimate the number of 
arenavirus infections but it is thought to be approximately 300,000 – 500,000 
infections per year with a mortality rate in the range of 15 – 30% (McCormick et al., 
1987, Bausch et al., 2001, Frame, 1975, Frame et al., 1970, Frame et al., 1984, 
McCormick and Fisher-Hoch, 2002). In hospitals with poor hygienic standards, 
nosocomial LASV infections are a major health concern during outbreaks where the 
mortality rate can reach levels of around 50% (Fisher-Hoch et al., 1995, Keenlyside et 
al., 1983, Webb et al., 1986). During pregnancy mortality rates are higher on average 
and risks are often accompanied with an increase in miscarriages (Mertens et al., 
1973, Price et al., 1988). OWAs can also cause neurological symptoms that can either 
be limited to a short period of time or can last for the rest of the patient’s life (Rybak, 
1990, Cummins et al., 1989, Cummins, 1990).  
 
The other OWA reported to cause haemorrhagic fever is LUJV, named after Lusaka 
(Zambia) and Johannesburg (South Africa) where a travelling infected woman is 
thought to have caused a nosocomial infection of four other people resulting in the 
death of four of these five patients in 2008 (Briese et al., 2009). Besides these cases 
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nothing is known about the ecology or epidemiology of this newly classified 
arenavirus.  
 
With the exception of WWAV that caused three cases of febrile illness in the USA in 
2000 (Fulhorst et al., 1996, Byrd et al., 2000b), the remaining arenaviruses pathogenic 
to humans are NWAs found in Clade B, namely CHPV, SABV, GTOV, JUNV and 
MACV (Figure 1.4). Transmission of the these viruses is thought to occur mainly by 
aerosol transmission from dried urine and excreta (Maiztegui, 1975). The most 
prevalent of these viruses is JUNV, the causative agent of Argentinian haemorrhagic 
fever (AHF), around Buenos Aires (Sabattini and Maiztegui, 1970). The virus was 
first characterised in the 1950s after causing outbreaks among harvest workers after 
deforestation increased the agriculturally used land in the region. Overall there are 
around 5 million people at risk of JUNV infection (Maiztegui, 1975, Maiztegui, 1986, 
Enria, 1998). Up until the end of the 1970s the virus had caused approximately 3,500 
infections annually with mortality rates of 14-17% (Maiztegui, 1979). After this time 
immune plasma treatment was introduced resulting in a drop in mortality rates to 
around 1%. In 1998 a vaccine against JUNV (Candid #1 strain of JUNV) was 
introduced in endemic areas and the vaccine is still the only anti-arenavirus vaccine 
available to date (Maiztegui, 1998). So far the efficacy of the vaccine seems to be 
excellent and cases of AHF have fallen to less than 100 reported cases per year 
(Emonet, 2011).  
 
Bolivian haemorrhagic fever (BHF) is caused by MACV with clinical symptoms 
resembling the ones of AHF (Johnson, 1965). Unlike AHF, outbreaks of BHF do not 
occur during harvest season, but during the rainy season (July – August) when the 
rodent host, Calomys callosus, invades houses and comes into closer contact with 
humans (Mercado, 1975). As the host is thought to be only a monophyletic group of 
the Vesper mouse, overall transmission is limited and thus outbreaks occur only in 
small numbers and in non-consecutive years (Salazar-Bravo et al., 2002).  
 
Another virus capable of causing haemorrhagic fever in Bolivia is CHPV, a virus that 
was associated with a small outbreak in the Chapare province in 2003/4 (Delgado et 
al., 2008). The host of the virus is unknown. Although the outbreak area overlapped 
with the MACV endemic area, genetic analysis showed that CHPV is more closely  
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: Arenavirus-related cases of haemorrhagic fever in South 
America.  
 
Case reports and information relating to human cases of haemorrhagic fever in South 
America. GTOV, JUNV and MACV endemic areas are shown in red. Individual 
reported cases of CHPV and SABV are shown in black. 
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related to SABV. Similar to CHPV, not much is known about SABV, the causative 
agent of Brazilian haemorrhagic fever (BrHF), which was isolated from a single fatal 
case and subsequently caused two non-fatal laboratory-acquired infections (Barry, 
1995, Coimbra, 1994). 
 
Venezuelan haemorrhagic fever (VHF) is caused by GTOV and the overall 
transmission seems to resemble AHF by being associated with an increase in 
deforestation and an increase in agricultural activity in endemic areas. The first case 
was reported in 1989 and since then the total number of confirmed cases is 
approximately 200. For unknown reasons the case reports fell sharply after 1992 
(Salas et al., 1991). A large genetic diversity was described for GTOV, but only the 
main genotype was associated with the development VHF in patients (Tesh et al., 
1999, Tesh et al., 1993, Weaver et al., 2000). However a caveat in these studies is that 
they relied on small sample sizes and results may not be statistically significant. 
 
Apart from the previously mentioned Candid #1 JUNV vaccine, there is currently no 
approved specific treatment against arenavirus infections. The vaccine works with a 
high efficacy of at least 84% in endemic areas (Maiztegui, 1998). Many attempts were 
made for the development of a vaccine against LASV, but these often failed due to 
poor long-term immunity (Bredenbeek et al., 2006, Geisbert et al., 2005, Lukashevich 
et al., 2008). The only treatment administered during acute cases of arenaviral 
haemorrhagic fever is the teratogen ribavirin (1-beta-d-ribofuranosyl-1,2,4-triazole-3-
carboxamide). This drug is used against a variety of negative-sense RNA viruses. 
However, ribavirin it is an incredibly toxic drug with such severe side effects that it is 
classed as a “drug of last resort”. A further caveat to the use of ribavirin is in its mode 
of action. Ribavirin is a nucleoside analogue that causes mutations of the viral 
genome during viral replication and as such it is often only effective if administered 
early in infection (McCormick et al., 1986). The lack of adequate and specific 
treatment highlights the need for the development of arenavirus-specific antiviral 
drugs that offer effective treatment without adverse effects and that clinicians are able 
to administer in areas affected by these viruses.  
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1.2 Arenavirus properties 
1.2.1 Virion 
 
Arenaviruses form pleomorphic to spherical virus structures of 50 – 300 nm in size 
(Salvato et al., 2011). The virion surface consists of a host cell-derived membrane 
(about 20% of dry weight) that is covered by club-like projections (Figure 1.5); 
(Salvato et al., 2011), which are trimers of the viral glycoprotein (GP; see Section 
1.2.3 Glycoprotein Precursor Complex (GPC)). GP can be heavily glycosylated to 
the extent of around 8% of the virion dry weight (Salvato et al., 2011). Below the 
lipid bilayer of the membrane, on the inside of the virion, there is a layer or the zinc-
finger protein (Z protein) (Neuman et al., 2005). The Z protein layer further binds 
another layer of the viral nucleoprotein (NP) to the inside of the virion (Neuman et al., 
2005). Although the exact mechanisms of virion formation are not known, the Z 
protein is capable of binding to all other viral proteins (see Section 1.2.3 Z protein) 
and would be capable of orchestrating this formation (Figure 1.5). The virion core 
contains the genome RNA segments (see Section 1.2.2 Genome structure) that are 
encapsidated by NP. The genome segments form helical circular structures ranging 
from 400 – 1300 nm in length (Young and Howard, 1983, Salvato et al., 2011). In 
addition to the viral genome segments, the virions also contain non-genomic RNA 
species. The virions also contain a large number of ribosomes, the appearance of 
which upon electron microscopic analysis led to the name “arena” -virus from the 
latin word for “sand” (Figure 1.5), but the functional significance of ribosome 
incorporation remains unclear (Muller et al., 1983, Bruns et al., 1983, Salvato et al., 
2011).  
 
 
1.2.2 Genome structure 
 
Arenaviruses are enveloped negative-sense RNA viruses with a bi-segmented genome 
(Figure 1.6). The genome of arenaviruses is segmented into the L (large; 
approximately 7.3 kb) and S (small; approximately 3.5 kb) segments. Each genome 
segment expresses two proteins, the nucleoprotein (NP) and glycoprotein precursor 
complex (GPC) are encoded on the S segment; the L protein (viral RNA-dependent  
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: Arenavirus virions.  
 
A) Thin electron microscopy sections of lymphocytic choriomeningitis virus 
(LCMV) budding from an infected BHK-21 cell. B) Cryo-electron microscopic 
image of purified and unstained LCMV virions. The arrows indicate the glycoprotein 
spikes on the virion surface. Sale bar represents 100 nm. C) Diagram representation 
of arenavirus virion composition with trimeric glyoprotein spikes. L – viral 
polymerase, IB – inclusion bodies that are either ribosomes or self-assembling Z 
bodies. D) Composition of virion membrane layers. From the outside to the inside of 
the virion: GP-C (glycoprotein spikes), LB (lipid bilayer), Z (zinc-finger protein) and 
NP (nucleoprotein). Adapted from Salvato et al., 2011 and Neuman et al., 2005.  
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Part II – The Negative Sense Single Stranded RNA Viruses
virions including poly (U) and poly (A) polymerases, and a protein kinase that can phosphorylate 
N. It is thought unlikely that these are virally encoded.
LIPIDS
Lipids represent about 20% of virion dry weight and are similar in composition to those of the host 
plasma membrane.
CARBOHYDRATES
Carbohydrates in the form of complex glycans on GP1 (five or six sites in lymphocytic choriomenin-
gitis virus [LCMV]) and GP2 (2 sites in LCMV) represent about 8% of virion dry weight.
Genome organization and replication
The L and S RNAs of arenaviruses each have an ambisense coding arrangement (Figure 2). The 
L RNA encodes in its viral-complementary sequence the L protein, and in the viral-sense 5!-end 
sequence the Z protein. The Z mRNA is small ("0.5 kb). The N protein is encoded in the viral- 
complementary sequence corresponding to the 3!-half of the S RNA, while the viral glycopro-
tein precursor (GPC) is encoded in the viral-sense sequence corresponding to the 5!-half of the S 
RNA. The two proteins are made from subgenomic mRNA species transcribed from the viral (for 
N mRNA) or full-length viral-complementary S RNA species (for GPC mRNA). The intergenic 
regions of both S and L RNAs contain nt sequences with the potential of forming one or more hair-
pin configurations. These secondary structural features may function to terminate mRNA tran-
scription from the viral and viral-complementary S RNAs. The mRNAs are capped and contain 1-5 
Figure 1: (Left) Electron microscopic images of lymphocytic choriomeningitis virus (LCMV). (A) Thin section showing sev-
eral virions budding from the surface of an infected BHK-21 cell. (B) Cryo-electron microscopic images of purified unstained 
virions frozen in vitreous ice. Arrowheads indicate glycoprotein spikes which are composed of trans-membrane GP2 and 
globular heads of GP1. The bar indicates 100 nm. (Courtesy R. Milligan, J. Burns and M. Buchmeier). (C) Diagrammatic rep-
resentation of virion structure with trimeric spikes (Eschli et al., 2006; Schlie et al., 2010). L protein is the RNA polymerase; IB 
is inclusion bodies that could be ribosomes or could be related to self-assembling Z bodies (Kentsis et al., 2002). (Courtesy C. 
Clegg and A. Featherstone, asrf@researchgraphix.co.uk.)
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55% of all virions, possess the approximate number of units
expected for T! 3 and T! 4 icosahedral capsids, respectively.
We have been unable to routinely identify fivefold axes char-
acteristic of icosahedral symmetry in arenavirus virion images
and class averages (data not shown). Furthermore, arenavi-
ruses are far larger than known T ! 3 or T ! 4 icosahedral
virions. The nonicosahedral packing of NP molecules in the
arenaviruses appears to be analogous to the paracrystalline but
nonicosahedral packing of Gag molecules in retrovirus virions
(18, 48).
Parallels to the design of other viruses. Arenavirus particles
display two concentric layers of protein beneath the lipid bi-
layer, the innermost of which contains punctate 50-Å densities
that we attribute to NP. Arenaviruses resemble enveloped ico-
sahedral and pleomorphic particles in the general arrangement
of inner and outer protein features. However, the supramo-
lecular design of arenaviruses differs from known virus archi-
tectures: alphaviruses, like flaviviruses, have an icosahedral
geometry with defined two-, three-, and fivefold axes, and ret-
roviruses have local paracrystalline symmetry with visible
seams located where paracrystalline arrays abut. We have not
detected a spiral or helical arrangement of irregularly coiled
NP filaments, as observed after release of nucleocapsids from
a variety of pleomorphic viruses. Spiral nucleoproteins have
been described previously for released arenavirus nucleocap-
sids (11, 49). It is possible that IT-2 NP molecules reflect local
approaches of the spiral nucleocapsid to the membrane, al-
though the data presented here do not address NP packing
inside IT-2. The proposed concentric density distribution is
consistent with more recent cryo-EM analyses of influenza
virus virions (1, 17) and immature retrovirus particles (18, 47,
48) (Fig. 6). Our density assignments are consistent with the
reported L/NP/GP-1/GP-2/Z molar ratio of Lassa virus of "1:
160:60:60:20 (43).
Parallels to the design of retroviruses. Arenaviruses and
retroviruses share assembly and budding mechanisms (Fig. 6).
The retroviral matrix (MA) domain of Gag and arenavirus Z
are essential budding factors. In addition, both proteins are
myristoylated (38). The arenavirus Z protein has multiple
functions. Z is a budding factor (37, 43) and a potent inhibitor
of arenavirus RNA synthesis (7, 8, 27). One recent study failed
to detect an interaction of Z with NP (27) by using immuno-
precipitation, which is implied in the images in Fig. 4. How-
ever, other studies have demonstrated an interaction between
Lassa virus NP and Z by immunoprecipitation and colocaliza-
tion (15) and between LCM NP and Z by cross-linking (40).
Both reside within "30 Å of the inner surface of the mem-
brane (18, 47, 48). Gag cleavage products, the matrix proteins
of negative-stranded viruses, and arenavirus Z proteins contain
the late domains that bind adaptor components of the
coatomer assembly machinery and are essential for viral bud-
ding. The late domains of retroviruses often occur as either the
sequence P-P-X-Y or P-S/T-A-P (where X is any amino acid)
between MA and CA or as a Y-X-X-# (where # is an amino
acid with a bulky hydrophobic side chain) sequence in the
domain following NC. Each allows the virus protein to bind a
different component of the host cell vacuolar protein sorting
pathway (33). The arenavirus Z protein contains either one or
two functional motifs of the P-P-X-Y and P-S/T-A-P type or, in
the case of Tac Z, a single Y-X-X-# motif (37, 43). It may be
significant that Tac NP is located "30 Å distal from the mem-
brane relative to the New and Old World arenavirus counter-
parts Pic and LCM and that Tac presumably interacts with
different parts of the coatomer assembly pathway. Late do-
mains in Z are also required for budding but not for associa-
tion of Z with membranes or for the interaction of Z and NP
(15, 37, 43). Furthermore, Z proteins of LCM and Lassa vi-
ruses can substitute functionally for the Rous sarcoma virus
late domains (37). Thus, analogous virus designs are realized
differently: retroviral Gag proteins are processed in place dur-
ing maturation, while arenaviruses are assembled as mature
particles from discrete components.
FIG. 6. (A) Schematic representation of the arenavirus and murine leukemia virus organization (based on reference 48 used with permission
of the National Academy of Sciences). The murine leukemia virus Gag domains matrix (MA), P12, capsid (CA), and nucleocapsid (NC) are shown
assembled at the viral lipid bilayer (LB) on the left, while the arenavirus GP, Z, and NP proteins are depicted on the right. (B) Schematic
representation of clathrin-coated vesicle organization, showing the position of the “cargo” protein, adaptor protein complex (AP), and clathrin coat
(CLA). Bar, "100 Å.
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virions including poly (U) and poly (A) polymerases, and a protein kinase that can phosphorylate 
N. It is thought unlikely that these are virally encoded.
LIPIDS
Lipids represent about 20% of virion dry weight and are similar in composition to those of the host 
plasma membrane.
CARBOHYDRATES
Carbohydrates in the form of complex glycans on GP1 (five or six sites in lymphocytic choriomenin-
gitis virus [LCMV]) and GP2 (2 sites in LCMV) represent about 8% of virion dry weigh .
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RNA. The two proteins are made from subgenomic mRNA species transcribed from the viral (for 
N mRNA) or full-length viral-complementary S RNA species (for GPC mRNA). The intergenic 
regions of both S and L RNAs contain nt sequences with the potential of f rming one or more hair-
pin configurations. These secondary structural features may function to terminate mRNA tran-
scription from the viral and viral-complementary S RNAs. The mRNAs are capped and contain 1-5 
Figure 1: (Left) Electron microscopic images of lymphocytic choriomeningitis virus (LCMV). (A) Thin section showing sev-
eral virions budding from the surface of an infected BHK-21 cell. (B) Cryo-electron microscopic images of purified unstained 
virions frozen in vitreous ice. Arrowheads indicate glycoprotein spikes which are composed of trans-membrane GP2 and 
globular heads of GP1. The bar indicates 100 nm. (Courtesy R. Milligan, J. Burns and M. Buchmeier). (C) Diagrammatic rep-
resentation of virion structure with trimeric spikes (Eschli et al., 2006; Schlie et al., 2010). L protein is the RNA polymerase; IB 
is inclusion bodies that could be ribosomes or could be related to self-assembling Z bodies (Kentsis et al., 2002). (Courtesy C. 
Clegg and A. Featherstone, asrf@researchgraphix.co.uk.)
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RNA polymerase) and the matrix-like Z protein are encoded on the L segment 
(Salvato et al., 2011, Buchmeier et al., 2013). Arenaviruses use a unique coding 
strategy compared to many other negative-sense RNA viruses by encoding their genes 
in ambisense orientation, with the NP and L open-reading frames (ORFs) of the viral 
genome in negative-sense orientation and the GPC and Z ORFs in positive-sense 
orientation (Auperin and McCormick, 1989, Auperin et al., 1984). Whereas the NP 
and L mRNAs can be transcribed directly from the genome, for transcription of the Z 
and GPC mRNAs an intermediate step of full-length genome transcription to produce 
the anti-genome (complementary RNA) must occur first as this is the template used to 
transcribe the Z and GPC mRNAs (Meyer, 2002).  
 
Between the two protein-encoding regions on each genome segment is a noncoding 
intergenic region (IGR) that is predicted to form one (e.g. in the case of LCMV) or 
two (e. g. in the case of TCRV), stable hairpin loops (Bishop and Auperin, 1987, 
Buchmeier et al., 2007, Franze-Fernandez et al., 1987) and has been described to form 
a bona fide transcription terminator (Franze-Fernandez, 2007, Pinschewer et al., 
2005). The transcribed mRNA species are non-polyadenylated and the 3’-ends 
terminate with different nucleotide lengths, so that it appears that the overall IGR 
structure is more important than the individual nucleotide sequence to act as a 
transcription-termination signal for the viral polymerase (Lelke et al., 2010, Iapalucci 
et al., 1991, Raju et al., 1990). 
 
The ORFs of each segment are flanked by non-coding regions containing 19 highly 
conserved nucleotides that are believed to form the viral promoter recognised by the L 
protein. The 5’-end of the genome is almost the exact reverse compliment sequence of 
the 3’-end (17 out of 19 nucleotides) (Perez and de la Torre, 2003, Hass et al., 2006). 
This, together with electron microscopy analysis, has suggested that the genome 
forms a panhandle structure (Palmer et al., 1977, Young and Howard, 1983, Bishop 
and Auperin, 1987). Although not proven, it is thought that the 5’-ends form cis-
acting signals for the encapsidation of the viral genome as well as the subsequent 
recognition by the viral polymerase (Meyer and Southern, 1993, Perez and de la 
Torre, 2003). Furthermore, RNA species are often found to contain a non-templated G 
at the 5’-end (Garcin and Kolakofsky, 1992, Raju et al., 1990). The presence of the 
additional base is likely due to a “prime and realign” strategy for replication  
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: Arenavirus genome organisation and transcription. 
 
 A) The overall genome organisation of arenaviruses. The genome consists out of 
two segments the (large) L Segment (approx. 7.2 kb) and the (small) S Segment 
(approx. 3.4 kb). Each genome segment comprises the 5’ and 3’ untranslated regions 
(UTRs) that contain the viral promoter sequences as well as the intergenic region 
(IGR) which forms a stable hair pin structure and acts as a bona fide transcription 
terminator. On each genome segment are two genes encoded in ambisense 
orientation (L and NP = negative sense; Z and GPC = positive sense). B) The 
replication and transcription strategy of arenaviruses. The genomic RNA in the 
negative sense orientation can be utilised by the L protein to transcribe the gene (L or 
NP) into mRNA directly, while the positive sense genes (Z or GPC) require the 
intermediate step of anti-genomic RNA production as this acts as the template for 
genomic RNA synthesis. The mRNAs possess a 5’ methylated cap that is acquired 
from cellular mRNAs by a mechanism of “cap-snatching”, however unlike cellular 
mRNAs they do not possess a 3’ poly(A) tail.  
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(Garcin and Kolakofsky, 1990, Perez, 2003), which has also been described for 
influenza viruses (Shaw and Lamb, 1984) and bunyaviruses (Bouloy et al., 1990). 
 
 
1.2.3 Arenavirus proteins 
 
As mentioned above arenaviruses express only four characterised gene products, two 
from each genome segment. Therefore these proteins have to fulfil many different and 
sometimes diverse functions throughout the viral replication cycle, resulting in the 
multifunctional nature of arenavirus proteins. 
 
Z protein 
The smallest Arenavirus protein is the zinc-finger protein (Z protein) encoded on the 
L genomic RNA segment. The Z protein is 90-99 amino acids long, depending on the 
virus species, is approximately 11 kDa in molecular weight and is a RING finger 
protein (Figure 1.7), which in turn belongs to the zinc finger proteins, from which its 
name is derived (Freemont et al., 1991, Brown et al., 1985, Miller et al., 1985). 
Members of this type of protein family are reported to be involved in protein-protein 
interactions, with two such virus-host interactions reported for Z, the interactions with 
the promyelocytic leukemia protein (PML) and eIF4E. The interaction between 
LCMV Z and PML (Volpon et al., 2010) potentially explains the non-cytolytic nature 
of this virus family, as PML can circumvent the function of p53, a key protein in 
apoptosis. eIF4E is the cap-binding protein of the eukaryotic translation initiation 
complex and previous studies suggest that the interaction between LASV Z and eIF4E 
seems to be involved in the repression of cellular protein translation (Borden et al., 
1998, Campbell Dwyer et al., 2000, Kentsis et al., 2001, Volpon et al., 2010). This 
has many implications in the evasion of host immune responses as the repression of 
cellular protein translation likely reduces the ability of the cell to produce and respond 
to antiviral cytokines such as interferon (IFN) (Colina et al., 2008). More recent 
studies have reported that the Z protein of NWAs can bind directly to the cytoplasmic 
pathogen recognition receptor RIG-I and thus inhibit a key pathway in the induction 
of type I IFN (Fan et al., 2010). 
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: MNR Solution structure of the RING domain of Z.  
 
Ribbon representation (residues 26 to 72 are shown).. The helix and the β-sheets are 
colored in green and blue respectively. Cysteine and histidine residues coordinating 
the zinc atoms (yellow spheres) are shown in orange. Adapted from Volpon et al., 
2010. 
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Results and Discussion
Solution Structure of the Z RING Protein. As a first step in under-
standing RING-eIF4E interactions, we solved the solution struc-
ture of the 99 residue Z protein from LASV. We chose LASV Z
because of its better solution behavior than PML RING (19).
This Z construct associates with eIF4E and reduces cap binding
to the same extent as previously used constructs derived from
LCMV Z (Fig. S1), making it an ideal candidate to investigate
RING-eIF4E interactions by NMR.
The RING domain of Z (residues 30 to 70) forms a well-
defined structure comprising a helix (residues 50–58), two short
antiparallel β-sheets (β1: residues 42–44, 47–49; and β2: 63–64,
69–70) and two loop regions: 35–39 (loop 1) and 58–62 (loop
2). For residues 30 to 70, the rmsd with respect to the mean
coordinate positions is 0.39 ð"0.06Þ and 0.91 ð"0.23Þ Å for back-
bone and heavy atoms, respectively (Fig. 1B and Table S1). These
residues are relatively rigid on the ns/ps timescales, while residues
in loop 1 have some degree of motion (Fig. 1C). In contrast, the
N terminus (1–29) and C terminus (71–99) exhibit very low het-
eronuclear NOE values, consistent with these being disordered.
Two zinc atoms bind the RING in a typical cross-brace fashion
(Fig. S2A). Interestingly, when Z was compared to the structu-
rally diverse family of RINGs using the DALI program (20),
no significant superimposition was obtained (DALI score
<3.0) due to its unique conformation around site II. Specifically,
its topology differs from most other RINGs by the location of the
first two zinc ligating residues within site II being arranged on
either side of the first small β-strand (β1). Further, Z has a second
small β-sheet (β2) also around site II (Fig. 1A). A comparison of
the structure of Z and PML RING domains revealed that these
are quite homologous around site I, in which certain aromatic and
charged side chains have nearly identical positions (Fig. S3).
The rmsd between PML (residues 9–16, 28–32) and Z (residues
31–38, 49–53) is 1.9 Å (Fig. S3F), which is striking given the low
identity between these proteins (Fig. S2C). Loop 1 in PML and Z
adopts a more open conformation than found in other RINGs
such as BRCA1 or Cbl, neither of which bind eIF4E (16). This
conformational difference is likely important for eIF4E recogni-
tion (see below).
Identification of a Unique Mode of RING Interaction. To map the Z
binding surface for eIF4E we employed 2D 1H-15N heteronuclear
single quantum correlation (HSQC) NMR chemical shift
mapping and transferred cross saturation (TCS) experiments
(21) (Fig. 2). Note that throughout this study we used cap-free
eIF4E. Upon addition of eIF4E, 15N Z undergoes relatively large
chemical shift changes and/or line broadening (in red and green,
respectively, in Fig. 2A–C) for residues around site I and on the
underside of the RING. In particular, residues in loop 1 of site I
were most affected, suggesting these are at the interacting surface
with eIF4E (Fig. S4 and Fig. 2A–C). Interestingly, in the free
form, loop 1 was somewhat less ordered than the rest of the Z
RING (Fig. 1B and C), which may be important for facilitating
local rearrangement upon eIF4E binding. Also, the N and C
termini of Z are not perturbed by eIF4E addition consistent with
previous studies where deletion of these regions did not affect
the Z-eIF4E interaction (16).
We performed TCS experiments (21) to distinguish chemical
shift perturbations arising due to ligand binding from conforma-
tional changes distal to the interaction surface. The TCS experi-
ment showed large reductions in signal intensity for residues
around site I of Z, particularly loop 1 (F30, K32, S33, W35,
and the Hδ side chain of N38), confirming chemical shift mapping
that these residues are at the complex interface (Fig. 2D). Muta-
tions W35A, F36A, N38A, or K39A within loop 1 of Z also ab-
rogated its association with eIF4E (Fig. 2E) further underlying
the importance of these residues. Consistent with previous data,
mutation of site II did not reduce association with eIF4E (Fig. 2E)
(16). In contrast, mutation of site I or addition of EDTA, both of
which unfold Z, abrogated its association with eIF4E [(16),
Fig. 2E]. This is consistent with mutational and biophysical
studies indicating that the integrity of site I, but not site II, is re-
quired for folding of PML and Z RINGs (16). Studies with
BRCA1 and PML RINGs suggested that zinc binding is anticoo-
perative with site I being the higher affinity site (22). This pre-
vious study suggested that the pliability in site II may enable
RINGs to bind different partners as a function of zinc levels.
Altogether, our studies indicate that the region comprising
residues 30 to 39 interacts with eIF4E. This region is highly con-
served among known Z proteins (Fig. S2B). Significantly, the Z
recognition site for eIF4E does not utilize a YXXXXLΦ or any
α-helix motif as used by eIF4G and the 4E-BPs. Thus, this repre-
sents a previously undescribed type of eIF4E binding domain.
BRCA1 and Cbl RINGs bind Ubcs using a shallow mainly
hydrophobic groove formed by the central helix and zinc sites
(Fig. S5A) (23). In the comparative region of Z and PML, resi-
dues K32, H47, R63, and K68 form a positively charged groove
(Fig. 2 and Fig. S5B) and association with eIF4E is mediated via a
surface formed by the residues around loop 1, which is distinct to
the region used by other RINGs to interact with Ubcs. The con-
formation of site I is conserved between PML and Z, and differs
from that observed in BRCA1 and Cbl. These analyses reveal that
the molecular underpinnings of RING-Ubc and RING-eIF4E in-
teractions are markedly different (see Fig. S5 for details).
Mapping of the Interaction Site on eIF4E.To characterize the binding
site of eIF4E for Z, we monitored perturbations in the NMR
signal of 15N-eIF4E as a function of Z addition (Fig. S6) and also
performed TCS studies of the 2H, 15N-labeled eIF4E/unlabeled
Z complex. The largest chemical shift perturbations were found
for residues in helices 1 and 2 of eIF4E, together with residues
preceding the initial β-strand (Fig. 3A). These were accompanied
by significant line broadening, some of which were broadened
beyond detection (green in Fig. 3A and B), e.g., the indole
NH of W73. The TCS experiments confirmed the chemical shift
Fig. 1. Solution structure of the RING domain of Z (residues 26 to 72 are
shown). (A) Ribbon representation. The helix and the two β-sheets are
colored green and blue, respectively. Cys and His residues coordinating
the zinc atoms (yellow spheres) are shown in orange. (B) Superposition of
the final 10 energy-minimized structures for residues 30 to 70. The structures
are superimposed for minimal mutual deviation of the backbone atoms
(Cα, N, and C). (C) Backbone f1Hg-15N heteronuclear NOE values for Z.
5442 ∣ www.pnas.org/cgi/doi/10.1073/pnas.0909877107 Volpon et al.
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The Z protein does not only play a role in regulation of cellular protein translation 
events, it is also involved in viral transcription processes and functions as a repressor  
(Borden et al., 1998, Campbell Dwyer et al., 2000, Kentsis et al., 2001, Volpon et al., 
2010). It was shown that the Z protein regulates arenaviral transcription in a dose-
dependent manner, and this is able to balance the viral replication cycle between 
driving transcription (i. e. when Z protein concentration is low) and virion assembly 
(i. e. when Z protein concentration is high) (Cornu and de la Torre, 2001, Hass et al., 
2004, Lopez et al., 2001, Loureiro et al., 2011, Kranzusch and Whelan, 2011). 
Arenaviruses do not posses a matrix protein (M) similar to other enveloped negative-
sense RNA viruses, however it was shown that the Z protein has adopted this function 
and therefore it has been characterised as a M-like protein (Perez et al., 2003, Urata et 
al., 2006). Similar to many other viral M proteins, the Z protein controls virus 
budding from the cell as it contains a Late (L) domain with one of the following 
characteristic L-domain amino acid motifs: PT/SAP, PPXY, YPXL and FPDL (there 
are major differences between OWA and NWA Z protein L domains) (Perez et al., 
2003, Strecker et al., 2003, Urata et al., 2006, Fehling et al., 2013). L-domains are 
able to interact with the cellular endosomal sorting complex required for transport-I 
(ESCRT-I) complex (Urata and de la Torre, 2011, Bieniasz, 2006, Chen and Lamb, 
2008). However, the Z protein of TCRV seems to function differently to the other 
arenaviruses as the two potential L-domains it possesses (ASAP and YLCL motifs) 
have been shown not to be required for viral budding to occur (Groseth et al., 2010, 
Urata et al., 2009). Conserved throughout all arenavirus species is the glycine residue 
at position 2 of the Z protein, which is responsible for myristoylation and the 
subsequent targeting to membranes (Urata et al., 2009, Perez et al., 2004, Strecker et 
al., 2006). Mutation of this residue or the block of myristoylation either reduces or 
completely inhibits arenavirus budding (Urata et al., 2009, Perez et al., 2004). Taken 
together the Z protein seems to coordinate the virus assembly and release from the 
cell, while impairing certain cellular processes.  
 
L protein 
The largest arenaviral protein is the L protein (about 250 kDa), which contains the 
RNA-dependent RNA polymerase (RdRp) domain (Fuller-Pace and Southern, 1989, 
Singh et al., 1987). Working with the L protein is rather difficult due to its size 
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(greater than 2200 amino acids) and often results in insolubility issues in vitro. 
However, bioinformatics predictions have identified several potential domains, which 
include the prediction of domain L3 as the active RdRp (Muller et al., 1994, Vieth et 
al., 2004). From further experiments, particularly after the identification of the 
influenza A virus PA polymerase subunit as an essential endonuclease required for 
cap-snatching (Dias et al., 2009, Plotch et al., 1981, Yuan et al., 2009), it was 
suspected that the L1 domain of the L protein is the arenavirus counterpart (Figure 
1.8). The endonuclease activity and structure of L1 was finally confirmed by Morin 
and colleagues in 2010  and recently work from Stephan Guenther’s group identified 
the L4 domain as the potential site of RNA cap-binding (Lehmann et al., 2014). This 
would map the cap-binding, endonuclease and RdRp activities to the same 
polypeptide, which is different to the cap-snatching prototypic influenza A virus 
(Guilligay et al., 2008, Dias et al., 2009, Yuan et al., 2009).  
It has also been shown that the L1 and L3 domains of L interact with the Z protein, 
which might indicate regulatory functions of the Z protein in the activity of L 
(Kranzusch and Whelan, 2011, Wilda et al., 2008). Previous work has also reported 
that L-L protein interactions are essential for polymerase function with mutations in 
the L3 domain disrupting replication (Sanchez and de la Torre, 2005, Kranzusch et 
al., 2010). The L protein seems to comprise further elements or uncharacterised 
binding-sites that causes its switch between replication and transcription. This is still 
poorly understood, however, the Z protein has been shown to block the activity of L 
in a dose-dependant manner (Kranzusch and Whelan, 2011, Meyer, 2002, Jacamo et 
al., 2003). 
 
Glycoprotein Precursor Complex (GPC) 
 
GPC (approximately 75 kDa) is encoded in a positive-sense orientation on the S 
genome segment. It is translated as a single polypeptide that is post-translationally 
cleaved into GP1 and GP2 by the cellular protease site-1 protease (SP-1; also referred 
to as subtilisin-kexin-isozyme-1) (Jacamo et al., 2003, Beyer et al., 2003, Kunz et al., 
2003, Lenz et al., 2001, Rojek et al., 2008a). After cleavage the glycoproteins 
assemble into homotrimers the structure of which forms the spike-like projections on 
the virion surface. GP2 is located at the bottom of these spikes, as it possesses a  
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: Overview of arenavirus L protein domains and 
structure of domain NL1 in comparison with the influenza PAN 
structure.  
 
A) Schematic representation of the TCRV L protein with the four predicted domains 
(I – IV). Domain III, the RNA-dependent RNA polymerase contains six motifs that 
are conserved in negative-sense RNA virus polymerases. B) Cartoon-representation 
of the NL1 structure. Secondary-structure elements are labelled and colored as 
follows: α-helices = blue; β-strands = orange; loops = green. Side-chains for 
residues within the NL1 endonuclease active site are shown as red sticks and 
labelled. C) Electrostatic surface representation shows NL1 in the same orientation 
as in panel B. The arrow indicates the putative RNA binding groove and the active 
site crevice. Negative charges are in red, positive charges are in blue and neutral in 
white. D) Superimposition (view in the same orientation as in B) of the structures of 
NL1 (grey) and the influenza A virus PAN (PDB code: 2W69, cyan) highlighting 
their shared structural core as well as variations in the form of an extra loop only 
present in the PAN structure (circled). The two Mn2+ ions in the PAN structure 
active site are depicted as green spheres. Adapted from Wilda et al. 2008 and Morin 
et al., 2010  
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transmembrane region, while GP1 is the receptor-binding region of GP that forms the 
tip of the spikes (Figure 1.9) to establish contact with potential host cells (Gallaher et 
al., 2001, Borrow and Oldstone, 1992). OWA and Clade C NWAs use α-dystroglycan 
(α-DG) as a primary receptor for binding to the host cell, whereas other arenaviruses 
either use TfR1 (Figure 1.9) or an as yet unidentified receptor (Imperiali et al., 2005, 
Kunz et al., 2005b, Kunz et al., 2005a, Radoshitzky et al., 2007, Rojek et al., 2007, 
Abraham et al., 2009, Cao et al., 1998, Spiropoulou et al., 2002a). Recently a second 
step in the binding and internalization step of arenaviruses has been identified, where 
the LASV undergoes a receptor-switch in the acidified endosome to bind to the 
lysosomal-associated membrane protein 1 (LAMP1) (Jae et al., 2014). After binding 
to the host cell receptor, GP2 functions as a fusion protein (Figure 1.9), to bring 
about the fusion of the viral and endosomal membranes, thereby allowing the vRNPs 
to gain entry into the cytoplasm of the cell (Gallaher et al., 2001, Eschli et al., 2006, 
York et al., 2005, Igonet et al., 2011). It was further shown that GP2 is heavily 
glycosylated (Parsy et al., 2013). A signal peptide is located in the first 58 amino 
acids of the GPC N-terminus that is post-translationally responsible for the correct 
maturation and transport of GPC to the site of assembly (Agnihothram et al., 2006, 
Eichler et al., 2003b, Froeschke et al., 2003, Saunders et al., 2007, York et al., 2004). 
This signal peptide is unusual as unlike other viral signal peptides, e. g. that of the 
influenza virus haemagglutinin (HA), it remains associated with GP1 and GP2 after 
cleavage and plays a crucial role in the pH-dependent fusion of the virion and 
endosomal membranes thereby describing a novel fusion strategy for viruses 
(Saunders et al., 2007, York and Nunberg, 2006, York and Nunberg, 2007a, York and 
Nunberg, 2007b). 
 
Nucleoprotein (NP) 
 
The arenaviral nucleoprotein (NP; 63 kDa) is the most abundantly expressed viral 
protein in infected cells (Fuller-Pace and Southern, 1988). NP is essential for the virus 
as together with the viral genomic RNA it forms the nucleocapsid, and when 
complexed with the L protein forms the viral ribonucleoprotein complex (vRNP; 
(Young and Howard, 1983, Buchmeier et al., 2007). It was shown that the 
nucleoprotein oligomerises (Figure 1.10) which could facilitate the encapsidation of 
the viral genome. NP is comprised of two domains separated by a flexible linker  
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: Structures of Arenavirus Glycoprotein components 
enabling the virus to bind to the cell.  
 
A) Schematic representation of the LCMV glycoprotein precursor complex (GPC) 
indicating the three individual components: the stable signal peptide (SSP), the 
receptor binding protein (GP1) and the fusion protein (GP2). B) Crystal structure of 
MACV GP1 in cartoon representation (α-helices and β-sheets) with a novel α/β 
fold. C) Crystal structure of trimeric GP2 of GTOV in cartoon format. Indicated are 
the aspargine residues that are subjected to N-linked glycosylation. D) C-terminal 
NMR spectroscopy structure of JUNV GP2 in ribbon representation. The lysine and 
arginine residues coordinating two zinc ions are indicated. E) Crystal structure of 
the binding of MACV GP1(blue) to the cellular transferrin receptor 1 (TfR1) that 
allows the virus to attach to the cell. F) Site to site comparison of crystal structures 
of different viral fusion proteins (post fusion state) in cartoon representation. 
Insertion into the membrane is indicated. Black arrows indicate the x layer type 
stutters. Abreviation of the virus proteins used: SARS-CoV – Severe acute 
respiratory syndrome coronavirus, NDV – Newcastle disease virus, EBOV – Ebola 
virus, HTLV-1 – Human T lymphotropic virus-1 and EBV – Epstein-Barr virus. 
Adapted from Bowden et al., 2009,  Parsy et al., 2013, Briknarova et al., 2011, 
Abraham et al., 2010,  Igonet et al., 2011. 
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coils—as well as a similar location of cysteine residues—shares
poor sequence identity (less than 20%) with the arenavirus GP2.
We report here the structure of the recombinant LCMV GP2
ectodomain at 1.8-Å resolution. As expected, it forms an alpha-
helical coiled coil similar to that of other class I viral fusion pro-
teins in their postfusion conformations. The structure also shows
a number of intrachain salt bridges stabilizing the postfusion
hairpin, one of them involving an aspartic acid that is believed
to interact with SSP in the prefusion conformation. Furthermore,
comparison with the available structures of other viral fusion pro-
teins reveals the striking conservation of a central stutter present
in the alpha-helical coiled coil of GP2. The stutter provides a
register allowing for unambiguous structural alignment of these
proteins along the coiled coil. We show that the shared central
location of the stutter in fusion proteins from many unrelated
viruses—including those from class III, which also exhibit a cen-
tral parallel 3-helix bundle—permits a direct comparison of the
relative location of their functional elements, revealing similari-
ties and clear distinctions among them that have not been dis-
cussed previously.
Results and Discussion
Structure Determination. The details of the construct used for
crystallization, the boundaries of which were delineated earlier
(25), are outlined in Fig. 1A. The details of the crystallization and
the structure determination procedures are described in SI Text.
In brief, we crystallized the fragment spanning amino acids 312–
438 of the LCMV GPC precursor, lacking the bipartite fusion
peptide/loop region of GP2, which was omitted to avoid aggrega-
tion of the protein. In addition, to prevent artificial interchain
disulfide bond formation, we mutated Cys316 to serine because
this residue is believed to make a disulfide bond with one of the
cysteines upstream (Cys285, Cys298, or Cys307; see Fig. 2A),
which are in the fusion loop region. The experimental electron
density map was interpretable for residues 313–422 (red arrow-
heads in Fig. 2A), with a break between amino acids 382–388
(dots above the sequence in Fig. 2A), which are disordered in
the crystal, as are the C-terminal residues 423–438.
Description of the Molecule. The structure shows that recombinant
LCMV GP2 is an elongated trimer about 75 Å long (Fig. 1C), in
which each protomer is folded in the typical “hairpin” postfusion
conformation of viral fusion proteins. The protomer begins and
ends as an alpha helix: a long amino-terminal helix spanning
amino acids 315–360 (N helix) and a carboxy-terminal helix com-
prising residues 408–420 (C helix), which interact with each other
in the trimer. Amino acids 313 and 422, at the amino and carboxy
termini, respectively, are thus located at the same level, at one
end of the trimeric rod (Fig. 1B). This conformation insures
proximity of the two membrane-interacting regions (C-terminal
TM segment and N-terminal fusion peptide/loop) in the full-
length GP2 protein after the fusogenic conformational change,
as shown for many other viral fusion proteins. Likewise, the N
helix forms a central trimeric coiled coil, while the C helices pack
against the grooves formed in between N helices in the trimer.
The C helix makes four full turns and spans only about one third
of the length of the N helix, which makes 13 turns (Fig. 1C). An
extended polypeptide segment, spanning residues 391–407 and
running “backwards” along the coiled coil grooves, connects
the C helix to the “turn” of the molecule—i.e., the region where
the chain reverts orientation at the C terminus of the N helix.
Several highly conserved bulky aromatic or aliphatic side chains
(Trp392, Leu400, Phe405; see Fig. 2A) anchor this segment in an
extended conformation into the interhelical grooves of the coiled
coil. At the end of the N helix, the chain reversal begins by a one-
turn 3/10 helix (η helix; Fig. 1B) running roughly at 90 degrees
Fig. 1. Overall structure of the LCMV GP2 trimer. (A) Diagram of the arenavirus GPC glycoprotein precursor (top) and the GP2 construct used in this study
(bottom, full black line), numbered according to their position in the LCMV (WE-HPI strain) GPC sequence (Genbank accession no. CAC01231.1). An arrowhead
marks the GP1/GP2 cleavage site. The boxes highlight the two fusion loops (N-FP and internal I-FP), the N and C helices, the T loop and the TM helix. IEGR
indicates the Factor Xa cleavage site. (B) Ribbon diagram of the LCMV GP2 protomer. The conserved disulfide is displayed in yellow ball-and-stick. Residues
involved in intrachain (B) and interchain (C) salt bridges are shown in orange. Full and empty arrowheads, respectively, mark conserved and nonconserved
potential N-glycosylation sites in arenavirus GP2. (C) LCMV GP2 trimer. A vertical, central black line marks the coiled coil axis, with a magenta sphere indicating
the location of a central Cl− ion. Green tubes mark the curved N-helix axes, with the stutter in red (highlighted with a full red arrow). (D) Blow up of the Cl− ion
(magenta sphere) binding site, viewed down the coiled coil axis. The ion is chelated by Asn325 which also hydrogen bonds a structural water molecule (red
spheres). (E) Interchain salt bridge stabilizing the base of the coiled coil mentioned in the text.
19968 ∣ www.pnas.org/cgi/doi/10.1073/pnas.1108910108 Igonet et al.
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region. While the N-terminal domain seems to be the RNA-binding domain, structural 
and biochemical analysis of arenaviral NPs have shown that the C-terminal domain is 
mainly comprised of a 3’ – 5’ exonuclease of the DEDDh family [Figure 1.10; 
(Levingston Macleod et al., 2011, Qi et al., 2010, Hastie et al., 2011a, Hastie et al., 
2011b)]. Members of this exonuclease family are normally involved in various repair 
or proof-reading mechanisms, but for arenavirus NP this exonuclease activity appears 
to be part of a mechanism of immune evasion (Minskaia et al., 2006, Martinez-
Sobrido et al., 2009, Martinez-Sobrido et al., 2007, Martinez-Sobrido et al., 2006, 
Bernad et al., 1989). Viruses can produce pathogen-associated molecular patterns 
(PAMPs) during viral replication, which include double-stranded RNA (dsRNA). 
These PAMPs are recognised by the cellular innate immune system, which 
subsequently leads to the induction of pathways that defend the host cell against viral 
infection. To overcome these cellular defence responses, it is thought that the NP 
exonuclease activity can destroy the formation of dsRNA and thus, the formation of 
PAMPs.  
 
Apart from NPs functions of viral genome encapsidation and innate immune evasion, 
the protein has further roles throughout the viral replication cycle. NP plays important 
roles in ensuring the packaging of the viral genome into progeny virions, is involved 
in virus budding and is further involved in a variety of protein-protein interactions 
with host cell proteins (Levingston Macleod et al., 2011, Eichler et al., 2004, Salvato 
et al., 1992, Groseth et al., 2010, Ortiz-Riano et al., 2012b).  
 
 
1.2.3.1 Roles of NP in the viral replication cycle 
 
Encapsidation of the viral genome is perhaps the most important function of 
arenavirus NPs. After publication of the LASV NP molecular structure, it was shown 
that NPs form a head-to-tail aligned homotrimer that resembles a doughnut shape (Qi 
et al., 2010). It was found that this trimeric form was required for transcriptional 
activity in mini-replicon assays, but that this oligomeric form was not required for 
other functions (Lennartz et al., 2013). The residues mainly responsible for this trimer  
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: Lassa virus nucleoprotein (NP). 
 
 A) Surface representation of LASV NP crystal structure. The two domains (N and C 
domains) are indicated. B) Cartoon representation of LASV NP trimer. The C 
domain of the first monomer is coloured in orange and the N domain in cyan. The 
other two proteins of the tirmer are coloured in blue and pink respectively. C) 
Comparison of the RNA-free and -containing structures of the LASV NP N domain. 
RNA binding seems to be regulated through conformational changes that open and 
close the RNA-binding pocket. In the RNA-free conformation (gray), the RNA gate 
is closed. Helix α5 is extended across the RNA- binding pocket and α6 is positioned 
on top of the pocket, preventing RNA from binding. When RNA is bound (blue), 
residues 112–122 are disordered, α6 shifts away from the pocket, and the RNA gate 
opens to accommodate the ssRNA. D) Cartoon representation the LASV C domain 
and location of residues important for the exonuclease and anti-IFN activities. 
Residues corresponding to the DEDDh motif are colored magenta, two argenine 
residues proximal to the active site are colored yellow, residues involved in 
coordination of the Zn2+ atom are colored blue, and residues corresponding to the 
basic arm are coloured orange. Adapted from Qi et al., 2010, Hastie et al., 2011a, 
Hastie et al., 2011b. 
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formation were found to be within two regions of the NP N-terminus, while residues 
in the C-terminus had only limited effects on NP-NP binding with the exception of a 
D471G mutation in LCMV NP (Ortiz-Riano et al., 2012a). When comparing 
structures of NPs with or without RNA bound, a conformational change was 
observed, something that has also been observed for NPs of other virus families. This 
observation is thought to represent a specific NP confirmation that allows 
transcription to occur preferentially over other functions of NP. RNA-binding 
experiments demonstrated that residues in both domains of NP are responsible for 
binding RNA, which has a direct affect on replication activity. NP is capable of 
affecting L polymerase activity during replication, which is achieved by direct NP-L 
binding, and the monomeric NP confirmation appears to be important for this 
(Lennartz et al., 2013, Ortiz-Riano et al., 2012a, Ortiz-Riano et al., 2012b). During 
the viral replication cycle NP appears to form aggregates in the cytoplasm of infected 
cells, in which replication is facilitated, similar to aggregates observed for other 
viruses (Baird et al., 2012). The exact reason for the formation of these aggregates 
remains unclear.  
 
After replication NP gains further importance in the egress of progeny viruses by 
being transported to the cellular membrane using cytoskeletal motorproteins. It is 
thought that NP is involved in the recruitment of ESCRT components, such as 
ALIX/AIP1. The NP-ALIX/AIP1 interaction in turn seems to enable the interaction 
between NP and the Z protein, thereby ensuring the incorporation of NP into the 
assembled progeny virion (Shtanko et al., 2011, Groseth et al., 2010). It was observed 
that residues 342-399 of the NP of Mopeia virus (MOPV) were required for this NP-Z 
interaction to occur. 
 
 
1.2.3.2 NP as a viral interferon-antagonist 
 
The interaction between a virus and the innate cellular defense mechanisms is an 
important battle in the cell that can decide the fate of the virus infection. The 
interaction between the anti-viral interferon system and arenaviruses is not only 
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important, but also very complex. Only a small subset of the interactions are currently 
known and understood. Making it more complex for arenaviruses is the fact that this 
virus family has the ability to cause persistent infections in their host, an ability that 
many other RNA viruses lack. Most observations of the impact arenaviruses have on 
the host innate immune system (see Section 1.4.6) come from animal studies that 
simply report the general impact the viruses have on the host and do not distinguish 
between individual factors responsible for these effects, i. e. individual arenaviral 
proteins. However, some of these observations can be attributed to specific protein-
protein interactions between NP and cellular proteins inside the host cell.   
 
The interferon system can be divided into the induction and signaling pathways. 
Stimulation of the induction pathway leads to the activation of either the IRF3 or NF-
κB promoter, which in turn result in the expression of type I interferons. On the other 
hand the signaling pathway is activated by auto- or endocrine signaling of IFN 
binding to the interferon receptors triggering the JAK/STAT pathway leading to the 
up regulation of the interferon stimulated response element (ISRE). The ISRE 
controls the expression of interferon-stimulated genes (ISGs) the products of which 
have specific antiviral functions [reviewed by (Randall and Goodbourn, 2008)].   
 
The exact interactions between arenavirus proteins and proteins of the cellular innate 
immune responses are still relatively poorly characterised, however a few studies 
have shown that the arenavirus NP is probably most important interferon antagonist 
expressed by the virus (Rodrigo et al., 2012, Pythoud et al., 2012, Fan et al., 2010). 
When transfected into cells in isolation the NPs show the greatest impact on disabling 
the host cell’s interferon system. So far it has been shown that arenavirus NPs have 
the ability to block two innate immunity induction pathways, one that leads to IRF3 
activation, the other to NF-κB activation.  It was shown that NP binds directly to IκB 
kinase ε (IKKε) (Pythoud et al., 2012). This interaction results in the disruption of the 
IKKε and TANK-binding kinase 1 (TBK1) heterodimer, which results in the failure 
of IRF3 phosphorylation and thus prevents its activation (Figure 1.11).  Mutations in 
either the NP exonuclease active site or a conserved DIEG amino acid motif in NP 
resulted in a defect in the ability of NP to block nuclear translocation of IRF3 as a 
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potential consequence of a reduced affinity to IKKε (Martinez-Sobrido et al., 2007, 
Martinez-Sobrido et al., 2006, Martinez-Sobrido et al., 2009, Rodrigo et al., 2012, 
Pythoud et al., 2012).  
Many viral interferon-antagonist proteins appear to be able to block several IFN-
induction pathways that lead either to the activation of IRF3, NF-κB or AP-1. In 
addition to blocking the IRF3 pathway, it was found that NP also blocks the NF-κB 
pathway (Rodrigo et al., 2012). Although the study has not shown the exact 
mechanism by which the NF-κB activation is blocked (Figure 1.11), the authors 
reported that IKKα in involved in this process. Again the exonuclease active site 
residues and the DIEGR motif were shown to be responsible for the block (Martinez-
Sobrido et al., 2007, Martinez-Sobrido et al., 2006).  
 
The NP-mediated block of IRF3 and NF-κB activation has been described for all 
studied arenavirus NPs except that of TCRV. However these studies suggest that 
TCRV NP is not completely incapable of blocking these activation pathways, but that 
the protein is about 40 times less efficient at this process than other arenavirus NPs 
(Pythoud et al., 2012). However, the majority of experiments performed in these 
studies used transiently expressed NPs rather than arenaviral infection experiments, 
therefore the importance of the difference between TCRV NP and other arenavirus 
NPs in the ability to block these pathways remains to be determined.  
 
 
1.2.3.3 NP and protein-protein interactions 
 
As NP is an essential multifunctional protein required throughout the viral replication 
cycle, it likely interacts with a large variety of host cellular proteins and these 
interactions likely affect numerous cellular processes to the benefit of the virus. To 
date only a few such interactions have been described.  
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: Block of interferon-induction by arenavirus proteins. 
 
Diagram shows the interferon (IFN) –induction pathway and its essential proteins. 
Indicated in red boxes are arenavirus proteins NP and Z that can block the 
induction in several positions of this pathway. The exonuclease in NP is thought to 
destroy viral dsRNA and ssRNA PAMPs that could be recognised by the cellular 
PPRs, such as RIG-I or MDA-5. New World, but not Old World, arenavirus Z bind 
directly to RIG-I and block downstream signalling by this receptor. NP can further 
interact with IKKε that subsequently interferes wit the dimerisation of IKKε with 
TBK-1 and subsequent phosphorylation of IRF3 and IRF7. Further, NP also blocks 
NF-κB activation by a yet unclear interaction that is thought to involve binding to a 
component to the IKK complex required for NF-κB activation. Adapted from 
Koma et al., 2013. 
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replication at early stage and induce virus-specific
CD8+ T cell, resulting in virus clearance. However,
a modest level of IFN production at early stage could
eventually allow persistent infection, as IFN response
is unable to suppress virus multiplication to the level
that is required for virus clearance by CD8+ T cells
later during infection [80–83]. On the other hand, the
details of the immune response to other arenaviruses
in their natural hosts are largely unknown.Experiments
using NW JUNV and NW Catarina virus to infect of
their natural hosts, C. musculinus and Neotoma
micropus, respectively, showed age-dependent anti-
body elevation and persistent infection [84–86]. It is
possible that arenaviruses may be maintained in their
natural hosts by suppression of both innate and
adaptive antiviral responses.
It is known that LASV infection causes immuno-
suppression in patients, as evidenced by the lack of
inductionof IFNproduction, proinflammatory response,
or T cell activation in vitro or in vivo [1,87–90].
Lymphopenia and lymphoid depletion in spleen and
lymph nodes has been reported in Lassa fever
patients [91–93]. Furthermore, it has been reported
that the level of type I IFNs and proinflammatory
cytokines such as TNF-α (tumor necrosis factor-α)
and IL-1β (interleukin-1β) are low in human macro-
phages and dendritic cells infected by LASV in vitro
[94,95]. Lack of induction of costimulatory molecules,
Fig. 1. Schematic diagram showing the interaction between NW arenaviruses and host innate immune response.
Arenavirus NPs possess 3′ to-5′ exonuclease activity and are proposed to degrade viral dsRNA or ssRNA to reduce the
exposure of viral RNA to RIG-I and MDA5. Z protein of the NW arenavirus, but not of the OW arenavirus, inhibits RIG-I
signaling cascade probably as a result of its direct binding to RIG-I protein. NP further interacts with IKKε and inhibits
TBK-1/IKKε activation to interfere with phosphorylation and activation of IRF-3 or IRF-7. NP prevents activation of NF-κB. It
is still unclear whether suppression of TBK-1/IKKε complex by NP could directly lead to inhibition of NF-κB activation. On
the other hand, NW arenavirus JUNV GP is recognized by TLR2 pathway and triggers IFN and cytokine production in
mouse macrophages.
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Most of the reported NP-mediated virus-host interactions appear to concern the role 
of NP during viral replication and the utilization of the cellular translation machinery. 
It was shown that NP forms aggregates during replication, something described as 
replication-transcription complexes (RTC). Immunofluorescence analysis has shown 
that during this phase of the viral replication cycle NP co-localises with eIF4GI and 
eIF4A, two members of the eukaryotic translation initiation complex (Baird et al., 
2012). The eIF4A component in this complex possesses a double function during 
translation initiation, it has the enzymatic function of a helicase that unwinds double-
stranded RNA and it is further required for the binding of the 40S ribosomal subunit 
to the mRNA (Rogers et al., 2002, Schutz et al., 2008). The eIF4GI subunit is known 
to be a scaffolding protein within the complex, which bridges the mRNA to the 40S 
ribosome. It is usually tightly associated with the cap-binding protein eIF4E and these 
two proteins together form the eIF4F complex, which in turn binds to the 
aforementioned eIF4A protein (Pause et al., 1994, Anthony and Merrick, 1991). 
Previously it has been shown that inhibition of eIF4A and eIF4GI prevented the 
synthesis of arenavirus proteins	  (Linero et al., 2013). The exact role and location of 
NP during the interaction with eIF4A and eIF4GI remains unclear, but for other 
viruses it was shown that viral proteins act as a substitute for the cap-binding protein 
eIF4E with a virus-expressed protein and can initiate translation using the helicase 
eIF4A and eIF4GI required for the ribosomal 43 S complex (Piron et al., 1998, Byrd 
et al., 2005, Aragon et al., 2000, Burgui et al., 2003). Concurrent with the NP-eIF4 
protein interactions, the S6 and L10a ribosomal subunits localise to the RTC and NP, 
however it is not yet clear whether this co-localisation is a result of an interaction with 
NP or just a consequence of the NP-eIF4 interactions. Another host component that 
appears to be involved in these processes is phosphatidylinositol 4-phosphate (PI4P) 
(Baird et al., 2012) . PI4P has been reported to interact with other viruses, such as 
Hepatitis C virus (HCV) or some picornaviruses, where it is thought to create distinct 
membranous structures that can facilitate viral replication whilst enabling the viral 
components to remain undetected from cellular defense mechanisms (Terragni et al., 
2011, Greninger et al., 2012, Hsu et al., 2010, Reiss et al., 2011). For arenaviruses it 
was shown that NP expression results in the redistribution of PI4P to RTC, but it was 
not involved in forming membranous structures. Therefore, the nature of this 
interaction remains to be investigated. 
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Previous studies have shown the inhibition of stress granules formation during 
arenavirus infection (Linero et al., 2011). Such stress granules represent a site in the 
cell where mRNAs can be stored when translation is stalled and is controlled by the 
phosphorylation-state of eIF2α. In these studies it was shown that NP blocks stress 
granule formation, however it appears to interact with the stress granule marker Ras 
GTPase-activating protein-binding protein 1 (G3BP1) in RTCs. This protein is known 
to have helicase and endonuclease functions (Thomas et al., 2011, Matthews and 
Frey, 2012, Yi et al., 2011), however, the exact reason for the interaction with NP is 
not yet understood. 
 
NP has also been shown to affect the distribution of cellular proteins that shuttle in 
and out the nucleus. During acute infection NP binds to heterogeneous nuclear 
ribonucleoprotein type A1 (hnRNP A1) and changes the cellular distribution of this 
protein such that it becomes predominantly cytoplasmic (Maeto et al., 2011). 
Reducing the expression of hnRNP A1 was shown to reduce viral titres, indicating 
that this interaction is somehow beneficial to virus replication. 
 
In many infections an infected host cell can sense the presence of the invading 
pathogen and one of the defense strategies involves the induction of apoptotic 
pathways to contain the infection thereby limiting the spread of the virus. Some 
viruses seem to have evolved various mechanisms to counteract these protective 
pathways. Flaviviruses activate phosphatidylinositol 3-kinase (PI3K), which blocks 
caspase-dependent apoptosis downstream of the pathway (Lee et al., 2005), while 
poxviruses have the ability to block tumour-necrosis factor (TNF) to inhibit apoptotic 
signalling (Tewari and Dixit, 1995). Cytomegalovirus (CMV) is able to block 
caspases, such as caspase 8, directly It was found that arenavirus NP is a substrate for 
caspase cleavage, but that some arenavirus NPs, such as that of TCRV, were shown to 
be cleaved to a lesser extent than others, such as JUNV (Wolff et al., 2013). These 
cleavage events coincided with a reduction in cell death through apoptosis induction.  
 
Another interaction between NP and a cellular protein was described in the interaction 
with type II keratin 1 (K1) (Labudova et al., 2009). Keratin forms intermediate 
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cytoskeleton protein filaments that are mainly found in epithelial tissue. It is thought 
that during persistent infection arenaviruses use the interaction with K1 to spread to 
neighboring cells as such cells form cellular protrusions, such as filopodia, 
orchestrated by the cellular keratin network.  
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1.3 Viral replication cycle 
 
Arenaviruses, as any other virus family, are obligate intracellular parasites that have 
to infect cells to replicate using various cellular machineries and mechanisms 
throughout. The replication cycle is characterised by the hallmarks of gaining entry 
into the host cell, replicating in the cytoplasm and finally budding of progeny virions 
from the cell membrane.  
 
 
1.3.1 Arenavirus entry 
 
As for every virus, the steps of cellular attachment and internalisation are crucial for 
the establishment of infection. Arenaviruses utilise the GP glycoprotein on the virion 
surface as its receptor-binding protein (Salvato et al., 2011). During infection of the 
host cell GPC is expressed as a single polypeptide from the S genome segment, which 
undergoes cleavage and myristoylation resulting in the maturation from GPC to the 
individual GP1 (cellular binding protein), GP2 (fusion protein) and SSP (signal 
peptide) components, followed by assembly into the mature trimeric form that is 
finally inserted into the viral membrane (Borrow and Oldstone, 1992, Lenz et al., 
2001, Beyer et al., 2003, Kunz et al., 2003, Eichler et al., 2003a, York et al., 2004). 
GP is probably the most important factor for the determination of cell topology, as it 
defines the virus’ ability to bind to specific receptors on a potential host cell.  
 
Receptor usage and the subsequent internalisation pathways of the virion vary within 
the arenavirus family (Figure 1.12). Thus, OWAs and Clade C NWAs utilise α-DG 
(Cao et al., 1998, Kunz et al., 2001, Spiropoulou et al., 2002a, Rojek et al., 2007, 
Rojek et al., 2006), while Clade B NWAs use TfR1 as cell receptor proteins for viral  
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: Arenavirus cell entry pathways. 
 
 Endocytotic pathways used by OWAs and NWAs. The entry mechanism of 
OWAs, such as LCMV, is independent of clathrin, dynamin or caveolin, however 
the virus enters a late endosome for viral fusion. The exact pathway remains 
unknown. MWAs, such as JUNV, bind transferrin receptor 1 (TfR1) and enter the 
host cell by a clathrin- and dynamin-dependent endocytotic pathway to a late 
endosome. LCMV cell entry resembles that of Simian virus 40 (SV40) to the 
extent that both are cholesterol-dependent. However, SV40 requires caveolin, 
dynamin and the actin filament, whereas LCMV does not. However in contrast, 
SV40 cell entry occurs at a neutral pH, whereas LCMV requires a low pH to 
facilitate membrane fusion. Adapted from Rojek and Kunz, 2008. 
 
 1. INTRODUCTION  	  
	  	  	  	  	   47	  	  
 
 
 
 
 
 
 
 
 
 
Likewise, infection of human cells with JUNV, MACV,
GTOV and SABV, but not LASV, was efficiently blocked
with anti-TfR1 antibodies. Together, this provides strong
evidence for a role of TfR1 as a major cellular receptor for
the South American HF viruses.
TfR1 is a ubiquitously expressed class II membrane
protein abundant in activated immune cells and vascular
endothelial cells, cell types critically involved in arenavirus
pathogenesis (Geisbert and Jahrling, 2004). In the host
cell, TfR1 is a classical example of a cargo receptor and
plays a central role in cellular iron metabolism and asso-
ciates with clathrin-coated pits of the plasma membrane
(Mellman, 1996). Binding of iron-loaded transferrin to
TfR1 induces clathrin-mediated endocytosis delivering
the transferrin–receptor complex to early endosomes.
Under the mildly acidic pH of the early endosome (pH
c. 6.0), iron is released from transferrin. The resulting
apotransferrin–receptor complex is recycled to the cell
surface, with each TfR1 molecule cycling up to 100 times
(Wang et al., 2000; McCaffrey et al., 2001). Addition of
neither holo-transferrin nor apo-transferrin interfered with
or enhanced virus infection of cells, indicating the use of
non-overlapping binding sites (Radoshitzky et al., 2007).
TfR1 serves also as a receptor for at least two other
groups of viruses, the canine and feline parvoviruses
(Parker and Parrish, 2000; Parker et al., 2001) and mouse
mammary tumour virus (Ross et al., 2002).
In line with the use of TfR1 as a primary receptor, recent
studies on the cellular entry of JUNV provided evidence
for virus internalization by a clathrin-dependent pathway
(Fig. 2). Infection of cells with JUNV was specifically
blocked by chlorpromazine, a drug that interferes with the
assembly of clathrin-coated pits at the plasma membrane
(Martinez et al., 2007). In contrast, sequestration of mem-
brane cholesterol by nystatin had only a mild impact in
JUNV entry. In line with the pharmacological data, over-
expression of dominant-negative mutants of the clathrin
coat-associated protein Eps15 and dynamin, which is
required for clathrin-mediated endocytosis, significantly
reduced JUNV infection (Rojek et al., 2007c). Immune-
EM visualized JUNV particles in coated vesicles (Martinez
et al., 2007), further supporting clathrin-mediated endocy-
tosis as a major route of entry of JUNV.
As mentioned above, upon binding to transferrin, TfR1 is
internalized and recycles through the early endosome,
which has a pH around 6.0. However, the GP of JUNV
requires a significantly more acidic pH (< 5.5) for optimal
fusion activity (York and Nunberg, 2006), which would
require delivery of the virus to late endosomal compart-
ments. This apparent discrepancy suggests that for pro-
ductive infection, the virus must somehow re-direct TfR1
from the normal recycling pathway towards late endo-
somes. A possible answer to this puzzle may lie in the
multivalent nature of the arenavirus particle. Indeed, while
monomeric transferrin recycles through early endosomes
in 4–10 min, an artificial 10-mer of transferrin was retained
in the endosome for over 1 h, suggesting that the trafficking
of TfR1 critically depends on the oligomeric state of the
ligand (Marsh et al., 1995). A similar alteration in cellular
trafficking of TfR1 may be induced by arenavirus binding,
providing another example of how viruses manipulate the
host cell’s endocytotic machinery for their purposes.
So far, no studies have been performed to address
modulation of TfR1 expression and/or cellular trafficking
by New World arenavirus infection. However, an interest-
ing correlation between cellular iron concentrations and
Fig. 2. Endocytotic pathways used by Old
World and New World arenaviruses. The
prototypic Old World arenavirus LCMV enters
host cells via a cholesterol-dependent,
clathrin- and actin-independent endocytotic
pathway that delivers virus to endosomes. In
contrast, the New World arenavirus JUNV
uses TfR1 as a cellular receptor and enters
cells by clathrin-mediated endocytosis. The
cholesterol-dependent pathway of entry used
by LCMV appears also different from the
caveolar pathway used by the non-enveloped
virus, e.g. SV40, which critically depends on
caveolin, actin, and delivers virus to pH
neutral organelles like the caveosome and the
ER.
Arenavirus entry 831
© 2008 The Authors
Journal compilation © 2008 Blackwell Publishing Ltd, Cellular Microbiology, 10, 828–835
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entry (Radoshitzky et al., 2007). Both receptors are ubiquitously expressed, so that 
most cells can become infected with arenaviruses. Viruses in Clade B were shown to 
be able to bind to rodent TfR1, whereas pathogenic members of this clade, GTOV, 
JUNV, MACV and SABV, were further shown to have adapted to bind human TfR1 
(Flanagan et al., 2008, Oldenburg et al., 2007). The same study showed that the 
human TfR1 valine at position 210 was responsible to prevent TCRV GP from 
binding to this receptor, whereas a glycine allowed binding. Cell entry for non-
pathogenic Clade B viruses (AMPV and TCRV) as well as WWAV can occur in a 
TfR1-indepdendent manner (Abraham et al., 2009, Reignier et al., 2008, Flanagan et 
al., 2008, Oldenburg et al., 2007), while Clade A species were not tested. In addition 
to α-DG Stephan Kunz’s group showed that LCMV and LASV can utilise the C-type 
lecin receptor Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing 
Non-integrin (DC-SIGN) in dendritic cells, which was followed by actin-dependent 
internalisation, as well as an entry mechanism that involves the use of intraluminal 
vesicles (ILV) of the multivesicular body (MVB) in connection with components of 
the ESCRT system (Pasqual et al., 2011, Goncalves et al., 2013). However, the 
authors speculated that viral entry via DC-SIGN was probably not a primary entry 
pathway because the process was slow compared to phleboviruses that use DC-SIGN 
as their primary receptor.  Recently it was shown that LASV uses a receptor switch to 
LAMP1 after internalisation in a low pH environment (Jae et al., 2014), whether or 
not this or another second receptor is used for other arenaviruses remains to be seen.  
After the virus attaches to the host cell by binding to the receptor, it can be 
internalised into the cell. This process is poorly understood for the majority of 
arenaviruses. The only internalisation pathway characterised for arenaviruses is for 
species using TfR1 as a receptor. It was shown that after GP1 bound to TfR1, the 
virus was internalised by the clathrin-dynamin-dependent endosomal pathway 
(Martinez et al., 2007, Rojek et al., 2008b), as inhibition of these vesicles reduced 
viral infection for JUNV. The internalisation of OWAs using α-DG is far less clear. It 
is known that LCMV enters the cells in a clathrin, caveolin and dynamin-independent 
pathway (Borrow and Oldstone, 1994, Rojek et al., 2008b, Vela et al., 2007) as seen 
by smooth-walled vesicles in electron microscopy (EM) studies. Later studies showed 
that the virus required cholesterol for internalisation, but not for initial binding to the 
cell (Shah et al., 2006, Vela et al., 2007). A similar entry mechanism was described 
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for Simian virus 40 (SV40; Figure 1.12), but it was highlighted that this process 
occurs at neutral pH, whereas arenaviruses require a low pH (pH < 5.5) for successful 
internalisation (Damm et al., 2005, Kirkham and Parton, 2005, Rojek and Kunz, 2008, 
York and Nunberg, 2006). 
 
Arenavirus GPs are very resistant to low pH and the fusion event between virus and 
host cell mediated by the type-I-like fusion protein GP2 requires a confirmation 
changed triggered by an acidic pH (Borrow and Oldstone, 1994, Di Simone et al., 
1994, Di Simone and Buchmeier, 1995, York and Nunberg, 2006) that occurs in late 
endosomes. Not much is know about the internalisation compartment that OWAs use, 
except that the process has to end up in a late endosome, similar to that of NWAs, for 
fusion to occur. Thus, it is hypothesised that either the virus uses an entry pathway 
that is not yet characterised or that the virus can manipulate the internalisation to 
cross through different pathways (Kunz, 2009). However, the exact mechanism 
remains to be determined. After the fusion event the vRNPs are released into the 
cytoplasm to establish viral replication (Buchmeier et al., 2013).  
 
 
1.3.2 Transcription/Translation 
 
Arenavirus virions often contain multiple species of viral-derived RNA. Apart from 
containing a copy of the L genome segment they often contain two copies of the S 
segment and several complimentary RNA species have also been isolated from 
virions. Significant levels of viral mRNA have also been observed in virions, but 
whether or not these are actively incorporated remains to be seen. After the virion and 
endosomal membranes have fused these RNAs are released through the fusion pore 
into the cytoplasm for transcription and replication to occur, which previous work 
suggests occurs within viral replication centres in the cytoplasm. These replication 
centres have been shown to contain high concentrations of NP (Baird et al., 2012, 
Salvato et al., 2011, Buchmeier et al., 2013). The ambisense nature of the genome 
enables arenaviruses to temporally regulate the expression of encoded proteins. As 
mentioned above the negative-sense ORFs encoding the NP and L proteins can be 
transcribed directly into mRNAs, while the Z protein and GPC mRNAs have to be 
transcribed from the intermediate complimentary RNA species (Figure 1.6; (Meyer, 
 1. INTRODUCTION  	  
	  	  	  	  	   50	  	  
2002, Auperin and McCormick, 1989, Auperin et al., 1984). This ensures that the NP 
and L proteins are expressed early in infection for genome transcription and 
replication and the structural Z and GPC proteins are expressed later in infection. All 
mRNAs generated are non-polyadenylated and vary in length at the 3’-end, mapping 
to multiple sites within the IGR 3’ of the ORF. The mRNA 5’-end was found to 
possess a cap structure as well as non-templated nucleotides, with the exact origin of 
neither accounted for (Lelke et al., 2010, Iapalucci et al., 1991, Raju et al., 1990). It is 
known that arenaviruses utilise the mechanism of “cap-snatching” whereby a viral 
endonuclease binds to cellular pre-mRNAs and cleaves off the 5’-cap, which it then 
uses to prime viral mRNA transcription. This feature is shared with other virus 
families, such as influenza viruses and bunyaviruses (Dias et al., 2009, Plotch et al., 
1979, Plotch et al., 1981, Polyak et al., 1995, Yuan et al., 2009). 
 
Arenaviruses possess two known cis-acting elements required for transcription, 
namely the 3’-promotor and the IGR between the two ambisense ORFs. The IGR 
functions as a bona fide transcription terminator by forming a stable hairpin structure, 
similar to the rho-independent transcription termination in prokaryotes (Lopez and 
Franze-Fernandez, 2007, Pinschewer et al., 2005). Previous work demonstrated that it 
is the IGR structure and not the actual sequence at the 3’ end of the gene that is 
important for the terminator function. From studies using virus-like particles (VLPs), 
it seems that the IGR also has a role in incorporation of the viral genome into the 
virions, but it is unclear whether this functions in a sequence- or structure-dependent 
manner. The 3’-promoter region has been mapped to 19 nucleotides that can be 
divided into 2 regions, nucleotides 1 - 12 that are sequence specific and nucleotides 
13 – 19 that are variable in sequence (Hass et al., 2006). The first region forms a 
panhandle structure with the 5’-end of the RNA. The panhandle structure was shown 
to be important for the recognition by the polymerase and for the initiation of 
transcription. The process seems to occur by base-specific interactions with the 
replication complex as mutations within this region abrogate transcription. The 
function of the second region appears to involve pairing the ends of the promoter 
regions of the 5’ and 3’ ends for optimal polymerase function. The regulation of the 
processes of RNA replication and transcription lies within the same cis-element, but 
the details about the control of these functions remain to be determined. The 
mechanism by which RNA synthesis occurs was described by the prime and realign 
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mechanism, which sees the addition of a non-templated guanine (G) at the 5’-ends of 
the genomic and complimentary RNA species (Garcin and Kolakofsky, 1990, Garcin 
and Kolakofsky, 1992).  
 
Arenaviruses also require trans-acting elements for efficient transcription and 
replication. The minimum elements required for these processes are the NP and L 
proteins, with the viral RdRp within the L protein responsible for this function (Lopez 
et al., 2001).  To perform this function it was shown that the L protein dimerises, 
similar to the polymerases of the paramyxovirus family (Lopez et al., 2001, Sanchez 
and de la Torre, 2005). Concurrently NP encapsidates the viral genome, but studies 
indicate that NP also has regulatory function on the polymerase. Although not 
essential for viral replication, the Z protein affects this process in vivo (Kranzusch and 
Whelan, 2011). It was shown that the Z protein inhibits arenavirus replication in a 
dose-dependent mechanism (Cornu and de la Torre, 2002, Cornu and de la Torre, 
2001, Kranzusch and Whelan, 2011). Recently this observation was explained as an 
ability of the Z protein to lock the viral polymerase onto the genome segment. This 
then ensures the polymerase is incorporated into progeny virions and is therefore 
present in subsequent infected cells. 
 
 
1.3.3 Arenavirus egression  
 
When the necessary proteins are translated during viral replication they migrate to the 
cellular membrane, from where they assemble to form progeny virions. At the final 
stages of transcription is was shown that the Z protein locks the L protein onto the 
newly transcribed genome RNA segments in a dose-dependent manner with the 
hypothesis that this is a mechanism to ensure the successful incorporation into 
progeny virions (Kranzusch and Whelan, 2011). For the transport through the cell the 
proteins seem to be able to utilise the cellular cytoskeleton and accessory proteins. 
For example it has been shown that the LASV Z protein uses the motor protein 
KIF13a to travel along cytoskeleton filaments (Fehling et al., 2013). Besides making 
use of the cellular proteins to migrate through the cell, arenavirus proteins possess 
signal sequences that include myristoylation sites in the SSP of the GPC as well as at 
position 2 of the Z protein (York et al., 2004, Perez et al., 2004, Strecker et al., 2006) 
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that targets these proteins to cellular membranes. Further, it was shown that to ensure 
the packaging of the viral genome into the progeny virion the interaction between Z 
and NP in the final stages of viral egression was essential (Groseth et al., 2010, 
Shtanko et al., 2011). In the case of MOPV, the packaging of vRNPs into the mature 
virion is regulated by the YxxL motif in the Z protein’s RING domain (Shtanko et al., 
2011), however to what extent and by which mechanism remains to be determined. 
 
Arenaviruses cause non-cytolytic infections in their host (Childs and Peters, 1993, 
Buchmeier et al., 2013), which can be explained by viral suppression of cellular 
mechanisms paired with viral budding from the cell membrane (Figure 1.13). The 
driving force for arenavirus budding is the Z protein, which was shown to initiate the 
budding process in isolation of other viral proteins (Perez et al., 2003, Strecker et al., 
2003); see Section 1.2.3 Z protein). Many matrix proteins of different virus families, 
including human immunodeficiency virus (HIV), Rabies virus (RABV), EBOV, 
paramyxoviruses or vaccina virus (VACV), were shown to initiate the viral budding 
processes, although it is worth noting that not all viruses depend on the ESCRT 
system, including influenza A and B viruses [reviewed by (Chen and Lamb, 2008)]. 
As the arenavirus Z protein is the M-like protein in this virus family, it also fulfils the 
function of mediating viral budding. For this the Z protein possesses L domains 
[reviewed by (Freed, 2002, Bieniasz, 2006)], which facilitate interactions with the 
cellular ESCRT system (Figure 1.13). Briefly, complexes of the ESCRT system are 
involved in the formation of MVBs and in the process of cytokinesis (Hurley, 2010, 
Hurley and Hanson, 2010) where the proteins are involved in the abscission of 
cellular membranes. The ESCRT system consists of six individual complexes with 
different functions, however, only a subset have so far been shown to be important for 
arenavirus budding, namely ESCRT-I, Vps4-Vta-1 and the Bro1/ALIX complexes 
(Urata et al., 2006, Urata et al., 2009, Groseth et al., 2010). The exception within the 
arenavirus family seems to be TCRV, which also utilises different late domains and in 
addition requires the activity of NP (Groseth et al., 2010). It is also important to note 
that not all arenaviruses use the same ESCRT complexes and thus, it is unclear 
whether these species use the same budding pathways (Urata et al., 2009, Groseth et 
al., 2010). It appears that the viruses can interact mainly with the ESCRT-I protein 
tumour susceptibility gene 1 (Tsg101) or to ALIX that in turn is capable of recruiting 
a ubiquitin ligase, such as Nedd4, resulting in the final recruitment of the ESCRT-III  
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: Role of the ESCRT system in arenavirus budding.  
 
Arenaviruses “hijack” the ESCRT system that usually facilitates that formation of 
multivesicular bodies (MVBs) to transport ubiquitinated cargo. The ESCRT system 
consists of six complexes and those involved in arenavirus budding, ESCRT-I, -II, 
III, Alix/AIP1 and Vps4, are indicated. Once ESCRT-I or Alix/AIP1 are activated 
and initiate budding, the final membrane scission step is performed by ESCRT-III, 
resulting in the release of newly formed vesicles. Vps4A/B mediates disassembly 
and recycling of the entire complex. The viral Z protein interacts with the ESCRT 
complexes via its late domain motifs, including PPxY, PT/SAP and/or YxxL. With 
these motifs the Z protein can recruit the ESCRT components Tsg101, Alix/AIP1 
and Nedd4-like ubiquitin ligases and can redirect their function towards viral 
budding. The glycine (G) at position 2 of the Z protein is essential for its 
myristoylation and thus redirection to cellular membranes. It seems that for some 
arenaviruses additional late domains within the nucleoprotein (NP) is important to 
interact with Alix/AIP1 in order to assist in the budding process. A direct NP-Z 
interaction is also important for the successful incorporation of viral nucleocapsids 
into the budding virions. Adapted from Wolff et al., 2013. 
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complex thereby catalysing the budding event (Urata et al., 2009, Perez et al., 2003, 
Urata et al., 2006, Im et al., 2010, Hurley, 2010, Hurley and Hanson, 2010, Groseth et 
al., 2010, Fehling et al., 2012). 
 
As previously mentioned budding is most likely a more diverse process within the 
arenavirus family, as they use different ESCRT complexes. This observation is most 
likely explained by differences in L domains within the Z protein [summarised by  
(Urata and de la Torre, 2011, Wolff et al., 2013)]. For most species budding seems to 
be regulated by the proline-rich PT/SAP and PPxY motifs in the C-terminus as well 
as the YxxL motif in the RING-domain of the Z protein. The exceptions in the 
areanviruses seem to be TCRV and the as yet uncharacterised Merino Walk virus 
(MWV) that do not possess L domains in the C terminus of the Z protein (Palacios et 
al., 2010, Wolff et al., 2013, Groseth et al., 2010). For TCRV it was shown that the 
lack of an L domain might be compensated for by NP of the virus, which possesses a 
potential L domain that significantly reduces budding when mutated (Groseth et al., 
2010). Whether NP can compensate for the missing L domains in TCRV Z or whether 
NPs play an important function in budding of other arenavirus species remains to be 
investigated. 
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1.4 Viruses and Innate Immunity 
 
To prevent infection, a cell has a variety of defences in place that include the physical 
barrier of cell membranes, and both innate and adaptive immune responses. Whereas 
adaptive immunity is very complex and takes time to achieve full activity against a 
viral infection, the non-specific innate immune responses are mounted quickly and 
efficiently and therefore form the first line of defence against infection.  
 
 
1.4.1 Detection of viral infection by the innate immune system 
 
As part of cellular innate immune responses pattern recognition receptor proteins 
(PRRs) are expressed that are capable of detecting invading pathogens. PRRs are 
germline encoded, are non-variable and can generally be divided into the following 
groups: Toll-like receptors (TLRs), NOD-like receptors (NLRs) and cytoplasmic 
RIG-I-like receptors (RLRs) (Figure 1.14) (Takeuchi and Akira, 2010). The invading 
pathogen is detected by PRRs as they recognise intrinsic structures referred to as 
PAMPs. Different PAMPs are thought to be generated by most viruses throughout 
their replication cycle. Generally PAMPs are molecules that differ from intrinsic 
cellular patterns and include tri-phoshorylated RNA, single-stranded DNA, 
cytoplasmic DNA or double-stranded RNA. The generation of PAMPs appears to 
increase when errors during viral replication occur in which these PAMPs are 
amplified.  
 
There are ten characterised TLRs, with TLRs 2 - 4 and 7 - 9 previously shown to 
function against viral invasion (Akira and Takeda, 2004). TLRs 2 and 4 are located at 
the cell surface and recognise extracellular pathogens. These two receptors were 
thought to act mainly against bacterial infection, but now it is believed that TLR2 and 
TLR4 form heterodimers with TLR1 and TLR6 to detect viral infection by binding 
glycoproteins located on viral surfaces (Sandor et al., 2003, Horng et al., 2001, 
Fitzgerald et al., 2001). The other TLRs active against viruses (3, 7, 8 and 9) are 
located in endosomal membranes and therefore recognise viruses during their 
internalisation. The individual internal TLRs recognise different PAMPs, for example 
TLR3 recognises dsRNA, TLR7 and TLR8 recognise uridine-rich ssRNA upon  
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: Interferon-induction and –signalling pathway.  
 
Pattern recognition receptors (PRRs), such as TLRs or RLRs, recognise a viral 
infection and activate the IFN-induction pathway. The individual TLRs relay the 
signals using the adaptor proteins MyD88, TRAF6 and/or TRAF3 and IRAKs. TLR2 
primarily mediates activation of NF-κB, whereas TLR3 and TLR4 also mediate 
activation of IRF3 via the adaptor molecule TRIF. TLR3 and TLR4 stimulation 
induces IFN-β production, while TLR7/8 and TLR9 primarily activate IRF7 leading 
to IFN-α and NF-κB. DNA sensors IFI16, DAI, and DDX41 signal via STING 
located at the ER whereas the RNA sensors RIG-I and MDA5 signal via MAVS. 
Finally, the DNA sensors AIM2 and IIF16 and the RNA sensor NLRP3 participate in 
inflammasome formation and cleavage of pro-IL-1β to IL-1β. Secreted IFN-I can 
activate the JAK/STAT signaling pathways in a paracrine and autocrine manner 
leading to enhanced IFN expression and induction of interferon-stimulated genes 
(ISGs), including OASs, PKR, IFIT1, APOBEC3, and viperin. The MAPK signaling 
pathway has been omitted in the figure. ER = endoplasmic reticulum. Figure 
modified from Melchjorsen, 2013. 
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release into endosomes and TLR9 is important for the recognition of unmethylated 
GpC motifs that are found in dsDNA viral genomes (Alexopoulou et al., 2001, Weber 
et al., 2006, Hornung et al., 2002, Paludan et al., 2011, Kawai and Akira, 2008).  
Viruses that either do not enter the cell by an endosomal pathway or that are 
recognised by the cellular innate immune system later during replication bypass 
recognition by TLRs but are subsequently detected by cytoplasmic nucleic acid 
receptors. The most important members of these cytoplasmic receptors are the RLRs. 
There are currently three characterised RLRs that are members of the DExD/H RNA 
helicases, namely retinoic acid-inducible gene (RIG-I), melanoma differentiation-
associated gene 5 (MDA-5) and laboratory of genetics and physiology-2 (LGP-2). 
While RIG-I recognises either short dsRNA or uncapped 5’-triphosphorylated 
ssRNA, MDA-5 recognises long dsRNA that often possess AT-rich repeats (Kang et 
al., 2002, Saito et al., 2008, Kato et al., 2006, Hornung et al., 2006). These sensing 
patterns enable the RLRs to distinguish between cellular and “foreign” RNA species 
within cells. The third member of these RNA-sensor helicases, LGP-2, appears to be a 
regulatory protein for RIG-I and MDA-5 and has been shown to act either positively 
or negatively on the interferon induction pathway, however the exact function 
remains unclear (Rothenfusser et al., 2005, Yoneyama et al., 2005). RIG-I and MDA-
5 exist as functionally repressed monomers inside the cytoplasm but upon substrate 
sensing these proteins undergo a conformational change and dimerise in an ATP-
dependent manner. The activated RLRs then interact with the adapter protein 
mitochondrial antiviral signalling protein (MAVS; also known as CARDIF, IPS-1 or 
VISA) and initiate an antiviral signalling cascade (Kawai et al., 2005, Kang et al., 
2002, Seth et al., 2005). There is another recently identified RNA helicase, DDX3, 
which appears to have antiviral functions, but whether the protein can induce an 
antiviral pathway individually or has to act together with either RIG-I or MDA-5 
remains to be seen (Oshiumi et al., 2010). To prevent viral infections in the cell there 
are not only RNA sensor proteins, but also DNA sensors in the cytoplasm, with a 
growing number of such proteins being reported. Proteins known to detect cellular 
DNA and that are involved in innate immune pathways include DNA-dependent 
activator of interferon-regulatory factors (DAI), leucine-rich repeat flightless-
interacting protein 1 (LRRFIP1), interferon-inducible gene 16 (IFI16) or DNA-
dependent protein kinase (DNA-PK) (Wang et al., 2008, Bagashev et al., 2010, 
Gariano et al., 2012, Ferguson et al., 2012). However, there also appears to be 
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proteins that are capable of detecting both invading DNA and RNA species in the 
cytoplasm. Examples are DDX9, DDX36 and RNA polymerase III. While DDX9 and 
DDX36 recognise unmethylated CpG-motifs in DNA (Kim et al., 2010), the function 
of RNA polymerase III is more indirect by recognising AT-rich DNA sequences and 
transcribing these sequences into 5’-triphosphorylated ssRNA, which is subsequently 
sensed by RIG-I leading to the activation of the downstream pathway (Chiu et al., 
2009, Ablasser et al., 2009).  
 
Another strategy of innate immunity is to up-regulate pro-apoptotic and 
inflammasome signals. There are some branch-points to induce these signals after 
TLR or RLR activation where the transcription factor NF-κB is primarily activated. 
The cell can contain a viral infection by committing suicide via the apoptotic 
pathways or it can attract professional immune cells, such as natural killer cells, 
macrophages or T cells to the site of infection by using inflammatory cytokines.  
Important members in activating these pathways are NLRs, such as NLRP3, NLRC2 
NLRC5 or AIM2 (Zhou et al., 2011, Correa et al., 2012, Kobayashi and van den 
Elsen, 2012, Hornung et al., 2009). These proteins can interact with caspase 1, which 
in turn cleaves pro-interleukin 1β (pro-IL 1β) or pro-IL 18 to functionally activate 
these molecules. This activation is not only by direct PAMP association, but can be 
the result of processes induced by viral infection, such as the generation of reactive 
oxygen species (ROS) during viral replication, membrane disruption or lysosomal 
disruption.  
 
 
1.4.2 Interferon induction 
 
When the cellular PRRs recognise a potential PAMP from a viral infection it sets a 
signalling cascade in motion, culminating in the production of interferons (IFN), with 
the aim of containing the infection to the individual cell and, if possible, to abrogate 
the infection inside the cell. RLRs and NLRs interact with the common adaptor 
protein MAVS at the mitochondrial membrane, which dimersises leading to the 
binding of either tumour necrosis factor receptor-associated factor 3 (TRAF3) or 
TRAF6 (Figure 1.14) (Yamamoto et al., 2002, Jiang et al., 2004, Hacker et al., 2006). 
There is a second pathway, mainly used by TLRs, that is MAVS-independent. This 
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pathway is the myeloid differentiation primary response gene 88 (MyD88) –
dependent pathway that finally feeds back into the IFN induction pathway by 
activating TRAF6 (Akira and Takeda, 2004, Medzhitov et al., 1998, Wesche et al., 
1997). The two TRAF proteins activate two separate pathways regulated by members 
of the IKK family. At this stage TLR3 is also able to activate these two distinct 
pathways by binding to either TRAF3 or TRAF6 via TIR-domain-containing adaptor-
inducing IFN (TRIF). The pathway of TRAF3 leads to the formation of the TANK-
binding protein 1 (TBK1) and IKKε heterodimer, which facilitates the hyper-
phosphorylation of the IRF3 and IRF7 transcription factors required for IFN-α/β 
promoter activation (Honda et al., 2005, Sato et al., 2000, Servant et al., 2002, Servant 
et al., 2003). The other pathway, downstream of TRAF6, forms a heterodimer of 
IKKα and IKKβ that subsequently activates the transcription factor NF-κB (Lenardo 
et al., 1989, Fujita et al., 1989, Visvanathan and Goodbourn, 1989, Chu et al., 1999). 
The hyper-phosphorylated transcription factors IRF3 and IRF7 can translocate from 
the cytoplasm into the nucleus where they can bind to positive regulatory domains 
(PRD) of the IFNα/β promoters. The IFNα promoter has one identified PRD, which is 
bound by IRF7, while the IFNβ promoter contains at least four PRDs (Goodbourn and 
Maniatis, 1988). IFNβ PRD II is recognised by NF-κB and PRD IV is recognised by 
the activating transcription factor 2 (ATF2) and c-jun heterodimer. The IFNβ 
promoter PRD domains I and III are recognised by homo- and heterodimers of IRF3 
or IRF7 respectively. It is still not fully resolved whether any of these IRFs are more 
important for the efficient activation of the IFNβ promoter, but the majority of studies 
indicate that IRF3 takes the lead. The activation of these promoters results in the 
production of IFNα and/or IFNβ, the type I IFNs.  
 
 
1.4.3 Interferon signalling 
 
Once IFNα/β are produced they are secreted by the cell and signal in an autocrine or 
paracrine manner (Figure 1.14). Subsequently IFNα/β bind to the IFN heterodimeric 
receptor formed by the protein products of the IFNAR1 and IFNAR2 genes (Novick 
et al., 1994, Stancato et al., 1996). The subsequent signalling occurs in a classical 
Janus kinase/ just another kinase (JAK) and signal transducers and activators of 
transcription (STATs) pathway. When the receptor is activated, tyrosine kinase 2 
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(Tyk2) and JAK1 trigger the phosphorylation of STAT1 and STAT2, which undergo 
conformational changes enabling the proteins to form heterodimers (Stancato et al., 
1996, Novick et al., 1994). The heterodimer interacts with IRF9 to form the IFN-
stimulated gene factor 3 (ISGF3) complex (Veals et al., 1992, Martinez-Moczygemba 
et al., 1997), which translocates into the nucleus and acts as a transcription factor for 
binding to the IFN-stimulated response element (ISRE). Binding to the ISRE triggers 
promoter activation resulting in the expression of hundreds of IFN-stimulated genes 
(ISGs), many of which have antiviral functions. A subset of ISGs appears to be 
transcribed after activation of IKKε, which phosphorylates STAT1 at tyrosine 708, 
resulting in the stabilisation of ISGF3-ISRE binding (Levy et al., 1989, Kessler et al., 
1990). 
 
Type II IFN is secreted by professional immune cells, such as NK cells, NK T cells, 
CD4 Th1 and CD8 CTLs (Schoenborn and Wilson, 2007). The main function of this 
cytokine appears to be to activate or up-regulate the activity of other immune cells, 
such as macrophages or dendritic cells. It is also important for increasing cellular 
MHC I presentation, to thereby increase detection of infection. Type II IFN uses a 
distinct receptor to type I IFN as it binds to the heterodimeric IFNγ receptor 1 
(IFNGR1) and IFNGR2 resulting in the activation of intracellular JAK1 and JAK2 
respectively (Igarashi et al., 1994). The activated JAK molecules, in turn, can 
phosphorylate STAT1, which is then able to form a homodimer that can translocate 
into the nucleus. The homodimer then acts as a transcription factor for genes under 
control of the distinct gamma-activation sequence (GAS) that is responsible for the 
transcription of a unique subset of ISGs (Levy and Darnell, 2002). There are also 
reports of different STAT1 and STAT2 homodimers that can interact with IRF9, but 
the biological function of these complexes remains unclear (Fink and Grandvaux, 
2013). The final result of the expression of these ISGs is the IFN-dependent induction 
of an antiviral state of a cell. The function of these ISGs is to reduce or limit viral 
replication within a host cell using several subsets of these gene products that can 
counteract viral infection using very specific mechanisms, almost tailored to 
individual viruses.  
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1.4.4. The roles of interferon stimulated genes (ISGs) 
 
During the IFN-signalling process cells are able to express hundreds of different 
ISGs, many of which have specific anti-viral functions, however the mechanism 
behind many of these functions are poorly understood. There are a large variety of 
targets for ISGs that include differences in mRNA 5’-caps, restricting trafficking to 
cellular compartments, disabling the cellular translation machinery or targeting viral 
proteins directly. Generally, ISGs either suspend particular cellular processes essential 
to many viruses or they target virus components directly by being able to distinguish 
between “self” and “non-self”, the mechanisms of which are poorly understood. 
ISG15 is one of the most highly expressed proteins in an IFN-induced antiviral state. 
The protein is induced by type I IFN signalling and consists of two ubiquitin-like 
domains that exert antiviral activity after becoming conjugated to potential target 
proteins (Loeb and Haas, 1992, Haas et al., 1987, Pattyn et al., 2008). Concurrent 
with ISG15 expression the E1 enzyme UbE1L (responsible for activation), the E2 
enzyme UbcH8 (responsible for conjugating ISG15 to the target protein), and the E3 
ligase Herc5 are co-expressed (Zhao et al., 2004, Ritchie et al., 2004, Dastur et al., 
2006, Wong et al., 2006). The same pathway also induces expression of the USP18 
enzyme, which is capable of removing ISG15 from proteins (Malakhov et al., 2002).  
Not only does ISG15 protect the cell against viral infection when it is conjugated to 
proteins, but it can also exert its protection against “cytokine storms” in its free form 
(Zhao et al., 2010, Werneke et al., 2011). The mode of action of this ISG is thought to 
be by obscuring potential binding or interaction sites of the newly synthesised viral 
proteins that are essential for the viral replication cycle. ISG15 acts against a variety 
of viruses, including influenza A and B virus, Sindbis virus, EBOV, Chikungunya 
virus (CHKV), HIV-1 or herpes simplex virus 1 (HSV-1) (Lenschow et al., 2007, 
Hsiang et al., 2009, Lai et al., 2009, Osiak et al., 2005, Okumura et al., 2008).  
 
The antiviral activity of the ISG myxovirus resistence gene 1 (Mx1), a member of the 
GTPase family, was initially observed in mice that were highly susceptible to 
influenza A virus infection due to mutations in this gene (Lindenmann, 1964, Staeheli 
et al., 1986). Homologues of Mx1 have since been discovered in humans (termed 
MxA) and many other animal species, with these proteins demonstrating antiviral 
activity against many different viruses within a large variety of virus families. The 
 1. INTRODUCTION  	  
	  	  	  	  	   64	  	  
common observation between the different viruses is that MxA acts early during viral 
infection and stops the virus in its early stages. Although many studies have been 
conducted on MxA and the related Mx1 protein (Verhelst et al., 2013), the exact 
mechanism of its antiviral activity remains elusive. Studies using the highly MxA-
sensitive Thogoto virus (THOV), a member of the orthomyxovirus family (Weber et 
al., 2000), demonstrated that MxA blocks the transport of vRNPs into the nucleus by 
obscuring the necessary nuclear localisation signal (NLS) of the viral NP, with a 
region around the L4 loop of MxA required for this function. MxA-mediated 
prevention of vRNP nuclear transport has since been shown for influenza A viruses 
(Xiao et al., 2013), although the mechanism behind this is likely different from that of 
THOV and remains unknown. For other viruses, such as VSV or La Crosse virus 
(LACV) the mechanism is less clear and is thought to vary between different viruses 
(Weber et al., 2000, Staeheli and Pavlovic, 1991, Frese et al., 1996, Kochs et al., 
2002, Andersson et al., 2004). Possible antiviral mechanisms include the 
oligomerisation of MxA into a doughnut-shaped ring structure able to block the vRNP 
from entering the nucleus, by blocking primary transcription, by impairing viral 
elongation during replication or by sequestering the vRNP complexes (Kochs et al., 
2002, Gao et al., 2011, Pavlovic et al., 1992, Daumke et al., 2010, Mitchell et al., 
2012). It is possible that these functions may overlap, as the outcome appears to be 
similar, if not the same. For some viruses, such as VSV, it has been shown that the 
GTPase activity of MxA is essential, another function that is poorly understood 
(Pitossi et al., 1993). Overall, the function of MxA is to stop viral replication early 
during the infection, the mechanisms of which requires further investigation. 
 
An ISG that uses its enzymatic function to counteract viral infection is the DEDDh 
family exonuclease ISG20 (Degols et al., 2007). This protein can be induced by either 
type I or type II IFN by the ISRE. The exact function of ISG20 as an antiviral protein 
remains unclear. It is known that the protein is a 3’ – 5’ exonuclease with a specificity 
for ssRNA or ssDNA substrates (Nguyen et al., 2001). It was found that this ISG was 
effective against influenza A virus, VSV, HCV, West Nile virus (WNV), 
encephalomyocarditis virus (EMCV), and HIV-1 among others (Espert et al., 2005, 
Espert et al., 2003, Zhang et al., 2007, Jiang et al., 2008, Jiang et al., 2010). 
Mutational studies of the exonuclease abolished antiviral activity and it was 
concluded that ISG20 uses the exonuclease to carry out its function. However, it is 
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still unclear whether or not the exonuclease activity is targeted against the viral 
genome directly or against specific cellular RNAs (Degols et al., 2007). For example 
studies of an HIV mutant showed that the virus could overcome restriction by ISG20 
by down-regulating virus-induced apoptosis, independently of ISG20 activity, 
however further analysis is required to fully characterise this (Maitra and Silverman, 
1998). 
 
There is indication that some ISGs can work together synergistically, such as IFN-
induced protein with tetratricopeptide repeats (IFIT) 1-3 (also known as ISG56, 
ISG54 and ISG60 respectively). IFIT1 and IFIT3 can both down-regulate cellular 
translation to about 60% by interacting and blocking the activity of the eukaryotic 
initiation factor 3 (eIF3), which is required for interaction with eIF4F to stabilizes the 
translation pre-initiation complex (Hui et al., 2005, Guo et al., 2000, Terenzi et al., 
2006). Therefore interaction between the two IFIT proteins and eIF3 are independent 
of the viral infection and can occur as soon as either of these IFIT proteins are 
expressed. However, very little is known about the specific mode of action against 
viral infection in regards to these three IFIT proteins. Looking at these three proteins 
individually, it is known that IFIT1 acts against mRNA species that are lacking the 
conventional 2’-O methylated cap structure. Some viruses, such as members of the 
paramyxoviridae or WNV, use RNA caps that are similar to cellular mRNAs, but 
these caps use different sites of methylation (Wei et al., 1975, Wei and Moss, 1975, 
Zhou et al., 2007, Daffis et al., 2010). The methylation pattern gives IFIT1 the 
opportunity to distinguish between “self” and “non-self” and to target the viral RNAs 
specifically. There is not much known about the action of either IFIT2 or IFIT3. Both 
of these proteins seem to interact at the mitochondria with other 
cellular/mitochondrial proteins. IFIT2 can induce apoptosis via the mitochondrial 
pathways and it is associated in binding the mitochondrial mediator of IRF3 
activation (MITA; also known as STING) protein (Stawowczyk et al., 2011). This 
protein has been shown to play a crucial part in the activation of the IRF3 as well as 
NF-κB, but the exact mechanisms by which this occurs is unknown. IFIT2 can also be 
negatively regulated by direct binding of IFIT3, which seems to disrupt the interaction 
with MITA. The action of IFIT3 is also poorly understood. It appears to bridge the 
MAVS and TBK1 proteins thereby affecting the IRF3 pathway, rather than having a 
direct action against a viral infection (Liu et al., 2011). IFIT1 can further control the 
 1. INTRODUCTION  	  
	  	  	  	  	   66	  	  
action of IFIT2 and IFIT3 as it functions as a negative regulator on the interactions 
with MITA, MAVS or TBK1 (Li et al., 2009). If and how the direct interactions of 
IFIT1, IFIT2 and IFIT3 are relevant to the antiviral functions of these proteins is yet 
to be seen. A previous study demonstrated an up-regulation of IFIT1 and IFIT2 in 
neuronal cells upon LCMV infection, but the study failed to show whether or not this 
ISG had an effect against LCMV infection (Wacher et al., 2007). 
 
Tetherin was initially described in the 1990s, but in 2008 it was further characterised 
and shown to be an ISG with antiviral activity against a variety of viruses, including a 
large number of retroviruses, paramyxoviruses and arenaviruses (Neil et al., 2008, 
Jouvenet et al., 2009, Sakuma et al., 2009a, Radoshitzky et al., 2010, Weidner et al., 
2010). Tetherin expression is up-regulated by either STAT3, IRF1 or ISGF3 upon 
type I or II IFN signalling. In contrast to many other ISGs that either prevent viral 
entry or replication, tetherin appears to inhibit viral budding from the infected cell. 
The protein has a unique architecture by possessing two membrane anchors, one at 
both the N- and C-terminus (Neil et al., 2008). The antiviral action was demonstrated 
using electron microscopy methods revealing that the protein tethers a budding virus 
to the cellular membrane or even to another virus by inserting the membrane anchors 
in either end of the cellular and/or viral membranes (Neil et al., 2007). Furthermore, 
tetherin appears to accumulate in cholesterol-rich rafts in membranes, regions that 
were shown be preferred budding sites, especially for retroviruses (Kupzig et al., 
2003). Interestingly, tetherin does not only show antiviral activity against viruses 
budding from the cellular membrane, but also against viruses that bud from 
intracellular membranes, such as HSV-1 or human coronavirus 229E (HCoV-229E) 
(Blondeau et al., 2013) (Wang et al., 2014). Tetherin also appears to have a secondary 
indirect function against infection. It seems to be able to recruit the adaptor proteins 
TRAF2 and/or TRAF6, TAK1 and TAB resulting in the activation of the NF-κB 
pathway (Galao et al., 2012). Tetherin is therefore potentially another PRR. 
 
 
1.4.5 Viral evasion of the interferon system  
 
The cellular innate immune system once activated is very effective in dealing with 
infections. To establish infection viruses have to either circumvent, block or 
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overcome the innate immunity presented by the host cell. In order to do so, viruses 
express “IFN-antagonist” proteins that interact with various stages of IFN-induction 
or –signalling pathways. Furthermore some viruses can deal with the consequences of 
activated IFN responses by blocking actions of particular ISGs, inhibiting global 
cellular transcription or even apoptosis responses in the host cell.  
 
Minimise the production of PAMPs that serve as ligands for PRRs, such as TLR3, 
RIG-I or MDA-5 is an effective method of preventing the induction of the IFN 
response. Some RNA viruses are thought to produce dsRNA during the replication 
process that is recognised by the cellular receptors inducing the IFN pathway. To 
circumvent this recognition, many viruses encode for proteins that can bind to dsRNA 
and either sequester or degrade this important PAMP. VACV and EBOV encode the 
E3L and VP35 proteins respectively, which act by sequestering dsRNA (Xiang et al., 
2002, Deng et al., 2008, Cardenas et al., 2006), while it is thought that the NP 
exonuclease of arenaviruses is able to destroy dsRNA in the cytoplasm (Qi et al., 
2010, Hastie et al., 2011a). As PRRs are responsible for the recognition of these 
PAMPs, another common viral strategy is to block the activity of TLRs and RLRs 
directly. The dsRNA sensors RIG-I and MDA-5 are directly inhibited by the 
paramyxovirus V proteins, influenza A virus NS1 or the NWA Z proteins (Figure 
1.11) (Andrejeva et al., 2004, Childs et al., 2007, Guo et al., 2007, Mibayashi et al., 
2007, Opitz et al., 2007, Fan et al., 2010). Further downstream in the IFN pathway 
there are several bottlenecks for the induction-relay. Such bottlenecks are the PRR 
adapter molecules MyD88, TRIF or MAVS. MyD88 signals upon TLR activation, 
while TRIF-signalling is dependent on TLR3 (see Section 1.4.2), and both pathways 
can be inhibited by the VACV proteins A52R and A46R respectively (Harte et al., 
2003) (Stack et al., 2005). The adaptor protein that is activated by RLRs, MAVS, is 
sequestered away from mitochondria and cleaved by the HCV NS3/4a protein (Li et 
al., 2005, Meylan et al., 2005, Cheng et al., 2006, Kaukinen et al., 2006, Lin et al., 
2006a). The signal relay passes through members of the IKK protein family that are 
involved in the transcriptional activation of IRF3, IRF7 and NF-κB. This step is 
blocked by adenovirus (AdV) E3, human papillomavirus (HPV) E7, arenavirus NP 
and the K1 protein of VACV (Friedman and Horwitz, 2002, Spitkovsky et al., 2002) 
(Rodrigo et al., 2012, Pythoud et al., 2012, Shisler and Jin, 2004). Downstream of 
these adaptor molecules is the next bottleneck of transcription factor activation in the 
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form of IRF3, IRF7 or NF-κB (Figure 1.14). Some viruses have evolved slightly 
different mechanisms of antagonising IFN induction that lead to prevention of 
transcription factor activation. For example the NPro (protease) of BVDV, rotavirus 
NSP1 and bovine herpesvirus-1 (BoHV-1) ICP0 proteins are able to degrade IRF3 
(Hilton et al., 2006b, Graff et al., 2007, Saira et al., 2007), while SARS-CoV PLpro 
and RABV P inhibit phosphorylation (and hence activation) of IRF3 (Devaraj et al., 
2007, Brzozka et al., 2005). Even after activation of these transcription factors, there 
are viruses that have evolved proteins to either recruit IRF3 or IRF7 away from 
cellular DNA, such as HSV-1 ICP0 (Melroe et al., 2007, Lin et al., 2004), or compete 
for binding of the transcriptional promoter, such as Karposi’s sarcoma associated 
herpesvirus (KSHV) LANA-1 (Cloutier and Flamand, 2010). 
 
Similar to the IFN-induction pathway, viruses can interfere with the IFN-signalling 
pathway at virtually every step. For the activation of this pathway functional IFNAR 
molecules are required that are bound by IFN-I cytokines. However, viruses, such as 
VACV, can either block these cytokines directly or block the receptor from binding 
these cytokines (Colamonici et al., 1995, Symons et al., 1995, Alcami et al., 2000). 
On the cytoplasmic side of the receptor, viruses can inhibit the signalling cascade by 
inhibiting the adaptor proteins JAK1 and Tyr2 from activating STAT proteins. While 
Japanese encephalitis virus (JESV) can block Tyk2 with its NS5 protein (Lin et al., 
2006b), there are several strategies used by viruses to inhibit JAK1 function. The 
levels of JAK1 in virus-infected cells can be manipulated by certain viruses. For 
example human cytomegalovirus (HCMV) infection leads to enhanced degradation of 
JAK1, while JAK1 expression is down-regulated during HSV-1 infection (Miller et 
al., 1998, Miller et al., 1999, Chee and Roizman, 2004). Activation of JAK1 can also 
be blocked by direct binding, a process induced by murine polyoma virus (MPyV) 
large T antigen (Weihua et al., 1998), or in the case of paramyxovirus infection by 
inhibition of JAK1 phosphorylation (Kubota et al., 2002, Yokota et al., 2003). The 
group of proteins that transfer the signal from the receptor to the nucleus for 
transcriptional activation are the STAT proteins. Viruses can block STAT activation 
or translocation into the nucleus either directly or indirectly. Some viral proteins, for 
example the V protein of paramyxovirus type V, can manipulate the STAT-levels in 
cells by targeting the proteins for proteosomal degradation (Palosaari et al., 2003, 
Kubota et al., 2001, Andrejeva et al., 2002b, Andrejeva et al., 2002a, Parisien et al., 
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2001). Availability of STAT molecules to form active dimers can be further reduced 
by an enhanced turnover (Chee and Roizman, 2004) or by preventing the dimer 
formation (Palosaari et al., 2003, Rodriguez et al., 2002, Rodriguez et al., 2003). 
Before the activated STAT proteins are able to translocate into the nucleus, STATs 
can be blocked by viral proteins manipulating the phosphorylation-state of the STAT 
proteins, a process performed by the C protein of Sendai virus (SeV) or RABV P 
protein (Saito et al., 2002, Komatsu et al., 2002, Brzozka et al., 2006, Vidy et al., 
2007). The nuclear transport of STATs can also be blocked by EBOV VP24 or 
SARS-CoV ORF6 through binding to nuclear import factors (Reid et al., 2006, 
Frieman et al., 2007). As activation of the IFN-signalling pathway depends on the 
formation of the transcription factor complex ISGF3 (see Section 1.4.3), viral 
proteins have also evolved to be able to block this step by either modifying STATs 
(Najarro et al., 2001, Christen et al., 2007, Duong et al., 2004) or by blocking the 
other ISGF3 protein, IRF9 (Barnard and McMillan, 1999). 
 
Viruses haven also developed ways to down regulate the signalling functions of ISGs, 
such as protein kinase R (PKR) or RNaseL. PKR senses dsRNA in cells and therefore 
the viral proteins able to bind to dsRNA, such as VACV E3L or HSV-1 Us11, often 
have the ability to interfere with PKR to prevent its antiviral activity (Poppers et al., 
2000, Poppers et al., 2003). RNaseL destroys all RNA within cells upon activation, 
thus certain viruses, such as HIV-1 or Encephalomyocarditis virus (ECMV), are able 
to block this activity by the indirect stimulation of a negative RNaseL-effector 
(Martinand et al., 1999, Martinand et al., 1998). Finally viruses have evolved 
mechanisms in which their IFN-antagonist proteins are able to block global protein 
transcription, such as Bunyamwera virus (BUNV) NSs (Thomas et al., 2004), or they 
prolong cellular survival by inhibiting many different pro-apoptotic proteins, such as 
the Bcl-2 protein family, TNF-α or p53 (Sundararajan and White, 2001, Sundararajan 
et al., 2001, Reading et al., 2002, Linzer and Levine, 1979, Yanai and Obinata, 1994, 
Querido et al., 2001). 
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1.4.6 Arenaviruses and the innate immune system 
 
Both in vitro and in vivo studies of LCMV have revealed many important features 
about innate and adaptive immunity. Important discoveries from the work with this 
virus include the characterisation of virus-induced immunopathological disease, major 
histocompatibility complex (MHC) restriction of T cell responses or T cell-mediated 
cell death of infected cells (Zinkernagel, 2002, Oldstone, 2002). Generally, 
observations resulting from arenavirus infections often appear intriguing from an 
immunological point of view. It is now apparent that arenavirus infections and the 
disease outcome are tightly intertwined with the hosts’ or patient’s immune system. 
Studies from LASV survivors showed a general immunosuppression characterised by 
low levels of type I IFN and pro-inflammatory cytokines such as tumour necrosis 
factor α (TNFα) or interleukin 1β (IL-1β). Fatal LASV infections are often directly 
associated with altered levels of IL-8, IFNγ-induced protein 10 (IP-10) and a few 
other cytokines (Yun et al., 2012, Peters et al., 1989, Baize et al., 2004, Baize et al., 
2006, Mahanty et al., 2003, Mahanty et al., 2001). On the other hand an elevation of 
IL-10 can be found, which supresses the induction of apoptotic genes. JUNV 
infections in mice showed age-dependency as well as maturation of immune 
responses to be important for the outcome of infection, resulting either in clearance or 
persistence of infection (Vitullo et al., 1987, Vitullo and Merani, 1990). Further 
indications that type I IFN plays an important role during arenavirus infection were 
derived from studies showing that type I IFN affected megakaryocytes leading to 
thrombocytopaenia in LCMV infection, and that type I IFN related inhibition of 
magakaryopoiesis was linked to haemorrhagic fever in JUNV patients (Binder et al., 
1997, Pozner et al., 2010). In LASV patients lymphopenia and lymphoid depletion is 
often observed in the spleen and lymph nodes that, when characterised in detail, is 
often a reduction in dendritic cells (DCs) and CD8+ T lymphocytes (Walker et al., 
1982b, Edington and White, 1972, Fisher-Hoch et al., 1988). Overall, there are often 
two outcomes of arenavirus infection, either there is a CD8+ T cell response upon an 
initial type I IFN stimulus and the infection can be cleared or there is a T cell 
exhaustion resulting in persistence in rodent hosts. 
 
The major factor involved in determining the outcome of infection is type I IFN. 
When the IFN response is able to limit viral replication the viral infection can be 
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cleared. When a mouse becomes infected with LCMV, an IFN burst from 6 – 48 
hours post infection can be observed (Biron et al., 2002, Zuniga et al., 2008, Lee et 
al., 2009). Although the viral titres peak at 3 – 5 days post infection, long after the 
IFN levels have declined, this initial IFN burst can be enough to restrict viral titres to 
levels manageable primarily by cellular immune responses. LCMV infections can 
then be cleared after 8 days in adult mice (Zuniga et al., 2008, Lee et al., 2009). The 
main cell type producing IFN during infection is plasmacytoid dendritic cells (pDCs) 
that can subsequently affect the activation and maturation of B and T cells (Montoya 
et al., 2005, Jung et al., 2008). Apart from secreting IFN, the activation of pDCs also 
increases the presentation of MHC class I and II molecules and leads to the 
production of co-stimulatory molecules and inflammatory cytokines. Before CD8+ T 
cells can become active against arenaviral infection, the early expression and down-
regulation of viral replication by ISGs is paramount. Currently, the only identified 
ISG playing an important role during arenavirus infection is tetherin (see Section 
1.4.4) (Sakuma et al., 2009a, Radoshitzky et al., 2010), but most likely a whole array 
of ISGs is involved in combating infection by these viruses. After IFN activates DCs, 
these cells can cross-prime CD8+ T cells, which become activated followed by 
population expansion, thereby triggering infected cell death.  
 
When the IFN system is suppressed arenavirus infection can result in T cell 
exhaustion, a process that is defined by dysfunction and physical deletion of antigen-
specific T cells, and infections are therefore not cleared (Wherry, 2011). Furthermore 
these special immune cells serve as initial site of viral infection, thereby limiting the 
effectiveness of the existing cell populations. Previous work has shown that LCMV 
establishes infection in the marginal zone in the spleen where reticuloendothelial cells 
and members of the leukocytes, namely metallophilic macrophages (MM), marginal 
zone macrophages (MZM), marginal zone B cells (MZ B cells) and conventional 
dentritic cells (cDCs), are present (Muller et al., 2002, Borrow et al., 1995). Cells 
isolated from infected mice showed an increased tendency to undergo apoptosis, 
which could be another explanation for the reduction of these immune cells (Montoya 
et al., 2005, Moskophidis et al., 1993).  
 
During arenavirus infection type I IFN can be produced by pDCs through TLR2 and 
MyD88-dependent pathways (see Section 1.4.2), with one study demonstrating that 
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TLR2 was specifically activated by the glycoprotein of JUNV (Jung et al., 2008, 
Zhou et al., 2008, Cuevas et al., 2011). Furthermore, in vitro studies using astrocytes 
and microglial cells infected with LCMV demonstrated the activation of TLR2 and 
MyD88-depdendent IFN induction pathways. It is thought that these MyD88-adaptor 
protein pathways are important very early on during infection to generate the initial 
IFN burst (Jung et al., 2008). At a later stage, approximately 2 days post infection, the 
IFN pathway is activated by RLRs, mainly MDA-5, and the MAVS-dependent 
pathway (Zhou et al., 2008).  
 
Despite the strong antiviral effects of the interferon response some arenaviruses, 
especially JUNV and MACV, are relatively resistant to IFN (Huang et al., 2012, 
Canonico et al., 1984). Individual viruses use different strategies and mechanisms to 
dampen down the host immune response for successful viral replication. Apart from 
the previously mentioned IFN-antagonist functions of NP (see Section 1.2.3.2), 
arenaviruses also; i) prevent IFN induction by inhibiting TLR-dependent pathways 
(Figure 1.15), with the resulting decrease in IFN levels impairing the activation of 
natural killer (NK) cells (Zuniga et al., 2008); and ii) arenavirus infection can 
interfere with the function of pDCs, the overall effects of which are reductions in 
immunopathological damage and the establishment of chronic infection in the rodent 
host (Oldstone, 2002). The viruses appear to be able to block the maturation of DCs, 
which is important for ISG and cytokine production, by inhibiting a STAT2 
dependent pathway (Hahm et al., 2005). Studies involving two strains of PICV, the 
non-virulent P2 and the virulent P18 strains, demonstrated the ability of this virus to 
modulate the NF-κB pathway. While PICV P2 infection resulted in the formation of 
the NF-κB activating heterodimer p65/50, the virulent P18 strain predominantly 
caused the activation of the transcription factor repressor p50/50 homodimer, which 
blocked the induction of cytokines and pro-inflammatory molecules by NF-κB 
(Fennewald et al., 2002, Bowick et al., 2009).  
 
Despite the majority of viruses encoding IFN-antagonistic proteins that function by 
supressing and blocking the innate immune response, previous work has shown that 
the ability of arenaviruses to maintain persistent infections in mice depends on low 
levels of IFN signalling that induces cytokines such as IL-10, a suppressive cytokine, 
or programmed cell death 1 ligand 1 (PD-L1) (Bahl et al., 2010, Teijaro et al., 2013). 
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When IFN signalling is blocked, the virus is cleared more readily, which seems to 
occur mainly in a CD4+ T cell-dependent manner (Teijaro et al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. INTRODUCTION  	  
	  	  	  	  	   74	  	  
1.5 Reverse Genetics 
1.5.1 History of Reverse Genetics 
For many decades after the discovery of RNA viruses the study of the molecular 
characteristics of these viruses posed great problems due to the fact that RNA is 
incredibly labile and therefore hard to manipulate. The advent of recombinant DNA 
technology significantly changed the way in which these viruses are studied. In 1978 
Taniguchi and colleagues were the first to use a complementary DNA (cDNA)-based 
approach to study RNA viruses by creating the first “reverse genetics” system in 
which the ssRNA bacteriophage QB was created entirely from DNA (Taniguchi et al., 
1978). The term “reverse genetics” refers to the fact that it is the opposite to classical 
“forward genetics” in which genotypes are identified as being responsible for 
particular phenotypes. In reverse genetics it is the genotype that is specifically altered 
to study the phenotypic changes associated with the mutations.  The introduction of 
reverse genetics systems has revolutionised the study of RNA viruses as these 
systems now allow the creation of viruses that contain site-specific mutations in a 
stable genetic background, such that any phenotypic differences in the virus are a 
direct consequence of the introduced mutations. In 1981 the pioneering work 
performed in the laboratory of the Nobel laureate David Baltimore resulted in the 
generation of the first reverse genetics system allowing recovery of a mammalian 
RNA virus, infectious poliovirus (Racaniello and Baltimore, 1981). Similar to 
Taniguchi’s QB system, the poliovirus reverse genetics system generated a positive-
sense RNA virus, the genome of which is infectious as it can act directly as viral 
mRNA. Therefore the single genomic RNA derived from the cDNA clone was the 
only factor required to generate infectious virus. Since this time similar reverse 
genetics systems have been described for many positive-sense RNA viruses. 
 
The creation of reverse genetics systems for negative-sense RNA viruses was more 
challenging, as this family of viruses required the formation of vRNPs as the minimal 
replicative unit, which include genomic RNA, NP and a polymerase. Since vRNPs are 
a mixture of nucleic acids and proteins, both have to be delivered into the cell for the 
synthesis of a virus. The first reverse genetics system for negative-sense RNA viruses 
was created for influenza A virus (Luytjes, 1989). However, all reported systems until 
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the mid-1990s relied on the use of a helper virus, which in turn required a strong 
selection processes (Kawaoka, 2004). A major advance was made when the 
bacteriophage T7 RNA polymerase (T7-RP) and promoter system was used for the 
successful recovery of rabies virus, the first negative-sense RNA virus recovered 
entirely from cDNA (Schnell et al., 1994).  This work eventually led to the 
development of T7-RP-based reverse genetics systems for all genera of the 
Rhabdoviridae and Paramyxoviridae (Collins et al., 1995, Garcin et al., 1995, Lawson 
et al., 1995, Radecke et al., 1995, Whelan et al., 1995, Kato et al., 1996, Baron and 
Barrett, 1997, Durbin et al., 1997, He et al., 1997, Hoffman and Banerjee, 1997, Jin et 
al., 1998, Buchholz et al., 1999a, Peeters et al., 1999, Romer-Oberdorfer et al., 1999, 
Clarke et al., 2000, Gassen et al., 2000). The recovery of segmented negative-sense 
viruses posed a further problem, as they required delivery of many more components 
into the cell. However in 1996, based on the T7-RP approach, a reverse genetics 
system was created allowing the recovery of the three-segmented BUNV 
(Bunyaviridae) entirely from cDNA (Bridgen and Elliott, 1996). However this system 
was not thought directly applicable to the generation of the eight-segmented influenza 
viruses due to the fact that these viruses replicate entirely in the nucleus, whereas T7-
RP is predominantly cytoplasmic. A major advance came with the use of human RNA 
polymerase I (hRNApolI), which normally transcribes ribosomal RNA (rRNA). Like 
vRNAs, rRNAs lack a 5’ cap and poly(A) tail, therefore the use of hRNApolI in place 
of T7-RP in the reverse genetics system allowed the production of authentic 
influenza-like vRNAs, which in 1999 was used to successfully recover influenza A 
viruses entirely from cDNA (Fodor et al., 1999, Neumann et al., 1999)  A similar 
hRNApolI-based approach was used in 2002 for the generation of influenza B viruses 
from cDNA (Hoffmann et al., 2002, Jackson et al., 2002). Since then, reverse genetics 
systems have been reported for all negative-sense RNA virus families. With the 
knowledge obtained through the use of reverse genetics, significant advances in 
virology, cell biology, gene therapy and vaccine development have been made 
(Subbarao and Katz, 2004, von Messling and Cattaneo, 2004). Today reverse genetics 
systems can be divided into mini-genome (MG) and recombinant virus recovery 
systems. While the purpose of MG systems is to focus on viral intrinsic cis- and 
trans-acting elements, recovery systems are used to generate recombinant infectious 
virus that allows the study of factors essential for virus viability, such as identifying 
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and determining the requirement of particular virus-host interactions or mechanisms 
of immune evasion.  
 
 
1.5.2 Arenavirus Reverse Genetics 
 
An arenavirus MG system was first reported for LCMV in 2000, and similar systems 
for TCRV, LASV, PICV, JUNV and MACV have since been developed (Hass et al., 
2004, Lopez et al., 2001, Lee, 2000, Lan, 2009, Albarino et al., 2009, Patterson et al., 
2014). These systems have resulted in many discoveries, including; i) that the L 
protein forms dimers to become an active polymerase and the discrimination of 
genome replication and mRNA transcription by the L protein (Hass et al., 2008, 
Sanchez and de la Torre, 2005, Brunotte et al., 2011b, Lelke et al., 2010); ii) that 
arenaviruses have a cap-snatching mechanism of priming viral mRNA transcription 
similar to that used by influenza viruses by obtaining 5’ methylated caps from host 
cell mRNAs (Morin et al., 2010); iii) that the viral promoter region is in the UTRs of 
the virus; and iv) that the Z protein impacts transcription, translation and is 
responsible for the budding of virions, which subsequently let to the characterisation 
of the arenavirus Z protein as a matrix-like protein (Cornu and de la Torre, 2001, 
Cornu and de la Torre, 2002, Cornu et al., 2004, Perez et al., 2003, Urata et al., 2006, 
Neuman et al., 2005).  
 
Systems for the recovery of recombinant viruses have been described for LCMV, 
PICV, JUNV, LASV, LUJV and MACV (Chen, 2008, Flatz, 2006, Sanchez and de la 
Torre, 2006, Emonet, 2011, Bergeron et al., 2012, Lan, 2009, Patterson et al., 2014, 
Carnec et al., 2011). The first of these systems was established in 2006, long after 
such systems were described for other virus families. The delay in establishing such a 
system for arenaviruses can be partially explained by the intrinsic difficulties in 
amplifying viral cDNA caused by complex genomic secondary structural elements. 
There are reported arenavirus reverse genetics systems based on both hRNApolI and 
T7-RP (Figure 1.15). The hRNApolI system generates viral RNA genome copies 
from two transfected DNA plasmids in the cell nucleus and requires NP and L protein 
expression, driven from individual mammalian expression plasmids. This system  
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: Overview of the generation of recombinant 
arenaviruses by reverse genetics. 
  
Arenavirus reverse genetics systems can either utilise the RNA polymerase I (pol-I) 
or make use of the bacteriophage T7 RNA polymerase (T7RP). The pol-I system 
requires transfection of cells with four plasmids, two of which are protein expression 
plasmids on which the L and NP proteins are encoded under the control of an RNA 
polymerase II promoter, and two further plasmids encoding the L and S viral RNA 
genome segments under the control of the pol-I promoter. The T7RP system only 
requires the transfection of the two genome-encoding plasmids with the genome 
segments in complimentary genome orientation under the control of the T7RP 
promoter. Recombinant virus generated after transfection is collected from the tissue 
culture supernatant 48 – 72 hours post transfection. Adapted from Emonet et al., 
2011. 
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therefore requires a total of four plasmids to be transfected into cells. The other, more 
preferred system uses the T7-RP approach that requires transfection of only two 
plasmids, which encode the L and S genome segments in complimentary genome 
(antigenome) orientation. The plasmids are transfected into a rodent cell line 
constitutively expressing T7-RP, located in the cytoplasm. Initial protein-expression 
of NP and L protein is a result of a poorly understood mechanism in which the 
antigenome RNAs can serve as templates for viral mRNA generation that 
subsequently results in viral protein expression (Kawaoka, 2004). The T7-RP-based 
system is perhaps a more relevant system to use for areanviruses given that in this 
system primary transcription and genome replication occur in the cytoplasm, similar 
to that during a natural infection, whereas in the hRNApolI system this occurs in the 
nucleus. Arenavirus reverse genetic systems allowing the recovery of infectious virus 
have been used to gain a better understanding of; i) viral cell entry; ii) the role of the 
IGR in transcription termination; iii) the essential cleavage of GPC by the cellular 
SP1 protease; and iv) the immune evasion functions of NP (Rojek et al., 2008a, 
Albarino et al., 2009, Rojek and Kunz, 2008, Urata et al., 2011, Martinez-Sobrido et 
al., 2009, Carnec et al., 2011). 
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1.6 Aims 
 
Arenaviruses are emerging human pathogens that cause up to half a million infections 
annually, thousands of which are fatal. Despite our knowledge of these viruses for 
over half a century, there remains no effective arenavirus-specific antiviral drugs and 
only a single vaccine effective against one specific virus. Therefore, there is a need to 
develop effective antivirals against this family of viruses. However, to do so there is a 
requirement for further study into the molecular details of arenavirus infection such 
that targets for antiviral drug design can be identified. The main aim of this study was, 
therefore, to identify and characterise such targets. 
 
JUNV and MACV are two viruses found in areas of South America that are able to 
cause fatal haemorrhagic fever in humans, with cases of each reported every year. 
Gaining a greater understanding of the molecular biology of these viruses would 
represent a significant step towards designing novel antiviral drugs that would have 
great clinical importance in South America. However, the ability to handle these 
viruses in the laboratory is limited due to their virulence and the required containment 
facilities. Therefore, this study aimed to develop a model system for studying these 
viruses based on the genetically and serologically related, but non pathogenic, TCRV. 
Studying certain molecular aspects of TCRV replication could uncover insights into 
how arenaviruses such as JUNV and MACV interact with the host cell, as this could 
help focus future antiviral drug design towards specific targets, with the potential of 
generating broad-spectrum anti-arenavirus drugs.  
 
The focus of this study was NP, the most highly expressed viral protein within 
arenavirus infected cells, with the aim of identifying novel NP-mediated virus-host 
interactions. This multifunctional protein is essential to the virus at stages throughout 
the replication cycle, and therefore represents an ideal target for potential antiviral 
drug design. However for this potential to be realised a greater understanding of the 
molecular characteristics of NP and the mechanisms it uses to interact with the host 
cell is needed. NP likely forms numerous as yet unidentified protein-protein 
interactions with both viral and cellular proteins during the course of infection. 
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Identifying and characterising these interactions is an ideal starting point toward 
development of future antiviral therapies. NP has also been described as an important 
IFN-antagonist and viral infections have shown that the interactions with the innate 
immune system are essential for the course of infection. Therefore, the arenavirus NP 
contributes to the overall pathogenicity of this virus family during infection. With this 
in mind, this study aimed not only to identify and characterise novel NP-mediated 
virus-host interactions but also to gain further insight into the role of NP in subverting 
the innate antiviral defences. 
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2.1 Bacterial Work 
2.1.1 bacterial expression/sub-cloning plasmids used in this study 
 
The following bacterial expression/ sub-cloning plasmids were used in this study.  
 
pLou3: Protein expression plasmid vector with a N-terminal 
6x His-tag followed by Maltose-binding protein 
(MBP) and Tobacco Etch virus (TEV) cleavage site 
(MAL-c2X-derived plasmid; kindly provided by Dr. J. 
Potter, University of St. Andrews.). 
pSUMO: Protein expression plasmid vector with N-terminal 6x 
His-tag followed by small ubiquitin-like modifier 
(SUMO) and a TEV-cleavage site (kindly provided by 
Mr C. D. Owen, University of St. Andrews). 
pGEX4T-1: Protein expression plasmid vector (GE Healthcare) 
using a N-terminal glutathione S-transferase (GST) –
tag (kindly provided by Dr. J. Potter, University of St. 
Andrews). 
pGEM-Teasy: Subcloning plasmid vector (Promega). 
pJET1.2: Subcloning plasmid vector (Thermo Scientific).  
pLou3-TEV Protein expression plasmid vector with N-terminal 6x 
His-tag followed by MBP and TEV cleavage site and 
another non-cleavable 6x His-tag expressing TEV 
protease (kindly provided by Mr F. Duthie, University 
of St. Andrews). 
 
Based on these plasmids the following plasmids were generated in this study and the 
correctness of these constructs was confirmed by DNA sequencing. 
 
pLou3-TCRV NP: Protein expression plasmid mentioned above 
expressing Tacaribe virus (TCRV) nucleoprotein 
(NP). 
pLou3-TCRV NP D386A: Based on pLou3-TCRV NP with D to A coding 
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change at amino acid 386 to make exonuclease 
inactive. 
pSUMO-JUNV NP: Protein expression plasmid mentioned above 
expressing Junin virus (JUNV) NP. 
pSUMO-JUNV  
NP D380A: 
Based on pSUMO-JUNV NP with D to A coding 
change at amino acid 380 to make exonuclease 
inactive. 
pSUMO-MACV NP: Protein expression plasmid mentioned above 
expressing Machupo virus (MACV) NP. 
pSUMO-MACV  
NP D380A: 
Based on pSUMO-MACV NP with D to A coding 
change at amino acid 380 to make exonuclease 
inactive. 
pGEX-TCRV NP: Protein expression plasmid based on pGEX4T-1 
(mentioned above) expressing TCRV NP. 
pGEX-TCRV NP 1-229: Protein expression plasmid based on pGEX4T-1 
(mentioned above) expressing the N-terminal 229 
amino acids of TCRV NP. 
pGEX-TVRV NP 230-333: Protein expression plasmid based on pGEX4T-1 
(mentioned above) expressing TCRV NP amino acids 
230 to 333. 
pGEX-TCRV NP 364-570: Protein expression plasmid based on pGEX4T-1 
(mentioned above) expressing TCRV NP lacking the 
N-terminal 363 amino acids. 
pGEX-TCRV NPmut1: Protein expression plasmid based on pGEX4T-1 
(mentioned above) expressing TCRV NP with the 
amino acids SYGN starting at position 237 changed to 
alanines. 
pGEX-TCRV NPmut2: 
 
 
 
Protein expression plasmid based on pGEX4T-1 
(mentioned above) expressing TCRV NP with the 
amino acids DGGNMLE starting at position 255 
changed to alanines. 
pGEX-TCRV NPmut3: Protein expression plasmid based on pGEX4T-1 
(mentioned above) expressing TCRV NP with the 
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amino acids RREGMFIDDR starting at position 282 
changed to the amino acid sequence AAAGMAIDAA. 
pGEX-PICV NP: Protein expression plasmid based on pGEX4T-1 
(mentioned above) expressing Pichinde virus (PICV) 
NP. Constructed by Mr. Thomas Whitehead during his 
undergraduate project in the lab. 
pGEX-AIF: 
 
Protein expression plasmid based on pGEX4T-1 
(mentioned above) expressing the human apoptosis-
inducing factor I (AIFI). 
pGEX-AIFΔ103: Protein expression plasmid based on pGEX4T-1 
(mentioned above) expressing the human apoptosis-
inducing factor I (AIFI) lacking the N-terminal 103 
amino acids. This results in the deletion of amino 
acids that are left in the mitochondria when AIF is 
cleaved. 
pGEX-AIFΔ262: Protein expression plasmid based on pGEX4T-1 
(mentioned above) expressing the human apoptosis-
inducing factor I (AIFI) lacking the N-terminal 262 
amino acids. This results in the deletion of the 
mitochondrial and the first FAD domains. 
pGEX-AIFΔ350: Protein expression plasmid based on pGEX4T-1 
(mentioned above) expressing the human apoptosis-
inducing factor I (AIFI) lacking the N-terminal 350 
amino acids. The truncation begins in the middle of 
the cyclophilin A and DNA binding site. 
pGEX-AIFΔ479: 
 
Protein expression plasmid based on pGEX4T-1 
(mentioned above) expressing the human apoptosis-
inducing factor I (AIFI) lacking the N-terminal 479 
amino acids. This truncation consists only of the C-
terminal domain. 
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2.1.2 Propagation of plasmids 
 
Escherichia coli DH5α cells (New England Bioscience) were grown in Luria-Bertani 
(LB) broth (10 g/l bacto-tryptone, 5 g/l yeast extract and 10 mM NaCl HCl, pH 7.5) 
or cells were plated on LB agar (LB broth supplemented with 1.5% (w/v) agarose and 
10 mM MgSO4). Media was supplemented with either 50 µg/ml ampicillin 
(Formedium) or 25 µg/ml kanamycin (Formedium) depending on the plasmid and the 
encoded antibiotic resistance gene. 
 
 
2.1.3 Generation of Competent cells  
 
E. coli DH5α and protein-expression E. coli Rosetta cells (Novagen; kindly provided 
by Mr. G. Wallat, University of St. Andrews) were grown in LB to a cell density of 
OD600 ~0.4-0.6 at 37 °C ( ~ 2 – 3 hours). When the required cell density was reached, 
cells were placed on ice for 20 minutes followed by centrifugation (~ 900 x g) to 
pellet the cells. Subsequently the pellet was resuspended in 100 mM CaCl2 (Fisher 
Scientific) and 40 mM MgSO4 (Fisher Scientific). The cell suspension was incubated 
on ice for 30 minutes followed by centrifugation (~ 900 x g). The supernatant was 
removed and the pellet was resuspended in 100 mM CaCl2, 40 mM MgCl2 and 10% 
(v/v) glycerol (Sigma Aldrich). Cell aliquots were frozen using liquid nitrogen and 
stored at -80 °C.  
 
 
2.1.4 Transformation of competent cells 
 
20 ng of plasmid was added directly to 50 µl of thawed, competent cells. The 
plasmid-cell mix was incubated on ice for 30 min before being transferred to a 42 °C 
water bath for 45 seconds. Cells were then placed back on ice for 2 minutes, mixed 
with 500 µl SOC media (20 g bacto-tryptone, 5 g bacto-yeast extract, 0.5 g NaCl and 
2.5 ml 1 M KCl adjusted to pH7.0 using NaOH to 1 l total volume followed by the 
addition of 20 ml 1 M glucose) and incubated at 37 °C for 1 hour in a shaking 
incubator. Cells were then plated onto LB-agar plates supplemented with either 
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ampicillin or kanamycin, plates inverted and incubated at 37 °C overnight. Individual 
colonies were picked for mini-cultures.  
 
 
2.1.5 Preparation of plasmid DNA 
 
For small-scale preparations of DNA, bacterial cultures of 7 ml LB broth, 
supplemented with either ampicillin (50 µg/ml) or kanamycin (25 µg/ml) were 
incubated at 37 °C in a shaking incubator overnight. The cells were pelleted by 
centrifugation and DNA was extracted using the GenElute Plasmid Miniprep kit 
(Sigma Aldrich), according to the manufacturer’s instructions. For large-scale DNA 
preparations 200 ml bacterial cultures in LB broth supplemented with either 
ampicillin or kanamycin were prepared and incubated at 37 °C in a shaking incubator 
overnight. The cells were pelleted by centrifugation and DNA was subsequently 
extracted using QIAfilter Plasmid Maxi kit (QIAGEN), according to the 
manufacturer’s protocol. DNA concentration and quality was assessed using a 
NanoDrop 1000 (LabTech) spectrophotometer. 
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2.2 Protein expression and purification 
2.2.1 Protein expression 
 
For protein expression in bacteria, plasmids were transformed into E. coli Rosetta 
cells (Novagen) as mentioned above. These cells express an additional plasmid 
encoding six eukaryotic transfer RNAs (tRNAs). The plasmid uses a chloramphenicol 
resistance gene (25 µg/ml; Formedium). Generally 1 l LB broth, supplemented with 
chloramphenicol and ampicillin was inoculated with 10 ml from a overnight starter 
culture and the cultures were incubated in a shaking incubator (220 rpm) at 37 °C 
until an OD600 ~0.8 was reached (~3-4 hours). Then protein expression was induced 
using Isopropyl-β-D-thiogalactopyranosid (IPTG; Formedium) at a concentration of 
0.4 mM for pGEX4T-1, 0.03 mM for pSUMO-JUNV NP and pSUMO-JUNV NP 
D380A and 0.1 mM for all other plasmids used in this study. The temperature was 
then reduced to 16 °C and cultures were incubated for a further 16 hours. Protein 
expression from the pSUMO-MACV NP and pSUMO-MACV NP D380A plasmids 
was performed using Auto Induction Medium (AIM; Formedium) instead of IPTG 
induction. For AIM protein expression 1 l media, supplemented with kanamycin (25 
µg/ml) and chloramphenicol (35 µg/ml), was inoculated with 5 ml of an overnight 
starter culture. The cells were incubated in a shaking incubator (220 rpm) at 37 °C for 
9 hours before reducing the temperature to 16 °C and incubation for a further 50 
hours. Cultures were harvested and cells were pelleted by centrifugation.  
 
 
2.2.2 6xHis-tagged protein purification  
 
Bacterial pellets were resuspended in buffer containing 20 mM HEPES pH 7.4 
(Sigma Aldrich), 700 mM NaCl (Fisher Scientific), 20 mM imidazole (Sigma 
Aldrich), 10% (v/v) glycerol (Sigma Aldrich), Complete protease inhibitor (Roche) 
and 1 µM DNase (Worthington) at a ratio of 5:1 (buffer to wet pellet). Cells were 
lysed using a cell disruptor (Constant System Ltd.) at 30 kpsi. The soluble 
components of the lysate were cleared by centrifugation (26.500 x g for 40 minutes) 
and filtered through a 0.45 µm membrane filter.  The 6xHis-tagged proteins were 
initially purified by affinity chromatography using nickel-equilibrated HisTrap FF 
columns (GE Healthcare). The columns were washed using the buffer mentioned 
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above followed by elution of the 6xHis-tagged protein using 150 mM imidazole.  
Following purification, the 6xHis-tag and the solubility-tag (MBP or SUMO) were 
cleaved from the protein of interest using TEV protease at a 1:20 dilution (OD280 of 
TEV to purified protein) at 4 °C overnight. Buffer exchange was performed using 
HiTrap Desalting columns (GE Healthcare) to remove the TEV. The buffer was 
changed to 20 mM HEPES pH 7.4, 200 mM NaCl, 10% Glycerol and 20 mM 
imidazole. After this TEV (6xHis-tag) was removed by repeated HisTrap FF 
purification. Subsequently the protein of interest underwent size exclusion 
chromatography using a Sephacryl S-200 HR column (GE Healthcare) with a buffer 
lacking imidazole. 
 
 
2.2.3 GST-tagged protein purification used for pulldown assays 
 
After protein expression the cell pellet was resuspended in either 50 mM Tris-HCl pH 
7.5 (Sigma Aldrich), 800 mM NaCl, 5% glycerol, 2% (w/v) N-Lauroylsarcosine 
sodium salt (sarkosyl; Sigma Aldrich), 0.5% (v/v) Igepal CA-630 (Sigma Aldrich) 
and Complete protease inhibitor (for all GST-NP constructs) or in 50 mM Tris-HCl 
pH 7.5, 150 NaCl, 1% Triton X-100 (Sigma Aldrich), 1% Igepal CA-630, 5 mM 
Ethylenediaminetetraacetic acid (EDTA; Sigma Aldrich) and Complete protease 
inhibitor (used for all GST-AIF constructs). The resuspended cells were lysed by 
sonication. Lysates were then clarified by centrifugation (2500 x g for 10 minutes). 
GST-tagged proteins were purified using glutathione-agarose beads (Agarose Bead 
Technologies (ABT) or SuperGlu). To lysates containing sarkosyl, 1% Triton X-100 
was added prior to incubation at 4 °C overnight. The GST-tagged proteins were 
purified by washing the agarose beads 5x with lysis buffer (without sarkosyl for GST-
NP constructs). 
 
 
2.2.4 Preparation of TEV protease 
 
The pLou3-TEV plasmid was transformed into E. coli Rosetta cells as described 
above and protein was expressed in 10x 1 l tryptone phosphate broth (TPB; 2% (w/v) 
enzymatic digest of casein, 0.2% (w/v) dextrose, 0.5% (w/v) NaCl, 0.25% disodium 
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phosphate). Cultures were supplemented with ampicillin and chloramphenicol and 
incubated in a shaking incubator at 37 °C until an OD600 of 0.6 was reached ( 
approximately 3 hours). Protein expression was then induced using 0.4 mM IPTG and 
the temperature was reduced to 30 °C for further 4 hours. Cells were harvested by 
centrifugation and pellets were resuspended in 20 mM Tris-HCl pH7.5, 500 mM 
NaCl, 30 mM imidazole. The cells were lysed using a cell disruptor and the lysate 
was cleared by centrifugation (26500 x g for 40 min) followed by 0.45 µm membrane 
filtration. The protein was loaded onto a HisTrap FF column and eluted in a step-
gradient with buffer containing 250 mM imidazole. Buffer was exchanged using 
dialysis (Slide-A-Lyzer Dialysis Cassette, Thermo Scientific) in buffer lacking 
imidazole and protein was mixed with 50% glycerol. Aliquots were stored at a protein 
concentration of 2.5 mg/ml at -80 °C.  
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2.3 Mammalian plasmid DNAs 
2.3.1 Mammalian expression plasmids used in this study 
 
The following plasmids were used in this study. These are plasmids provided by 
others either directly or which served as parental plasmids for plasmids generated in 
this study. The correctness of the individual plasmids was confirmed by DNA 
sequencing. Plasmids generated are listed in the individual sections below.  
 
pCAGGS: Mammalian expression plasmid vector for expressing 
a gene of interest under the control of a chicken beta-
actin promoter (kindly provided by Dr. D. Jackson, 
University of St. Andrews). 
pCAGGS-TCRV  
NP-HA: 
Mammalian expression plasmid expressing Tacaribe 
virus (TCRV) nucleoprotein (NP) with a C-terminal 
HA-tag (previously described (Martinez-Sobrido et al., 
2007); kindly provided by Dr. L. Martinez-Sobrido, 
University of Rochester, USA). 
pCAGGS-JUNV  
NP-HA: 
Mammalian expression plasmid expressing Junin virus 
(JUNV) NP with a C-terminal HA-tag (previously 
described (Martinez-Sobrido et al., 2007); kindly 
provided by Dr. L. Martinez-Sobrido, University of 
Rochester, USA). 
pCAGGS-MACV  
NP-HA: 
Mammalian expression plasmid expressing Machupo 
virus (MACV) NP with a C-terminal HA-tag 
(previously described (Martinez-Sobrido et al., 2007); 
kindly provided by Dr. L. Martinez-Sobrido, 
University of Rochester, USA). 
pTVT7R: Plasmid vector used for reverse genetics systems. 
Plasmid contains T7 promoter and terminator 
sequences and a Hepatitis delta virus ribozyme 
sequence (previously described (Johnson et al., 2000); 
kindly provided by Dr. B. Brennan, University of 
Glasgow). Plasmid vector was modified by mutating 
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BamHI restriction endnuclease site. 
pTVT7R-TCRV Lseg: Plasmid vector (as described above) to express the 
large (L) genome segment of TCRV in anti-genomic 
orientation. 
pTVT7R-TCRV Sseg: Plasmid vector (as described above) toe xpress the 
small (S) genome Segment of TCRV in anti-genomic 
orientation. 
pCMV-ISG56-HA-
GW: 
Protein expression plasmid expressing ISG56/IFIT1 
with a C-terminal haemagglutinin-tag (HA–tag) 
(kindly provided by Dr. J. Andrejeva, University of St. 
Andrews). 
pCMVR8.91: Plasmid vector expressing HIV-1 genes gag/pol, tat 
and rev. The plasmid is used for lentivirus particle 
production (kindly provided by Dr. D. Jackson, 
University of St. Andrews). 
pMD-G: Plasmid vector expressing the vesicular stomatitis 
virus glycoprotein (VSV-G) gene required for the 
generation of lentivirus particle production (kindly 
provided by Dr. D. Jackson, University of St. 
Andrews). 
pdl’BVDV/Npro 
(N’V5): 
Lentivirus plasmid vector expressing BVDV Npro 
with a N-terminal V5-tag (kindly provided by Dr. M. 
Killip, University of St. Andrews). 
pLKO: Lentivirus plasmid vector for the expression of short-
hairpin RNA (shRNA) resulting in the downregulation 
of protein expression in mammalian cells (kindly 
provided by Dr. D. Jackson, University of St. 
Andrews). 
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2.4 Cell-lines and cell culture 
2.4.1 Cell lines used in this study 
 
 
A549: A human epithelial lung cell-line derived from a lung carcinoma 
(kindly provided by Prof. R. E. Randall, University of St. Andrews). 
BHK21: Fibroblast cells from 1-day old unsexed hamster kidney (kindly 
provided by Ms. Fiona Tulloch, University of St. Andrews). 
BSR T7/5: A cell-line stably expressing the T7 bacteriophage RNA-polymerase. 
The cell-line was derived from BHK21 cells (clone BSR-CL13) and 
the establishment of the cell-line was described previously 
((Buchholz et al., 1999b); cells kindly provided by Prof. R. M. Elliott, 
University of Glasgow).  
HEK 293T: Adenovirus-transformed epithelial human embryonic kidney cell-
line, which constitutively expresses Simian vacuolating virus 40 
(SV40) large T-antigen (kindly provided by Prof. R. E. Randall, 
University of St. Andrews). 
HuH7: A human epithelial liver carcinoma derived cell-line (kindly provided 
by Prof. R. M. Elliott, University of Glasgow). 
Vero E6: A sub-clone of Vero cells, an African Green Monkey epithelial-like 
kidney derived cell line of a normal adult monkey. This cell-line 
supports the growth of slow-replicating viruses, such as certain 
haemorrhagic fever-causing viruses (kindly provided by Prof. R. M. 
Elliott, University of Glasgow). 
 
 
In addition of the listed parental cell-lines, the following lentivirus-transduced cell-
lines were used in this study (generated by others): 
 
A549-pr(IFNβ).GFP: A549 cells stably expressing green fluorescent protein (GFP) 
under the control of the interferon β (IFNβ) promoter (kindly 
provided by Ms. A. Vasou, University of St. Andrews). 
A549-pr(ISRE).GFP: A549 cells stably expressing green fluorescent protein (GFP) 
under the control of the interferon-stimulated response element 
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(ISRE; kindly provided by Ms. A. Vasou, University of St. 
Andrews). 
A549shMxA: A549 cells that knock-down the expression of the interferon-
stimulated GTPase MxA (kindly provided by Prof. Rick 
Randall, University of St. Andrews). 
HuH7pdlIFIT3: HuH7 cells expressing the interferon-stimulated gene IFIT3 
with a C-terminal V5-tag (kindly provided by Mr. D. Young, 
University of St. Andrews). 
  
  
  
The following lentivirus-transduced cell lines were generated in this study (for 
method see Section 2.5): 
 
HuH7shAIF: HuH7-based cell line in which expressed shRNA 
downregulates the expression of Apoptosis-inducing 
factor (AIF). 
Huh7pdlNpro: 
 
 
Huh7 based cell line that expresses Bovine Viral 
Diarrhoea virus (BVDV) Npro protein (N-terminal V5-
tag) that cleaves IRF3. 
Huh7pdlIFIT3/Npro: HuH7pdlFIT3 based cell line that in addition to IFIT3 also 
expresses the BVDV Npro protein (N-terminal V5-tag). 
Huh7pdlIFIT3/NS3/4a: 
 
 
 
Huh7pdlIFIT3 based cell line that additionally expresses 
the Hepatitis C virus (HCV) NS3/4a protein of subtype 
4a. This protein cleaves the mitochondrial MAVS. The 
pdlNS3/4a plasmid was kindly provided by Dr. C. 
Adamson (university of St. Andrews).  
VeroshAIF: VeroE6-based cell line in which expressed shRNA 
downregulates the expression of Apoptosis-inducing 
factor (AIF). 
VeropdlAIF: VeroE6 cells overexpressing Apoptosis-inducing factor 
(AIF). 
VeroshCypA: Huh7 based cell line in which expressed shRNA 
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downregulates the expression of cyclophilin A (CypA). 
  
 
 
2.4.2 Cell maintenance 
 
All individual cell-lines were maintained using DMEM (Dulbecco’s modified Eagle’s 
medium; Life Technologies), which was supplemented with 10% (v/v) heat-
inactivated foetal bovine serum (FBS; Life Technologies) and 500 units/ml Penicillin 
and Streptomycin (Life Technologies), in 75 cm2 tissue culture flasks (Greiner). Cells 
were maintained at 37 °C in a humidified incubator with 5% CO2. The individual cell-
lines were routinely passaged after reaching full confluency (depending the individual 
growth rates) using trypsin/EDTA (Becton Dickinson Ltd.) to detach cell monolayers. 
 
 
2.4.3 Treatment of cells 
 
         Interferon treatment 
Cells were treated using 1000 units/ml human recombinant interferon α-2a (IFNα-2a; 
Roferon; Roche Diagnostics) for 12 hours prior to viral infection.  
 
         Apoptosis  
To induce apoptosis, cells were treated with 1 µg/ml staurosporine (LC Laboratories) 
in serum-free DMEM. Caspase-dependent apoptosis was inhibited using 50 µM N-
Benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (Z-VAD-fmk; VDM 
Biochemicals) as a growth media supplement.  
 
Cyclosporin A 
Cyclosporin A (CsA; LC Laboratories) was diluted in dimethyl sulfoxide (DMSO) to 
a stock concentration of 10 mM. Cells were initially treated between 1 – 7 µM to test 
for cytotoxicity and thereafter cells were treated with 5 µM CsA at times and 
durations indicated in the individual experiments.  
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Latrunculin A 
Latrunculin A (Santa Cruz Biotechnologies) is a natural compound produced by 
sponges, which binds reversibly to actin monomers and prevents polymerisation into 
filamentous actin. The compound was added to the cell media at a final concentration 
of 1 µM for the duration indicated in the experiment. 
 
        Transfection with plasmid DNA 
Cells were transfected with plasmid DNA at a cell density of 70-90% using FuGENE 
6 transfection reagent (Promga) according to the manufacturer’s instructions.  
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2.5 Generation of stable cell-lines using lentivirus transduction 
2.5.1 Lentivirus production 
 
HEK 293T cells were grown in 75 cm2 tissue culture flasks. At approximately 70% 
confluency the cells were transfected with 3 µg pCMVR8.91, 3 µg pMD-G and 5 µg 
of either pdl or pLKO plasmids containing the gene or shRNA sequence of interest. 
Lentivirus-containing supernatant was harvested at 48 and 72 hours post transfection 
and supernatants were cleared by centrifugation (3000 x g for 10 minutes) followed 
by filtration through a 0.45 µm membrane filter.  
 
 
2.5.2 Lentivirus transduction of mammalian cells 
 
Mammalian target cells were grown in 6-well plates to approximately 40% 
confluency. 1,5-dimethyl-1,5-diazaundecamethylene polymethobromide 
hexadimethrine bromide (Polybrene; Sigma Aldrich) at 8 µg/ml was added to the 
lentivirus samples (described above) and the target cells were transduced with the 
lentivirus supernatant (3 ml per well) for 48 hours. Then cells were pooled and 
transferred to a 75 cm2 tissue culture flask and cells expressing the transduced 
construct were selected using either puromycin (10-15 mg/ml; Melford) or blasticidin 
S (10-15 mg/ml; Melford) until control cells were dead. Cells were kept under 
repeated selection with the exception of experimental procedures. The quality of each 
cell-line was assessed by detection of the expressed or down-regulated gene(s) using 
Western Blot and/or Immunofluorescence analysis. 
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2.6 Virus work 
2.6.1 Viruses used in this study 
 
The New World Arenavirus species TCRV was kindly provided by Prof. Dr. S. 
Becker (Phillips Universität Marburg, Germany). DNA plasmids for the recovery of 
recombinant PICV were kindly provided by Dr. L. Yiang (University of Minnesota, 
USA). Pichinde virus was recovered and maintained by Dr. D. Jackson (University of 
St. Andrews). For the activation of the interferon (IFN)-induction pathway the 
paramyxovirus SeV, a stock rich in defective interfering particles (DIs), was used 
(kindly provided by Ms. A. Vasou). 
 
 
2.6.2 Virus infections 
 
Virus preparations were diluted to an appropriate multiplicity of infection (MOI) in 
DMEM. Mock infections were carried out using DMEM only. The virus dilutions 
were inoculated onto cell monolayers, cell-line and cell density were dictated by 
experimental setup, and the adsorption of the virus was performed at 37 °C / 5% CO2 
for a period of 1 hour with repeated shaking of the tissue culture flasks or dishes. 
After the adsorption period the virus inoculum was removed and replaced with 
DMEM supplemented with 3% FBS and 50 units/ml Penicillin and Streptomycin. The 
cells were incubated at 37 °C / 5% CO2 until virus or cells were harvested. The 
following volumes were used as the inoculum: 300 µl for 12-well plate wells, 400 µl 
for 6-well plate wells, 3 ml for 75 cm2 tissue culture flasks / 10 cm tissue culture 
dishes.  
 
 
2.6.3 Preparation of virus stocks 
 
To prepare virus stocks of TCRV, 80% confluent monolayers of BHK21 cells in 75 
cm2 tissue culture flasks (~ 6.72 x 105 cells) were inoculated with virus. The virus was 
diluted to 0.1 plaque-forming units (PFU) per cell (an MOI of 0.1) in DMEM. The 
cells were inoculated with the diluted virus preparation and left at 37 °C / 5% CO2 for 
an adsorption period of 1 hour. After this period the inoculum was removed and 
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replaced with 10 ml DMEM supplemented with 3% FBS and 50 units/ml Penicillin 
and Streptomycin per flask. Virus was harvested after 3.5 days post infection by 
removing the supernatant from the tissue culture flask. Subsequently cellular debris 
was removed by centrifugation (3000 x g for 10 minutes) followed by filtering the 
supernatant through a 0.45 µm syringe filter. Aliquots of the cleared supernatant were 
stored at -80 °C. Virus concentrations of virus stocks were determined by plaque 
assay as described below. 
 
 
2.6.4 Virus titration / Plaque assay 
 
 To determine virus concentrations in virus stocks as well as during experimental 
procedures, virus was titrated onto 80% confluent monolayers of Vero E6 cells grown 
in 6-well plates. Virus titrations were carried out using 10-fold serial dilutions in 
DMEM. The monolayers were inoculated with 400 µl of the diluted virus 
preparations. The virus was absorbed at 37 °C / 5% CO2 for 1 hour with repeated 
shaking of the plates. After the adsorption period the inoculum was removed and 
replaced with 2 ml overlay medium per well. The overlay medium contained 
minimum essential media (MEM; Life Technologies), 26.2 mM sodium bicarbonate 
(Fisher Scientific), 2% (v/v) FBS, 1.5% (w/v) Avicel (IMCD UK Ltd.), 2 mM L-
Glutamine (Life Technologies) and 50 units/ml Penicillin and Streptomycin. Cells 
were incubated at 37 °C / 5% CO2 for 6 – 7 days. After this incubation period the 
overlay medium was removed and cell monolayers were fixed and plaques were 
visualised using crystal violet solution – 0.1% (w/v) crystal violet (Sigma Aldrich 
Aldrich), 20% (v/v) methanol (Sigma Aldrich), 5% (v/v) paraformaldehyde (Sigma 
Aldrich) in phosphate buffered saline (PBS; Fisher Scientific). Cells were incubated 
with crystal violet solution for at least 30 minutes followed by rinsing the monolayer 
with water. Individual plaques were counted and viral titres were calculated as 
PFU/ml using the counted plaques and taking the serial dilutions of the virus 
preparations into account.  
 
 
 
 
 2. METHODS  	  
 
	  	  	  	  	  	   99	  	  
2.6.5 Virus yield assay 
 
To determine viral titres from individual experiments, cell monolayers grown in 12-
well plates were inoculated with virus at a MOI indicated for individual experiments. 
After an adsorption period of 1 hour the inoculum was removed and 1 ml DMEM 
supplemented with 3% FBS and 50 units/ml Penicillin and Streptomycin was added to 
each well. Cells were then incubated at 37 °C / 5% CO2 in a humidified incubator. 
Virus samples were harvested by removing the supernatant at various times post-
infection and frozen at -80 °C. Virus titres were determined by plaque assay on Vero 
E6 cells as described above.  
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2.7 Molecular biology 
2.7.1 Polymerase chain reaction (PCR) 
 
To amplify DNA fragments polymerase chain reactions (PCRs) were carried out. 
Individual reactions were carried out using either enzymes with proofreading ability, 
Phusion (Thermo Scientific), Pfu (Promega) or KOD (Merck Millipore), or without 
this ability, Taq (Promgea), depending on the purpose of the reaction. Reactions were 
performed according to manufacturer’s instructions. Briefly, reactions were set up in 
either 30 or 50 µl reactions usually containing enzyme buffer (at appropriate dilution), 
0.2 mM of each dNTP, 3-10% Dimethyl Sulfoxide (DMSO; Thermo Scientific), ~10 
ng of DNA template, forward and reverse primers at appropriate concentration (varied 
with polymerase used) as well as polymerase (unit definition depending on 
manufacturer) in sterile water. Reactions were performed using thermocyclers with a 
general setting of initial denaturing step at 94-98 °C (varies with enzyme used), 
followed by 25-35 cycles of denaturing 94-98 °C, annealing 50-65 °C and extension 
of DNA primer strands at 70-72 °C, with a final extension step at the same 
temperature. 
 
 
2.7.2 Agarose gel electrophoresis 
 
DNA samples were analysed by gel electrophoresis in horizontal mini-gels of 0.7 – 
2% (w/v) agarose (HydraGene) in TAE buffer (40 mM Tris, 50 mM EDTA and 5.7% 
(v/v) glacial acetic acid) and ethidium bromide (1 µg/ml; Promega) depending on 
DNA size. Prior to loading of DNA samples, loading buffer (3% glycerol, 
bromophenol blue; Fisher Scientific) was added to the samples at appropriate volume. 
Samples were resolved on the agarose gel with 90 V in TAE buffer. Alongside DNA 
samples, a DNA marker with known DNA size fragments (1 kb ladder; Promega) was 
loaded onto the gel. DNA was visualised on an ultra-violet transilluminator. If 
required DNA samples were excised from the gel and DNA was recovered using the 
GenElute Gel Extraction kit (Sigma Aldrich).  
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2.7.3 Restriction enzyme digestion of DNA 
 
For restriction digest reactions of DNA plasmids or fragments enzymes from Thermo 
Scientific, New England Biolabs (NEB) or Promega were used depending on enzyme 
performance or compatibility in double digest (use of two different enzymes at the 
same time). Restriction digests were performed using manufacturer’s instructions, but 
usually 3 µg DNA from plasmids or PCR reactions was digested in 20 µl reactions at 
37 °C for 3 hours or as suggested by the manufacturer. In addition to DNA and 
reaction buffer, 1 mg/ml acetylated BSA (NEB, Promega) and 5 units of the desired 
restriction enzyme were used per reaction. 
 
 
2.7.4 Ligation of DNA fragments 
 
DNA samples used for ligation were prepared by restriction digest or gel purification 
after PCR as described above. 50 ng of vector backbone was mixed 1:3 (molar ratio) 
with insert, 1 µl of 10x T4 DNA ligase buffer and 0.2 µl T4 ligase (Thermo Scientific) 
was added to the mix and the total volume was adjusted to 10 µl. The sample was 
incubated at room temperature for 30 minutes. The ligation mix was used to transform 
into competent E. coli DH5α cells as described above at a ratio of 1:10 (v/v).  
 
 
2.7.5 RNA isolation and reverse transcription 
 
Cells were seeded in 35 mm tissue culture dishes. They were either grown to full 
confluency for RNA extraction (e.g. for AIF) or infected with TCRV at a cell density 
of ~70% followed by further incubation at 37 °C/5% CO2 for 2 days prior to RNA 
extraction. Growth media was removed, cells were rinsed with PBS and cells were 
lysed/resuspended in 1 ml TRIzol Reagent (Life Technologies). The sample was 
incubated for 5 minutes with repeated mixing before cell debris was removed by 
centrifugation (12000 x g for 5 minutes). To the cleared TRIzol mix 200 µl 
chloroform was added and vortexed for 20 seconds before incubating at room 
temperature for 3 minutes. The RNA-containing aqueous phase was separated by 
centrifugation (12000 x g for 15 minutes) and was subsequently incubated with 500 µl 
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isopropanol for at least 30 minutes at -20 °C. The sample was centrifuged (12000 x g 
for 10 minutes) and the isopropanol was removed from the RNA pellet. The pellet 
was washed with 70% ethanol. Finally the ethanol was removed by centrifugation 
(8000 x g for 5 minutes) and the air-dried RNA pellet was resuspended in an 
appropriate volume of nuclease-free water. The isolated RNA sample was 
subsequently used for reverse transcription using either ReverseAID (Promega) or 
SuperScript II (Life Technologies) reverse transcriptase according to manufacturer’s 
protocols. For the reverse transcription either oligo-dT primers (Promega; for cellular 
mRNAs) or gene-specific primers (viral RNA) were used. The obtained cDNA was 
subsequently used in a PCR reaction (outlined above) to amplify the obtained DNA 
fragment of interest.  
 
 
2.7.6 SDS polyacrylamide gel electrophoresis 
 
Protein samples were prepared for SDS-PAGE analysis in either 2x disruption buffer 
(2% (w/v) Sodium dodecyl sulphate, 1.4 M 2-Mercaptoethanol, 100 mM Tris-HCl pH 
7.0, 5% (v/v) Glycerol and bromophenol blue) or 6x Laemmli buffer (60 mM Tris-
HCl pH 6.8, 1.2% (w/v) SDS, 47% (v/v) glycerol, 6 mM DTT and bromophenol 
blue). Samples were heated to 100 °C for 5 minutes before loading onto the gel. 
Proteins were separated on 10, 12 or 15% polyacrylamide gels (37.5%:1; Sigma 
Aldrich) at 180 V using Tris-Glycine running buffer (25 mM Tris and 190 mM 
glycine) until necessary separation was achieved.  Gels were then either stained with 
Coomassie stain (0.5% (w/v) G250 Coomassie Blue (BDH Chemicals), 40% (v/v) 
methanol, 10% acetic acid) and destained using hot water or gels were subjected to 
immunoblotting (see below). 
 
 
2.7.7 Immunoblotting 
 
Protein samples that were used in SDS-PAGE (described above) were transferred to 
Polyvinylidene difluoride (PVDF; Millipore) membrane by using either the XCell II 
Blot Module (Invitrogen) for wet transfer or the Trans-Blot Turbo Transfer System 
(Biorad) according to manufacturer’s protocols. After the transfer, membranes were 
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blocked for either 1 hour (room temperature) or overnight (4 °C) in blocking buffer 
(5% (w/v) skimmed milk powder, 0.1% (v/v) Tween 20 (Sigma Aldrich) in 50 mM 
Tris-HCl pH 7.5 and 150 mM NaCl). After the blocking step, membranes were 
incubated for either 1 hour (room temperature) or overnight (4 °C) with blocking 
buffer containing a primary antibody diluted according to manufacturer’s instructions. 
After incubation with primary antibody, membranes were washed several times with 
TBS-T (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% (v/v) Tween 20) on a shaking 
platform. Membranes were then incubated with a fluorophore-conjugated secondary 
antibody (Licor), using a species raised against the primary antibody, in blocking 
buffer at room temperature for 1 hour followed by repeated washes in TBS-T. Probed 
proteins were subsequently detected using the Odyssey CLx Imaging System (Licor).  
 
 
2.7.8 Immunofluorescence 
 
Cells were grown on either 10 or 15 mm cover slips (Fisher Scientific). At the desired 
time cells were fixed using 5% (v/v) paraformaldehyde/PBS for 30 min followed by 
permeabilisation (10% (w/v) sucrose, 0.5% (v/v) Igepal, 0.5% (v/v) Triton X-100 in 
PBS) for 1 hour. To block free aldehyde groups the cells were incubated with 100 
mM glycine in PBS for 30 minutes before blocking non-specific binding sites with 
5% BSA (Melford), 0.1% (w/v) sodium azide (Sigma Aldrich) in PBS for 1 hour. 
After the blocking steps, cells were incubated with primary antibody at appropriate 
dilutions for 1 hour. Unbound antibody was washed away using PBS before 
incubating the cells with Alexa Fluor (488 or 594, Life Technologies) conjugated 
antibody and 4', 6-diamidino-2-phenylindole (DAPI; 0.5 µg/ml; Sigma Aldrich) to 
stain nuclei for 1 hour. After washing unbound antibody with PBS coverslips were 
mounted onto glass slides with Fluoprep (Biomerieux) that was supplemented with 
3% (v/v) 1,4-diazabicyclo[2.2.2]octane (DABCO; Sigma Aldrich). Images were taken 
using either a Zeiss Axioplan 2 or a Zeiss Pascal 500 confocal microscope.  
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2.7.9 Antibodies 
 
The following primary antibodies were used in immunoblotting and 
immunofluorescence as described above: 
 
WB = Western blot, IF = immunofluorescence  
 
 
Antibody target Manufacturer Concentration 
β-actin (mouse monoclonal) 
 
Sigma Aldrich 
 
1/10.000 (WB) 
 
Apoptosis-inducing factor 1 (C-
terminus; rabbit monoclonal) 
Abcam 
 
1/1000 (WB) 
Apoptosis-inducing factor 1 (N-
terminus; mouse monoclonal) 
Abcam 1/1000 (WB), 
1/250 (IF) 
Haemaglutinin (HA) tag 
(monoclonal) 
Sigma Aldrich 
 
1/1000 (WB) 
 
Phospho-IRF3 (rabbit 
monoclonal) 
Cell Signaling  1/1000 (WB) 
TCRV NP (rabbit peptide 
antibody) 
Eurogentec – raised against 
the following peptide 
sequence: 
KRREGMFIDDRPGSR, 
KSKDSPPSPSPDEPHC 
1/1000 (WB), 
1/200 (IF) 
 
TCRV (sheep polyclonal) Serum from Diagnostics –
raised against split TCRV. 
1/200 (IF)  
TCRV NP (sheep polyclonal) Serum from Diagnostics 
Scotland. Affinity-purified  
by Dr. M Smith 
(University of St. 
Andrews). 
1/1000 (WB) 
V5 (monoclonal) 
 
Serotec 
 
1/1000 (WB) 
1/200 (IF) 
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To detect these primary antibodies, the following secondary antibodies were used: 
Antibody  Manufacturer concentration 
Alexa Fluor 488 (anti-mouse) 
Alexa Fluor 594 (anti-rabbit) 
IRDye 680RD (anti-mouse, anti-
rabbit, anti-goat) 
IRDye 800CW (anti-mouse, anti-
rabbit, anti-goat) 
Alexa Fluor 488 conjugated 
phalloidin  
 
Life Technologies 
Life Technologies 
Licor 
 
Licor 
 
Santa Cruz 
Biotechnologies  
1/200 (IF) 
1/400 (IF) 
1/25.000 (WB) 
 
1/25.0000 (WB) 
 
1/200 (IF) 
WB = Western blot, IF = immunofluorescence 
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2.8 Miscellaneous assays 
2.8.1 Phylogenetic analysis 
 
For the phylogenetic analysis the following viruses and attributed PubMed reference 
numbers were used. Note that previously observed changes in TCRV NP are take into 
consideration and are indicated below: 
 
Virus name: PubMed reference number: 
Allpahuayo virus NP: AAG42532.1, GPC: AAG42531.1 
Amapari virus NP: AAN32968.1, GPC: AAN32967.1 
Bear Canyon virus NP: AAN32966.1, GPC: AAN32965.1 
Chapare virus NP: ABY87069.1, GPC: ABY87068.1 
Cupixi virus NP: AAN32964.1, GPC: AAN32963.1 
Flexal virus NP: AAN32962.1, GPC: AAN32961.1 
Guanarito virus NP: NP_899211.1, GPC: NP_899210.1 
Ippy virus NP: ABC71141.1, GPC: ABC71140.1 
Junin virus NP: NP_899219.1, GPC: NP_899218.1 
Lassa virus NP: ADY11069.1, GPC: ADY11068.1 
Latino virus NP: AAN09941.1, GPC: AAN09940.1 
Lujo virus NP: YP_002929491.1, GPC: YP_002929490.1 
Luna virus NP: BAM45325.1, GPC: BAM45324.1 
Lymphocytic choriomeningitis virus NP: ACV72571.1, GPC: ACV72572.1 
Machupo virus NP: NP_899213.1, GPC: NP_899212.1 
Mobala virus NP: YP_516227.1, GPC: YP_516226.1 
Mopeia virus NP: YP_170710.1, GPC: YP_170709.1 
Oliveros virus NP: AAC54655.1, GPC: AAC54654.1 
Parana virus  NP: YP_138544.1, GPC: YP_138543.1 
Pichinde virus NP: YP_138544.1, GPC: YP_138543.1 
Pirital virus NP: YP_025081.1, GPC: YP_025080.1 
Sabia virus NP: YP_089666.1, GPC: YP_089665.1 
Tacaribe virus NP: NP_694850.1, GPC: NP_694849.1 
NP substitutions: I72M, P129S, L244S, 
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S266T, D389G, L390P, Q391P, L392T, 
L490Q, V543M 
Tamiami virus NP: AAN32956.1, GPC: AAN32955.1 
Whitewather Arroyo virus NP: AAK60498.1, GPC: AAK60497.1 
 
Sequences of either NP or GPC of all 25 viruses were aligned using ClustalW2 
alignment tool (EMBL-EBI) at default settings. At this stage, the outgroups influenza 
A virus NP (ADJ37778.1) or human respiratory syncytial virus (RSV) glycoprotein 
(AGN92836.1) were used respectively. Phylogenetic trees were generated using the 
bayesian model software MrBayes (Altekar et al., 2004). Trees were generated using 
general-time reversible substitution types with both rate variation and invariable sites. 
For the analysis 1.500.000 generations of the Markov Chain Monte Carlo (MCMC) 
algorithm analysis cycles with a sample frequency of 1000 and a chain number of 10 
were used. The individual trees were finally visualised with FigTree v1.4.  
 
 
2.8.2 Protein Crystallisation 
 
After protein purification of JUNV, MACV and TCRV NPs (described above), the 
proteins were used in crystallisation trials.  For this proteins were concentrated with 
Vivaspin 20 centrifugal concentrators (Sartorius) to a final protein concentration of 8-
15 mg/ml. Protein samples were incubated with 0.5 mg/ml RNase A (Worthington) 
for 2 hours prior to crystallisation screens. Crystallisation conditions were tested with 
the commercial and departmental crystallisation screens JCSG+, PACT, Classics II, 
PEGs I and II suites (all QIAGEN), Clear Strategy Screen I and II, ProPlex, 
Morpheus, PEG-Ion (all Molecular Dimensions), Stochastic screens 16 – 22 and 
Stochastic PEG screens 1 – 4 (kindly provided by Prof. J. Naismith). Each screen 
consisted of 96 conditions, thus overall around 2000 conditions were tested. 
Individual crystal screens were set up as sitting drops in MRC crystallisation plates 
(Molecular Dimensions) with The Gryphon LCP (Art Robbins Instruments) liquid 
handling robot. Crystallisation drops were set up at ratios of 1:1 and 1:2 (protein to 
precipitant) and plates were incubated at a constant temperature of 20 °C.  
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2.8.3 Small Molecule Screen (Thermal Shift assay) 
 
TCRV and MACV NPs were purified as previously described. Buffers used for the 
screen were 20 mM HEPES (pH 7.4), 150 mM NaCl, 10 mM EDTA and 18% (v/v) 
Glycerol for TCRV NP and 20 mM HEPES (pH 7.4), 300 mM NaCl, 10 mM EDTA 
and 18% (v/v) Glycerol for MACV NP respectively. Reactions were set up to a total 
volume of 100 µl using 500 µM TCRV or 700 µM MACV NP respectively. The 
SYPRO Orange (Molecular Probes) concentration of 0.1% (v/v) was used. The 
addition of 160 µM (for TCRV NP) and 200 µM (for MACV NP) Adenine served as a 
control for a negative temperature shift. Compounds of the Maybridge library 
(Thermo Scientific) were dissolved at a stock concentration of 10 mM in 5% (v/v) 
DMSO and were added to the protein solution at a final concentration of 1 mM and 
0.5% (v/v) DMSO or 0.5% (v/v) DMSO only. After mixing the individual 
components, the samples were incubated for 20 minutes at room temperature before 
increasing the temperature from 25 °C to 95 °C in 0.5 °C intervals every 60 seconds 
using a Stratagene Mx3005p thermocycler. Individual Tm values were calculated by 
nonlinear regression using the Boltzmann equation:  
 
Where: 
 F(pre) = fluorescence reading before the transition of fluorescence at start of the 
analysis area. 
F(post) = fluorescence after the transition of fluorescence at the end of the analysis 
area. 
Tm = the melting temperature. 
C = enthalpy of the reaction. 
The raw data was analysed and the Boltzmann equation was calculated using the 
software GraFit.  
 
 
 
 
  27 
analysis. 
Instrument 
Type 
The Applied Biosystem Real-time instrument on which the experiment was run needs 
to be selected to ensure that software applies the algorithm parameters that are suitable 
for the chosen instrument.  
 
 
Appendix 
 
Boltzm nn Fitti g Method 
 
The Boltzmann equation: 
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where: 
• F(pre) is the fluorescence reading before the transition or melting at the start of the 
analysis region 
• F(post) is the fluorescence reading after the transition or melting, at the end of the 
analysis region 
• Tm is the melting temperature 
• C is the enthalpy o  the r action 
Data are fit to this equation to generate the Tm. 
 
 
 
© 2010 Life Technologies Corporation. All rights reserved.  
The trademarks mentioned herein are the property of Life Technologies Corporation unless otherwise 
noted.  Windows and Excel are registered trademarks of Microsoft Corporation in the United States and 
other countries. 
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2.8.4 Cell viability assay 
 
Cells were grown in 48-well plates (Nunc, Thermo Scientific) and treated with 
different concentrations of drugs (as indicated for the individual experiments) and 
were further incubated as described for individual experiments. The supernatant was 
removed and replaced with 200 µl serum-free DMEM supplemented with 4% (v/v) 
AlamarBlue stain (Thermo Scientific) per well. The cells were incubated for a further 
45 minutes at 37 °C before measuring fluorescence with a Tecan Infinite 200Pro plate 
reader using 560 nm emission and 590 nm emission wavelengths.  
 
 
2.8.5 Interferon induction and signalling assays 
 
A549-pr(IFNβ).GFP or A549-pr(ISRE).GFP cells were seeded into 12-well plates. 
Cells were either mock infected or infected with TCRV or PICV at MOIs of 1, 5 or 
10, followed by incubation at 37 °C for 24 hours. The A549-pr(IFNβ).GFP cells were 
then either left uninfected or infected with SeV (MOI 10) for 48 hours. The A549-
pr(ISRE).GFP cells were either left untreated or treated with 1000 units/ml IFN-α 
(Roferon; Roche) and incubated for 48 hours. Cells were then fixed with 5% 
paraformaldyde for 5 minutes and transferred into the IncuCyte ZOOM (Essen 
BioScience) cell imager. Green fluorescence intensity of each well was measured at 
488 nm. After these measurements cells were treated with DAPI and fluorescence was 
measured using a Tecan Infinite 200Pro plate reader at 358 nm excitation / 461 nm 
emission to normalise green fluorescence to cell density.  
 
 
2.8.6 GST-pulldown assay 
 
Purified proteins containing an N-terminally-fused GST-tag (described above) were 
used for pulldown (precipitation) assays. For this, protein concentrations were 
initially determined by visualisation on coomassie stained polyacrylamide gels 
(described above). After visual averaging of protein samples GST-agarose beads with 
either GST only, NP- or AIF constructs were diluted, if necessary, for equal protein to 
bead ratios between samples. Equal amounts of beads were incubated with cell-
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lysates. The initial pulldown assay used lysates from A549, BHK and HuH7 cell-lines 
(~4 x 106 cells for each sample) in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% 
Igepal (lysis buffer) containing Complete protease inhibitor. Samples were incubated 
with agitation overnight and washed 5x (8x for assays using NPs as prey proteins) 
with lysis buffer. After the final wash, pelleted beads were mixed with 2x disruption 
buffer (2% (w/v) Sodium dodecyl sulphate, 1.4 M 2-Mercaptoethanol, 100 mM Tris-
HCl pH 7.0, 5% (v/v) Glycerol and bromophenol blue) and heated to 100 °C for 5 
minutes before subjecting to SDS-PAGE. From the initial pulldown assays individual 
lanes were excised and submitted to the University of St. Andrews mass spectrometry 
facility for MS/MS analysis. Resulting protein hits were analysed using Scaffold 3 
(Proteome Software) and hits were eventually confirmed using immunoblot analysis. 
For subsequent pulldown assays lysates from HuH7 cells were used. For pulldown 
assays that used TCRV NP-HA, JUNV-NP-HA, MACV NP-HA and ISG 56-HA as 
prey proteins, HuH7 cells (~1 x 106 cells for each sample) were transfected (FuGENE 
6) with 2 µg of individual expression plasmids (mentioned above) for 24 hours prior 
to lysis.  
 
 
2.8.7 Exonuclease assay 
 
RNA substrates used in the exonuclease assays were prepared by purifying the RNA 
oligonucleotides by denaturing polyacrylamide:TBE gel electrophoresis (20 % (v/ v) 
acrylamide, 7 M Urea, 1x TBE, 0.12% (v/ v) TEMED and 0.44% (v/ v) APS) using 
RNA-shadowing followed by sodium acetate precipitation. One of the 
oligonucleotides was labelled with P32 using T4 polynucleotide kinase (Thermo 
Scientific) as instructed by the manufacturer. After labelling of the RNA 
oligonucleotide with P32, the complimentary RNA oligonucleotide was added in a 
molar concentration of 5:1. The mixture was incubated for 5 min at 95 °C before 
allowing to slowly cool to room temperature. The formed oligonucleotide duplex was 
purified as above, with the omission of the denaturing agent urea.  
 
Exonuclease assay samples contained nuclease buffer (20 mM Tris, pH 7.5, 50 mM 
NaCl and 0.1 mg/ ml BSA), 5 mM MgCl2 and about 10 nM P32-labelled RNA 
substrate. The reactions were incubated 1 min prior to addition of individual purified 
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NP proteins (30 µM). The reactions (10 µl) were stopped (at times stated) with 10 µl 
formamide (Sigma Aldrich). For visualisation the samples were loaded onto a 20% 
denaturing polyacrylamide: TBE gel and run at 15 W (pre-run before loading at 15W 
for 1 h) for approximately 4 h before scanning the gel with Typhoon FLA 7000 (GE 
Healthcare) after overnight exposure. For all assays two controls were performed 
including a negative control that was incubated under the same conditions as the 
individual reactions, but without NP present, a control incubated without MgCl2 and 
with 5 mM EDTA. These control reactions were all incubated for the longest time 
point and at 37 °C. 
 
 
2.8.8 Cytotoxicity / apoptosis assay 
 
VeroE6 or VeroshAIF cells were seeded into 24-well plates. Cells were either left 
untreated, treated with 1 µg/ml staurosporine, which induces apoptosis, as a positive 
control or treated with the general caspase inhibitor Z-VAD-fmk (50 µM; VDM 
Biochemicals) for the entire duration of the experiment. Cells were then infected with 
TCRV at an MOI of 1. At the same time the CytoTox-Fluor substrate (Promega) was 
added to the supernatant and the cells were incubated in a IncuCyte Zoom (Essen 
BioScience) equipped cell incubator at 37 °C. The IncuCyte Zoom took four images 
per well, phase and fluorescence at 488 nm, every 45 minutes under live conditions 
over a period of 72 hours. The system-included software calculated the number of 
green-fluorescent cells that were measured in green objects/mm2 and calculated the 
standard error accordingly.  
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3. Results 
 
In this section experiments were conducted to evaluate using the non-pathogenic 
TCRV, specifically the NP protein, for the identification of potential targets for a 
arenavirus-specific antiviral drug design. Ideally the findings of these experiments 
would show conservation among many members of the Arenaviridae family such that 
a strategy for broad-spectrum antiviral activity could be developed, thereby allowing 
the treatment of human infections caused my multiple NWAs, such as GTOV, JUNV 
or MACV. This section will focus initially on compound screens designed to identify 
molecules that interact directly with arenavirus NPs and thus can be used as starting 
points for rational drug design. Then possible interactions with the innate immune 
system will be explored, as it was shown that these responses may be crucial for the 
outcome of arenaviral disease (see Section 1.4.6) and identification of important 
innate immune responses could serve as starting points for antiviral treatments. The 
arenaviral NP is a multifunctional protein that likely interacts with a variety of 
cellular proteins. Therefore this section also describes the experiments performed to 
identify and characterise such virus-host protein-protein interactions, which could 
hold the key for future rational drug design. Finally, the development and use of a 
reverse genetics system for TCRV will be explored, as such a system represents a 
powerful tool in the research of arenaviruses that could be used to evaluate the 
importance of disrupting protein-protein interactions. Such a system is required for 
uncovering targets for protein-protein interaction disruption and is therefore an 
essential tool for antiviral drug design and in the studies of antiviral drug efficacy.  
 
 
3.1 Discovery of anti-arenaviral compounds 
 
As arenaviruses express only four proteins, it is likely that each expressed protein is 
multifunctional in vivo. Several studies have shown the arenavirus NP protein is part 
of the vRNP complex (Young and Howard, 1983, Buchmeier et al., 2007), is involved 
in viral replication (Lennartz et al., 2013),  and is an IFN-antagonist (Rodrigo et al., 
2012, Pythoud et al., 2012). Although these general features where attributed to NP, it 
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appears that there are also fine, but important, differences between NP proteins from 
different arenaviruses. For example, TCRV NP is about 78 – 79% homologous to the 
NPs of the pathogenic JUNV and MACV on amino acid level, but the protein shows a 
reduced ability to interfere with the IFN-induction (see Section 1.2.3.2). In order to 
develop a broad-spectrum anti-arenavirus drug it is important to identify potential 
binding-pockets present in the NP protein from many different arenaviruses, that 
would potentially enable molecules to bind to the protein and prevent it from 
functioning to its full capacity.  
 
Currently there are no specific anti-arenaviral drugs available that could be used to 
treat infections. Thus, it is important to find potential compounds that can be used as a 
starting-point for the development of a specific drug. It is reported that there were 
more than 400,000 small molecule compounds tested against NWAs (Bolken et al., 
2006) and around 80,000 compounds against LASV (Lee et al., 2008, Larson et al., 
2008). The high throughput screens (HTS) resulted in the identification of only a 
handful of potential arenavirus inhibitors [summarised in (Lee et al., 2011, Nunberg 
and York, 2012, Radoshitzky et al., 2012)], the majority of which appear to interfere 
with the viral GP in different ways. However, there are also compounds that act 
against viral RNA synthesis, the Z protein or viral egression (Radoshitzky et al., 
2012). None of these compounds was reported to act specifically on the 
multifunctional NP. As NP is involved in almost every step of the viral replication 
cycle (see Section 1.2.3 Nucleoprotein) this protein is an ideal antiviral drug target. 
Therefore the following section describes studies conducted into clade B NWA NPs 
to identify compounds acting specifically against NP of multiple viruses as potential 
starting points for antiviral drug design.  
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   Purification of Clade B New World arenavirus NPs.  
 
Purification profiles (left panel) of (A) TCRV, (B) JUNV and (C) MACV NP using 
a Sephacryl S-200 HR (GE Healthcare) size exclusion column. Purification of 
TCRV NP was performed using an MBP-tag, while both JUNV and MACV NP 
were purified using a SUMO-tag. The grey bar above the profiles represents the 
fractions pooled after the final purification step. The coomassie gels (right panel) 
show each of the purification steps for the individual proteins. M- Marker (Thermo 
PageRuler Plus), L – total lysate, FT – flow through after nickel purification, Ni – 
elution of nickel purification, TEV – sample after TEV cleavage, GF – pooled 
sample after gel filtration.	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3.1.1 Protein expression and purification 
 
Previously it was shown that full-length arenavirus NPs could be expressed in a 
prokaryotic Escherichia coli system (Qi et al., 2010), or in a more complex eukaryotic 
Baculovirus system using Spodoptera frugiperda SF9 cells (Brunotte et al., 2011a), 
while other truncated NP expressions also used the approach of bacterial expression 
(West et al., 2014, Jiang et al., 2013, Hastie et al., 2011a, Hastie et al., 2011b). For 
initial protein expression tests, NPs of TCRV (kindly provided by Prof. S. Becker, 
Philipps Univerity Marburg), JUNV and MACV (Martinez-Sobrido et al., 2007) were 
cloned into different plasmid vectors that all utilise a poly-histidine (6xHis) tag for 
affinity chromatography as well as a variety of solubility tags. For the duration of 
protein purification, solubility-tags can be used to stabilise the fusion-protein for the 
time of purification (Esposito and Chatterjee, 2006). The solubility-tags tried were 
green fluorescent protein (GFP), MBP and SUMO tag (Wang et al., 2010). All of 
these fusion proteins were separated by a TEV protease cleavage site that allows the 
removal of the solubility-tag towards the end of the purification process. The plasmids 
used were pHisTEV (Liu and Naismith, 2009), pGFP (Liu and Naismith, 2009), the 
pMAL-c2X- derived pLou3 plasmid (MBP tag) (di Guan et al., 1988) and the 
pHisTEV derived pSUMO plasmid (kindly provided by C. D. Owen, University of St. 
Andrews). The cloned plasmids were transformed into the E. coli Rosetta strain 
(Novagen), which expresses the eukaryotic tRNAs encoding for the codons AGG, 
AGA, AUA, CUA, CCC and GGA to enhance the expression of eukaryotic proteins 
in this bacterial system. 
No soluble NP-fusion proteins could be expressed using pHisTEV or pGFP plasmids 
(data not shown). The expression profiles for the three NPs differed depending on the 
use of solubility-tag as well as expression conditions. TCRV NP was expressed using 
pLou3 and its MBP-tag, whereas JUNV and MACV were not soluble when using this 
tag (data not shown). For the expression of JUNV and MACV NPs the pSUMO 
plasmid was used. The SUMO-MACV NP fusion protein was stable enough to be 
expressed using Auto Induction Media (Formedium), which expresses the protein 
over a duration of three days at 16 °C. The SUMO-JUNV NP fusion protein was not 
as stable as it resulted in the expression of E. coli chaperone GroEL (ca. 60 kDa), 
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which tightly bound to the expressed protein and could not be separated from the 
purified protein by affinity- nor size exclusion chromatography. Therefore, SUMO-
JUNV NP was expressed under gentle conditions using LB media and 0.03 mM IPTG 
for protein-induction at 16 °C for 16 hours. After collecting the bacterial pellets, the 
purification procedure for the three NPs was identical. The initial purification step 
was affinity chromatography using immobilised nickel (HisTrap HP column; GE 
Healthcare), which used a buffer containing 700 mM NaCl to reduce background as 
well as to stabilize the individual fusion-proteins. The next step involved the removal 
of the fusion protein (MBP or SUMO) using TEV, where the high-concentration salt 
buffer ensured the stability of the individual NPs during the enzymatic cleavage 
event. The solubility-tag was removed by a second affinity chromatography step 
before a final purification step using size exclusion chromatography (Figure 3.1) 
(Sephacryl S 200; GE Healthcare). The identity and purity of the protein was 
determined using MS and MS/MS MALDI-TOF mass spectrometry. The individual 
proteins were finally concentrated to the concentration required for the individual 
assays the proteins were used in. These protein expression strategies yielded 
approximately 1.5 mg/L TCRV NP, 2.5 mg/L MACV NP and 0.1 mg/L JUNV NP.  
 
3.1.2 Crystallisation 
 
Protein crystallisation is a powerful tool to understand the properties of an individual 
protein, as it gives the opportunity to visualise the protein’s three-dimensional 
structure. This method began development in 1840 with continuous advances made 
up to the present day [reviewed by (Giege, 2013)]. The principle of protein 
crystallisation is the alignment of individual proteins in an ordered manner to form 
crystals that, when exposed to X-rays, amplifies the diffraction pattern of the 
individual atoms within a crystal, so that the position of each atom and thus, the 
protein structure can be determined.  
 
Protein crystallisation was utilised in the attempt to discover the molecular structure 
of the NP protein from TCRV, JUNV and MACV. The aim was to use the generated  
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   Arenavirus NP crystals. 
 
 Protein crystals from individual crystal screens. A) Protein crystals obtained for 
TCRV NP. Crystallisation conditions were 22% PEG 3350, 0.1 M CHES pH 7. 5, 
0.07 M Magnesium chloride (left) and 0.1 M Tris pH 7.5, 34.2 % PEG MME 2000 
(right). B) Protein crystals obtained for MACV NP. Crystallisation conditions were 
0.2 M Ammonium tartrate dibasic, 20% PEG 3350 (left), 0.2 M Sodium tartrate 
dibasic dihydrate, 20% PEG 3350 (middle) and 0.1 M Sodium malonate pH 7.0, 
12% PEG 3350 (right). Scale bars indicate 1 µm. 	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structures to identify conserved regions of arenavirus NP proteins that may act as 
binding pockets for small molecule inhibitors of NP. After purification of the 
individual NPs (see Section 3.1.1), the proteins were concentrated to a final 
concentration of 10 mg/ml and used for sitting-drop crystallisation screens. Initial 
screens were performed at protein-to-precipitant concentrations of 1:1 as well as 2:1 
to affect eventual nucleation conditions. Crystallisation conditions for the three NPs 
were used with JCSG+, PACT, Classics II, PEGs I and II suites (QIAGEN), Clear 
Strategy Screen I and II, ProPlex, Morpheus, PEG Ion (all Molecular Dimensions), 
Stochastic screens 16 – 22 and Stochastic PEG screens 1 – 4 (all Scottish Structural 
Proteomics Facility). Each screen consisted of 96 conditions, thus overall around 
2000 conditions were tested. Initial hits from the crystal trials led to the optimisation 
of small crystals of TCRV NP using 22% PEG 3350, 0.1 M CHES pH 7.5, 0.07 M 
Magnesium chloride at room temperature, which appear to form after approximately 
24 h (Figure 3.2A left image). Further TCRV NP crystals were obtained using 0.1 M 
Tris pH 7.5, 34.2 % PEG MME 2000 (Figure 3.2A right image). Crystals could not 
be further optimised by changing the concentrations or pH of the individual 
precipitant components or the temperature (4 °C). For MACV NP, crystals were 
obtained from the PEG Ion crystal screen (Figure 3.2 B). Crystals for MACV NP 
were obtained in three conditions, firstly, 0.2 M Ammonium tartrate dibasic, 20% 
PEG 3350, secondly, 0.2 M Sodium tartrate dibasic dihydrate, 20% PEG 3350 and 
thirdly, 0.1 M Sodium malonate pH 7.0, 12% PEG 3350. No crystal growth was 
observed for JUNV NP under the conditions tested. No TCRV or MACV crystals 
exceeded the size of 1 µm on their longest side, therefore the crystals were too small 
for diffraction in the in-house X-ray facility.  
 
 
3.1.3 Small molecule screen 
 
In 2004 Lo and colleagues established an easy and feasible HTS for small-molecule 
compounds by fluorescence-based thermal shift assays. The method uses the 
fluorophore SYPRO orange (Sigma), which binds to hydrophobic residues, in 
connection with the thermal melting curve (Tm) of the specific protein (Figure 3.3 A).  
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   TCRV NP thermal shift profile.  
 
Purified TCRV NP was used in thermal shift assays using SYPRO orange dye, 
which binds to hydrophobic residues, in a thermocycler (0.5 °C increase per 
minute). A) Melting curve profile of TCRV NP using standard buffer conditions 
(black) and with the addition of 100 mM Adenine (red) as a positive control. B) 
Thermal shift profile of TCRV NP screened with 633 compounds from the 
Maybridge small molecule compounds library. Blue bars indicate compounds that 
resulted in a temperature shift of more than 2 °C (stabilising or destabilising) with 
the compound number indicated above or below and further information of the 
individual compounds can be found in Appendix Table 1 and 2. 	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Small-molecule compounds that bind specifically to the protein shift the melting 
temperature (ΔTm) by either stabilising (positive ΔTm) or destabilising (negative ΔTm) 
the protein.  
 
A compound library was screened using the aforementioned screening method to 
identify compounds that had a stabilising or destabilising effect on TCRV NP. Such 
“hits” would therefore represent compounds that bind to and potentially inhibit the 
function of NP. For this method the buffer composition for TCRV NP was initially 
optimised to obtain a single Tm as various multimeric forms of the protein could affect 
the curve. The addition of EDTA and changing the concentration of glycerol shifted 
the Tm from a biphasic curve to a curve with a single peak. The protein concentration 
was then optimised (160 µM) as was the SYPRO orange concentration (0.1%) to 
improve the obtained fluorescent profile. To test that this HTS approach was possible 
for TCRV NP, the protein was incubated with adenine, optimised to 7 mM. Adenine 
is a purine derivative that was chosen because it is known that adenosine triphosphate 
(ATP), a purine analogue comprised of adenine and a ribose ring, is an inhibitor of 
some exonucleases of the DEDDh family (McRobbie et al., 2012) and arenaviral NPs 
not only bind to nucleotides but also exhibit exonuclease activity similar to DEDDh 
exonucleases (Qi et al., 2010). Interestingly, adenosine is also an analogue of an anti-
TCRV compound, MY-24, reported in 2010 (Gowen et al., 2010).  Indeed, the 
compound affected the overall Tm of 53.6 ± 0.3 °C and resulted in a ΔTm -24.8 ± 0.96 
°C (Figure 3.3 A), thereby indicating the validity of the screening method.  
 
After optimising the overall experimental conditions, TCRV NP was screened with 
643 compounds at a concentration of 1 mM from the Maybridge Rule of 3 fragment 
library, similar to Major and Smith (2011). The Z-factor, which is indicative of the 
reproducibility of the HTS, between the nine screened 96-well plates was 0.92 ± 0.06, 
therefore the conducted assay can be recognised as a robust screen. For the full list of 
compounds screened see Appendix Table 3. To validate the screened compounds a 
cut off of ΔTm ± 2 °C was chosen, which resulted in 10 stabilising and 14 
destabilising small-molecule compounds (Figure 3.3 B). The most stabilising 
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compound within this screen was 3-furoic acid with a ΔTm  of 9.07 °C. Although all 
stabilising compounds contain a ring structure, either pentamer or hexamer, there is 
no obvious chemical property shared between these molecules. Similar to the 
stabilisers, the destabilisers did not share an obvious property that would explain the 
binding mode to TCRV NP. From the 16 destabilising molecules, there were 5 
compounds that were strongly destabilising, namely 3-(trifluoromethyl)pyrazole (ΔTm  
-9.94 °C), methyl 3-aminobenzoate (ΔTm  -9.94 °C), ethyl 4-piperodomecarboxylate 
(ΔTm  -9.38 °C), 2H-chromene 3-carothioamide (ΔTm  -10.58 °C) and tert-butyl-N-(3-
thienyl)carbamate (ΔTm  -16.0 °C). 
 
TCRV NP was derived from a virus that is non-pathogenic in humans. TCRV is a 
Hazard Group 2 agent in the UK (BSL-2 in the USA), and was used in the 
aforementioned screen such that potential hits can be validated in vivo under standard 
lab conditions. However viruses with more clinical importance to human health, such 
as MACV and JUNV, are Hazard Group 4 (BSL-4) agents and require special 
containment laboratories. Therefore to identify compounds that have potential broad-
spectrum antiviral activity and to show that they are potentially active against viruses 
with human importance, the same thermal shift assay was performed with MACV NP 
(200 μM), based on the hits obtained for TCRV NP.  
 
Adenine was used as a control for the MACV NP (Tm 50.2 ±0.3 °C) screen, resulting 
in a ΔTm  -15 °C ±0.3 °C. Similar to the TCRV NP screen the Z-factor for the MACV 
NP screen was 0.9, while the samples for TCRV NP on the same 96-well plate scored 
a Z-factor of 0.97. The convoluted screen included 29 compounds (compounds 
included Appendix Table 1 and 2). 17 compounds showed the same trend, but only 
two had a larger effect on the ΔTm than the 2 °C threshold (Figure 3.4). The melting 
point of the proteins was stabilised by [5-(2-Furyl)thien-2-yl]methanol, ΔTm 8.1 °C 
for TCRV NP and ΔTm 10.4 °C for MACV NP. On the other hand cyclosporin A 
(CsA) had the opposite effect on protein stability as it reduced the melting point by 
ΔTm 10.4 °C for TCRV NP and ΔTm 16.6 °C for MACV NP. General trends for the 
two proteins bound by the same compound should remain the same, whereas specific 
differences in ΔTm between TCRV and MACV NP can be explained by different  
 3. RESULTS 	  
 
	  	  	  	  	  	   125	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   Thermal shift profile of MACV NP in comparison with 
TCRV NP.  
 
Thermal shift profile of TCRV and MACV NP screened with the small molecules 
from the Maybridge library that gave temperature shifts in the initial screen of 
more than 2 °C. Two compounds gave similar results for both NP proteins,  
[5-(2-Furyl)thien-2-yl]methanol (stabilising) and Cyclopsorin A (destabilising), the 
structures of which are shown. 	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molar concentrations of these two proteins, 160 µM (TCRV NP) compared to 200 µM 
(MACV NP). Although these two compounds are not the only ones resulting in a ΔTm 
difference greater than 2 °C, both [5-(2-Furyl)thien-2-yl]methanol and CsA are the 
only two compounds that show a similar trend for both proteins and thus, a potential 
shared binding mode between TCRV and MACV NP. 
 
 
3.1.4 [5-(2-Furyl)thien-2-yl]methanol 
 
There is not much known about this compound. The molecule itself consists of a 
furan and a thiophene ring structure as well as a methanol group. To the author’s 
knowledge this small-molecule compound has not been directly used in patents or 
publications with the exception of Major and Smith (2011) using the compound in a 
Maybridge library screen against a trypanosome protein with no significant result.  
 
 
3.1.4.1 [5-(2-Furyl)thien-2-yl]methanol cytotoxicity 
 
To assess cytotoxicity of [5-(2-Furyl)thien-2-yl]methanol, VeroE6 cells were either 
left untreated or treated with various concentrations (300 – 600 µM) of this compound 
over the period of five days and the cell viability was measured using AlamarBlue. 
AlamarBlue has the advantage over alternative methods of measuring cell viability, 
such as MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], that the 
absorbance reading is linear and correlates well with the number of viable cells, 
whereas the dynamic enzymatic reaction of MTT can give an overrepresentation of 
viable cells. The results suggest that cell viability was not significantly affected by the 
compound (Figure 3.5). As a result further experiments can be conducted using the 
maximum concentration tested (600 µM) without compromising validity of the results 
observed. A caveat when interpreting these results is that at the time that these 
experiments were conducted the concentration of the only stock solution of [5-(2-
Furyl)thien-2-yl]methanol available may have been slightly inaccurate due to  
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   Cytotoxicity of [5-(2-furyl)thien-2-yl]methanol.  
 
The cytotoxicity of [5-(2-furyl)thien-2-yl]methanol was measured using 
AlamarBlue. VeroE6 cells were grown in 48 well plates and treated with [5-(2-
furyl)thien-2-2yl]methanol at the concentrations indicated (0-600 µM). The 
concentrations are estimates as the concentration of the only available stock may 
have been slightly inaccurate. At the indicated times post-treatment cell viability 
was determined using AlamarBlue, the fluorescence of which was measured in a 
Tecan Inifinity 2000Pro platereader. Values for mock samples were set to 100% 
cell viability. Results represent the average of six individual experiments ± 
standard deviation (SD). 	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inadequate storage conditions. Therefore the concentrations indicated are only an 
estimated value and cytotoxicity assays will have to be repeated. 
 
 
3.1.4.2 [5-(2-Furyl)thien-2-yl]methanol effect on arenavirus infection 
 
VeroE6 cells were either left untreated or were treated with 600 µM [5-(2-Furyl)thien-
2-yl]methanol after TCRV infection at an MOI of 3 and cells were fixed at various 
times post-infection. Immunofluorescence analysis of the samples showed that at 24 
hours post-infection NP was not observed in cells treated with [5-(2-Furyl)thien-2-
yl]methanol, whereas NP was detected in untreated cells (Figure 3.6). It is worth 
mentioning F-actin was also not observed in drug-treated cells at this time point. 
However at 48 hours post infection the level of NP staining in drug-treated cells had 
recovered to that of untreated samples, with a similar NP distribution for both 
conditions. At 72 hours post infection in untreated cells NP localised around the 
cytoplasmic membrane, whereas in drug-treated cells it had a more diffuse 
distribution throughout the cytoplasm. This staining pattern observed in drug-treated 
cells at 72 hours post infection is usually observed in VeroE6 cells at earlier times 
post-infection, therefore it appears that viral replication in these cells was delayed. It 
is worth noting that the length of time by which [5-(2-Furyl)thien-2-yl]methanol 
remains active before the effects against TCRV NP begin to wear off, is currently 
unknown.  
 
The inhibitory effect of [5-(2-Furyl)thien-2-yl]methanol was then tested in a viral 
context by analyzing the infectious titre of virus released from drug-treated cells. 
After VeroE6 cells were infected with TCRV at an MOI of 1 cells were either treated 
with [5-(2-Furyl)thien-2-yl]methanol or left untreated and at 24 hours post-infection 
virus-containing supernatants were collected. The infectious titre of the samples was 
determined by plaque assay. The results showed that drug-treatment reduced the 
infectious titre by approximately 1 log (Figure 3.7 A). As previously mentioned the 
stock concentration of the compound may have been inaccurate and therefore 
experiments will have to be repeated with more accurate concentrations. This will  
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Effect of [5-(2-furyl)thien-2-yl]methanol on TCRV NP. 
 
VeroE6 cells were infected with TCRV at an MOI of 3 and either left untreated or 
were treated with 600 µM [5-(2-furyl)thien-2-yl]methanol after virus adsorption. At 
the indicated time points the cells were fixed and subjected to immunofluorescence 
analysis using a TCRV-specific NP antibody (red) or stained with phalloidin to 
detect filamentous actin (green). The nucleus was visualized using DAPI. Images 
were taken at 630 x magnification, with scale bars representing 10 µm. 	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include a variety of compound concentrations to get a better estimate of the efficiency 
of the compound against TCRV infection.  
 
NP levels in infected cells that were pre-treated with 600 µM [5-(2-Furyl)thien-2-
yl]methanol 12 hours before infection (with continuous drug treatment after 
infection), cells that were treated with the same compound concentration only after 
virus adsorption or in untreated cells, were analysed by Western blot. When cells 
were lysed at 24 hours post-infection the results show that drug treatment after 
infection resulted in a slight reduction in NP expression levels, while pre-treatment 
had a more pronounced effect on NP levels (Figure 3.7B). By 48 hours post-infection 
the levels of NP in cells treated only after virus adsorption were similar to those in 
cells that had been pre-treated with the compound. In contrast to the 
immunofluorescence results (Figure 3.6), where NP levels appeared similar between 
treated and untreated cells, NP concentrations measured by Western blot remained 
low in drug-treated cells at 48 hours post infection.  
 
 
3.1.5 Cyclosporin A (CsA) 
 
Cyclosporin A was discovered in 1972 as a product from the fungal fermentation of 
Trichoderma polysporum and Cylindrocarpon lucidum (Borel et al., 1977). The 
compound is a cyclic peptide composed of 11 amino acids, which is licensed and used 
in the clinic (brand names include: Gengraf©, Neoral©, Sandimmune© Capsorin© 
and Capimune©). The drug is classed as an immunosuppressant that is primarily 
administered after organ transplantations. Although the exact mode of action in vivo is 
described as largely unknown, the main immunosuppressant action is thought to 
involve the interaction with the cellular protein cyclophilin A (CypA) and the CsA-
CypA complex in turn prevents T lymphocyte activation by blocking calcineurin (Ho 
et al., 1996, Matsuda and Koyasu, 2000). It is worth noting that there are non-
immunosuppressant analogues of CsA (Twentyman et al., 1992, Landrieu et al., 
2010), which might be of particular interest for antiviral applications.  
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Effect of [5-(2-furyl)thien-2-2yl]methanol on TCRV 
during infection.  
 
A) VeroE6 cells were infected with TCRV at an MOI of 1 and then either left 
untreated or were treated with 600 µM [5-(2-furyl)thien-2-2yl]methanol after virus 
adsorption. At 24 hours post-infection supernatants were collected and the 
infectious titres determined by plaque assay. B) Western blot analysis of TCRV NP 
of VeroE6 cells infected with TCRV (MOI of 1) that were either left untreated 
(Mock) treated with 600 µM [5-(2-furyl)thien-2-2yl]methanol 12 hours before 
infection and throughout infection (Pre-treat) or cells that were treated with 600 
µM [5-(2-furyl)thien-2-2yl]methanol after virus adsorption (treat). The loading 
control was β-actin. 	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Interestingly, it was found that CsA treatment affects different viruses, including 
HBV (Xie et al., 2007), HCV (Nakagawa et al., 2004, Nakagawa et al., 2005), 
influenza A virus (Schiltknecht and Ada, 1985, Liu et al., 2012b) and VACV 
(Damaso and Keller, 1994). CsA is the prototypic inhibitor of the cellular cyclophilin 
protein family, which consists of 17 different proteins (Frausto et al., 2013). These 
proteins have been demonstrated to have important roles during replication of many 
different viruses including HIV [summarised in (Frausto et al., 2013)], HCV 
[summarised in (Frausto et al., 2013)], WSN (Qing et al., 2009), rotavirus (He et al., 
2012), VSV (Bose et al., 2003), HPV (Bienkowska-Haba et al., 2012) and 
coronaviruses (de Wilde et al., 2011, Pfefferle et al., 2011, Favreau et al., 2012).  
After the initial compound screen (see Section 3.1.3) the effect of CsA on TCRV NP 
during the viral replication cycle was investigated further.  
 
 
3.1.5.1 CsA cytotoxicity 
 
Depending on the study and on the cell lines used the active concentration of CsA 
varies widely. Also many studies do not specify the duration of treatment, which can 
have an impact on cell survival. Thus, a cytotoxicity assay using AlamarBlue was 
used to determine the maximum concentration of CsA that can be used in further 
experiments without inducing cytotoxic effects. 
 
For this Huh7 or VeroE6 cells were seeded into a 48-well plate and either left 
untreated or were treated with 1 – 7 µM CsA. Individual plates were then incubated 
with AlamarBlue for 30 min before reading fluorescence intensities with a Tecan 
Infinity 2000Pro plate reader. Measurements of cytotoxicity were taken daily over a 
period of four days (Figure 3.8). On day five after addition of CsA the drug loses its 
activity and the reduction in cell viability is reversed (data not shown). Constant 
treatment of the human liver cell line Huh7 with CsA is not well tolerated. Treatment 
with 1 µM CsA resulted in a reduction of 10% in viability on day one post-treatment  
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Cytotoxicity of Cyclosporin A (CsA).  
 
The cytotoxicity of cyclosporine A was measured using AlamarBlue. Huh7 (A) or 
VeroE6 (B) cells were grown in 48 well plates and treated with cyclosporine A at 
the concentrations indicated (0 – 7 µM). At the indicated times post-treatment cell 
viability was determined using AlamarBlue, the fluorescence of which was 
measured in a Tecan Inifinity 2000Pro platereader. Values for mock samples were 
set to 100% cell viability. Results represent the average of six individual 
experiments ± standard deviation (SD). 	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(Figure 3.8 A), which dropped further by day two post-treatment to 64% (1 µM 
CsA). The viability was progressively reduced up to day four after addition of CsA to 
the supernatant, so that the final cell viability ranged from only 39% (1 µM CsA) to 
19% (7 µM CsA) compared to the untreated samples. Overall, the cell viability data 
show that CsA treatment over a period of time is not well tolerated by Huh7 cells and 
the drug can be considered toxic to these cells.  
 
CsA treatment of the VeroE6 African green monkey cell line resulted in less cytotoxic 
effects than those observed in the Huh7 cells upon constant drug treatment. While 
only a concentration of 7 µM CsA showed a significant reduction after day one 
(90%), from day two onwards there was a significant reduction in viability of cells 
treated with 6 or 7 µM CsA compared to those treated with concentrations of 5 µM or 
less (Figure 3.8 B). This trend continued through the four days of treatment.  
 
 
3.1.5.2 CsA effect on NP during infection 
 
The effect of CsA on TCRV NP expression and distribution was investigated by 
immunofluorescence. Cells were infected with TCRV at a MOI of 3, either left 
untreated or treated with 5 µM CsA and fixed every 12 hours up to 60 hours post 
infection. Immunofluorescence analysis was performed with an anti-TCRV NP 
antibody to analyse the expression level and distribution of NP within the infected 
cells (Figure 3.9).  
 
In untreated cells after the establishment of infection NP appeared to be located in 
punctuated aggregates inside the cytoplasm up to 24 hours post infection (Figure 
3.9). After 36 hours the levels of NP in the cell drastically increased and the cells 
showed a mixture of punctuated and diffuse staining spread throughout the cytoplasm. 
NP began a major redistribution inside the host cell after about 48 hours post 
infection, when NP relocated to the cytoplasmic membrane, while some punctuated 
staining within the cytoplasm still remained. The redistribution of NP appeared to be  
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Cyclosporin A causes redistribution of arenavirus NP. 
 
Immunofluorescence images in VeroE6 cells over the course of a TCRV infection 
cycle. VeroE6 cells were infected with TCRV at an MOI of 3 and either left 
untreated or were treated with 5 µM cyclosporine A after virus adsorption. At the 
indicated time points the cells were fixed and subjected to immunofluorescence 
analysis using a TCRV-specific NP antibody (red) or stained with phalloidin to 
detect filamentous actin (green). The nucleus was visualized using DAPI. Images 
were taken at 630 x magnification, with scale bars representing 10 µm. 	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completed after about 60 hours post infection, when almost all NP was visible at the 
plasma membrane.  
 
However, this pattern of NP distribution in infected cells was altered when cells were 
treated with CsA. The typical punctate staining of NP early in infection was not as 
obvious and did not appear in all infected cells. After approximately 24 hours post 
infection NP was entirely distributed around the plasma membrane, an observation 
that did not occur for untreated cells until 60 hours post-infection. This pattern, of NP 
distributed to the plasma membrane, remained throughout the viral replication cycle 
in CsA treated cells. It is worth noting that the staining for NP in CsA treated cells 
appeared to be brighter than in untreated cells. 
 
 
3.1.5.3 CsA effect on viral titre 
 
To see whether or not the treatment with CsA had an effect on viral titers and whether 
the brighter NP staining in immunofluorescence resulted in increased titer, growth 
curves where conducted with CsA treated and untreated TCRV infected VeroE6 cells. 
The time of CsA addition was also studied in these experiments by either pre-treating 
cells 24 hours before infection, after viral adsorption (0 h) or every 24 hours thereafter 
(Figure 3.10 A). The growth kinetics indicated that during the first two days of the 
experiment the presence or absence of CsA had no effects on the infectious titre of 
released virus (Figure 3.10 B). The released titres from all CsA treated samples were 
similar at day three post-infection, except for a slight reduction in the samples treated 
24 h post infection. There was also a slight difference on day 5 post infection, where 
pre-treated samples, those treated after adsorption and those treated 72 hours after 
infection resulted in an approximate 0.5 log reduction, compared to the other treated 
samples. However these differences were not significant and from day three post-
infection the infectious titres of all CsA treated samples were in decline, indicating 
the cells were likely no longer producing infectious virus and the infection had run its 
course. Therefore in the productive phase of infection (up to day three post-infection)  
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Effect of Cyclosporin A treatment on viral titres.  
 
To see whether and when cyclosporine A has an effect on the titres of released 
TCRV, cells were treated with CsA at various times post infection as indicated in 
the schematic (A). Samples were either left untreated or were treated with 5 µM 
CsA 24 hours prior to infection, after virus adsorption, 1 day, 2 day or 3 days post 
infection. Infections were performed at an MOI of 1. After infection supernatants 
from CsA treated and untreated cells were harvested every 24 hours for a total of 7 
days. The infectious titre of TCRV in each of the samples was then determined by 
plaque assay (B). Results are the average of three independent experiments ± SD. 	  
 3. RESULTS 	  
 
	  	  	  	  	  	   144	  	  
 
A 
1.0E+02'
1.0E+03'
1.0E+04'
1.0E+05'
1.0E+06'
1.0E+07'
1' 2' 3' 4' 5' 6' 7'
B 
Days p. i. 
V
ira
l t
itr
e(
pf
u 
/ m
l) 
Mock 
 
 
 - 24 h 
0 h 
24 h 
48 h  
72 h 
Treatment: 
 3. RESULTS 	  
 
	  	  	  	  	  	   145	  	  
The time of CsA addition had no significant effect on the infectious titre of release 
virus. 
 
When comparing the CsA treated samples to the uninfected mock sample, the 
maximum titre was reached at day 3 post infection for all samples. The infectious titre 
of the CsA treated samples began to decline from day three post-infection, 
demonstrating the lack of further virus release and the loss of infectivity of the virus 
present in the culture supernatant. However the infectious titre of the mock sample 
remained static between days three and four post-infection before the decline in titre. 
This may suggest that either virus release halted by day three post-infection but in the 
absence of CsA the release virus was stable for slightly longer, or that low levels of 
infectious virus were released between days three and four post-infection which when 
combined with loss of infectivity of previously released virus results in a static titre. 
Overall these results suggest that the absence of CsA may have allowed the virus 
infection to persist for slightly longer, but that CsA treatment did not have any effect 
on the peak titre of released virus.  
 
 
3.1.5.4 Time required for CsA to affect NP 
 
The time required for CsA to exert its effect on the translocation of NP inside the cell 
was then addressed. VeroE6 cells were infected with TCRV and either left untreated 
or treated with CsA at different time points post-infection. Cells were fixed at 48 
hours post-infection when the NP distribution within infected cells appears diffuse in 
the cytoplasm. Cells were treated with CsA from 2 to 10 hours prior to the 48 hour 
fixation time point to identify how long it would take for CsA treatment to show the 
previously observed effect of redistributing NP towards the plasma membrane 
(Figure 3.11). Immunofluorescence analysis showed that NP distribution was not 
affected by CsA treatment until 8 hours prior to fixation. Between 8 and 10 hours of 
CsA treatment the effect on NP relocalisation can be described as an intermediate 
between untreated samples of this time point and samples previously seen that were  
 3. RESULTS 	  
 
	  	  	  	  	  	   146	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Duration of Cyclosporin A treatment affects NP 
distribution.  
 
To evaluate how long it takes for NP to redistribute within an infected cell after 
CsA treatment, cells were infected with TCRV at an MOI of 3 and at various times 
(2 – 10 hours) prior to fixation were treated with 5 µM CsA. Samples were fixed 
after 48 hours post infection and subjected to immunofluorescence analysis using a 
TCRV-specific NP antibody (red) or stained with phalloidin to detect filamentous 
actin (green). The nucleus was visualized using DAPI. Images were taken at 630 x 
magnification, with scale bars representing 10 µm. 	  
 3. RESULTS 	  
 
	  	  	  	  	  	   147	  	  
 
 
 
 
F-Actin  NP DAPI MERGE 
Mock 
CsA 
-2h 
CsA 
-4h 
CsA 
-6h 
CsA 
-8h 
CsA 
-10h 
 3. RESULTS 	  
 
	  	  	  	  	  	   148	  	  
treated with CsA over longer periods of time. The redistribution of NP was fully  
visable after 10 hours of CsA treatment. 
 
 
3.1.5.5 Investigation into possible mode of action of CsA in arenavirus infection 
 
The potential mechanism by which CsA affects TCRV NP during viral replication 
was investigated. Reports from Liu et al. (2012b) or Damaso and Keller (1994) 
showed that CsA treatment inhibited the replication of influenza A virus and VACV 
in tissue culture by suppressing viral protein expression levels. To address whether 
similar observations occur during arenavirus replication, TCRV NP levels were 
compared every 24 hours over four days of TCRV infection in cells either left 
untreated or that were continuously treated with 5 µM CsA (Figure 3.12). Western 
blot analysis of NP levels normalised to cellular actin levels showed that there is 
effectively no difference between the treated or untreated samples. Therefore it can be 
concluded that although CsA treatment affects NP distribution it does not affect a role 
of NP in transcription and subsequent translation of viral proteins. 
 
CsA is the prototypic inhibitor of cyclophilins (Frausto et al., 2013) and therefore the 
interference with this protein family could indirectly affect arenavirus NPs. CypA has 
previously been shown to be important during HIV replication by interacting with the 
Gag protein (Cacalano et al., 1992, Zhao et al., 1997, Franke et al., 1994). CypA is 
actively incorporated into the mature virion as a consequence of this interaction and 
results in a higher infectivity of the progeny virus (Braaten et al., 1996a, Braaten et 
al., 1996b, Kootstra et al., 2003). The role of CypA during arenavirus infection was 
assessed by generating a lentivirus transduced VeroE6 cell line expressing a shRNA 
against CypA, VeroshCypA (Figure 3.13 A and B). The expression of CypA in these 
cells was reduced to 0.7% of naïve VeroE6 cells and immunofluorescence showed 
that the remaining CypA expression was predominantly in the nucleus and absent in 
the cytoplasm, the site of arenavirus replication (Figure 3.13 B). Naïve VeroE6 and 
VeroshCypA cells were infected with TCRV at MOIs of either 0.1 or 1, supernatant  
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TCRV NP expression in CsA treated cells.  
 
VeroE6 cells were either left untreated or treated with 5 µM CsA 24 hours before 
infection with TCRV at an MOI of 1. Cells were lysed at 1, 2, 3 and 4 days post 
infection and the lysates were used for analysis by western blot (A). NP expression 
was normalised against actin levels and expressed as relative NP expression (B). 
Relative NP expression levels were determined by densitometry. Results are the 
average of three independent experiments ± SD. 	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samples were taken over a period of five days and the infectious titres determined. 
Although there was a slight attenuation in the CypA knockdown cells, especially at 
the lower MOI, the difference was not significant (Figure 3.13 C). Therefore it is 
unlikely that the effect of CsA treatment on arenavirus infection is due to drug-related 
samples were taken over a period of five days and the infectious titres determined. 
Although there was a slight attenuation in the CypA knockdown cells, especially at 
the lower MOI, the difference was not significant (Figure 3.13 C). Therefore it is 
unlikely that the effect of CsA treatment on arenavirus infection is due to drug-
relatedeffects on CypA. Furthermore immunofluorescence analysis of TCRV NP 
during infection of VeroshCypA cells did not result in any redistribution of NP as 
observed with CsA treatment (data not shown).  
 
A previous study suggested that CsA affected the morphology of HK-2 cells by 
changing the cytoskeletal filamentous actin (F-actin) (Moss et al., 1992, Slattery et al., 
2005). Therefore immunofluorescence analysis was performed on TCRV-infected 
VeroE6 cells treated with 5 µM CsA to assess the drug-mediated effects on F-actin. 
The results demonstrated that CsA treatment changed the filamentous staining of F-
actin to a more punctate staining with different degrees of cytoskeletal rearrangement 
(Figure 3.14). This was likely due to stress-fibre formation leading to large clusters of 
punctuated F-actin (Luftig and Lupo, 1994, Gladnikoff et al., 2009, Pellegrin and 
Mellor, 2007, Tojkander et al., 2012). While TCRV NP expression levels did not 
seem to be affected in cells that demonstrated stress-fibres, it was in these cells that 
NP redistributed towards the cell membrane. To investigate whether the F-actin 
network was also important for the distribution of NP or whether NP migrates through 
the cell using the F-actin filaments similarly to the observation for LASV Z protein 
(Fehling et al., 2013), the F-actin filaments were depolarised using Latrucullin A. As 
treatment of cells with this drug can only be tolerated for a limited amount of time no 
assessment of protein levels can be made, but a different staining pattern for TCRV 
NP could be observed compared to mock treated cells (Figure 3.14). NP appeared 
more diffuse in cells with partially increased staining proximal to the cytoplasmic 
membrane, although not as well defined as observed in CsA-treated cells. However 
when Latrucullin A was removed and the cells allowed to recover for a further six 
hours prior to fixation, the effects on F-actin were reversed. Both F-actin and NP  
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Effect of Cyclophilin A on arenavirus infection.  
 
A cyclophilin A (Cyp A) knockdown VeroE6 cell-line was generated by lentivirus-
transduction to express shRNA against Cyp A mRNA. Cyp A expression was 
analysed in naïve VeroE6 and VeroE6shCypA cells by Western blot (A) and 
immunofluorescence (B). C) Replication kinetics of TCRV in the two cell-lines. 
Cells were infected with TCRV at an MOI of either 1 or 0.1 and supernatant 
samples harvested every 12 hours post-infection. The infectivity of the samples was 
measured by plaque assay. Results represent the average of three independent 
experiments ± SD. 	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staining returned to that observed in untreated cells, which suggests that the 
redistribution of NP was as a result of the rearrangement of F-actin. As CsA treatment 
was also responsible for a redistribution of F-actin these results may indicate CsA-
mediated effects on the actin network as the reason for NP redistribution in CsA-
treated cells. 
 
 
3.1.6 Conclusions 
 
In this section it was shown that the bacterial expression of TCRV and MACV NP 
yielded enough soluble and purified protein to perform both biochemical assays and 
protein crystallisation. Expression of JUNV NP was more challenging than either 
TCRV or MACV NP and yielded smaller amounts of pure protein preparations. The 
predominant limiting factor for purification of JUNV NP is the co-purification of the 
bacterial chaperone protein GroEL, which is approximately the same size as JUNV 
NP and binds the protein, so that removal of this purification contaminant was 
challenging. Crystalllisation trials with the three NPs resulted in the generation of 
small protein crystals for TCRV and MACV NP. During the course of this project 
these crystals could not be further optimised to a size required for x-ray diffraction. 
Later work performed during the small molecule screens, using thermal shift assays, 
revealed that the addition of EDTA changes the NP preparations from a mixture of 
protein present in dissimilar configurations into a more homogeneous protein sample 
as could be observed with the shift from a melting curve with several melting 
temperatures to a homogenous, single melting curve when EDTA was present. A 
homogenous protein sample would likely favour the growths of larger crystals in 
future crystallisation trials. 
 
Here a novel approach for the HTS of small molecule compounds against 
arenaviruses was shown. The purified NPs can be used to screen large small molecule 
libraries, such as the Maybridge Rule of 3 fragment library used in this study. In 
contrast to previous studies (Bolken et al., 2006, Lee et al., 2008, Larson et al., 2008) 
the approach using during this project involved a thermal shift-based screening  
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Effects of drug treatment on actin filaments during 
TCRV infection.  
 
VeroE6 cells were infected with TCRV at an MOI of 3 and either left untreated 
(Mock) or treated with 5 µM CsA after viral adsorption. To investigate the 
importance of F-actin, cells were treated with the actin depolimerising Latrucullin 
A (1 µM) for 4 hours before fixation. To observe the effects of drug removal cells 
were treated with Latrucullin A (1 µM) for 1.5 hours before the drug was removed 
and incubated in the absence of the drug for a further 6 hours before fixation. All 
cells were fixed with 5% paraformaldehyde at 48 hours post infection. Cells were 
stained for F-actin (green; phalloidin), TCRV NP (red) and the nucleus was 
visualized using DAPI. Images were taken at 630 x magnification, with scale bars 
representing 10 µm.  	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method to identify small molecule compounds that directly targeted the test protein, 
NP, thereby removing the requirement of alternative methods of testing against off-
target effects. This method also has an advantage over alternative methods in that it is 
not restricted by biological containment regulations that apply to highly pathogenic 
viruses, such as MACV or JUNV. The screens resulted in the identification of 24 
compounds that showed a shift in the melting temperature of TCRV NP, 10 of which 
stabilised and 14 of which destablised the protein. However, to find potential broad-
spectrum anti-arenaviral these 24 compounds were further tested against MACV NP, 
which resulted in the identification of two compounds, [5-(2-Furyl)thien-2-
yl]methanol and CsA that demonstrated effects against both TCRV and MACV NP.  
 
While [5-(2-Furyl)thien-2-yl]methanol resulted in an increase in Tm by 8.1 (TCRV 
NP) and 10.4 °C (MACV NP), CsA had the opposite effect and the Tm was reduced 
by 10.4 (TCRV NP) and 16.6 °C (MACV NP). The fact that these two compounds 
showed the same temperature shifts against the two proteins tested indicate a similar 
mode of action or position of binding, which can be confirmed once the protein 
structures of the two NPs is solved by protein crystallography. At the same time this 
also means that the other small molecule compounds that resulted a Tm change for 
TCRV NP should not be discarded, but most likely indicate binding-sites that are 
specific to the protein. Similar observations could possibly be made when the whole 
fragment library is screened against MACV NP or other arenavirus NPs. These 
screens could still reveal powerful anti-viral compounds against specific arenavirus 
proteins.  
 
The compounds were tested for cytotoxicity in tissue culture and while [5-(2-
Furyl)thien-2-yl]methanol showed low levels of cytotoxicity, the results for CsA were 
of mixed nature depending on the cell line used, despite the fact that this compound is 
already approved for clinical use. This might imply off-target effects, such as binding 
and inhibiting cyclophilins (Frausto et al., 2013), by CsA. Whereas the low 
cytotoxicity for [5-(2-Furyl)thien-2-yl]methanol could mean that this compound is 
very selective for the viral proteins.  
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As previously mentioned experiments performed using [5-(2-Furyl)thien-2-
yl]methanol will be repeated with more accurate concentrations of the compound to 
test for its activity against TCRV infection. Preliminary results shown in this section 
are promising by showing reductions in NP levels in cells and a reduction in viral 
titres. More importantly for the use of this compound, both the duration it remains 
active against arenavirus infection and the maximum concentration that can be used in 
cells without showing cytotxoxity, will have to determined.  
 
Experiments shown in this section with CsA-treated cells revealed that the viral NP is 
redirected to the cellular membrane, for a reason currently unknown. The effect takes 
approximately 8 – 10 hours after CsA treatment to become fully obvious. Viral 
growth kinetic analysis in the presence of the drug showed that the timing of 
treatment is not important, but virus release halted 24 hours prior to control samples 
resulting in a quicker loss of viral infectivity. The results shown in this chapter 
suggest that the effect of CsA on viral replication is likely not due to effects on the 
cellular protein CypA, however the compound might affect other cellular proteins, 
such as other cyclophillins that indirectly impact the viral NP in infected cells. The 
involvement of the cytoskeleton was tested as a reason for the relocalisation of NP by 
focusing on F-actin. CsA changed the F-actin filaments and caused the formation of 
stress fibres as well as the disruption of filamentous actin. Similar effects were 
observed in cells treated with the reversible actin–depolimerising agent Latrucullin A, 
resulting in a change of NP distribution in the cell, which was reversed once the drug 
was removed from the cell. This observation means that the actin cytoskeleton likely 
plays an important role during NP transport. The localisation of NP after Latrucullin 
A treatment changed from a cytoplasmic punctate staining to a more diffuse staining 
that showed areas of accumulated NP around the plasma membrane. Although it 
appears therefore that F-actin is a factor for the relocalisation of NP after CsA-
treatment, the effect of Latrucullin A does not fully reflect the staining-pattern in CsA 
treated cells and thus, it is believed that there might be cellular proteins, such as 
cyclophilins, that further contribute to the observed distribution changes. To which 
extent the direct binding of CsA to NP contributes to the redistribution is also unclear 
and requires further investigation that could include NP mutants that are no longer 
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binding to CsA or the use of different CsA analogues that do not longer effectively 
bind to NP, but can still affect the cytoskeleton.  
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3.2 Arenaviruses and the innate immune system 
 
The interactions between arenaviruses and the innate immune system are important 
early during infection (see Section 1.4.6). The majority of the knowledge about 
arenavirus-innate immunity interactions comes from animal studies that focused 
mainly on cytokine levels and outcome of infection [reviewed in (Koma et al., 2013)]. 
The only molecular interactions known between this virus family and the proteins of 
the innate immunity is the inhibition of the IFN-induction pathway at different stages 
(see Section 1.2.3 and Section 1.2.3.2). Mouse studies further showed that LCMV 
can interfere with the IFN-signaling pathway in a STAT2-dependent manner (Hahm 
et al., 2005). It was noticed that the DIEG motif around the DEDDh exonuclease in 
the NP C-terminal domain is involved in evading the immune system (Martinez-
Sobrido et al., 2007, Martinez-Sobrido et al., 2006, Martinez-Sobrido et al., 2009, 
Rodrigo et al., 2012, Pythoud et al., 2012), but so far it has not been investigated in 
great detail. As interactions with the innate immune system are important during 
arenavirus infections, this section investigates aspects of these interactions in vitro. 
  
 
3.2.1 The ability of arenaviruses to block interferon induction and signalling 
 
In previous studies the authors hypothesised that the difference between TCRV and 
other arenaviruses in terms of disease in humans can be partially explained by the 
inability of TCRV NP to block IRF3 nuclear translocation in transfection 
experiments, thereby leading to the production of IFN (Martinez-Sobrido et al., 2007, 
Rodrigo et al., 2012). However these experiments were not performed in a viral 
context, in which other factors might play key roles. Therefore the ability of TCRV to 
inhibit the IFN-induction or signaling pathways could still represent potential 
drugable targets. PICV was used as a control due to the report by Martinez-Sobrido et 
al. (2007) that PICV NP was capable of inhibiting IRF3 translocation similar to other 
arenavirus NPs, but in contrast to TCRV NP.  
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IFN induction upon arenavirus infection.  
 
Activation of the IFN-induction pathway was measured using the A549-
pr(IFNβ).GFP reporter cell line, which expresses GFP when the IFNβ-promoter is 
activated. A) Quantification of GFP expression in A549-pr(IFNβ).GFP cells that 
were infected with either TCRV or PICV (MOIs 1, 5 and 10). As a positive control 
for the induction of the IFN-pathway cells were superinfected with SeV (an inducer 
of IFN) 24 hours after the initial infection with TCRV or PICV. After an additional 
48 hours GFP fluorescence was measured and standardised to cell levels, as 
determined by DAPI fluorescence. Results represent the average of four 
independent experiments ± SD.  B) Representative immunofluorescence images of 
either mock infected or TCRV infected cells (MOIs 1, 5 and 10) that were either 
superinfected with SeV (+) after 24 hours or left without superinfection (-). TCRV 
proteins (red) were detected using an anti-TCRV antiserum. The nucleus was 
visualized using DAPI. Images were taken at 400 x magnification. 	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The ability for TCRV and PICV to inhibit IFN-induction was assessed using A549-
pr(IFNβ).GFP cells, an A549 cell-line that expresses GFP when the IFN-β is 
activated. The promoter was activated using a DI-rich stock of Sendai virus (SeV), 
which is known to be a strong IFN inducer. Surprisingly, both TCRV and PICV 
induced IFN-expression at an intermediate MOI of 5 (Figure 3.15 A) to levels of 
86.5% and 73.5% of the SeV-infected control respectively. However at an MOI of 10 
the IFN-induction by the two arenaviruses differed with TCRV infection resulting in 
54.6% GFP expression, while PICV infection induced 9.6% GFP levels compared to 
the SeV-infected control. When the arenavirus infections were challenged with SeV-
superinfections to activate the IFN-β promoter, neither TCRV nor PICV were able to 
efficiently inhibit GFP-expression at MOIs of 1 or 5 (Figure 3.15 B). However, while 
PICV infections at these MOIs showed similar GFP expression levels to the control, 
the GFP expression levels in TCRV infections (MOIs of 1 and 5) were higher than the 
control sample (106% and 124.5% respectively), indicating that the TCRV infection 
likely induced further GFP expression above the level induced by SeV. When 
infecting the cells at an MOI of 10, both TCRV and PICV appeared to be capable of 
inhibiting the SeV-mediated IFN-induction to similar levels with 49.3% GFP 
expression for TCRV and 52.6% for PICV infected cells. It is worth noting that the 
GFP levels in cells infected with TCRV at an MOI of 10 were approximately the 
same level, regardless of whether or not they were superinfected with SeV, indicating 
this level of IFN-β promoter induction as the maximum at this particular MOI.  
To assess the capability of the two arenaviruses to inhibit the IFN-signalling pathway, 
a similar cell line to the IFN-β promoter cell line was used. Instead of expressing GFP 
upon IFN-β promoter activation, this A549-pr(ISRE).GFP cell line expresses GFP 
when the signaling pathway ISRE is activated instead. The experimental setup was 
similar to that of investigating the IFN-induction, but instead of superinfecting the 
cells with SeV, for activating the IFN-signalling pathway the cells were treated with 
IFNα instead (Figure 3.16). Neither TCRV nor PICV induced the IFN-signalling 
pathway at an MOI of 1, however both viruses induced GFP-expression at the 
intermediate MOI of 5 (Figure 3.16 A). Interestingly, in the high MOI infection 
(MOI = 10) the two arenaviruses had opposite effects on IFN signalling. While cells 
infected with TCRV showed a further increase in ISRE-activation (95% that of the 
control), PICV infected cells showed a markedly reduced activation (14%). These  
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IFN signalling upon arenavirus infection.  
 
Activation of the IFN-signalling pathway was measured using the A549-
pr(ISRE).GFP reporter cell line, which expresses GFP when the ISRE-promoter is 
activated. A) Quantification of GFP expression in A549-pr(ISRE).GFP cells that 
were infected with either TCRV or PICV (MOIs 1, 5 and 10). As positive control 
for the induction of the IFN-pathway cells were treated with IFN (IFN2α; 1000 
units/ml) 24 hours after virus infection to activate the IFN-signalling pathway. 
After an additional 48 hours GFP fluorescence was measured and standardised to 
cell levels, as determined by DAPI fluorescence. Results represent the average of 
four independent experiments ± SD. B) Representative immunofluorescence 
images of either mock infected or TCRV infected cells (MOIs 1, 5 and 10) that 
were either left untreated (-) or treated with IFN (+) at 24 hours post infection. 
TCRV proteins (red) were detected using an anti-TCRV antiserum. The nucleus 
was visualized using DAPI. Images were taken at 400 x magnification. 	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observations were further affirmed by challenging the cells with IFN treatment to 
actively induce GFP-expression. TCRV was incapable of reducing the ISRE-
induction levels at all three different MOIs, whereas PICV showed levels of 
inhibition. At MOIs of 1 and 5 PICV infection resulted in a GFP expression of 85% 
and 80.5% respectively, indicating a relatively weak efficiency of inhibition at these 
viral concentrations (Figure 3.16 B). However, at an MOI of 10, PICV was able to 
significantly inhibit the signaling pathway, which was also observed in the samples 
lacking IFN treatment. The inhibition resulted in only 40% ISRE-activation of that 
observed in the control cells.  
 
 
3.2.2 NP exonuclease 
 
The DEDDh family 5’-3’ exonuclease in the C-terminus of arenavirus NPs was 
implicated in the viral immune evasion strategy of the virus (Martinez-Sobrido et al., 
2007, Martinez-Sobrido et al., 2006, Martinez-Sobrido et al., 2009, Rodrigo et al., 
2012, Pythoud et al., 2012) by destroying dsRNA (Qi et al., 2010, Hastie et al., 
2011a), which is potentially formed during viral replication. However, TCRV NP was 
shown to be less capable of suppressing the innate immune response (Martinez-
Sobrido et al., 2007) and it was hypothesised that the exonuclease function might play 
into this observation. For this reason, the exonuclease activity for TCRV, JUNV and 
MACV NP was investigated as JUNV and MACV are pathogenic arenaviruses for 
which it was shown that the NPs were able to inhibit innate immune responses 
(Martinez-Sobrido et al., 2007).  
To assess the activity of the exonuclease of the three NPs (TCRV, JUNV and MACV 
NP), the proteins were purified as previously described (Figure 3.1). In addition to 
the three wild type NPs, exonuclease-inactive mutants of TCRV, JUNV and MACV 
NPs were made that destroys the active-site of the DEDDh exonuclease by mutating 
the first aspartic acid (D) of the active-site to an alanine (A) residue resulting in 
inactive-exonucleases. The expression and purification of the individual NP mutants 
was adapted from that of the wild type proteins (Figure 3.17). It is worth noting the  
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Purification of active-site exonuclease mutants of Clade 
B New World arenavirus NPs.  
 
Purification profiles (left panel) of TCRV D386A (A), JUNV D380A (B) and 
MACV D380A NP proteins using a Sephacryl S-200 HR (GE Healthcare) size 
exclusion column. Purification of TCRV D368A NP was performed using an 
MBP-tag, while both JUNV D380A and MACV D380A NP proteins were purified 
using a SUMO-tag. The grey bar above the profiles represents the fractions pooled 
after the final purification step. The commassie gels (right panel) show the 
individual purification steps for the individual proteins.  M- Marker (Thermo 
PageRuler Plus), L – total lysate, FT – flow through after nickel purification, Ni – 
elution of nickel purification, TEV – sample after TEV cleavage, GF – pooled 
sample after gel filtration. 	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protein expression level in E. coli was considerably higher with the inactive 
exonucleases than the wild type proteins. This resulted in the purification of 
approximately 4 mg/L TCRV NP D386A, 6 mg/L MACV NP D380A and 1 mg/L 
JUNV NP D380A respectively. 
The activity of the individual exonucleases was assessed. The protein concentrations 
were adjusted to 30 µM for all NPs and the proteins were incubated with a P32-
labelled dsRNA substrate (25-mer). The samples were incubated at 37 °C for different 
lengths of time up to 60 min, followed by analysis by SDS-PAGE. Results show that 
no obvious differences were observed between TCRV, JUNV and MACV NPs 
(Figure 3.18 A-C). The individual proteins cut the dsRNA substrate at comparable 
rates. However, at this time the results have to be considered with caution because the 
three mutants TCRV NP D386A, JUNV NP D380A and MACV NP D380A that 
based on previous reports (Hastie et al. (2011a) should abolish the activity of the 
exonuclease, did not inhibit the degradation of the dsRNA substrate (Figure 3.18 D). 
This activity is possibly a result of RNase contamination of the protein preparations, 
but this issue requires further investigation and potential re-purification of the 
individual proteins to rule out residual exonuclease-activity by the three NP mutants.  
 
 
3.2.3 Arenavirus – Interferon stimulated genes (ISG) screen 
 
The protein translation profile of cells changes dramatically upon encountering a 
“danger signal” from neighbouring cells in the form of secreted IFN (Isaacs and 
Lindenmann, 1957, Onoguchi et al., 2007, Platanias, 2005, Li et al., 1996, Decker et 
al., 1991, Schoggins and Rice, 2011). As a consequence cells responding to the IFN 
signal up-regulate the expression of hundreds of ISGs, leading to the production of 
proteins that have specific functions in the innate immunity against pathogens such as 
viruses [reviewed by (Schoggins and Rice, 2011)]. The exact function of these ISGs, 
are only defined for a small subset and thus, generally poorly understood (Randall and 
Goodbourn, 2008, Schoggins and Rice, 2011, Schoggins, 2014). However, the ISGs  
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Arenavirus NP exonuclease assays.  
 
P32-labelled dsRNA substrate (25-mer) was incubated with purified TCRV NP (A), 
MACV NP (B) or JUNV NP (C) at 37 °C between 1 – 60 min with samples taken 
at 1, 2, 5, 10, 15, 20 ,30, 45 and 60 min. Reactions were stopped with formamide 
and samples were analysed by denaturing SDS-PAGE. P32-signal was detected 
after overnight exposure using a Typhoon FLA 7000 (GE Healthcare) 
phosphoimager. C – dsRNA only control that was incubated at 37 °C for 60 min, 
EDTA – control using 5 mM EDTA. D) Exonuclease reactions with TCRV NP, 
TCRV NP D386A, MACV NP, MACV NP D380A, JUNV NP and JUNV NP 
D380A either with or without the addition of 5 mM EDTA at 37 °C for 60 min. 	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interfere with important steps in the viral replication cycle, such as cell entry, 
transcription, translation or egress (see Section 1.4.4).  
 
The only ISG that was recently described as a restriction factor for arenaviruses is 
tetherin, which interferes with the release of progeny virions from the host cell 
(Radoshitzky et al., 2010, Sakuma et al., 2009a). Therefore studies were conducted to 
investigate whether IFN treatment and the subsequent expression of other ISGs could 
restrict arenavirus replication. For this A549 and Huh7 cells were treated with IFN, 
infected with TCRV and IFN-mediated effects on the released infectious TCRV titres 
were assessed (Figure 3.19). A549 cells displayed the most significant effect of IFN-
pretreatment, demonstrating an approximate 1.5 log reduction in infectious titre after 
24 hours post-infection, when compared to the IFN negative control (Figure 3.19 A). 
Infectious titres remained approximately one log lower in IFN-treated cells for the 
first three days post-infection, whereas titres were similar after 4 days post-infection. 
IFN pre-treatment had no significant effect on virus titres released from Huh7 cells  
(Figure 3.19 B). However it cannot be excluded that the action of the IFN-treatment 
is short-lived in these cells and therefore effects of IFN-treatment on viral replication 
would need to be studied prior to 24 hours post-infection. It is worth noting that in 
both lines the peak released viral titre was unaffected by the IFN treatment and in 
A549 cells it was simply delayed by 24 hours (Figure 3.19 A). This is in contrast to 
the results observed for influenza A virus, as in IFN-treated A549 cells numbers of 
virus-infected cells did not increase over time, demonstrating the inability of 
influenza A virus to overcome the IFN-mediated block in viral replication (Xiao et al., 
2013). 
 
To investigate which ISGs are involved in restricting arenavirus infection, A549 and 
Huh7 cell lines were used in which expression of particular ISGs was either knocked 
down or enhanced by lentiviral transductions (cells were kindly provided by Prof. R. 
Randall, University of St. Andrews). The individual IGSs assessed were IFI35, IFIT1, 
IFIT2, IFIT3, ISG15, ISG20 and MxA (see Section 1.4.4). As ISGs can act directly 
on a virus infection or require an extra IFN-mediated effect for full activity, cells were 
either left untreated or treated with IFN for 12 hours prior to infection with TCRV at  
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TCRV growth kinetics in IFN pre-treated cells.  
 
A549 (A) and Huh7 (B) cells were either left untreated or treated with IFN (1000 
units / ml; Roferon) 16 hours prior to infection with TCRV at an MOI of 3. 
Supernatant samples were harvested daily for up to 7 days post infection and 
infectious titres determined by plaque assay. Result represents only one 
experiment. 	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an MOI of 10. The infectious titre released from the cells at 32 hours post-infection 
was then determined. In A549 cells the two assessed ISGs were MxA and IFIT1 by 
reducing their expression using shRNA (Figure 3.20). In both cases the reduction in 
expression resulted in an increase of viral titres compared to the naïve A549 cell line 
of more than 1 log. Also the viral titres from IFN-treated cells were higher than from 
untreated naïve A549 cells. Interestingly, for A549shMxA and A549shIFIT1 cells the 
difference between IFN-treated and untreated cells resulted in a reduction of 
approximately 1 log in IFN-treated A549shMxA cells and 1.5 logs in A549shIFIT1 
cells, while the effect in naïve A549 cells was not as significant at approximately 0.1 
log. The “protective” function of the IFN-response might be amplified by the higher 
overall titres in the two knockdown cell lines compared to the naïve cells.  
 
The ISGs tested in Huh7 cells were IFIT3, IFI35, ISG15, ISG20 (by overexpression) 
and IFIT2 (by shRNA-mediated knock down). Expression of IFIT3, IFI35 and ISG15 
resulted in reductions in viral titre compared to naïve Huh7 cells, while the expression 
of ISG20 or the knockdown on IFIT2 did not result in any significant difference in 
viral titres. However, differences were observed when cells were treated with IFN. 
IFN-treatment of naïve Huh7 cells resulted in only a modest reduction in viral titre, 
with this reduction slightly increased in IFN-treated IFI35 and ISG15-expressing cells 
compared to non-IFN treated cells. However a large reduction in viral titre was 
observed in IFN-treated IFIT3-expressing Huh7 cells compared to untreated cells. 
This suggests that the IFN-treatment augmented the antiviral effect of IFIT3 and the 
enhanced IFN-mediated reduction in viral titres in these cells compared to the IFN-
mediated reduction in naïve Huh7 cells demonstrates that IFIT3 has the ability to 
restrict arenavirus replication. The data also suggests that there is likely an IFN-
mediated effect on IFIT3 that enhances its antiviral activity, possibly through 
modification of IFIT3 or a co-operative interaction with another ISG. A similar 
finding was recently reported for the ISG MxA in that its ability to inhibit the 
replication of influenza A virus was significantly enhanced by IFN-treatment, likely 
through expression of a co-operative ISG (Xiao et al., 2013). 
Overall, MxA, IFIT3, IFI35 and IFIT1 demonstrated antiviral activity against TCRV, 
with the expression of IFIT3 resulting in the largest reduction in viral titres.  
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ISG screen against TCRV.  
 
Different interferon-stimulated genes (ISGs) were tested for their role during 
TCRV infection. A549 or Huh7 cells in which particular ISGs (MxA, IFI35, 
ISG15, ISG20, IFIT1, IFIT2 and IFIT3) were either knocked down (sh) or 
overexpressed (pdl) were either left untreated or pre-treated with 1000 units/ml IFN 
(Roferon) 12 hours prior to infection with TCRV at an MOI of 10. Supernatants 
were collected 32 hours post infection and viral yield was analysed by plaque 
assays. Results represent the average of three independent experiments ± SD.  
P values were calculated using a Student T test and adjusting the values with the 
Bonferroni correction independently for A549 and Huh7 cell lines. The p values 
refer to mock-treated and IFN-treated samples separately. 	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3.2.4 The role of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) 
during arenavirus infection 
 
The previous section identified the ISG IFIT3 as a potential restriction factor for 
TCRV infection. Interestingly the ISG screen showed that the antiviral activity 
against TCRV was significantly increased when cells were treated with IFN, which 
could be due to an IFN-mediated activation step or through the expression of co-
factor after activation of the IFN-signalling pathway. However, a study by Liu et al. 
(2011) showed that IFIT3 exhibits its antiviral function by bridging the IFN-induction 
pathway transducer proteins MAVS and TBK1 together, which enables the 
downstream activation of IFN-induction transcription factors for IFNα, IFNβ and NF-
κB genes. To test the hypothesis that IFIT3 that forms a bridge between IFN-
signalling and IFN-induction pathways to subsequently cause the transcription of 
genes with antiviral function, several cell lines were generated based either on Huh7 
or Huh7pdlIFIT3 cell lines (Figure 3.21). The generated cell lines stably expressed 
BVDV Npro, which was reported to target the transcription factor IRF3 for 
proteasomal degradation (Hilton et al., 2006a) or HCV NS3/4a, which amongst others 
cleaves mitochondrial MAVS (Li et al., 2005) to prevent downstream signalling. The 
plasmids for creating the Npro and NS3/4a cell-lines were obtained from other groups 
and unfortunately due to the design of the constructs the V5-tag on the proteins 
products, for use in detecting protein expression, are ultimately cleaved off during 
processing of these proteases in cells. Therefore the confirmation of protein 
expression in lentivirus-transduced cells proved difficult. The presence of a V5-tag 
could only be observed by immunofluorescence and the signal for the cells expressing 
two V5-tagged proteins, HuhpdlIFIT3/Npro and HuhpdlIFIT3-NS3/4a, was masked 
by the strongly expressed IFIT3.  
 
The role of the IFN-induction pathway was investigated in more detail using the 
newly generated cell-lines. Cells were either treated with IFN or left untreated 
followed by infected with TCRV at an MOI of 10. Supernatant samples were 
collected at 24 and 42 hours post-infection and the infectious titres of each determined 
by plaque assay. The results showed that the presence of IFIT3 in Huh7 cells reduced  
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Huh7 cell line characterisation.  
 
The characterisation of protein expression in lentivirus transduced cell lines based 
on Huh7 cells. A) Western blot analysis of Huh7 and Huh7-IFIT3 cells that were 
either left untreated (-IFN) or treated with 1000 units/ml Roferon (+IFN) for 16 
hours. IFIT3 is fused to a V5-tag that was used for detection using an anti-V5 
antibody. B) Immunofluorescence characterisation of Huh7-based cell lines using 
the V5-tag for detection of IFIT3, BVDV Npro and HCV NS3/4a proteins. Cells 
were either left untreated (-IFN) or treated with 1000 units/ml Roferon (+IFN) for 
16 hours before cells were fixed with 5% paraformaldehyde . Green – V5-tag, blue 
– DAPI. 	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the viral titre by approximately 0.5 log at both 24 and 42 hours post infection (Figure 
3.22 A). The effect of this ISG was enhanced when the cells were pre-treated with 
IFN prior to infection, as the viral titre was reduced by 1.5 log when comparing 
untreated and treated Huh7pdlIFIT3 cells, but only by1 log in naive Huh7 cells.  
 
It has been suggested that IFIT3 interacts with MAVS and TBK1 to activate the 
downstream pathway (Liu et al., 2011). To confirm these findings Huh7pdlIFIT3-
NS3/4a cells were used in the same analysis (Figure 3.22 B). The protease NS3/4a of 
HCV cleaves the mitochondrial form of MAVS (Li et al., 2005), which is an essential 
adapter protein for the IFN-induction pathway to relay the signal from RLRs, such as 
RIG-I and MDA-5, eventually resulting in the transcription of IFNα, IFNβ and/or NF-
κB. The expression of NS3/4a in addition to IFIT3 resulted in virus titres similar to 
naïve Huh7 cells and the effects of viral titre reduction previously observed in 
Huh7pdlIFIT3 cells could no longer be observed. This suggested that IFIT3 activity 
against TCRV requires functional MAVS. 
 
The IFN-induction pathway was then analysed further downstream using the protease 
Npro of BVDV. The study by Liu et al. (2011) showed an up regulation of IFNβ 
expression, which is a result of IRF3 activation. To determine the involvement of 
IRF3 in the effects shown by IFIT3, the cell lines Huh7pdlNpro and 
Huh7pdlIFIT3/Npro were used, as Npro targets IRF3 for degradation. The results 
were similar to those observed in the Huh7pdlIFIT3-Ns3/4a cells (Figure 3.22 C), in 
that the viral titres were almost identical to those from naïve Huh7 cells. Furthermore 
Huh7pdlNpro cells showed that there is no effect on viral titres by the IFN-induction 
pathway without the overexpression of IFIT3. This means that the specific function of 
IFIT3 is necessary to potentially activate the IFN-induction pathway. Using these 
different cell lines also showed that IFN-treatment of the individual cell lines affected 
viral titres by about 1 log at 24 hours post infection. This observation is independent 
of IFIT3 and the IFN-induction pathway, therefore other ISGs must be responsible for 
this effect.  
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Dissecting the effect of IFIT3 during TCRV infection.  
 
The diagrams represent the IFN-induction pathway. Briefly, RLRs, such as RIG-I 
and MDA-5 sense PAMPs in the cell and signal via the adaptor protein MAVS. 
MAVS activation eventually leads to the activation and dimerisation of TBK1 and 
IKKε. This heterodimer triggers the phosphorylation of the transcription factors 
IRF3, IRF7 or the activation of NF-κB, which finally leads to the activation of 
either IFNα, IFNβ or NF-κB promoters and the expression of type I IFNs and pro-
inflammlatory cytokines. Indicated is IFIT3, which was reported to bridge MAVS 
to TBK1 (Liu et al., 2011). The expression of the viral proteins HCV NS3/4a and 
BVDV Npro are indicated together with either MAVS or IRF3, whose function 
these proteins are inhibiting. (A) Naïve Huh7 or Huh7pdlIFIT3 cells were either 
left untreated or were treated with 1000 units/ml Roferon 12 hours prior to 
infection with TCRV at an MOI of 10. Supernatant samples were collected at 24 
and 42 hours post infection and the infectious titres determined by plaque assay. 
The same experiment was repeated in Huh7 cells expressing HCV NS3/4a and 
IFIT3 (B), or BVDV Npro ± IFIT3 (C). Results represent the average of three 
independent experiments ± SD. P values were calculated using a Student T test and 
refer to mock-treated and IFN-treated samples separately. 
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The activation of IRF3 was then examined by Western blot analysis using an antibody 
that detects the phosphorylation of IRF3 at serine 396, which was shown to be 
essential for the activation of this transcription factor (Lin et al., 1998). Surprisingly, 
no effective phosphorylation of IRF3 was observed between 24-42 hours post 
infection (Figure 3.23), or at earlier time points between 2 – 12 hours post infection 
(data not shown). Therefore it can be assumed that either the activation of the IFNβ-
promoter is not triggered at all in TCRV infected cells, even when IFIT3 is 
overexpessed, or the promoter is activated by another pathway.  
 
 
3.2.5 Conclusions 
 
Previous studies showed that arenaviruses inhibit the IFN-induction by IRF3 via 
IKKε (Martinez-Sobrido et al., 2007, Pythoud et al., 2012) and by blocking NF-κB 
activation (Rodrigo et al., 2012). In this section, the investigation into IFN-induction 
and signaling was expanded. It was shown that the arenaviruses TCRV and PICV 
cause the induction of IFN by the IFN-β promoter. Although low-level infections 
(MOI of 1) did not cause the induction of IFN, neither of the viruses were capable of 
successfully suppressing the IFN-induction cascade once activated. Previously it was 
reported that PICV was capable of inhibiting IRF3, while TCRV was not (Martinez-
Sobrido et al., 2007), but these experiments were performed with transfection 
experiments using overexpressed viral NP proteins, not in the context of viral 
infection. The results shown in this thesis were generated under more appropriate 
conditions using live, infectious virus and are therefore more relevant in determining 
the effects of the different viruses on suppression of IFN induction. In low-levels 
infections neither virus was capable of blocking IFN-induction, however at a higher 
MOI (MOI of 10) both viruses were able to down-regulate the IFN-response to 
comparable levels (approximately 50%) after IFN induction. As a result the previous 
hypothesis that TCRV is non-pathogenic to humans due to an inability to effectively 
block the IFN-response (Martinez-Sobrido et al., 2007, Rodrigo et al., 2012, Pythoud 
et al., 2012) has to be revisited.  
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IRF3-phosphorylation in TCRV-infected Huh7 and 
Huh7pdlIFIT3 cells.  
 
Cells were either left untreated or were treated with 1000 units/ml IFN (Roferon) 
12 hours before infection. Huh7 (A) and Huh7pdlIFIT3 (B) cells were then infected 
with an MOI of 10. Cell lysates were collected at the time points indicated (24 – 42 
hours post infection) and used for Western blot analysis. The total cell lysates were 
probed for phospho-IRF3 (pIRF3) and actin as a loading control. For the positive 
control (demonstrating phosphorylation of IRF3), Huh7 and Huh7pdlIFIT3 cells 
were infected with SeV at an MOI of 10 and cell lysates were collected at 12 hours 
post infection. 	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When studying the ability of arenaviruses to inhibit the IFN-signalling pathway 
differences between TCRV and PICV then became apparent. TCRV did not show the 
ability to inhibit the IFN-signalling pathway at any MOI tested (MOIs 1, 5 and 10), 
whereas PICV was able to do this at higher MOIs. TCRV infection did not cause the 
induction of the signaling pathway at an MOI of 1, but at higher MOIs the pathway 
was activated to almost its full capacity. In contrast, PICV infections at MOIs of 1 and 
5 resulted in an induction of the signaling pathway of approximately 80% of the 
positive control when challenged with IFN. At an MOI of 10 PICV was able to reduce 
the pathway activation to 40%. Currently it is not known which exact IFN-signalling 
pathway is activated by arenaviruses and which virus-host interaction could inhibit 
this pathway activation. The only reports thus far came from mouse studies indicating 
an involvement of STAT2 in a response against arenavirus infection (Hahm et al., 
2005). As the most signification difference between TCRV and PICV appears to be 
the IFN-signalling pathway and not the IFN-induction pathway, as originally thought, 
this observation needs revisiting to understand which possible interactions and 
molecular differences in arenavirus proteins could be the explanation for these 
experimental results.  
 
Another hypothesis for the inability of TCRV to effectively block the IFN-response in 
vitro was associated with the exonuclease in the C-terminus of NP (Hastie et al., 
2011a, Martinez-Sobrido et al., 2007, Martinez-Sobrido et al., 2006, Martinez-
Sobrido et al., 2009, Ortiz-Riano et al., 2012a, Rodrigo et al., 2012, Pythoud et al., 
2012). Although experiments shown in this section using exonuclease assays with the 
NPs of TCRV, JUNV and MACV must currently be taken with the caveat that the 
exonuclease-inactive mutants of these proteins still showed enzymatic activity on 
dsRNA-substrates, currently there is no evidence to suggest that the exonucleases of 
these three NPs cut at different efficiencies. If the assays shown in this section are 
repeated and show similar results in cutting-efficiency, the hypothesis of the 
exonuclease being responsible for differences in suppressing PAMP-formation will 
have to be reconsidered. 
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The inability of these viruses to efficiently inhibit the IFN-signalling pathway 
indicates the importance of ISGs during arenavirus infection as a major cellular 
defense mechanism. Currently the only ISG described in the literature as a restriction 
factor acting against arenaviruses is tetherin (Sakuma et al., 2009a, Radoshitzky et al., 
2010). Previously reported ISGs, IFIT1, IFIT2, IFIT3, MxA, IFI35, ISG15 and 
ISG20, which showed restrictive functions against other viruses, were tested against 
TCRV infection. The screen resulted in the findings that IFI35, IFIT1, IFIT3 and 
MxA have antiviral-activity against TCRV to different degrees. The exact mode of 
action of these ISGs is unclear (see Section 1.4.4) and requires further investigation, 
particularly in the context of arenaviral infection.  
 
The results in this chapter have shown that IFIT3 represents an important restriction 
factor in TCRV infection. The inhibition of virus production was significantly 
enhanced in IFIT3-expressing cells by the treatment with IFN, which indicates the 
requirement for an IFN-induced activation step for IFIT3 or the additional expression 
of a co-factor required for the efficient function of IFIT3. This observation will have 
to be investigated in more detail. To address reports of the function of IFIT3, which 
was proposed to activate the IFN-induction pathway (Liu et al., 2011), rather than 
acting directly on viral infection, cell lines were generated that inhibit the signaling 
cascade within the IFN-induction pathway. To do this, cells were created that 
expressed the viral protein NS3/4a, which cleaves the mitochondrial form of MAVS 
(Li et al., 2005), or BVDV Npro, which results in the degradation of IRF3 (Hilton et 
al., 2006a). The expression of either of these viral proteins resulted in a reversal of the 
effects displayed by IFIT3. This means, that IFIT3 is indeed an important factor 
bridging the IFN-signalling pathway with the IFN-induction pathway of the innate 
immune response. Although the degradation of IRF3 was shown to be important to 
reverse the effects of IFIT3 as shown in this section, the phosphorylation and 
therefore activation of IRF3 could not be observed during the course of TCRV 
infection in Huh7 or Huh7pdlIFIT3 cells. This observation suggests that activation of 
the IFNβ-promoter during TCRV infection must be achieved using a pathway that is 
independent of IRF3. However, this does not explain the results observed in 
Huh7pdlIFIT3/Npro cells, which abrogated the effects of IFIT3. This is something 
that requires further examination. 
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3.3 Arenavirus NP protein-protein interactions 
 
Arenaviruses encode for only four proteins, therefore like most RNA viruses they 
likely rely on numerous virus-host protein-protein interactions for essential steps in 
the viral replication cycle. Only a small number of such protein-protein interactions 
have previously been described (see Section 1.2.3), but there are potentially many 
more of these interactions awaiting discovery. Such protein-protein interaction could 
provide the explanation for differences in disease caused by pathogenic and non-
pathogenic arenaviruses due to interactions with a different subset of host proteins. 
Furthermore identifying viral-host protein-protein interactions essential for virus 
replication that are conserved among the different arenaviruses will likely uncover 
novel targets for the design of braod-spectrum anti-arenavirus drugs. For these 
reasons potential protein-protein interactions between arenavirus NPs and host cell 
proteins were investigated.  
 
 
3.3.1 GST Pulldowns 
 
There are several approaches to study protein-protein interactions that include co-
immunoprecipitation, yeast two-hybrid (Y2H) systems, tandem affinity purification 
(TAP) or stable isotope labeling by amino acids in cell culture (SILAC) 
(Burckstummer et al., 2006, Joung et al., 2000, Ong et al., 2002, Free et al., 2009, Xu 
et al., 2010). However, in this study the approach used was GST pulldown 
experiments in which GST-fusion-proteins were used to precipitate interacting partner 
proteins followed by their identification by mass spectrometry (mass spec) [reviewed 
by (Vikis and Guan, 2004)]. 
 
For this, the NPs of TCRV, MACV and JUNV were cloned into a vector that allowed 
the expression of NP with an N-terminal GST-tag. The two protein domains (GST 
and NP) were separated by an immunoglobulin G (IgG) hinge linker (11 amino acids)  
 
 3. RESULTS 	  
 
	  	  	  	  	  	   190	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arenavirus NP-mediated protein-proteins interactions.  
 
GST-pulldown experiments were performed in human or rodent cell-line lysates in 
which immobilized arenavirus NPs derived from TCVR, MACV and JUNV were 
used to precipitate interacting cellular proteins. Mass spectrometry analysis resulted 
in the identification of a total of 202 cellular protein hits split between the three 
NPs and the three cell lines used. A) The graph represents the numbers of proteins 
identified between the different cell lines – A549 (blue) 145, BHK (red) 127 and 
Huh7 (green) 140 proteins, of which 77 are proteins that were identified in all three 
cell lines. B) Of the 202 identified proteins, 166 were identified to interact with 
TCRV NP (blue), 163 interact with JUNV NP (red) and 193 interact with MACV 
NP (green). The majority of proteins (145) were precipitated by all three NPs. 	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that ensured the independent folding of both domains. Theoretically this would enable 
a more native NP protein conformation, thereby enhancing the likelihood of forming 
the relevant interaction(s) with cellular binding partners. Individual proteins were 
expressed in E. coli Rosetta cells and cell lysates were incubated with immobilized 
glutathione before incubating the bound GST-NP fusion proteins with cell lysates 
from three mammalian cell lines A549 (human lung cells), BHK (rodent cells) and 
Huh7 (human liver cells). The GST-NP fusion protein and bound cellular proteins 
were precipitated and separated by SDS-PAGE before samples were excised and 
prepared for mass spec analysis by tandem mass spec (MS/MS). Results from mass 
spec were blasted against the MASCOT server, potential prokaryotic contaminating 
proteins were deducted from further analysis, and the remaining protein hits were 
further analysed using the Scaffold3 software. Proteins were scored after a minimum 
of two peptides resulted in protein identification and any proteins that bound to the 
free GST control (102 proteins) were eliminated from the analysis.  
 
The analysis resulted in the identification of 202 proteins (Figure 3.24) that include 
proteins involved in regulating cellular transport, energy, translation, cyctoskeleton or 
chaperone proteins. Although the experiment attempted to cover a wide range of cell 
types that might be relevant for the arenavirus replication cycle, many identified 
proteins were specific to particular cell-lines (Figure 3.24 A). Approximately 10% of 
proteins identified in each cell-line were specific for that particular cell type, 
however, the lack of detection of these proteins in the other cell lines may be due to 
issues in detection threshold. Of the 202 identified proteins 77 were identified in all 
cell-lines tested. When looking at the proteins precipitated by the individual NPs, the 
vast majority of cellular proteins identified, 145 from 202 proteins, were precipitated 
by all three NPs (Figure 3.24 B). 87% of proteins precipitated by TCRV NP were 
also precipitated by the NP of JUNV and MACV. These percentages were 89% and 
74% for JUNV NP and MACV NP respectively. A small proportion of the 
precipitated proteins was shared between only two of the three NPs. While there are 
only 3 proteins for TCRV NP and 1 protein for JUNV NP that were precipitated 
exclusively by these individual proteins, there were 23 proteins precipitated only by 
MACV NP. As above this may be partially explained by issues with detection 
thresholds. 
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GST-NP expression and Western Blot confirmation of 
NP-AIF interaction.  
 
A) Representative commassie stained gel showing bacterially expressed GST-NP 
fusion proteins used for GST-pulldown experiments. For these experiments the NP 
proteins from TCRV, JUNV, MACV and PICV were fused to GST. B) Western 
blot showing the NP-AIF interaction. GST-NP fusion proteins were immobilised 
onto glutathione beads and used in a GST pulldown experiment using Huh7 cell 
lysates. Precipitated proteins were separated by SDS-PAGE, followed by western 
blot analysis using an AIF-specific antibody. The input represents 1/100 of the 
lysate used in the pulldown experiment.   
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3.3.2 NP – apoptosis-inducing factor 1 (AIF) interaction 
 
One of the 145 proteins that interacted with all three NPs was AIF. This protein was 
first described in 1996, where the protein was described as a mitochondrial 
flavoprotein that is capable of inducing caspase-independent apoptosis (Susin et al., 
1996, Susin et al., 1999, Lorenzo et al., 1999, Zamzami et al., 1996). Besides the 
function of causing apoptosis in cells, AIF has also been described to bind to favin 
adenine dinucleotide (FAD) and possesses the enzymatic activity of an NAD(P)H 
oxi/reductase (Susin et al., 1999, Miramar et al., 2001). Importantly AIF was shown 
to interact with proteins from a number of viruses and these interactions either 
inhibited AIF-dependent apoptosis, such as the interaction formed with the hepatitis B 
virus (HBV) X protein (Liu et al., 2012a) and EBV (Kim et al., 2006) or to induce 
apoptosis via this pathway as shown for enterovirus 71 (EV-71) (Lu et al., 2013). The 
interaction between arenavirus NPs and AIF was investigated in this section as 
arenaviruses have the capability of causing persistence infections, which may require 
interactions to prevent cellular apoptotic responses. 
 
 
3.3.2.1 Conserved interaction between arenavirus NP and AIF 
 
To confirm the initial observation of an NP-AIF interaction, various GST-NP fusion 
proteins were generated. In addition to the NPs of TCRV, JUNV and MACV the NP 
of the non-pathogenic clade A PICV was also inserted into a pGEX plasmid 
(encoding the N-terminal GST-tag) and expressed in bacteria (Figure 3.25 A). The 
four NPs were included in a GST-pulldown experiment and western blotting used to 
cofirm the precipitation of AIF by all four NPs (Figure 3.25 B). This indicated that 
the NP-AIF interaction is conserved among arenaviruses of different clades. 
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Mapping of the NP-binding site in AIF.  
 
A) Schematic representation of AIF indicating its known domains. The schematic 
shows the five AIF constructs made for GST-fusion proteins used in subsequent 
pulldown experiments. B) Representative coomassie stained gel of bacterially 
expressed GST-AIF fusion proteins as indicated in (A). C) GST pulldown analysis 
of the NP-AIF interaction using truncated AIF proteins. Huh7 cells were 
transfected with plasmids that expressed HA-tagged versions of TCRV, JUNV and 
MACV NP. Cells were lysed 24 hours post-transfection and lysates used in GST-
pulldown experiments using the GST-tagged AIF constructs. GST-AIF proteins 
and interacting cellular proteins were precipitated, separated by SDS-PAGE, 
followed by western blot analysis using an antibody against the HA tag. As a 
control for eliminating protein bands resulting from non-specific interactions 
between AIF and the HA tag, a HA-tagged version of ISG56 was used. The input 
represents 1/100 of the lysate used in the pulldown experiment.    	  
 3. RESULTS 	  
 
	  	  	  	  	  	   197	  	  
 
TCRV NP-HA 
JUNV NP-HA 
ISG56-HA 
MACV NP-HA 
1 103 128 262 400 480 613 
Mito FAD1 FAD2 NADH C-term 
C-term 
Mito FAD1 FAD2 NADH C-term 
Mito FAD1 FAD2 NADH C-term 
aa 
AIF Δ103 
AIF 
AIF Δ262 
AIF Δ350 
AIF Δ479 
Mito FAD1 FAD2 NADH C-term 
A 
B 
C 
GST-AIF Δ103 
GST-AIF 
GST-AIF Δ262 
GST-AIF Δ350 
GST-AIF Δ479 
GST 
100 
70 
130 
55 
35 
25 
kDa 
 3. RESULTS 	  
 
	  	  	  	  	  	   198	  	  
3.3.2.2 Characterisation of the NP-binding site in AIF 
 
To identify the region of AIF that is responsible for binding to NP a panel of GST-
AIF expressing constructs were generated in which AIF was serially truncated based 
on the protein’s known domain architecture (Lorenzo et al., 1999, Cande et al., 2002). 
This generated five individual GST-AIF constructs that either expressed full-length 
AIF, AIF without a mitochondrial localization signal (MLS; AIF Δ103), AIF without 
the first half of the flavin adenine dinucleotide (FAD) domain (AIF Δ262), a construct 
disrupting the DNA- and CypA-binding abilities (AIF Δ350) and only the C-terminal 
domain of AIF (AIF Δ479) (Figure 3.26 A).  The C-terminal domain of AIF has been 
reported to span from the inner mitochondrial membrane into the cytoplasm (Yu et 
al., 2009) , which theoretically would allow for a direct NP-AIF interaction with the 
mitochondrially-associated AIF.  
 
The individual GST-fusion proteins were expressed in bacteria, immobilized onto 
glutathione agarose and purified (Figure 3.26 B). To determine which of these AIF 
truncations binds to different NPs, Huh7 cells were transfected with plasmids that 
express HA-tagged forms of TCRV NP, JUNV NP and MACV NP (Martinez-Sobrido 
et al., 2007), and transfected cell lysates were incubated with the GST-AIF fusion 
proteins in a GST-pulldown experiment. To rule out any interaction between AIF and 
the HA-tag, an HA-tagged protein unlikely to bind to AIF, ISG56-HA, was expressed 
in Huh7 cells and used as a negative control sample in the GST-pulldown. The results 
showed that all NPs bound to each form of AIF, thereby indicating that the NP-
binding site is located in the C-terminal domain of AIF (480-613 aa) (Figure 3.26 C). 
 
 
3.3.2.3 Characterisation of the AIF-binding site in NP 
 
The AIF-binding site within NP was then investigated in a similar manner. For this 
four constructs were generated that expressed either full-length or truncated versions 
of TCRV NP (Figure 3.27 A). The truncated versions of NP encoded either the first  
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Mapping of the AIF-binding site in NP.  
 
A) Schematic representation of TCRV NP showing the reported N- and C-terminal 
domains. Indicated are the four constructs used for GST-pulldown experiments. B) 
Representative commassie stained gel of bacterially expressed GST-NP fusion 
proteins as indicated in (A). C) AIF pulldown experiment using GST-NP fusion 
proteins incubated with Huh7 cell lysates. Proteins were precipitated, separated by 
SDS-PAGE, followed by western blot analysis using an AIF-specific antibody. The 
input represents 1/100 of the lysate used in the pulldown experiment.   	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299 residues of NP (NP 1-299), a region expressing residues 230-233 of NP (NP 230-
333) or the C-terminal domain (NP 363-570). The individual constructs were 
expressed in bacteria (Figure 3.27 B) and the GST-fusion proteins were bound to 
glutathione agarose similarly to the process described earlier. The individual GST-
TCRV NP proteins were incubated with Huh7 cell lysates to allow binding to 
endogenous AIF and the complexes were precitpitated in a GST-pulldown 
experiment. The results showed that AIF was precipitated by both full-length NP and 
to the truncated version of NP that contains residues 230-333 (Figure 3.27 C), a 
region that overlaps with the nucleotide-binding capability of NP (Hastie et al., 
2011b). 
 
After computational analysis using the ClusPro server likely AIF-binding sites in NP 
between residues 230 and 333 were identified. Three regions were identified (Figure 
3.28 A). The first two regions are conserved between the NPs used so far in this study 
as well as for the NP protein from the medically important OWA LASV, for which a 
full-length x-ray crystal structure is available (PDB: 3MWP). The residues are 
situated on the protein surface so that these could facilitate binding. The third region 
is not conserved by specific amino acids, but by amino acid properties, therefore this 
region was investigated as well. The three regions were individually mutated in the 
construct used to express GST-TCRV NP by changing all residues in each region to 
alanine, and the mutant proteins were subsequently expressed in bacteria and bound to 
glutathione agarose (Figure 3.28 B). The mutant proteins were used in a GST-
pulldown experiment and the resulting precipitates probed for AIF by western blot. 
All three of the alanine mutant constructs retained the ability to bin AIF (Figure 3.28 
C), therefore these three regions were not responsible for mediating the NP-AIF 
interaction.  
 
Protein alignment analysis highlighted a fourth region that is highly conserved 
between individual NPs (Figure 3.29 A). When analysing the corresponding binding 
region in the LASV NP crystal structure (Figure 3.29 B) this conserved region forms 
a pocket (blue) that was revealed to be highly charged (Figure 3.29 C). After 
analysing the potential binding-site in NP, which is positively charged, the  
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Mutational analysis to map NP-AIF binding.  
 
To determine which amino acids between residues 230 to 333 in TCRV NP were 
responsible for the NP-AIF interaction, the interaction was mapped in closer detail 
by mutational analysis of TCRV NP. A) Protein alignment of the arenavirus NPs 
shown to interact with AIF (JUNV, MACV, TCRV and PICV) as well as LASV 
NP. Amino acids in the green boxes were mutated to alanine residues within GST-
TCRV NP fusion proteins. Mutations were based on docking-experiments between 
NP and AIF using the ClusPro protein-protein docking server. B) Representative 
commassie stained gel of GST-TCRV NP mutants that correspond to alanine 
substitutions as indicated in the green boxes in A). C) AIF pulldown experiment 
using GST-NP fusion proteins incubated with Huh7 cell lysates. Proteins were 
precipitated, separated by SDS-PAGE, followed by western blot analysis using an 
AIF-specific antibody. The input represents 1/100 of the lysate used in the 
pulldown experiment.   	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Computational analysis of potential NP-AIF interaction.  
 
A) Protein alignment of arenavirus NPs shown to interact with AIF and LASV NP. 
The green boxes represent residues that were previously mutated to alanine 
residues, but still allowed NP-AIF binding. The blue box is the only remaining 
large conserved amino acid sequence within the residues 230 – 333 for TCRV NP. 
B) Monomoeric x-ray crystal structure of LASV NP (PDB: 3MWP) shown in grey. 
The amino acids corresponding to TCRV NP residues 230-333 that are largely not 
conserved are shown in red, in green and blue are the amino acids inducted in the 
green and blue boxes in (A). The black arrow points towards a potential binding-
pocket that would allow an interaction with AIF. C) Surface charge representation 
(generated in Pymol) indicating positively charged regions in blue and negatively 
charged regions in red. The black arrow highlights the same potential negatively 
charged binding-pocket indicated in (B). D) X-ray crystal structure of AIF (PDB: 
4LII) shown in grey. Amino acids highlighted in red indicate the C-terminal 
domain, for which an interaction with NP was shown. E) AIF shown in a surface 
charge representation (generated in Pymol). The black arrow in (D) and (E) 
indicates amino acids that are highly negatively charged and would allow binding 
to the potential binding-pocket of NP. Electrostatic representation in C) and E) 
range from strong negative charge in red to strong positive charge in blue. 	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corresponding region in AIF would have to be negatively charged to allow binding. 
For this reason the NP-binding C-terminal region of AIF was analysed using the 
crystal structure of the protein (PDB: 4LII) (Figure 3.29 D). Electrostatically analysis 
of the AIF crystal structure revealed that AIF is highly negatively charged (Figure 
3.29 E). It is plausible that binding to NP could be facilitated through an interaction 
around two proline (P) residues (amino acids 544 and 545), however this requires 
experimental confirmation. 
 
 
3.3.2.4 Co-localisation of NP and AIF in virus-infected cells 
 
To characterise the NP-AIF interaction in virus-infected cells the distribution of the 
two proteins were analysed by immunofluorescence analysis at various times post-
infection (Figure 3.30). The results show that the two proteins colocalise throughout 
the first 48 hours of infection, with a punctate staining pattern observed for each. At 
time points later than 48 hours post-infection NP is distributed throughout the 
cytoplasm of the cell and it therefore makes conclusions on colocalisation difficult. 
However before 48 hours post-infection NP is distributed in a characteristic punctate 
staining pattern previously shown to be arenavirus replication centers (Baird et al., 
2012). Confocal microscopy analysis showed that at each time point all areas of 
intense NP staining overlapped with areas of AIF staining, suggesting colocalisation. 
It is worth noting that not all aggregates of AIF were colocalised with NP. The 
colocalisation of the two proteins is likely a result of the NP-AIF interaction being 
functionally relevant during infection, however this needs to be proven 
experimentally. 
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Colocalisation of NP and AIF during viral replication.  
 
VeroE6 cells were infected with TCRV at an MOI of 3, fixed at the indicated times 
post infection and stained for TCRV NP (red) and AIF (green) for 
immunofluorescence analysis. Images were taken at 630x magnification. Analysis 
of protein colocalisation was performed using Exciter software. The white arrow 
indicates the measured pixels, which is represented in graphical form adjacent to 
the individual images.  	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Characterisation of AIF cell lines.  
 
Knockdown and overexpression cell lines of AIF were created using lentivirus-
transduction methods. A) Western blot analysis of AIF expression levels in VeroE6 
based cell lines, where AIF was either knocked down (VeroshAIF) or 
overexpressed (VeropdlAIF). B) Quantitative analysis of AIF expression in 
VeroE6-based cell lines. The expression levels of AIF were normalised to actin. C) 
Immunofluorescnece analysis of AIF expression levels in the VeroE6-based AIF 
cell lines. AIF = green, nucleus = blue (DAPI). Scale bars represent 10 µm. D) 
Western blot analysis of AIF expression levels in naïve Huh7 cells and AIF-
knockdown cells Huh7shAIF. E) Quantitative analysis of AIF expression levels in 
Huh7 and Huh7shAIF cell lines as described for B). F) Immunofluorescence 
analysis of AIF expression in Huh7 and Huh7shAIF cells. AIF = green, nucleus = 
blue (DAPI). Scale bars represent 10 µm. 	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3.3.2.5 Consequence of AIF-interaction during viral replication 
 
The biological importance of the NP-AIF interaction in context of the viral replication 
cycle was examined. To do so, AIF expression was either down regulated using short-
hairpin RNA (shRNA) expression or overexpressed using lentiviral transduction 
systems to create stable knockdown or overexpression cells. Both VeroE6 (Figure 
3.31 A-C) and Huh7 (Figure 3.31 D-F) cells were used for these experiments to 
exclude cell line dependent effects. In VeroE6 cells AIF expression could be reduced 
to 21% of naïve cell expression, while overexpression resulted in 1.8-fold expression 
compared to naïve cells. However, in Huh7 cells overexpression of AIF was not well 
tolerated, therefore the cells were excluded from further analysis. The shRNA 
knockdown of AIF in Huh7 cells resulted in 3% of its original expression levels. No 
further differences could be observed in the generated cell lines.  
 
When infecting the VeroE6 based cell lines with TCRV at an MOI of 0.1 (Figure 
3.32 A), viral growth in VeropdlAIF was initially attenuated compared to naïve cells, 
but the viral titers caught up quickly and were similar from 36 hours post infection. 
On the other hand, viral replication in VeroshAIF cells was reduced by approximately 
1 log compared to naïve VeroE6 cells up to 72 hours post infection and although the 
peak viral titres were similar, there was a 24 hour delay in reaching these titres in 
VeroshAIF cells. The attenuation was more pronounced in Huh7 cells (Figure 3.32 
B-C), likely due to the greater reduction in AIF expression levels. The viral titers 
were almost identical after the initial rounds of virus release (24 hour post infection) 
after infection at MOIs of both 0.1 and 1 . However over the next 48 hours the rate of 
virus released from Huh7shAIF cells was significantly slower than that of naïve cells, 
resulting in an approximate 1 log reduction in viral titre. The virus reached its peak 
titre in both cell-lines by three days post-infection, however the titre released from the 
Huh7shAIF cells never reached the level of that from naïve cells.  
 
NP expression levels were analysed in each of the VeroE6 cell-lines at various time 
points post infection with TCRV by Western blot (Figure 3.33 A). The NP levels in 
VeropdlAIF cells were initially reduced compared to naïve VeroE6 cells with the  
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Effect of AIF levels on TCRV titres.  
 
Growth curves of TCVR in VeroE6 and Huh7-based cell lines to investigate the 
effect of AIF on viral replication. A) TCRV growth curve at an MOI of 0.1 in 
VeroE6, VeroshAIF and VeropdlAIF cells. B) Growth curve in Huh7 and 
Huh7shAIF cells infected at an MOI of 0.1. C) Growth curve as in (B) using an 
MOI of 1. Results represent the average of three independent experiments ± SD. P 
values were calculated for VeroshAIF and Huh7shAIF cell lines in respect to the 
naïve VeroE6 and Huh7 cell lines respectively using a Student T test 	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levels becoming comparable after 60 hours post infection (Figure 3.33 B). Therefore 
NP expression levels appeared to correlate with the growth kinetics of the virus in 
these cell-lines. When standardising the NP levels to actin (Figure 3.33 C) the trend 
remains the same with two exceptions, which are i) the initial NP levels are much 
lower at approximately 13% (days 1.5 and 2 post infection) of that of the peak on day 
3 post infection and ii) NP expression on day 3 post infection is largely increased 
compared to other time points. The NP levels in naïve VeroE6 cells drastically 
increase on 3 post infection, which then returns to levels on day 4 similar to those on 
day 2.5 post-infection. In VeropdlAIF cells the NP levels do not raise as sharply on 
day 3 post infection (about 65% of NP in VeroE6), but the levels are markedly 
increased for this time point similar to that in naïve VeroE6 cells.  
 
The NP expression levels in the VeroshAIF cell line (Figure 3.33 D) followed the 
trend observed in the viral growth kinetics analysis (Figure 3.32 A), except that the 
maximum NP levels in VeroshAIF cells did not reach the same maximum expression 
levels in VeroE6 cells. Interestingly the NP expression curve was shifted in 
VeroshAIF cells compared to naïve cells with peak expression in VeroshAIF cells at 4 
days post infection, compared to 1.5 days post-infection for naïve cells. However, 
when NP expression was adjusted to actin levels, the peak level in VeroshAIF cells 
was on day 3 post infection, similar to that of naïve cells (Figure 3.33 E). However 
the data showed that NP levels in VeroshAIF cells were markedly reduced, with the 
maximum NP expression level in VeroshAIF cells on day 3 post-infection only 23% 
that of naïve VeroE6 cells. 
 
 
3.3.2.6 Arenavirus NP-AIF interaction and apoptosis 
 
During analysis of NP expression levels it appeared that the peak of expression was 
accompanied by cell death as actin levels dropped significantly. There are several 
reports that indicate that proteins from other viruses interact with AIF to either inhibit 
(Kim et al., 2006, Liu et al., 2012a) or to induce apoptosis (Lu et al., 2013). As the  
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Effect of AIF on NP expression levels.  
 
A) VeroE6, VeroshAIF and VeropdlAIF cells were infected with TCRV at an MOI 
of 0.1. At the indicated times post-infection cells were lysed and analysed for NP 
expression levels by Western blot analysis. B) Relative NP expression levels in 
VeroE6 and VeropdlAIF cells were determined by densitometry. Results are the 
average of three independent experiments ± SD. C) NP expression levels shown in 
(B) after normalization against actin levels. D) Relative NP expression levels in 
VeroE6 and VeroshAIF cells were determined by densitometry. Results are the 
average of three independent experiments ± SD. E) NP expression levels shown in 
(D) after normalisation against actin levels. 	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functional consequence of the arenavirus NP-AIF interaction is unknown the role of 
this interaction in apoptosis was analysed during TCRV infection.  
 
To identify whether apoptosis is induced during infection and if so, at which stage 
during viral infection, a cytotoxicity assay under live conditions was performed using 
VeroE6 and VeroshAIF cells either mock infected or infected with TCRV at an MOI 
of 1. Surprisingly, the VeroshAIF cell-line was more sensitive to cytotoxicity than the 
naïve cell line, VeroE6 (Figure 3.34 A). While in infected cells the onset of 
cytotoxicity occurred at 36 hours post infection in VeroshAIF cells, the same effect 
was observed in VeroE6 with a delay of around 6 hours. The onset of cell death in 
uninfected cells was also earlier in the case of VeroshAIF cells, compared to naïve 
cells, indicating that the VeroshAIF cells were more prone to the induction of cell 
death than naïve cells. 
 
As the cytotoxicity data only indicated the kinetics of cytotoxicity, but not the 
pathway by which cytotoxicity was induced, the next step was to investigate the mode 
of cell death induction. For this, the cytotoxicity assay was repeated in VeroE6 and 
VeroshAIF cells using an inducer and an inhibitor of certain apoptotic pathways. The 
readout was chosen to be at 72 hours post infection as both cell lines showed 
cytotoxic effects at this time point post infection. Cells were either left untreated or 
were treated with the apoptosis inducing drug staurosporine (Figure 3.34 B), which 
induces cell death by the AIF-dependent pathway. Results showed that staurosporine 
induced the AIF-dependent cell death pathway in both cell lines. When cells were 
infected with TCRV (MOI 1) the levels of cell death were similar between the cell 
lines and comparable to the drug treatment. To probe whether the cell death observed 
was due to caspase-dependent or –independent pathways, the cells were infected with 
TCRV (MOI 1) in the presence of the universal caspase inhibitor Z-VAD-fmk (50 
µM). Interestingly, the cytotoxicity observed in both TCRV infected cell lines was 
reduced to levels of mock infected cells, indicating that the TCRV-mediated induction 
of cell death was caused by caspase-dependent apoptotic pathways and therefore 
independent of AIF.  
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TCRV infection and apoptosis. 
 
A) Vero E6 and VeroshAIF cells were infected with TCRV at an MOI of 1  and at 
various times post-infection levels of apoptosis were determined using CytoTox-
Fluor dye. The fluorescence of individual cells was scored using the IncuCyte 
ZOOM (Essen Bioscience) under live conditions over a period of 72 hours post 
infection. B) Vero E6 and VeroshAIF cells were either left untreated and 
uninfected (mock), treated with 1 µg/ml staurosporine, infected with TCRV at a 
MOI of 1 or infected with TCRV in the presence of the universal caspase inhibitor 
Z-VAD-fmk (50 µM; LC Labs). Levels of apoptotic cells were measured as in (A) 
at 72 hours post-infection. Results represent the average of three independent 
experiments ± standard error (SE). 	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3.3.3 Conclusions 
 
For the development of specific anti-arenaviral drugs, not only can viral proteins be 
targeted directly, but cellular proteins that interact with viral proteins and the 
interactions themselves might be suitable targets for antiviral drug design. Therefore, 
it is important to identify and characterise such virus-host protein-protein interactions. 
Effective broad-spectrum drug treatment would potentially affect protein-protein 
interactions conserved among different virus species. Here, cellular proteins were 
identified that interact with the NP of the non-pathogenic clade B TCRV NP as well 
as NP from two pathogenic species JUNV and MACV. GST-pulldown experiments 
identified 202 potential cellular protein targets, of which approximately one third 
were conserved between arenaviral NP species and found in cells from different hosts 
(human and rodent). 
 
The data in this chapter showed that the NP-AIF interaction is conserved between 
NPs of different virus species from both clade A and clade B NWAs. From protein 
alignments it appears that this interaction might be conserved for the whole arenavirus 
family. The interaction was mapped to the C-terminal domain in AIF (480-613 aa) 
and to amino acids 230-333 in TCRV NP. Computational analysis of NP and AIF 
identified a conserved 21 amino acid sequence in NP that forms a potential binding-
pocket. This pocket has a strong positive charge which would allow for binding to the 
strongly negatively charged region in the C-terminal domain of AIF. This requires 
further experimental analysis. However the interaction is formed it appears to occur 
during the active viral replication phase, at a time at which NP forms aggregates in 
the cytoplasm thought to be replication centers.  
 
Overexpression of AIF does not have a large impact on viral titers or cell viability, 
but when expression is reduced, viral titers are reduced, indicating that the virus 
requires this NP-AIF interaction for optimal replication.  
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Previous reports have suggested that the main function of AIF is the induction of 
apoptosis (Kim et al., 2006) and protein encoded by certain viruses interact with this 
protein to either block or induce apoptosis (Liu et al., 2012a). If arenaviruses had to 
inhibit the apoptotic function of AIF in infected cells and thus, AIF was a restriction 
factor for the virus, one would expect that reducing cellular AIF levels would 
potentially result in an increase in viral titers. However, the results reported here 
suggest the opposite was true as viral titers were reduced in VeroshAIF cells. The 
investigation into apoptosis during TCRV infection revealed that TCRV infection did 
indeed induce apoptosis, however this was due to activation of the caspase-dependent 
apoptotic pathway, and therefore independent of AIF. Therefore the NP-AIF 
interaction does not seem to be involved in regulating apoptosis.  
 
Taken this information together, the nature of the arenavirus NP-AIF interaction is 
currently unknown, but does not seem to involve apoptosis. From preliminary data the 
interaction does not seem to involve calcium-deregulation in infected cells, ATP 
levels or changes in mitochondrial membrane potentials (data not shown) and 
therefore, this interaction requires further investigation.  
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3.4 Tacaribe virus (TCRV) reverse genetics 
 
Viral reverse genetics systems are very powerful tools for virus research. These 
systems allow the generation of viruses in which mutations are introduced in a 
systematic manner, thereby allowing investigations into the molecular aspects of viral 
replication. Such systems have answered many questions in the past (see Section 1.5). 
Development of a reverse genetics system for TCRV would allow the results 
presented so far in this thesis to be validated in the context of a viral infection. For 
example a reverse genetics system would allow one to study the effects of preventing 
specific virus-host interactions without the requirement of modified cell-lines or the 
addition of drugs. The system would also allow the characterisation of resistance 
mutations in viruses produced during compound screening experiments. Therefore 
one of the main aims of the work presented in this thesis was to develop such a 
system allowing the recovery of TCRV entirely from cDNA. Successful recovery of 
other arenavirus species has been reported previously based on one of two systems, 
hRNApolI or T7-RP (see Section 1.5.2). For generating the TCRV reverse genetics 
system the more commonly used T7-RP strategy was chosen, thereby requiring the 
production of plasmids expressing each of the two genome segments (S and L 
segments) of TCRV.  
 
 
3.4.1 TCRV S segment 
 
The TCRV S segment RNA was isolated either from virus in the supernatant of 
VeroE6 cells 3 days post infection or directly extracted from infected VeroE6 cells 2 
days post infection. It was found that full-length RNA was more readily isolated from 
infected cells. RNA samples were processed by phenol-chloroform extraction 
followed by reverse transcription using S segment-specific primers. Due to the size of 
the S segment (approximately 3.4 kb) the entire segment was amplified by PCR in 
three separate fragments. From reports of other arenavirus reverse genetics systems, it  
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Cloning strategy for TCRV S segment virus recovery 
plasmid - pTVT7R-TCRV Sseg.  
 
The viral genome of the TCRV S segment was isolated by phenol-chloroform 
extraction followed by reverse transcription. The generated cDNA was subcloned 
in three individual fragments into pJET1.2 (pJET) subcloning plasmids, which 
were subsequenlty amplified by PCR and ligated into the recovery plasmid 
pTVT7R in anti-genomic orientation by restriction-free InFusion cloning. The 
numbers represent the nucleotide positions in genomic orientation.  	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Nucleotide*
Position*
(genome*5’*–*3’)*
Published*nucleotide* Observed*
nucleotide*
Region* Coding*
change*49# A# AA# UTR# /#318# T# C# GPC# /#348# C# T# GPC# /#414# T# C# GPC# /#416# AAGTGAACTTAACATCAATTAATTTGACGAGATCGA# /# GPC# deletion#839# T# C# GPC# /#1014# C# T# GPC# /#1077# C# T# GPC# /#1303# G# A# GPC# S/G#1423# GA# AG# GPC# R/E#1546# A# /# IGR# /#1562# G# GCGGCC# IGR# /#1568# G# GGG# IGR# /#1595# G# GGCA# IGR# /#1695# T# C# NP# K/E#1710# C# T# NP# V/M#1730# C# T# NP# /#1800# A# G# NP# /#1888# A# T# NP# /#2181# AGTTGGAGGT# GTAGGAGGTC# NP# DLQL/#GPPT#2237# T# C# NP# I/V#2282# T# C# NP# /#2560# C# G# NP# S/T#2626# A# G# NP# L/S#2853# G# A# NP# /#2972# G# A# NP# P/S#3141# T# C# NP# I/M#3387# G# AG# UTR# /##
Changes in pTVT7R-TCRV Sseg in comparison to the published 
TCRV S segment sequence.  
The table indicates the nucleotides in the published TCRV S segment on the NCBI 
server (NC-004293.1), shown in genome orientation. The differences observed in 
the pTVT7R-TCRV Sseg plasmid are shown, including the region of the segment 
affected by the changes and any coding changes as a consequence of the mutations. 
UTR – untranslated region, GPC – glycoprotein precursor complex, IGR – 
intergenic region, NP – nucleoprotein.  	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was reported that the stem-loop structure of the IGR, which contains high levels of 
complementary base-pairing, was problematic during PCR reactions (Bergeron et al., 
2012). The same problems were observed during cloning of the TCRV S segment, 
especially as the IGR has two predicted stem-loops, while the majority of 
arenaviruses possess only one stem-loop in the S segment. The three individual 
fragments (nucleotide sequences 1-1417, 1403-2041 and 2028-3432 in genome-sense 
orientation) were amplified by PCR and subcloned into the blunt-cloning vector 
pJET1.2 (Figure 3.35). The fragments were designed to contain a 15-nucleotide 
overhang for use in the restriction-free InFusion cloning (Clontech) method. The 
overhangs of the extreme 5’ and 3’ ends of the cDNA insert were designed to clone 
the entire S segment cDNA into the pTVT7R plasmid (Johnson et al., 2000), which 
contains a T7 promoter, a Hepatitis delta ribozyme and a T7 terminator sequence. 
After subcloning into pJET1.2, the individual fragments were amplified by PCR and 
mixed together with the linearized pTVT7R vector and ligated by InFusion cloning to 
generate the reverse genetics “rescue” plasmid containing the TCRV S segment 
sequence in anti-genome orientation. The sequence of the insert was then confirmed 
by DNA sequencing. The sequence was compared with the NCBI-deposited sequence 
of the TCRV S segment (NC-004293.1) (Table 3.1). The sequence of the cloned 
rescue plasmid showed at total of 28 mutations or mutated regions compared to the 
published sequence, 10 of which resulted in coding changes at the amino acid level 
(Table 3.1 and Appendix Figures 1 and 2). The GPC sequence of the cloned 
plasmid contained a large deletion compared to the published TCRV sequence 
starting at nucleotide position 416. However, this observation was previously reported 
in 1991 (Allison et al., 1991), and an alignment of all characterised arenavirus GPCs 
also failed to show the extra nucleotides found in the published TCRV sequence. It 
therefore appears that the published TCRV S segment sequence is incorrect and the 
sequence in the cloned rescue plasmid is more likely the actually TCRV S segment of 
the GPC ORF sequence found in the vRNA. Computational analysis of the other 
coding changes in GPC did not show any significant differences in the protein’s 
secondary structure.  
Besides showing seven individual single amino acid mutations in NP, there is also a 
mutated region that would result in 4 consecutive amino acid mutations (DLQL to 
GPPT) within the protein compared to the published sequence. In addition to the two 
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coding regions for GPC and NP, there are a further five regions that are altered in the 
UTRs and IGR of the S segment, all but one (in the IGR) are additions of nucleotides. 
Overall the changes observed in the S segment within the “rescue” plasmid resulted in 
the total nucleotide number changing from 3432 to 3406 nucleotides. 
 
 
3.4.2 TCRV L segment 
 
Constructing the TCRV L segment into a reverse genetics plasmid was more 
challenging than the cloning of the S segment. The viral RNA was isolated as 
described previously for the S segment utilising either supernatant from infected cells 
(day 3 p. i.) or directly from infected cells (day 2 p. i.). After reverse transcription and 
PCR the amplified cDNA fragments were ligated into the blunt cloning vector 
pJET1.2 in antigenomic orientation. This approach resulted in five initial constructs 
(Figure 3.36 a-e) for assembly into the full viral L segment using stepwise restriction 
digest and ligation procedures. To accomplish this, the plasmid encoding the 5’-end 
(Figure 3.36 a) was subcloned into the second plasmid encoding an overlapping 
portion of L segment sequence (Figure 3.36 b) using a NotI site located in pJET1.2 
and a SpeI site at nucleotide position 2399 in the L segment (genomic orientation 
numbering; NC_004292.1). The same strategy was used for the two plasmids at the 
3’-end (Figure 3.36 d and e), which also contained a SpeI site at nucleotide 5912. 
The final L segment combined the two second generation sub-genomic plasmids with 
a final portion of the L segment using two DraIII sites at positions 2858 and 5129 
(Figure 3.36 c) of the viral genome respectively and a third DraIII restriction site 
present in pJET1.2 in a 3 fragment ligation. As DraIII is a remote cutting restriction 
enzyme, the assembled L segment fragments could only assemble in one order and 
additional directionality screening was not necessary.  
 
The vector used for virus recovery, pTVT7R (Johnson et al., 2000), was modified by 
site-directed mutagenesis (SDM) to remove a BamHI site (GGATCC) present in the 
plasmid. Subsequently, the entire plasmid was amplified by PCR with primers that 
contained the 5’ and 3’ UTRs including the BamHI sites (positions 9 and 7090 in  
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Cloning strategy for TCRV L segment virus recovery plasmid – 
pTVT7R-Lseg.  
 
The viral genome of the TCRV S segment was isolated by phenol-chloroform 
extraction followed by reverse transcription. The generated cDNA was subcloned 
in five individual subcloning plasmids (a-e; pJET1.2). Plasmids a) and b) were 
ligated using a SpeI restriction site at nucleotide position 2399 and a NotI 
restriction site in the plasmid. The same strategy was used with plasmids d) and e), 
which were joined using a SpeI site at nucleotide position 5912 and a NotI 
restriction site in the vector. The two newly generated plasmids aas well as plasmid 
c) were digested using DraIII restriction sites and ligated to generate the full length 
L segment in anti-genome orientation in pJet1.2. A BamHI restriction side was 
removed from the recovery plasmid pTVT7R by SDM and linearised with primers 
containing the TCRV L segment UTRs. The linearised pTVT7R plasmid with the 
UTRs and the subcloned TCRV L segment were digested using BamHI restriction 
sites and ligated into the final pTVT7R-TCRV Lseg plasmid. 	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Changes in pTVT7R-TCRV Lseg in comparison to the published 
TCRV L segment sequence.  
The table indicates the nucleotides in the published TCRV L segment on the NCBI 
server (NC_004292.1), shown in genome orientation. The differences observed in 
the pTVT7R-TCRV Lseg plasmid are shown, including the region of the segment 
affected by the changes and any coding changes as a consequence of the mutations. 
IGR – intergenic region, L- polymerase.	  
Nucleotide*
Position*
(genome*5’*–*3’)*
Published*
nucleotide*
Observed*
nucleotide*
Region* Coding*
change*405$ G$ GC$ IGR$ /$650$ C$ T$ L$ /$1702$ G$ A$ L$ /$1943$ A$ G$ L$ /$2201$ T$ C$ L$ I/M$2511$ T$ C$ L$ G/D$2884$ G$ T$ L$ Q/K$3249$ G$ T$ L$ P/Q$3320$ T$ C$ L$ /$3588$ C$ T$ L$ S/N$4197$ C$ T$ L$ R/K$4220$ A$ G$ L$ /$4261$ C$ T$ L$ /$4327$ T$ A$ L$ M/L$4880$ A$ G$ L$ /$5416$ C$ T$ L$ G/R$5830$ C$ G$ L$ E/Q$5898$ C$ T$ L$ /$6024$ T$ C$ L$ /$6851$ A$ C$ L$ S/R$6978$ T$ G$ L$ H/Q$$
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genome orientation) occurring in the viral genome. In addition to the sequences of the 
UTRs, one primer also contained an additional C nucleotide (upstream of the viral 5’ 
UTR). Other arenavirus reverse genetics systems have only reported the successful 
virus recovery after insertion of this base (Albarino et al., 2009, Lan, 2009) because 
of the virus’ “prime and re-align” transcriptional mechanism (see Section 1.3.2).  
The product from this PCR was ethanol precipitated and treated with DpnI, calf 
intestinal alkaline phosphatase (CIAP) and BamHI. The assembled L segment was 
cleaved from the pJET2.1 vector by restriction digestion with BamHI and the purified 
L segment was ligated into pTVT7R generating the rescue plasmid for the TCRV L 
segment. After assembly of the final rescue plasmid, pTVT7R-TCRV Lseg, the insert 
was initially screened for directionality, before sequence analysis of the generated 
plasmid was carried out. 
 
Sequence comparison with the newly generated pTVT7R-TCRV Lseg with the TCRV 
L segment sequence (NC_004292.1) from the NCBI database revealed a total of 21 
nucleotide changes (Table 3.2). Interestingly, no changes were observed in either of 
the UTRs or the coding region of the Z protein. An additional C nucleotide was 
observed in the IGR between position 405 and 406 of the published sequence in 
genomic orientation, which resulted in the overall L segment of 7103 nucleotides in 
the rescue plasmid. The remaining 20 differences observed were all located within the 
coding region of the L protein, 11 of these nucleotide differences resulted in amino 
acid changes. Computational analysis of the secondary structure using Jpred 3 (Cole 
et al., 2008) did not show changes in the secondary structure of the L protein as a 
consequence of the amino acid changes.  
  
3.4.3 Conclusions 
 
The TCRV “rescue” plasmids were cloned and sequenced. Comparison with the 
published sequence of TCRV resulted in 28 differences in the S segment and 21 
changes in the L segment between the cloned and the published sequences. The two 
plasmids have recently been used in the attempt to generate infectious virus. 
Unfortunately this has so far proven to be unsuccessful. However it is likely that the 
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conditions required for TCRV recovery need to be optimised, which unfortunately is 
outside of the time frame of this project. Furthermore, potential differences between 
observed and published sequences of the TCRV genome segments could also account 
for the unsuccessful recovery of recombinant TCRV. This has to evaluated by 
resequencing of TCRV cDNA or can be accessed using minigenome, as was reported 
by Lopez et al. (2001) approach that can evaluate the individual UTR, IGR and ORF 
components.   
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4.1 Discovery of arenavirus-specific antiviral compounds 
 
There are several antiviral compounds available that show broad-spectrum activity 
against a number of viruses, such as ribavirin (McCormick et al., 1986, Kilgore et al., 
1995), or those in clinical trials such as T705 (6-fluoro-3-hydroxy-2-
pyrazinecarboxamide) (Gowen et al., 2007) that also seem to be active against 
arenaviruses. However there are significant drawbacks with these compounds, such as 
problems with toxicity and availability. To discover novel compounds with anti-
arenavirus properties previous studies have used the approach of HTS (Bolken et al., 
2006, Lee et al., 2008, Larson et al., 2008). Approximately 480,000 compounds were 
screened with only a handful of them shown to be active against arenaviruses 
[reviewed by (Lee et al., 2011, Radoshitzky et al., 2012, Nunberg and York, 2012)]. 
A major problem with many of these screens for identifying arenavirus-inhibiting 
compounds is that positive results in the screens are based on the cytopathic effect 
(CPE) caused by the virus being tested (Bolken et al., 2006), an approach rather 
difficult with a virus family that shows only little to no CPE in cell culture. Other 
approaches used lentiviral pseudotype screens (Larson et al., 2008, Lee et al., 2008). 
Although these screens resulted in the discovery and generation of potent anti-
arenaviral compounds, such as ST-294 or ST-193 (Bolken et al., 2006, Larson et al., 
2008), with inhibitory concentrations 50 (IC50) values in the low nM concentrations, 
these approaches are rather limiting in the discovery of drugs against arenaviral 
infection. The CPE-based HTS approach is entirely random and initial hits need 
extensive deconvolution processes, as the compounds do not only act against the virus 
directly, but can have many unpredictable cellular effects and might be cytotoxic. The 
viral pseudotype method can help identifying viral entry inhibitors and circumvents 
the high-containment requirements for pathogenic arenaviruses, but it cannot be used 
for discovering drugs that act against other stages of the viral replication cycle. 
Therefore, a more direct HTS approach is required that can identify compounds able 
to bind directly to arenavirus proteins and thus having the potential of inhibiting 
important functions of these proteins throughout the entire viral replication cycle. 
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4.1.1 Small molecule screens for structure-based drug design 
 
This study employed a different approach for HTS, by purifying a specific component 
of an arenavirus, the TCRV NP protein, and screening the activity of compounds 
against it. NP is a multifunctional protein with roles throughout the viral replication 
cycle. Therefore any compounds that bind to and inhibit the function of NP 
potentially inhibit multiple steps during viral replication. This method also allows one 
to use NP proteins from highly pathogenic arenaviruses without the need for high 
containment facilities, as only a single viral protein is required.  
 
Previous studies, such as those concerning the hormone receptor for erythropeitin 
(EPO), have shown that most proteins only use a small amino acid cluster for 
mediating protein-protein interactions, which can be interrupted by small molecules 
(Livnah et al., 1996, Wells, 1996, Wells and de Vos, 1996, Wrighton et al., 1996). 
Therefore, the identification of small molecule compounds that bind to a specific 
protein would allow the optimisation of this compound by chemical modification, to 
increase binding affinity and potentially render the target protein non-functional. 
Preferably this approach would be carried out when it is supported with structural data 
of the small molecule bound to the target protein so that the binding-pocket can be 
identified and chemical modification of the compound can be better designed. 
However, although the structure of TCRV and MACV NPs are currently unknown, 
the molecular structure of LASV NP has been reported. Despite LASV being an 
OWA, LASV NP shares some structural and sequence homology to the NWA NPs 
and it can serve as a surrogate for the computational models. How and where small 
molecule compound hits from the HTS bind to the proteins remains to be seen. 
Crystallisation of TCRV, MACV and JUNV NPs was attempted (see Section 3.1.2, 
Figure 3.2) and protein crystals were subsequently obtained for TCRV and MACV 
NP, however no structure has yet been determined. It is difficult to speculate on 
potential differences in the protein structures of the individual NPs and what impact 
differences might have. However in this study it was shown that the individual 
proteins were affected by different small molecule compounds (see Section 3.1.3, 
Figure 3.4), which is potentially a result of small differences in secondary or tertiary 
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structure of these proteins. Once the structures of these proteins are obtained, these 
could lead to rational drug design [summerised by (Hoffman, 2012)]. The small 
molecule compounds identified in this project could then be chemically modified to 
improve potency based on the information obtained about the binding pocket and 
potential drug-protein contacts. On the other hand if determination of the molecular 
structures of these proteins proves difficult the identified small molecule compounds 
could also prove helpful in solving the protein crystal structures, as binding to these 
compounds might lock the proteins into a conformation that favours crystallisation 
(Hassell et al., 2007, Tiefenbrunn et al., 2013, Boivin et al., 2013). 
 
In contrast to previously reported approaches for HTS screening of compounds 
against arenaviruses, this study employed a method of screening compounds directly 
against NPs using thermal shift assays. This method has been reported previously (Lo 
et al., 2004, Major and Smith, 2011), and it has been shown to be a robust screening 
method allowing the identification of compounds acting directly against target 
proteins. Thermal shift assays are also inexpensive and realistically executable in an 
academic setting.  
 
 
4.1.2 [5-(2-furyl)-tien-2-yl]methanol and cyclosporin A (CsA) 
 
The thermal shift-based HTS of small molecule compounds identified [5-(2-furyl)-
tien-2-yl]methanol as a compound that binds to TCRV and MACV NP directly 
resulting in a stabilisation of melting temperature (see Section 3.1.3). Not much is 
known about this compound as it has not been previously reported as a protein-ligand. 
The molecule is a promising candidate as it increases the protein’s melting 
temperature, which possibly indicates that the multifunctional arenavirus NP is 
“locked” into a specific conformation (Mittermaier and Kay, 2006, Lange et al., 2008, 
Henzler-Wildman et al., 2007, Teague, 2003, Boehr et al., 2009, Tuffery and 
Derreumaux, 2012). Due to the multifunctional nature of NP one can speculate that 
many specific and potentially important functions of NP may be inhibited when the 
protein is only present in one conformation. At this stage it is not known where the 
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small molecule binds in NP and what consequences this ligand-binding has for the 
protein. With the obtained information, the small molecule compound can be subject 
to molecule optimisations to improve binding-affinity as well as inhibitory functions 
(Davis et al., 2005, Arkin and Wells, 2004, Hopkins et al., 2014). Thus, the next step 
will be to identify the binding-site, together with the identification of how and at 
which stage of the viral replication cycle NP might be inhibited from functioning to 
its full capacity. From preliminary results presented in this study (see Section 3.1.4) it 
seems that overall expression of NP is inhibited, which could be a result of inefficient 
viral mRNA production, an observation that could be investigated in more detail by 
quantifying virus-specific mRNAs using quantitative real-time PCR (qRT-PRC). The 
effect appears to be limited in time (Figure 3.6), which could be a result of the 
compound being degraded in the cell so that the effect of inhibiting NP is reversed. 
Therefore it will be important to investigate the duration the compound is active for in 
cells. The compound will also have to be tested against other arenaviruses to place 
importance on [5-(2-furyl)-tien-2-yl]methanol as an effective anti-arenavirus drug 
candidate. Therefore whether [5-(2-furyl)-tien-2-yl]methanol is a viable broad-
spectrum anti-arenavirus drug remains to be seen in future experiments. 
 
This project identified CsA as a compound that inhibited arenavirus replication. An 
advantage of using CsA as a therapeutic treatment for viral infection is that the 
compound is already approved for clinical use, currently for the purpose of 
immunosuppression after organ transplantation (Borel and Kis, 1991, Kahan, 1999, 
Borel et al., 1977, Ho et al., 1996, Matsuda and Koyasu, 2000). However the 
drawback with using CsA as an antiviral is the fact that it acts as an 
immunosuppressive by inhibiting T cell activation (Ho et al., 1996, Matsuda and 
Koyasu, 2000), which would be severely detrimental to the chances of clearing a viral 
infection. However derivatives of CsA have been reported that do not possess this 
immunosuppressive function (Twentyman et al., 1992, Landrieu et al., 2010), which 
may represent promising candidates for anti-arenavirus drug discovery.  
 
In this study it was shown that although CsA binds to arenavirus NP it does not affect 
the expression of NP in infected cells (see Section 3.1.5.5, Figure 3.12). However 
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CsA treatment of virus-infected cells reduced the length of time that infectious viruses 
were released from the cell (see Section 3.1.5.3, Figure 3.10). It therefore appears 
that rather than interfering with viral replication, CsA treatment affects the effective 
formation of progeny virions late in infection, thereby allowing for a quicker 
reduction in infectivity. This observation is different to observations made for HBV 
(Xie et al., 2007), HCV (Nakagawa et al., 2004, Nakagawa et al., 2005), influenza A 
virus (Schiltknecht and Ada, 1985, Liu et al., 2012b) and VACV (Damaso and Keller, 
1994), where CsA affected replication. CsA directly affects areanvirus NP by direct 
binding as shown in thermal shift assays (see Section 3.1.3, Figure 3.5), which 
results in the redistribution of NP away from RTCs to a cytoplasmic membrane 
localisation (see Section 3.1.5.2, Figure 3.9).  
 
At this stage it is difficult to identify the the precise mode of action of CsA in 
arenavirus infections. For HCV it was shown that CsA most likely impacts the correct 
processing of the NS2/3 cleavage site in a CypA-dependent mechanism (Ciesek et al., 
2009). Currently for all reported viral infections that are affected by CsA treatment, 
the mode of action was linked to CypA [summarised in (Zhou et al., 2012)]. The role 
of CypA was investigated for TCRV infection in this study (see Section 3.1.5.5, 
Figure 3.13), however no obvious differences were observed when CypA expression 
was knocked down. This suggests the mode of action of CsA in inhibiting arenavirus 
infection is not linked to CypA. 
 
A study by Slattery et al. (2005) suggested that CsA-treatment affected the 
cytoskeleton. which was investigated in this study (see Section 3.1.5.5, Figure 3.14), 
after CsA-treatment showed an increased formation of stress fibres in 
immunofluorescence images (Figure 3.14). Treatment with the F-actin 
depolymerising agent Latrucullin A, demonstrated that cellular NP distribution 
changed when F-actin integrity was affected (Figure 3.14). Similar effects were 
previous shown in studies using measles virus (Wakimoto et al., 2013, Dietzel et al., 
2013), where the disruption of F-actin resulted in the accumulation of the M protein 
below the cytoplasmic membrane. This resulted in a reduction in virus egress despite 
no obvious differences in viral protein expression levels. The exact same observations 
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were made with TCRV in this study. Furthermore Wakimoto et al. (2013) showed that 
measles virus infection induced stress fibre formation, which was also observed upon 
TCRV infection. For many viruses it was shown that stress fibre formation was 
disadvantageous for the course of infection, although the reason is not really 
understood, and these viruses subsequently seem to have evolved mechanisms to 
circumvent this formation [summarised by (Taylor et al., 2011)]. For measles virus it 
was hypothesised that the disruption of F-actin inhibits the vRNP transport of viral 
inclusion bodies to budding sites at the cell membrane (Dietzel et al., 2013). Although 
the exact mechanism vRNP transport in arenaviruses is not know, so was shown that 
LASV Z utilised the cytoskeletal protein KIF13a for cellular trafficking (Fehling et 
al., 2013), thus the cytoskeleton might also be important for NWA, such as TCRV. 
Another potential reason for requiring an intact F-actin network, besides trafficking of 
viral proteins through the cell, is that many viruses rearrange the cytoskeleton for 
efficient budding from the cell (Sattentau, 2008, Taylor et al., 2011, Arakawa et al., 
2007). Currently it is not known if arenaviruses require the formation of cytoskeleton 
components, such as filopodia, microvilli or lamellipodia, for efficient budding from 
cells, which is something that could be investigated by EM studies in the future.  
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4.2 Innate Immunity 
 
4.2.1 Inteferon (IFN) induction and signalling 
 
Most of the information that is currently known about the interactions of arenaviruses 
with the innate immune responses, especially early during arenavirus infections, is 
based on general observations from animal studies (see Section 1.4.6). The only 
exceptions are the molecular characterisations of the direct interactions with RIG-I for 
NWA (Fan et al., 2010) and IKKε (Rodrigo et al., 2012). Further, it was shown that 
the viruses are capable of blocking NF-κB activation (Rodrigo et al., 2012) and a 
potential interaction with STAT2 was reported.(Hahm et al., 2005) The majority of 
such interactions therefore inhibit the IFN-induction pathway and it appears that 
arenaviruses use much “effort” to prevent its successful activation. It was 
hypothesised that TCRV does not cause human disease partly due to the fact that it 
has a reduced ability to interfere with this pathway. However, in this study the data 
presented show that the ability to block the IFN-induction pathway does not lag much 
behind that of PICV (see Section 3.2.1, Figure 3.15), for which an inhibition of IRF3 
activation was previously shown (Martinez-Sobrido et al., 2007). This raises the 
questions as to whether there are other factors involved that inhibit this pathway to 
compensate for this reported reduced capability to inhibit IFN-induction, or whether 
arenaviruses are less sensitive to IFN as reported. However, the ability of TCRV to 
interfere with the IFN-signalling pathway was reduced compared to PICV (see 
Section 3.2.1, Figure 3.16). Therefore the presented results could indicate the 
importance of the IFN-signalling pathway as a starting point for targeted arenavirus-
specific therapy utilising the innate immune response. Virus-induced haemorrhagic 
fever in humans is currently treated with a supportive therapy approach that aims to 
stabilise the patient and to hold the ongoing infection in check until the adaptive 
immune system can clear the infection (McCormick and Fisher-Hoch, 2002, 
McCormick et al., 1986, Fisher-Hoch et al., 1988, Johnson et al., 1987, Vela, 2012). It 
was further shown that the viral load correlated with a patient’s disease outcome 
(Johnson et al., 1987, McCormick and Fisher-Hoch, 2002). Therefore, investigating 
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the role of the IFN-signalling pathway in order to reduce the viral load could offer a 
potential early treatment option.  
 
 
4.2.2 Interferon-stimulated genes 
 
Cells defend themselves by upregulating or expressing ISGs upon a “danger” stimulus 
through IFN-signalling pathways. Using this mechanism cells can either enter an 
antiviral-state by which the cell can defend itself against an incoming virus, or it can 
respond to being infected by a virus to eventually terminate the ongoing viral 
replication. The proteins a cell expresses upon IFN-stimulation are thought to be 
several hundreds in number, with most of them currently unknown, let alone fully 
understood [reviewed by (Schoggins and Rice, 2011, Diamond and Farzan, 2013, 
Schneider et al., 2014, Schoggins, 2014). The common features of ISGs can be 
summarised as proteins that inhibit viral infection either during cell entry, during 
replication, translation or viral exit (Schoggins and Rice, 2011, Schneider et al., 
2014). 
 
Currently not much is known about ISGs that are capable of defending a host cell 
from arenavirus infection, with the exception of tetherin (Sakuma et al., 2009b, 
Sakuma et al., 2009a, Radoshitzky et al., 2010). Surprisingly, studies focusing on 
IFN-induced transmembrane proteins (IFITMs) (Diamond and Farzan, 2013, Li et al., 
2013, Perreira et al., 2013) found that arenaviruses are not inhibited by these broad-
spectrum ISGs (Brass et al., 2009, Huang et al., 2011). IFITMs have been shown to 
restrict cell entry of a large number of viruses and it has been postulated that, at least 
in the case of IFITM3, this involves prevention of pH-mediated viral fusion 
mechanisms within late endosomes, thereby preventing the viral genome exiting the 
endosome (Feeley et al 2011). It is surprising that arenaviruses are shown to be 
resistant to the antiviral activity of this group of proteins given that like many other 
enveloped RNA viruses, they enter the cell through endocytosis involving a pH-
dependent fusion mechanism. It is to note, however, that the previous studies were 
conducted using arenavirus pseudotyped lentiviral particles and that there might be 
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unknown differences and limitations using pseudotypes particles for IFN-based 
assays. It is also possible that arenaviruses are able to bypass the antiviral action of 
IFITMs through fusion occurring in early endosomes, in which the IFITMs are not 
thought to be antivirally active. 
 
As there are ISGs that have been described to act directly against arenavirus 
infections, although the actions of the innate immune response are thought to be 
essential during the early stages of human infection, it is particularly important to 
identify ISG that shown antiviral activity against arenavirus infection. These ISGs 
then could give important clues for the identification of viable drug targets at various 
stages of arenavirus infections. Such treatment could potentially restrict replication of 
the virus inside a host cell, thereby reducing viral titres, aiding clearance of the virus 
and reducing the onset of serious disease symptoms. The other application of such 
knowledge is to find mechanisms to specifically up-regulate the identified ISGs in 
vivo (Patel et al., 2012), so that an “anti-viral state” is induced in the host, thereby 
limiting any potential infection.  
 
 
4.2.3 IFIT3 
 
The ISG-screen initially identified IFIT3 as an interferon-induced protein, which 
restricts TCRV infection (see Section 3.2.3). During these experiments it was 
observed that the action of IFIT3 against TCRV infection was enhanced with IFN-
treatment of cells prior to infection. The function of this protein is currently poorly 
understood. IFIT3 was initially identified as an ISG in 2010 (Schmeisser et al.) and 
not much is known about the exact mechanism of action. The induction of IFIT3 has 
previously been shown in response to a variety of infections, including influenza A 
virus, HBV, HCV, WNV, JEV or LCMV (Rathi et al., 2010, Wacher et al., 2007, 
Matthys et al., 2011, Lietzen et al., 2011, Saha et al., 2006, Saha and Rangarajan, 
2003). However, these studies did not investigate any possible antiviral effect of 
IFIT3. Other studies however, showed IFIT3 as a restriction factor for a variety of 
viruses, such as porcine reproductive and respiratory syndrome virus (PRRSV) 
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(Zhang et al., 2013b) or Dengue virus (DENV) (Chen et al., 2013). The studies do not 
present a function of how IFIT3 restricts PRRSV or DENV, but an earlier study by 
Liu et al. (2011) showed that IFIT3 causes the activation of TBK1 via MAVS. This 
activation eventually leads to the phosphorylation of the IRF3 transcription factor and 
activation of the IFNβ-promoter (Liu et al., 2011). These observations were 
confirmed in this study using different viral protein-expression cell lines to dissect the 
IFN-induction pathway (Figure 3.22). Overall the results suggest that IFIT3 bridges 
the IFN-induction and IFN-signalling pathways. Similar observations were previously 
reported for other members of the IFIT-family. IFIT2 was shown to enhance IFN-
mediated TNF-α secretion after lipopolysaccharide-stimulation (Siegfried et al., 2013) 
and IFIT5 enhances IFNβ induction potentially by interacting with RIG-I and MAVS 
(Zhang et al., 2013a). The results shown in this study (see Section 3.2.4, Figure 3.22) 
suggest a similar effect for IFIT3, which could potentially form a feedback-loop for 
IFN-induction and –signalling. Although the observation in A549pr(IFNβ).GFP cells 
that IFNβ-induction occurs during TCRV and PICV infection (see Section 3.2.1, 
Figure 3.15), activation of IRF3 could not be observed in Huh7 cells (Figure 3.23). 
However the results also showed, through the expression of BVDV Npro, that 
induction of IFN was important for the efficient restriction of TCRV by IFIT3 
(Figure 3.22). It is known that BVDV Npro targets IRF3 for proteasomal degradation 
(Hilton et al., 2006a), however this study only looked at IRF3 and NF-κB as potential 
targets for Npro, and demonstrated that NF-κB activation is not affected by Npro. 
However, the IFNβ-promoter can also be activated by other transcription factors, such 
as IRF7, which can be expressed in an IFN-dependent and independent mechanism 
(Ning et al., 2005, Honda et al., 2005, Lu et al., 2000, Sato et al., 1998). Interestingly, 
the closely related Npro of classical swine fever virus (CSFV) was shown to not only 
affect IRF3, but also IRF7 (Fiebach et al., 2011). If BVDV Npro is also able to affect 
IRF7 this could explain the observation in this study that the expression of BVDV 
Npro can reverse the antiviral effect of IFIT3 (Figure 3.22). Furthermore previous 
studies have shown that infections with the arenavirus LCMV in mice resulted in a 
strong upregulation of IRF7 (Ousman et al., 2005, Christensen et al., 2012), therefore 
there is likely an important role of this transcription factor during arenavirus infection. 
Compared to IRF3, which is responsible for the activation of the IFNβ promoter 
(Hiscott et al., 1999), IRF7 appears to have more potential in the antiviral response 
against viral infection as it can be activated by several IFN-dependent and –
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independent pathways and importantly, triggers the expression of IFNα and IFNβ 
genes as well as affecting the NF-κB pathway (Honda et al., 2005).  
 
Taken together the results shown in this study and previous reports from the literature, 
the following model is proposed for the function of IFIT3 during arenavirus infection 
(Figure 4.1). Arenavirus infection initially triggers the induction of IFN, likely 
through the presence of PAMPs recognised by cellular PRRs. This leads to the 
expression of type I IFN, which is secreted from the cell and can be recognised by 
para- and autokine signalling via the IFNR1/IFNR2 receptor (see Section 1.4.2, 
1.4.3). This, in turn, triggers the phosphorylation and formation of the STAT1/STAT2 
heterodimer and together with IRF9 forms the active transcription factor ISGF3. As a 
result the ISRE is activated and leads to the transcription and translation of ISGs, such 
as IFIT3 and IRF7. These two proteins act in a feedback-loop between IFN-induction 
and –signalling pathways. While IFIT3 activates the pathway upstream by interacting 
with MAVS and TBK1, the increased expression of IRF7 could serve as a substrate 
for enhanced activation of this transcription factor and enhanced transcription of IFNα 
and IFNβ genes. A potential negative regulator of this feedback-loop might be IFIT2 
(Siegfried et al., 2013). Thus, the efficient induction of IRF7 and IFIT3 during 
arenavirus infection could be investigated as potential treatment options. 
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Model of IFIT3 role during arenavirus infection. 
 
Overview of IFN-induction and –signalling pathways (see Section 1.4.2 and 1.4.3) 
with proteins highlighted that are thought to play essential roles during arenavirus 
infection. Briefly, initial activation of the IFN-induction pathway leads to the 
expression of type I IFNs. These IFNs trigger the induction of the IFN-signalling 
pathway with the upregulation of ISGs by the ISRE. The ISGs upregulated include 
IFIT3 and IRF7, which form an amplifying feedback-loop between the IFN-
induction and –signalling pathway. IFIT3 triggers the activation of TBK1 via 
MAVS and further downstream in the IFN-induction pathway upregulated IRF7 
can be phosphorylated by the TBK1-IKKε heterodimer, eventually leading to an 
increased transcription of IFNα and IFNβ genes. 	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4.3 Arenavirus NP protein-protein interactions 
 
4.3.1 Arenavirus NP interactions with host-cell proteins 
 
GST-pulldown experiments with arenavirus NPs resulted in the identification of more 
than 200 cellular protein-hits (Appendix Table 4). The proteins identified represent 
different function-clusters in the host cell, which include involvement in transcription, 
translation initiation, cytoskeleton or protein trafficking. A more comprehensive 
overview can be achieved using the STRING database (Franceschini et al., 2013), 
which can show hotspots and networks of possible protein-protein interactions. If 
these hits do represent actual interactions formed during infection the list 
demonstrates the degree of multifunctionality of arenavirus NPs during the course of 
infection and indicates potential therapy targets through the disruption of these 
interactions. Thus, interactions that are potentially essential for viral replication 
include interactions with members of the eIF4 protein family (Iacoangeli and Tiedge, 
2013, Hernandez and Vazquez-Pianzola, 2005). 
 
 
4.3.2 NP-AIF interaction 
 
In this study the interaction between a number of different arenavirus NPs and the 
cellular protein AIF was identified and partially characterised. The interaction appears 
to be conserved among certain members of the Arenaviridae family found within 
clade A and B viruses. The suspected binding sequence (residues 294-316 in TCRV 
NP) is highly conserved throughout the virus family, therefore the NP-AIF interaction 
may have been established early during virus evolution and thus is most likely 
important at some stage during viral replication.  
 
For viruses, such as EBV or HSV, it was shown that these viruses interact specifically 
with AIF to block apoptosis (Zhou and Roizman, 2000, Kim et al., 2006) , while the 
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picornavirus entrovirus 71 induces apoptosis via an interaction with AIF (Lu et al., 
2013). In all cases AIF was shown to be activated by calcium-dependent proteases 
followed by translocation of AIF into the cytoplasm. EBV was shown to be able to 
block the progress of AIF into the nucleus (Kim et al., 2006), while HSV inhibits the 
AIF-mediated fragmentation of DNA inside the nucleus (Zhou and Roizman, 2000). 
However, in these reports the activation of AIF resulted in the truncation of the 
protein due to protease cleavage events, something that could not be shown during 
TCRV infections (data not shown), also the preceding calcium flux that activates the 
proteases could not be observed (data not shown). If arenavirus NPs have to inhibit 
the apoptotic function of AIF, one would expect it to be a restriction factor either 
early in the establishment of infection or throughout the viral replication cycle. 
However results shown in this thesis when using AIF overexpression and knockdown 
cell lines suggest this is not the case. One might expect increased levels of AIF to 
induce apoptosis more readily and therefore negatively affect viral replication. 
However the overexpression of AIF had little to no effect on viral replication. In the 
AIF knockdown cell lines viral replication was actually reduced, which suggest the 
interaction is beneficial to the virus and contradicts the notion that AIF is possibly an 
apoptotic restriction factor during arenavirus infection. The other possibility was that 
arenaviruses induce apoptosis via an AIF-dependent pathway through the interaction 
with NP. Although TCRV infection caused apoptosis at late stages during infection, 
the results in this thesis demonstrate that this was via the caspase-dependent cell death 
induction pathway and therefore independent of AIF. So far interactions of other viral 
proteins with AIF have been reported to involve regulation of apoptosis during viral 
infection. Therefore the results presented in this thesis are the foundation for a novel 
aspect of an interaction between AIF and a virally-encoded protein. Whatever the 
reason and mechanism behind this interaction, the results presented here demonstrate 
that this interaction between AIF and arenavirus NPs is required for efficient viral 
replication. 
 
Although most reported work with AIF has focused on the protein’s ability to induce 
apoptosis, there are several other cellular functions that have been attributed to AIF 
that could potentially be involved in the interaction with arenavirus NPs. In 2001 
Guido Kroemer’s group described that AIF is not only an apoptosis inducing factor, 
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but also possesses NADH oxidase activity in vitro (Miramar et al., 2001). Since this 
discovery, the characterisation of AIF as a protein that primarily induces apoptosis 
has slightly shifted away from AIF being a pro-apoptotic protein with functions that 
are not fully understood, but seem to involve cellular stress responses (Joza et al., 
2009). In agreement with this are experiments in ES AIF knockdown cells and a 
transgenic AIF knockdown mouse strain, the harlequin mouse, in which AIF-
expression is reduced by 80% (Klein et al., 2002). This particular mouse strain shows 
in increased neuronal degeneration that most likely results from oxidative stress. 
Further data from ES cells suggest that AIF is involved in regulation of the 
mitochondrial respiratory chain, namely complex I, as the cells show an increase in 
lactate production that correlates with a dependence on glycolytic ATP as an energy 
source (Vahsen et al., 2004). How and why AIF is involved in complex I respiration 
is currently unknown. It is thought, however, that the reduction of AIF in harlequin 
mice disrupts the ATP synthesis by complex I, which eventually leads to the build up 
of ROS (Klein et al., 2002) and the NADH oxidase activity (Miramar et al., 2001) 
might be protective of this chain of events. Interestingly, a study showed that AIF 
down regulates the formation of cytoplasmic stress granules (SG) (Cande et al., 
2004), which form after stalled translation initiation complexes accumulate in distinct 
cellular structures (Kedersha and Anderson, 2002, Anderson and Kedersha, 2002). 
Stress granules can also be induced when the cell is depleted of ATP/GTP (Kedersha 
and Anderson, 2002). Although it is not entirely proven, it is thought that SGs are a 
cellular mechanism to deal with misfolded proteins. It was shown that HeLa cells 
transfected with small interfering RNA (siRNA) against AIF showed increased 
formation of SGs (Cande et al., 2004) and the mechanism could be partially attributed 
to the NADH oxidase activity, as treatment of these cells with an antioxidant reduced 
the observed SG formation.  
 
As described in Section 1.2.3.3, arenavirus NP was reported to colocalise with 
translation initiation factors (eIF4A) (Baird et al., 2012), which has led to speculation 
that the virus uses the eIF4 complex for the translation of its own proteins during viral 
infection. It is possible that during the viral protein translation process there is the 
chance of accumulation of large amounts of viral proteins that bear the risk of 
misfolding in the cell, which could potentially induce SG formation. Not only was the 
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colocalisation with eIF4A reported, but also the interaction between NP and the SG 
protein G3BP1 was indicated (Baird et al., 2012). Immunofluorescence images from 
this study show a colocalisation of G3BP1 and NP in arenavirus RTCs, but the reason 
for any potential interaction remains unclear. An earlier paper, however, showed that 
JUNV infection reduced the formation of SGs, even when induced with arsenate 
(Linero et al., 2011). The study attributed the reduction of SGs to a reduction in eIF2α 
phosphorylation, which can be induced via PKR by arsenate treatment (Brostrom et 
al., 1996, Daher et al., 2009). But neither a direct nor an indirect interaction could be 
shown, leaving the exact mechanism open for speculation. It is plausible that AIF 
might be involved during these cellular stress responses that lead to the inhibition of 
SG formation during arenavirus infection. The reports of JUNV infection blocking 
SG formation could be independent from AIF, but they could also be linked, which 
requires further investigation. It is plausible that the virus has multiple “fail-safe” 
mechanisms to ensure viral protein translation, a strategy that many other viruses 
deploy (Reineke and Lloyd, 2013). The consequence of the inhibition of SGs most 
likely is that the efficient translation of viral proteins is ensured during infection, an 
observation that matches the reduced NP levels in AIF knockdown cells in this study.  
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4.4 TCRV reverse genetics system 
 
Reverse genetics systems are very powerful tools in molecular research of viruses. 
With this method many different aspects of a viral replication cycle can be analysed 
by introducing specific mutations into a viral genome (see Section 1.5).  
At this stage it is rather difficult to predict the reason for the unsuccessful recovery of 
TCRV. However, since the development of a functional MG system for TCRV 
(Lopez et al., 2001), the sequences for the S segment UTRs and IGR have been 
characterised and are known to be functional. Both UTRs in the cloned S segment 
reported in this thesis show single nucleotide additions compared to the published 
sequence used for the TCRV MG system. As these nucleotides are not found within 
the promoter regions of the UTR it is unlikely that they are responsible for the lack of 
virus recovery, however this needs to be investigated further. Other approaches can 
include the re-isolation of the viral genome followed by re-sequencing analysis or 
Northern blot analysis for the identification of transcribed viral RNA species to 
identify potential sequences or regions that contain a mutation responsible for the 
non-functional reverse genetics system. The other possibility is that the conditions 
required for efficient virus generation have not yet been determined. Reverse genetics 
systems are not always straight forward, and despite all plasmid sequences being 
correct, finding the correct conditions for virus generation can be troublesome. 
Therefore extensive optimisation of conditions, such as cell type, transfection 
conditions, amount of plasmid DNA and time-lines of transfection/propagation, needs 
to be performed.  
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4.5 Outlook 
4.5.1 Protein work/drug discovery 
 
Solving the molecular structures of the arenavirus NPs studied in this thesis would be 
central to the rational design of antiviral compounds targeted these proteins. In this 
study the successful expression and purification of TCRV, JUNV and MACV were 
shown, with small protein crystals for TCRV and MACV NP. During optimisation 
experiments for small molecule compound screens it was observed that the addition 
of EDTA to the protein sample changed the bi-phasic melting curve of the proteins to 
a single melting curve, indicating a heterogeneous protein sample without the addition 
of EDTA. This heterogeneous protein sample could explain the growth of only small 
protein crystals. Therefore future work should involve changing the conditions by the 
addition of EDTA, which may result in larger crystal formation and potential structure 
determination. 
 
The Maybridge Rule of 3 fragment library screen could be extended to screen all 
compounds with MACV NP as well as NPs of other arenavirus species. However, the 
obtained hits, CsA and [5-(2-furyl)-tien-2-yl]methanol, have to be evaluated in more 
detail. For [5-(2-furyl)-tien-2-yl]methanol cytotoxicity effects will have to be studied 
in several cell lines, such as Huh7. From results obtained in this study, it became 
apparent that the half-life of the compound might be short, which will have to be 
tested in cellular assays. Treatment with this compound reduced TCRV NP levels in 
cells, which could be due to altered NP effects on transcription or translation. 
Therefore virus-specific mRNA levels will have to monitored, potentially through 
primer extension or qRT-PCR analysis, and translational effects could be studied 
using in vitro translation analysis. Finally, [5-(2-furyl)-tien-2-yl]methanol can be used 
as a starting template for chemical optimisation of this molecule to explore the 
possibility of increased binding and therefore efficiency of inhibiting viral replication 
in vivo. For CsA, a cyclophilin siRNA-screen should be performed to determine 
whether or not any cyclophilin proteins are involved in the effects of NP 
relocalisation in treated cells. Overall, several arenaviruses will have to be screened 
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with the compounds to show whether or not these molecules can serve as broad-
spectrum arenavirus-specific antiviral compounds. 
 
 
4.5.2 Innate immunity 
 
After performing IFN-induction and –signalling screens (see Section 3.2.1), it became 
apparent that TCRV is ineffective at blocking IFN-signalling, while PICV was more 
effective in inhibiting this pathway. However, this raises the questions of what are the 
differences between these viruses to allow this observation and how does PICV 
inhibit this pathway.  
 
To rule out or to confirm the involvement of the NP exonuclease as a mode of IFN-
evasion, the exonuclease assays shown in this study (Figure 3.18) will have to be 
repeated. At the same time exonuclease-inactive mutants generated by reverse 
genetics will allow effects to be determined in the context of a viral infection. 
  
Several ISGs were identified to be effective against TCRV infection, which include 
MxA, IFI35, IFIT1 and IFIT3 (see Section 3.2.3). These anti-arenavirus effects of 
these ISGs should be characterised in more detail. It will also be important to 
investigate whether these ISGs have a general effect on arenaviruses or whether this 
observation is restricted to specific virus species. It was shown that IFIT3 is a potent 
restriction factor against TCRV infection. It will have to be investigated whether this 
protein also affects other arenavirus species. In this section a model for the role of 
IFIT3 during TCRV infection was proposed, which will have to be assessed in closer 
detail. For this the expression and importance of IRF7 will have to be characterised, 
in the presence and absence of IFIT3. To comment on the importance of IRF7, 
cytokine assays will have to performed and results compared when the expression of 
individual proteins (IFIT3, IRF3 and IRF7) are knocked down.  
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4.5.3 Protein-protein interactions 
 
Pulldown experiments with three different arenavirus NPs were performed and 
identified a list of more than 200 protein hits (Appendix Table 4). These proteins can 
be confirmed or ruled out as interacting proteins with the different NPs. This study 
focused on AIF, a protein that interacted with all three proteins. However another 
approach could be taken by focusing on the proteins that only interacted with a subset 
of the tested arenavirus NPs or interactions that were only facilitated in a specific cell 
line. This approach could allow the identification of important differences in the roles 
of host cell restriction factors between the non-pathogenic TCRV and the pathogenic 
JUNV and MACV. This could uncover important information on the mechanisms 
used by certain arenaviruses to become pathogenic in humans. 
 
The interaction between NP and AIF should be characterised in more detail. A region 
in NP was identified (Figure 3.29), which is thought to facilitate the protein-protein 
interaction. GST-pulldown experiments using NP proteins containing alanine 
mutations in this region should elucidate the exact amino acids responsible for the 
interaction and the effects of the mutations can then be analysed in a viral context. 
Currently, it is thought that the reason for the NP-AIF interaction during viral 
infection is to reduce stress granule formation and to ensure efficient viral 
transcription and translation. This hypothesis can be tested with the cell lines 
generated in this study using protein markers for stress granule formation. 
 
4.5.4 Reverse Genetics System 
 
The recovery plasmids for a TCRV reverse genetics system were generated in this 
study, but currently no virus has been obtained. The published sequence of TCRV 
gene segments varied considerably from the sequences isolated from the virus, which 
could be due to incorrect sequencing analysis in the previous studies or through PCR-
based mutations. Such mutations may be responsible for preventing virus recovery 
due to alterations of protein structure/function, through altered viral promoter 
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sequences, genome packaging sequences or alterations of the IGR. All of these points 
could be addressed through generation of a reporter-based minigenome-system for 
TCRV in order to test the viral components, proteins, IGR and UTRs, individually for 
functionality. 
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4.6 Conclusions 
 
There is currently no licensed drug available that acts specifically against arenavirus 
infections. This is partially because pathogenic arenaviruses are poorly understood as 
a consequence of high-containment research, but also because of lack of research in 
these areas. This study aimed to use the non-pathogenic New World arenavirus, 
TCRV, as a model for studying the molecular biology of arenaviruses, thereby giving 
potential insights into how the highly pathogenic relatives JUNV and MACV interact 
with the host. Although there are differences between the viruses, that are likely 
responsible for the differences in human infection and pathogenicity, there are many 
sequences and molecular aspects that are conserved between these viruses. As a 
consequence TCRV can serve as model for other pathogenic arenaviruses once a 
conserved function can be established.  
 
As there are currently no arenavirus-specific drugs available to treat arenavirus 
infections, this study aimed to address this problem in three different ways. The direct 
approach was to screen small molecule compounds directly against a viral protein, 
NP, resulting in hit molecules which can be further investigated as lead compounds 
for broad-spectrum anti-arenaviral drugs. Another approach was to study virus-
mediated effects on the innate immune responses of the host. It is known that the 
innate immune system plays a crucial role in the fight against arenavirus infections in 
patients. However, not much was known about individual cellular proteins that were 
responsible for these observations. Here, it was shown that several ISGs have the 
potential to restrict arenavirus infections, which could eventually serve as a basis for a 
modulating immune therapy approach to treat human infections. Finally specific 
virus-host protein-protein interactions were identified as potential targets for antiviral 
drug design. As arenaviruses encode only four proteins they are all likely 
multifunctional in nature, as they have to fulfil all necessary functions throughout the 
viral replication cycle. Therefore the virus likely relies heavily on virus-host 
interactions to perform essential functions throughout its replication cycle. Not much 
is known about arenavirus protein-protein interactions and its consequences. In this 
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study, initial pulldown experiments delivered insights into the network of interactions 
formed between the arenavirus NP protein and various cellular proteins, and the 
consequence of the interaction with AIF was investigated further. Further work into 
identifying and characterising virus-host protein-protein interactions essential to these 
viruses during their replication could offer potential drug targets for future drug 
therapy approaches. Thus, overall this study indicated several starting points for the 
research into effective and specific anti-arenaviral drug design.  
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Small molecule compounds stabilising TCRV NP in 
thermal shift assays.  
List of small molecule compounds from the Maybridge Rule of 3 small molecule 
compound library used in TCRV NP thermal shift assay screens that resulted in a 
positive (stabilising) temperature shift. Indicated is the compound number within 
the library, the chemical name, the compound structure, the CAS registry number 
and the temperature shift in °C. The temperature shift resulted from the addition 
of 1 mM compound to 160 µM TCRV NP. 	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Small molecule compounds destabilising TCRV NP in 
thermal shift assays.  
List of small molecule compounds from the Maybridge Rule of 3 small molecule 
compound library used in TCRV NP thermal shift assay screens that resulted in a 
negative (destabilising) temperature shift. Indicated is the compound number 
within the library, the chemical name, the compound structure, the CAS registry 
number and the temperature shift in °C. The temperature shift resulted from the 
addition of 1 mM compound to 160 µM TCRV NP. 	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Alignment of TCRV L Segment nucleotide 
sequences from the published database and the 
pTVT7R-TCRV Lseg plasmid.  
 
Aligned are the NCBI database TCRV L segment sequence (p; NC_004292.1) 
and the sequence observed (o) from the cloned pTVT7R-TCRV Lseg plasmid. 
Both sequences are in genome orientation. The alignment was generated using the 
EMBL-EBI bioinformatics tool ClustalW. 	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L Segment – published vs plasmid (genome orientation) 
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Amino acid alignment of the L and Z proteins 
encoded on the TCRV L Segments from the 
published database and the pTVT7R-TCRV Lseg 
plasmid.  
 
Protein alignments of the two proteins expressed on the L segment. The amino 
acid sequence of the L and Z proteins encoded on the mRNAs derived from 
pTVT7R-TCRV Lseg (observed) were aligned with the NCBI entries (published) 
for L (AAA47901.1) and Z (AAA479000.1). The alignments were generated 
using the EMBL-EBI bioinformatics tool ClustalW. The colours represent 
different amino acid properties: red – small, hydrophobic; blue – acidic; magenta 
– basic; green – hydroxyl, sulfhydryl, amine, G; grey – others. 	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Alignment of TCRV S Segment nucleotide 
sequences from the published database and the 
pTVT7R-TCRV Sseg plasmid.  
 
Aligned are the NCBI database TCRV L segment sequence (published; 
NC_004293.1 ) and the sequence observed (observed) from the cloned pTVT7R-
TCRV Sseg plasmid. Both sequences are in genome orientation. The alignment 
was generated using the EMBL-EBI bioinformatics tool ClustalW. 	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S Segment – published vs plasmid (genome orientation) 
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Amino acid alignment of the GPC and NP 
proteins encoded on the TCRV S Segments from 
the published database and the pTVT7R-TCRV 
Sseg plasmid.  
 
Protein alignments of the two proteins expressed on the S segment. The amino 
acid sequence of the GPC and NP proteins encoded on the mRNAs derived from 
pTVT7R-TCRV Sseg (observed) were aligned with the NCBI entries (published) 
for GPC (NP_694849.1) and NP (described in Groseth et al., 2010). The 
alignments were generated using the EMBL-EBI bioinformatics tool ClustalW. 
The colours represent different amino acid properties: red – small, hydrophobic; 
blue – acidic; magenta – basic; green – hydroxyl, sulfhydryl, amine, G; grey – 
others. 	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Full list of Maybridge Rule of 3 small molecule compound 
library compounds used for TCRV NP thermal shift 
assay screens.  
The table shows the library number, the chemical name, the molecular weight of 
the individual chemical, the purity of the compound as indicated by the 
manufacturer (Thermo Scientific) and the CAS registry number to identify the 
compound.  	  
Library 
number Chemical Name Molecular Weight Purity CAS Number 
2 pyridin-4-amine 94.1164 97% 504-24-5 
3 pyrrolidine-1-carbonitrile 96.1322 97% 1530-88-7 
4 3,5-dimethylisoxazole 97.1163 97% 300-87-8 
5 3-furylmethylamine 97.1163 97% 4543-47-9 
6 3-methyl-1H-pyrazol-5-amine 97.1203 95% 31230-17-8 
7 1-methyl-1H-pyrazol-5-ylamine 97.1203 97% 1192-21-8 
8 1-methyl-1H-pyrazol-3-amine 97.1203 97% 1904-31-0 
9 5-methylisoxazol-3-amine 98.1044 97% 1072-67-9 
10 3-methylisoxazol-5-amine 98.1044 97% 14678-02-5 
11 2-methyltetrahydrofuran-3-one 100.1162 97% 3188-00-9 
12 tetrahydro-4H-pyran-4-one 100.1162 97% 29943-42-8 
13 1,4-diazepane 100.1638 97% 505-66-8 
15 1-methyl-1H-imidazole-5-carbonitrile 107.1155 97% 66121-66-2 
16 5-methylpyridin-2-amine 108.1432 97% 1603-41-4 
17 3-methyl-1,2-dihydropyridin-2-one 109.1273 97% 1003-56-1 
18 4-pyridinylmethanol 109.1273 97% 586-95-8 
19 6-methylpyridin-2-ol 109.1273 97% 3279-76-3 
20 1-(1H-pyrrol-3-yl)ethan-1-one 109.1273 97% 1072-82-8 
23 2-pyrazinylmethanol 110.1154 97% 6705-33-5 
24 1,3,5-trimethyl-1H-pyrazole 110.159 97% 1072-91-9 
25 2-ethyl-4-methyl-1H-imidazole 110.159 97% 931-36-2 
26 1,3-dimethyl-1H-pyrazol-5-amine 111.1471 97% 3524-32-1 
27 2-furoic acid 112.0836 97% 88-14-2 
28 3-furoic acid 112.0836 97% 488-93-7 
29 4-fluorophenol 112.1025 97% 371-41-5 
30 (5-methyl-2-furyl)methanol 112.1272 97% 3857-25-8 
31 6-methyl-2,3,4,5-tetrahydropyridazin-3-one 112.1312 97% 5157-08-4 
32 3,4-dimethylisoxazol-5-amine 112.1312 97% 19947-75-2 
33 (5-methyl-3-isoxazolyl)methylamine 112.1312 97% 154016-48-5 
34 (1-methyl-1H-imidazol-2-yl)methanol 112.1312 97% 17334-08-6 
35 1,3-dimethylimidazolidin-2-one 114.147 97% 80-73-9 
36 2,5-dimethylpiperazine 114.1906 97% 2815-34-1 
37 D-proline 115.1311 97% 344-25-2 
38 1,3-thiazol-2-ylmethanol 115.1555 97% 14542-12-2 
39 5-methyl-1,3,4-thiadiazol-2-amine 115.1595 97% 108-33-8 
40 4-piperidylmethanol 115.1747 97% 6457-49-4 
42 tetrahydro-2-furancarboxylic acid 116.1152 97% 16874-33-2 
43 tetrahydro-2H-pyran-4-ylmethanol 116.1588 97% 14774-37-9 
44 1H-indole 117.15 97% 120-72-9 
45 tetrahydrothiopyran-4-ylamine 117.2149 97% 21926-00-1 
46 2-(2-pyridyl)acetonitrile 118.1384 97% 2739-97-1 
47 tetrahydro-2H-thiopyran-4-ol 118.199 97% 29683-23-6 
48 3-chlorothiophene 118.5867 97% 17249-80-8 
49 2,3-dihydrobenzo[b]furan 120.1502 97% 496-16-2 
50 3-(1H-pyrrol-1-yl)propanenitrile 120.1542 97% 43036-06-2 
51 4-fluorobenzonitrile 121.1136 97% 1194-02-1 
52 2-ethyl-6-methylpyridine 121.1819 95% 1122-69-6 
53 3,5-dimethyl-4-isoxazolecarbonitrile 122.1264 97% 31301-46-9 
55 3-methylbenzene-1,2-diamine 122.17 97% 2687-25-4 
56 N-methyl-N-(4-pyridinylmethyl)amine 122.17 97% 6971-44-4 
57 N-methyl-N-(3-pyridylmethyl)amine 122.17 97% 20173-04-0 
58 2-pyridinecarboxylic acid 123.1105 97% 98-98-6 
60 isonicotinic acid 123.1105 97% 55-22-1 
61 3-methoxyaniline 123.1541 95% 536-90-3 
62 (6-methylpyridin-2-yl)methanol 123.1541 97% 1122-71-0 
63 2-(3-pyridyl)ethan-1-ol 123.1541 97% 6293-56-7 
64 2,6-dimethylpyridin-3-ol 123.1541 97% 1122-43-6 
65 2-methoxypyridin-3-amine 124.1422 97% 20265-38-7 
66 (6-amino-3-pyridinyl)methanol 124.1422 97% 113293-71-3 
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Library number Chemical Name Molecular Weight Purity CAS Number 
67 2-methyl-1,3-thiazole-4-carbonitrile 124.1666 97% 21917-76-0 
68 2-aminothiophene-3-carbonitrile 124.1666 97% 4651-82-5 
69 1-methyl-1H-pyrrole-2-carboxylic acid 125.1263 97% 6973-60-0 
70 3-fluorobenzylamine 125.1452 97% 100-82-3 
71 4-fluorobenzylamine 125.1452 95% 140-75-0 
72 1,3,5-trimethyl-1H-pyrazol-4-amine 125.1739 97% 28466-21-9 
73 (1,3-dimethyl-1H-pyrazol-5-yl)methylamine 125.1739 97% 499770-63-7 
74 3-hydroxy-2-methyl-4H-pyran-4-one 126.1104 97% 118-71-8 
75 2-methyl-3-furoic acid 126.1104 97% 6947-94-0 
76 (1,5-dimethyl-1H-pyrazol-3-yl)methanol 126.158 97% 153912-60-8 
78 (2,5-dimethyl-1,3-oxazol-4-yl)methanol 127.1421 97% 92901-94-5 
79 1-(1,3-thiazol-2-yl)ethan-1-one 127.1665 97% 24295-03-2 
80 thiophene-2-carboxamide 127.1665 97% 5813-89-8 
81 2-(2-thienyl)ethylamine 127.2101 97% 30433-91-1 
82 2-propyl-1,3-thiazole 127.2101 97% 17626-75-4 
83 (3-methyl-2-thienyl)methylamine 127.2101 97% 104163-35-1 
84 4-ethylcyclohexanamine 127.2293 95% 23775-39-5 
85 thiophene-2-carboxylic acid 128.1506 97% 527-72-0 
86 isoxazole-5-carbothioamide 128.1546 97% 175334-72-2 
87 azepan-2-one oxime 128.1738 97% 19214-08-5 
88 2,4-difluoroaniline 129.1085 97% 367-25-9 
89 3,5-difluoroaniline 129.1085 97% 372-39-4 
90 piperidine-4-carboxylic acid 129.1579 97% 498-94-2 
91 3-piperidinecarboxylic acid 129.1579 97% 498-95-3 
92 tetrahydro-2H-pyran-4-carboxylic acid 130.142 97% 5337-03-1 
93 tetrahydropyran-2-carboxylic acid 130.142 97% 51673-83-7 
94 2,6-dimethylbenzonitrile 131.1771 97% 6575-13-9 
95 7-methyl-1H-indole 131.1771 97% 933-67-5 
96 1-eth-1-ynyl-4-methoxybenzene 132.1612 97% 768-60-5 
97 2-amino-4-methylbenzonitrile 132.1652 97% 26830-96-6 
98 2-(4-hydroxyphenyl)acetonitrile 133.1493 97% 14191-95-8 
99 indolin-2-one 133.1493 97% 59-48-3 
100 1-benzofuran-5-amine 133.1493 97% 58546-89-7 
101 1H-indazol-5-amine 133.1533 97% 19335-11-6 
102 6-amino-2-methylnicotinonitrile 133.1533 97% 183428-90-2 
103 1,3-thiazolane-2-carboxylic acid 133.1703 97% 16310-13-7 
104 indan-2-amine 133.1929 95% 2975-41-9 
107 1,2-benzisoxazol-3-amine 134.1374 97% 36216-80-5 
108 6-methoxynicotinonitrile 134.1374 97% 15871-85-9 
109 6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile 134.1374 97% 4241-27-4 
110 3,4-dihydro-1H-benzo[c]pyran 134.177 97% 493-05-0 
111 5,6,7,8-tetrahydroquinoxaline 134.181 97% 34413-35-9 
112 benzo[d]isoxazol-3-ol 135.1215 95% 21725-69-9 
113 2,3-dimethylbenzylamine 135.2087 97% 51586-20-0 
114 3-(trifluoromethyl)-1H-pyrazole 136.0757 97% 20154-03-4 
115 2-amino-6-fluorobenzonitrile 136.1285 97% 77326-36-4 
116 5-methyl-1,3-benzodioxole 136.1492 97% 7145-99-5 
117 1-(3-methylpyrazin-2-yl)ethan-1-one 136.1532 97% 23787-80-6 
118 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine 136.1532 97% 20348-23-6 
119 (3,4-dimethylphenyl)methanol 136.1928 95% 6966-10-5 
120 2-fluoro-4-hydroxybenzonitrile 137.1126 97% 82380-18-5 
121 1,3-benzodioxol-5-amine 137.1373 97% 14268-66-7 
122 2-phenoxyethylamine 137.1809 95% 1758-46-9 
123 benzene-1-carbothioamide 137.2053 97% 2227-79-4 
124 1,3-benzodioxol-5-ol 138.1214 97% 533-31-3 
125 1-(3-fluorophenyl)ethan-1-one 138.1403 95% 455-36-7 
126 2-(4-methyl-1,3-thiazol-2-yl)acetonitrile 138.1934 97% 19785-39-8 
128 (1,3,5-trimethyl-1H-pyrazol-4-yl)methylamine 139.2007 97% 352018-93-0 
129 2-fluorobenzoic acid 140.1125 97% 445-29-4 
130 2,5-dimethyl-3-furoic acid 140.1372 97% 636-44-2 
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131 3-(2-furyl)propanoic acid 140.1372 97% 935-13-7 
132 methyl 2-methyl-3-furoate 140.14 97% 6141-58-8 
133 1-(3-amino-2-thienyl)ethan-1-one 141.1933 97% 31968-33-9 
134 4-methylthiophene-2-carboxamide 141.1933 97% 83933-16-8 
135 2-methyl-1H-imidazole-4-carbothioamide 141.1973 97% 129486-91-5 
136 2-chlorobenzylamine 141.6002 97% 89-97-4 
138 methyl thiophene-2-carboxylate 142.1774 97% 5380-42-7 
139 4-methylthiophene-2-carboxylic acid 142.1774 97% 14282-78-1 
140 5-methylisoxazole-3-carbothioamide 142.1814 97% 77358-26-0 
141 2-(2-methyl-1,3-thiazol-4-yl)ethylamine 142.225 97% 165115-15-1 
142 2-methyl-1-(1-pyrrolidinyl)-2-propanamine 142.2442 97% 34155-39-0 
143 (2-chlorophenyl)methanol 142.5843 97% 17849-38-6 
144 N1-methyl-2,4-difluoroaniline 143.1353 95% 138564-16-6 
145 4-Methyl-thiazole-5-carboxylic acid 143.1655 97% 20485-41-0 
146 2-methyl-1,3-thiazole-4-carboxylic acid 143.1655 97% 35272-15-2 
147 (2,4-dimethyl-1,3-thiazol-5-yl)methanol 143.2091 97% 50382-32-6 
148 thiophene-3-carbothioamide 143.2335 97% 24044-76-6 
149 4-phenyl-1H-imidazole 144.1762 97% 670-95-1 
150 3-phenyl-1H-pyrazole 144.1762 97% 2458-26-6 
151 3-(1H-pyrrol-1-yl)pyridine 144.1762 97% 72692-99-0 
152 quinolin-2-amine 144.1762 97% 580-22-3 
153 isoquinolin-3-amine 144.1762 95% 25475-67-6 
154 (1,4-dimethyl-2-piperazinyl)methanol 144.2164 95% 14675-44-6 
155 4-acetylbenzonitrile 145.1603 97% 1443-80-7 
156 5-phenyl-1,3-oxazole 145.1603 95% 1006-68-4 
157 2-methylindan-1-one 146.188 97% 17496-14-9 
158 1-methyl-1H-indol-5-amine 146.192 97% 102308-97-4 
159 morpholine-4-carbothioamide 146.213 97% 14294-10-1 
160 3-chloro-4-fluorophenol 146.5476 97% 2613-23-2 
161 2-(4-methoxyphenyl)acetonitrile 147.1761 95% 104-47-2 
162 1H-indol-3-ylmethanol 147.1761 97% 700-06-1 
163 1H-indol-4-ylmethanol 147.1761 97% 1074-85-7 
164 4-hydroxy-2,6-dimethylbenzonitrile 147.1761 97% 58537-99-8 
165 1-benzofuran-5-ylmethylamine 147.1761 97% 37798-08-6 
166 8-methyl-1,2,3,4-tetrahydroquinoline 147.2197 97% 52601-70-4 
167 1-benzofuran-2-ylmethanol 148.1602 97% 55038-01-2 
168 1-benzofuran-5-ylmethanol 148.1602 97% 31823-05-9 
169 1H-benzimidazol-2-ylmethanol 148.1642 95% 4856-97-7 
170 1H-benzimidazol-5-ylmethanol 148.1642 97% 106429-29-2 
171 imidazo[1,2-a]pyridin-6-ylmethanol 148.1642 97% 132213-07-1 
172 imidazo[1,2-a]pyridin-2-ylmethanol 148.1642 97% 82090-52-6 
173 7-methylindan-4-ol 148.2038 97% 16400-13-8 
174 1-(3-ethylphenyl)ethan-1-one 148.2038 95% 22699-70-3 
175 6-amino-1,3-dihydroisobenzofuran-1-one 149.1483 95% 57319-65-0 
176 2,3-dimethylbenzamide 149.1919 97% 5580-34-7 
177 3,4-dimethylbenzamide 149.1919 97% 5580-33-6 
178 4-(tert-butyl)aniline 149.2355 97% 769-92-6 
179 3-(tert-butyl)aniline 149.2355 97% 5369-19-7 
180 N-(4-ethylbenzyl)-N-methylamine 149.2355 97% 568577-84-4 
181 1-methyl-3-(trifluoromethyl)-1H-pyrazole 150.1025 97% 154471-65-5 
182 6-hydroxy-2,3-dihydrobenzo[b]furan-3-one 150.1324 97% 6272-26-0 
183 methyl 2-methylbenzoate 150.176 97% 89-71-4 
184 1-(2-hydroxy-5-methylphenyl)ethan-1-one 150.176 97% 1450-72-2 
185 methyl 3-methylbenzoate 150.176 97% 99-36-5 
186 2,3-Dihydrobenzo[b]furan-7-methanol 150.176 97% 151155-53-2 
187 2,3-dihydro-1-benzofuran-2-ylmethanol 150.176 97% 66158-96-1 
188 N1-(3-pyridylmethyl)acetamide 150.18 97% 22977-34-0 
189 3-[(2-furylmethyl)amino]propanenitrile 150.18 97% 6788-68-7 
190 2-amino-4-methylbenzamide 150.18 97% 39549-79-6 
191 1,3-benzothiazol-6-amine 150.2044 97% 533-30-2 
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192 2-(4-hydroxyphenyl)acetamide 151.1641 97% 17194-82-0 
193 2,3-dihydro-1,4-benzodioxin-6-amine 151.1641 97% 22013-33-8 
194 methyl 3-aminobenzoate 151.1641 97% 4518-10-9 
195 4,5-dihydro-1,3-benzodioxine-6-amine 151.1641 97% 22791-64-6 
196 2-amino-4-methylbenzoic acid 151.1641 97% 2305-36-4 
198 5-acetylthiophene-2-carbonitrile 151.1885 97% 88653-55-8 
199 N-(4-methoxybenzyl)-N-methylamine 151.2077 97% 702-24-9 
200 1,3-benzodioxol-5-ylmethanol 152.1482 97% 495-76-1 
201 2-(2-hydroxyphenyl)acetic acid 152.1482 97% 614-75-5 
202 2-hydroxy-2-phenylacetic acid 152.1482 97% 90-64-2 
203 1,3-benzodioxol-4-ylmethanol 152.1482 97% 769-30-2 
204 1-(2,6-dihydroxyphenyl)ethan-1-one 152.1482 97% 699-83-2 
205 2-methylbicyclo[2.2.1]hept-5-ene-2-carboxylic acid 152.1918 97% 825-03-6 
206 bicyclo[3.3.1]nonane-2,6-dione 152.1918 97% 16473-11-3 
207 1-acetylpiperidine-4-carbonitrile 152.1958 97% 25503-91-7 
208 3-hydroxyquinuclidine-3-carbonitrile 152.1958 97% 6238-30-8 
209 adamantan-1-ol 152.2354 97% 768-95-6 
210 2-amino-6-chlorobenzonitrile 152.5835 97% 6575-11-7 
211 2,5-dichlorothiophene 153.0318 97% 3172-52-9 
212 N1-(2-fluorophenyl)acetamide 153.1552 97% 399-31-5 
213 2,4-dimethoxyaniline 153.1799 97% 2735-04-8 
214 methyl 2,5-dimethyl-1H-pyrrole-3-carboxylate 153.1799 95% 69687-80-5 
215 N-(4-pyridyl)thiourea 153.2083 97% 164670-44-4 
216 3-(tert-butyl)-1-methyl-1H-pyrazol-5-amine 153.2275 97% 118430-73-2 
217 2-(methylthio)benzylamine 153.2479 97% 56004-83-2 
218 5-chloro-2-hydroxybenzonitrile 153.5676 97% 13589-72-5 
219 2-(4-fluorophenyl)acetic acid 154.139 95% 405-50-5 
220 methyl 2-fluorobenzoate 154.1393 97% 394-35-4 
221 imidazo[2,1-b]thiazol-6-ylmethanol 154.1924 97% 349480-74-6 
222 4-hydroxy-1-methylbicyclo[2.2.2]octan-2-one 154.2076 97% 5122-77-0 
223 (2-butyl-1H-imidazol-4-yl)methanol 154.2116 97% 68283-19-2 
224 3-[(tetrahydrofuran-2-ylmethyl)amino]propanenitrile 154.2116 97% 90322-18-2 
225 5-chloro-2,1,3-benzoxadiazole 154.5557 95% 19155-86-3 
226 1-(2,4-dimethyl-1,3-thiazol-5-yl)ethan-1-one 155.2201 97% 38205-60-6 
227 1,3-dimethyl-1H-pyrazole-5-carbothioamide 155.2241 97% 844891-03-8 
228 2,2,6,6-tetramethyltetrahydro-4(1H)-pyridinone 155.2393 97% 826-36-8 
229 4-(tert-butyl)-2-methyl-1,3-thiazole 155.2637 97% 15679-11-5 
230 2-chlorobenzamide 155.5834 97% 609-66-5 
231 N-(4-chlorobenzyl)-N-methylamine 155.627 97% 104-11-0 
233 3-chloro-4-methylbenzylamine 155.627 97% 67952-93-6 
234 1-(3,4-difluorophenyl)ethan-1-one 156.1304 97% 369-33-5 
235 4,4'-dipyridyl 156.1872 97% 553-26-4 
237 3-(2-thienyl)propanoic acid 156.2042 97% 5928-51-8 
238 methyl 2-(3-thienyl)acetate 156.2042 97% 58414-52-1 
239 2-amino-4-methylthiophene-3-carboxamide 156.2082 97% 4651-97-2 
240 4-chloro-5-methylbenzene-1,2-diamine 156.6151 95% 63155-04-4 
241 methyl 3-aminothiophene-2-carboxylate 157.1923 97% 22288-78-4 
242 methyl 2-aminothiophene-3-carboxylate 157.1923 97% 4651-81-4 
243 2-(2-methyl-1,3-thiazol-4-yl)acetic acid 157.1923 97% 13797-62-1 
244 methyl 4-aminothiophene-3-carboxylate 157.1923 95% 69363-85-5 
245 ethyl piperidine-4-carboxylate 157.2115 97% 1126-09-6 
246 5-chloro-2-methoxyaniline 157.5992 97% 95-03-4 
247 methyl 3-hydroxythiophene-2-carboxylate 158.1764 97% 5118-06-9 
248 3-(1H-pyrrol-1-ylmethyl)pyridine 158.203 97% 80866-95-1 
249 2-(1H-pyrrol-1-ylmethyl)pyridine 158.203 97% 78210-51-2 
250 4-(1H-pyrrol-1-yl)aniline 158.203 97% 52768-17-9 
251 3-(1H-pyrrol-1-yl)aniline 158.203 97% 89353-42-4 
252 2-methyl-1,3-thiazole-4-carbothioamide 158.2484 97% 174223-29-1 
253 6-chloroimidazo[2,1-b][1,3]thiazole 158.6117 97% 23576-81-0 
255 6-quinolinylmethanol 159.187 97% 100516-88-9 
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256 2-quinolinylmethanol 159.1871 95% 1780-17-2 
257 4-(2-furyl)aniline 159.1871 97% 59147-02-3 
258 4-methyl-2-quinolinol 159.1871 97% 607-66-9 
259 5-(4-methylphenyl)-1,3-oxazole 159.1871 97% 143659-19-2 
260 2-(1H-pyrazol-1-yl)aniline 159.1911 97% 54705-91-8 
261 3-methylcinnolin-5-amine 159.1911 95% 300690-74-8 
262 2-(1H-imidazol-1-yl)aniline 159.1911 97% 26286-54-4 
264 3-chloro-4-fluorobenzylamine 159.5903 97% 72235-56-4 
265 6-methyl-2H-chromen-2-one 160.1712 97% 92-48-8 
266 4-(1H-imidazol-1-yl)phenol 160.1752 97% 10041-02-8 
267 3-(1,3-oxazol-5-yl)aniline 160.1752 97% 157837-31-5 
268 3-(aminomethyl)-N,N-dimethyltetrahydro-3-thiophenamine 160.2834 97% 176445-79-7 
269 4-chloro-5-fluorobenzene-1,2-diamine 160.5784 97% 139512-70-2 
270 4-(trifluoromethyl)aniline 161.1254 97% 455-14-1 
271 1H-indole-6-carboxylic acid 161.159 95% 1670-82-2 
272 3-phenyl-4,5-dihydroisoxazol-5-one 161.1593 97% 1076-59-1 
273 1H-indole-3-carboxylic acid 161.1593 97% 771-50-6 
274 methyl 2-cyanobenzoate 161.1593 97% 6587-24-2 
275 1H-indole-2-carboxylic acid 161.1593 97% 1477-50-5 
276 1-(4-fluorophenyl)-1H-pyrrole 161.1782 97% 81329-31-9 
277 2-(1H-indol-3-yl)ethan-1-ol 161.2029 97% 526-55-6 
278 (1-methyl-1H-indol-6-yl)methanol 161.2029 97% 199590-00-6 
279 1,2,3,4-tetrahydronaphthalen-1-one oxime 161.2029 97% 3349-64-2 
280 6-amino-1,2,3,4-tetrahydronaphthalen-1-one 161.2029 97% 3470-53-9 
281 (1-methyl-1H-benzimidazol-2-yl)methylamine 161.2069 97% 20028-40-4 
282 3,5-dichloroaniline 162.0185 97% 626-43-7 
283 5-(trifluoromethyl)pyridin-2-amine 162.1135 95% 74784-70-6 
284 2-benzo[b]furan-3-ylethanol 162.187 95% 75611-06-2 
285 (2-methyl-2H-indazol-3-yl)methanol 162.191 95% 58536-48-4 
286 (1-methyl-1H-indazol-3-yl)methanol 162.191 97% 1578-96-7 
287 (2-methylimidazo[1,2-a]pyridin-3-yl)methanol 162.191 97% 30489-44-2 
288 1-(4-propylphenyl)ethan-1-one 162.2306 95% 2932-65-2 
289 2-pyrrolidin-1-ylaniline 162.2346 97% 21627-58-7 
290 3-chlorothiophene-2-carboxylic acid 162.5957 97% 59337-89-2 
292 indoline-2-carboxylic acid 163.1751 97% 78348-24-0 
293 2,3-Dihydrobenzo[b]furan-7-ethylamine 163.2187 97% 850375-00-7 
294 1-benzothiophen-5-ylmethylamine 163.2431 95% 56540-52-4 
295 5-(trifluoromethyl)-2,3-dihydro-1H-1,4-diazepine 164.1293 97% 177545-13-0 
296 5-fluoroquinazolin-4-ol 164.1385 97% 436-72-6 
297 2,3-dihydrobenzo[b]furan-7-carboxylic acid 164.1592 97% 35700-40-4 
299 3,4-dihydro-2H-chromen-2-ylmethanol 164.2028 97% 83278-86-8 
300 3,4-dihydro-2H-chromen-3-ylmethanol 164.203 97% 76727-28-1 
301 1-benzothiophen-2-ylmethanol 164.2272 97% 17890-56-1 
302 2-methyl-1,3-benzothiazol-6-ylamine 164.2312 97% 2941-62-0 
303 N1-(2-hydroxy-5-methylphenyl)acetamide 165.1909 97% 6375-17-3 
304 methyl 4-amino-3-methylbenzoate 165.1909 97% 18595-14-7 
305 N-(1,3-benzodioxol-5-ylmethyl)-N-methylamine 165.1909 97% 15205-27-3 
306 2,3-dihydro-1,4-benzodioxin-6-ylmethylamine 165.1909 95% 17413-10-4 
307 3,4-dihydro-2H-1,4-benzoxazin-2-ylmethanol 165.1909 97% 82756-74-9 
308 3,4-dihydro-2H-1,5-benzodioxepin-7-amine 165.1909 97% 175136-34-2 
309 2,3-dihydro-1,4-benzodioxin-2-ylmethylamine 165.1909 97% 4442-59-5 
310 3-methyl-1,3-benzoxazole-2(3H)-thione 165.2153 97% 13673-63-7 
311 thieno[2,3-b]pyridin-2-ylmethanol 165.2153 97% 131337-81-0 
312 1,3-benzothiazol-2-ylmethanol 165.2153 97% 37859-42-0 
313 5-thien-2-yl-1H-pyrazol-3-amine 165.2193 97% 96799-03-0 
314 [5-(trifluoromethyl)-2-furyl]methanol 166.0975 97% 65865-28-3 
315 1-methyl-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-5-one 166.1015 97% 1481-02-3 
316 1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-ol 166.1015 95% 119022-51-4 
317 4-(trifluoromethyl)cyclohexan-1-one 166.1411 95% 75091-99-5 
318 6-fluorochroman-4-one 166.1503 97% 66892-34-0 
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319 2,3-dihydro-1,4-benzodioxin-2-ylmethanol 166.175 95% 3663-82-9 
320 2,3-dihydro-1,4-benzodioxin-6-ylmethanol 166.175 97% 39270-39-8 
321 2-(1,3-benzodioxol-5-yl)ethanol 166.175 97% 6006-82-2 
322 2,3-dihydro-1,4-benzodioxin-5-ylmethanol 166.175 97% 274910-19-9 
323 3-(2-hydroxyphenyl)propanoic acid 166.175 97% 495-78-3 
324 3a,6a-dimethylperhydropentalene-2,5-dione 166.2186 97% 21170-10-5 
325 N-methyl-N-phenylthiourea 166.247 97% 4104-75-0 
326 N-(2-methylphenyl)thiourea 166.247 97% 614-78-8 
327 2,3-dihydrothieno[3,4-b][1,4]dioxine-5-carbonitrile 167.1875 95% 859851-02-8 
328 4H-thieno[3,2-b]pyrrole-5-carboxylic acid 167.1875 97% 39793-31-2 
329 2,5-dimethoxybenzylamine 167.2067 97% 3275-95-4 
330 ethyl 3,5-dimethyl-1H-pyrrole-2-carboxylate 167.2067 97% 2199-44-2 
331 (4-methyl-4H-thieno[3,2-b]pyrrol-5-yl)methanol 167.2311 97% 121933-59-3 
332 1,7,7-trimethylbicyclo[2.2.1]heptan-2-one oxime 167.2503 97% 13559-66-5 
333 4-(trifluoromethyl)cyclohexan-1-ol 168.1569 97% 30129-18-1 
334 N-(4-fluorobenzyl)urea 168.1701 97% 76523-24-5 
335 6-fluoro-1,3-benzothiazol-2-amine 168.195 97% 348-40-3 
336 2-(1H-pyrrol-1-yl)benzonitrile 168.1982 97% 33265-71-3 
338 3-(2-furyl)benzonitrile 169.1823 97% 112598-77-3 
339 3-(1H-imidazol-1-yl)benzonitrile 169.1863 97% 25699-85-8 
340 2-(1H-pyrazol-1-yl)benzonitrile 169.1863 97% 25775-03-5 
342 6-chloro-1,3-benzoxazol-2-ol 169.5666 97% 19932-84-4 
343 1,2,3,4-tetrahydroisoquinoline hydrochloride 169.6538 97% 14099-81-1 
344 6-(2-furyl)nicotinonitrile 170.1704 97% 619334-28-0 
345 2-hydroxybicyclo[3.2.1]octane-6-carboxylic acid 170.2066 97% 257932-29-9 
346 3-pyridin-3-ylaniline 170.214 97% 57976-57-5 
347 4-pyridin-3-ylaniline 170.214 97% 82261-42-5 
348 2-pyridin-3-ylaniline 170.214 95% 177202-83-4 
349 2-methyl-1-(4-methylpiperidino)-2-propanamine 170.2978 97% 690632-11-2 
350 4-chloro-2-methylbenzoic acid 170.5943 97% 7499-07-2 
351 3-chloro-4-methylbenzoic acid 170.5943 97% 5162-82-3 
352 methyl 2-chlorobenzoate 170.5943 97% 610-96-8 
353 3-pyrimidin-5-ylaniline 171.2021 97% 69491-59-4 
354 methyl 3-amino-4-methylthiophene-2-carboxylate 171.2191 97% 85006-31-1 
355 2-methylbenzene-1-sulfonamide 171.2191 97% 88-19-7 
356 ethyl 2-methyl-1,3-thiazole-4-carboxylate 171.2191 97% 6436-59-5 
357 3-(pentylthio)-4H-1,2,4-triazole 171.2667 97% 71705-07-2 
358 4-(trifluoromethyl)nicotinonitrile 172.1087 95% 13600-43-6 
359 2-(3,5-difluorophenyl)acetic acid 172.1294 97% 105184-38-1 
360 1-(3,5-difluoro-2-hydroxyphenyl)ethan-1-one 172.1294 97% 140675-42-9 
361 2,3-dihydrothieno[3,4-b][1,4]dioxin-5-ylmethanol 172.2032 97% 859851-01-7 
362 3-pyrrolidin-1-ylbenzonitrile 172.2298 95% 175696-73-8 
363 [2-(1H-pyrrol-1-yl)phenyl]methylamine 172.2298 97% 39243-88-4 
364 3-(1H-pyrrol-1-yl)benzylamine 172.2298 97% 368869-95-8 
365 4-(1H-pyrrol-1-yl)benzylamine 172.2298 97% 465514-27-6 
366 N-methyl-N-(quinolin-6-ylmethyl)amine 172.2298 95% 179873-36-0 
367 1-(3-chloro-4-fluorophenyl)ethan-1-one 172.5854 97% 2923-66-2 
368 quinoline-4-carboxylic acid 173.1703 97% 486-74-8 
369 2-quinolinecarboxylic acid 173.1703 95% 93-10-7 
370 quinoline-6-carboxylic acid 173.1703 97% 10349-57-2 
371 [2-(1H-pyrrol-1-yl)phenyl]methanol 173.2139 97% 61034-86-4 
372 [4-(1H-pyrrol-1-yl)phenyl]methanol 173.2139 97% 143426-51-1 
373 [4-(2-furyl)phenyl]methylamine 173.2139 97% 771573-27-4 
374 (2-methyl-6-quinolinyl)methanol 173.214 97% 108166-02-5 
375 4-(1H-imidazol-1-ylmethyl)aniline 173.2179 97% 56643-85-7 
376 1-methyl-3-phenyl-1H-pyrazol-5-amine 173.2179 97% 10199-50-5 
377 3-(1H-imidazol-1-ylmethyl)aniline 173.2179 97% 120107-85-9 
378 4-(1H-pyrazol-1-yl)benzylamine 173.2179 97% 368870-03-5 
379 4-(Prop-2-ynyl)thiomorpholine 1,1-dioxide 173.2349 97% 10442-03-2 
380 3-chloro-4-fluorobenzamide 173.5735 97% 701-43-9 
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381 pyridin-3-ylacetic acid hydrochloride 173.5982 97% 6419-36-9 
382 5-chloro-2-(methylthio)aniline 173.6662 95% 16423-54-4 
383 [4-(2-furyl)phenyl]methanol 174.198 97% 17920-85-3 
384 5-methyl-3-phenyl-4-isoxazolamine 174.202 97% 21169-65-3 
385 [4-(1H-pyrazol-1-yl)phenyl]methanol 174.202 97% 143426-49-7 
386 [4-(1H-imidazol-1-yl)phenyl]methanol 174.202 97% 86718-08-3 
387 2-(1,3-benzothiazol-2-yl)acetonitrile 174.2264 97% 56278-50-3 
388 1-butoxy-4-eth-1-ynylbenzene 174.2416 97% 79887-15-3 
389 5-(methylthio)thiophene-2-carboxylic acid 174.2434 97% 20873-58-9 
390 4-(trifluoromethyl)benzylamine 175.1522 95% 3300-51-4 
391 2-(1H-indol-3-yl)acetic acid 175.1861 97% 87-51-4 
392 methyl 1H-indole-3-carboxylate 175.1861 97% 942-24-5 
393 (5-phenylisoxazol-3-yl)methanol 175.1861 97% 1619-37-0 
394 1-methyl-1H-indole-5-carboxylic acid 175.1861 95% 186129-25-9 
395 4-hydroxy-1-methyl-1,2-dihydroquinolin-2-one 175.1861 97% 1677-46-9 
396 methyl 1H-indole-7-carboxylate 175.1861 97% 93247-78-0 
397 (5-phenyl-1,3-oxazol-4-yl)methanol 175.1861 95% 352018-88-3 
398 1-methyl-1H-indole-6-carboxylic acid 175.1861 97% 202745-73-1 
399 1-methyl-1H-indole-4-carboxylic acid 175.1861 95% 90924-06-4 
400 N1-(2,3-dihydro-1H-inden-5-yl)acetamide 175.2297 97% 59856-06-3 
401 N-methyl-N-[(1-methyl-1H-indazol-3-yl)methyl]amine 175.2337 97% 124491-38-9 
402 ethyl thiomorpholine-3-carboxylate 175.2507 97% 58729-31-0 
403 3-(2-thienyl)aniline 175.2541 95% 92057-12-0 
404 3-thien-3-ylaniline 175.2541 97% 161886-96-0 
405 3,5-dichlorobenzylamine 176.0453 95% 39989-43-0 
407 [2-(trifluoromethyl)phenyl]methanol 176.1363 97% 346-06-5 
409 3-oxoindane-1-carboxylic acid 176.1702 97% 29427-69-8 
410 benzo[b]furan-3-ylacetic acid 176.1702 97% 64175-51-5 
413 4-piperidinoaniline 176.2614 97% 2359-60-6 
414 [4-(1-pyrrolidinyl)phenyl]methanamine 176.2614 97% 114365-04-7 
415 3-(pyrrolidin-1-ylmethyl)aniline 176.2614 97% 183365-31-3 
416 quinuclidin-3-one oxime hydrochloride 176.6457 97% 76883-37-9 
418 2-(trifluoromethoxy)aniline 177.1244 97% 1535-75-7 
419 3-(trifluoromethoxy)aniline 177.1244 97% 1535-73-5 
420 5-fluoro-2-(1H-imidazol-1-yl)aniline 177.1812 97% 251649-52-2 
421 (S)-4-BENZYL-2-OXAZOLIDINONE 177.2019 97% 90719-32-7 
422 methyl 2-indolinecarboxylate 177.2019 95% 96056-64-3 
423 3-phenyl-1,2,4-thiadiazol-5-amine 177.23 97% 17467-15-1 
424 5-phenyl-1,2,4-thiadiazol-3-amine 177.2303 97% 27182-54-3 
426 N1-(4-propylphenyl)acetamide 177.2455 97% 20330-99-8 
427 [4-(1-pyrrolidinyl)phenyl]methanol 177.2455 95% 676245-12-8 
428 (3-pyrrolidin-1-ylphenyl)methanol 177.2455 97% 859850-72-9 
429 2-piperazin-1-ylaniline 177.2495 95% 13339-02-1 
430 1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethan-1-one 178.186 97% 2879-20-1 
431 3-chromanecarboxylic acid 178.186 97% 115822-57-6 
432 1-benzothiophene-3-carboxylic acid 178.2104 97% 5381-25-9 
434 (2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)methanol 178.2296 97% 38002-89-0 
435 4-morpholinoaniline 178.2336 97% 2524-67-6 
436 2-morpholinoaniline 178.2336 97% 5585-33-1 
437 [6-(1-pyrrolidinyl)-3-pyridinyl]methanol 178.2336 97% 690632-01-0 
438 (2-pyrrolidin-1-ylpyrid-4-yl)methanol 178.2336 97% 906352-65-6 
439 2,2-dimethyl-N-(4-pyridinyl)propanamide 178.2336 97% 70298-89-4 
440 [2-(1-pyrrolidinyl)-3-pyridinyl]methanol 178.2336 97% 690632-85-0 
441 3-morpholin-4-ylaniline 178.2336 97% 159724-40-0 
442 5-Methylbenzo[b]thiophene-2-methanol 178.254 97% 22962-49-8 
443 N,N-diethyl-N-[2-(2-pyridyl)ethyl]amine 178.2772 95% 25877-30-9 
444 1,3-benzothiazole-6-carboxylic acid 179.1985 97% 3622-35-3 
445 thieno[2,3-b]pyridine-2-carboxylic acid 179.1985 97% 59944-76-2 
446 ethyl 2-(4-aminophenyl)acetate 179.2177 95% 5438-70-0 
447 3-morpholinophenol 179.2177 97% 27292-49-5 
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448 2-morpholinophenol 179.2177 97% 41536-44-1 
450 1-methyl-3-(2-thienyl)-1H-pyrazol-5-amine 179.2461 97% 118430-78-7 
451 methyl 2-(3-methoxyphenyl)acetate 180.2018 97% 18927-05-4 
452 3-(2-methoxyphenyl)propanoic acid 180.2018 97% 6342-77-4 
453 3,4-dihydro-2H-1,5-benzodioxepin-7-ylmethanol 180.2018 95% 62823-14-7 
454 2-(2,5-dimethylphenyl)-2-hydroxyacetic acid 180.202 97% 5766-40-5 
456 6-phenylnicotinonitrile 180.2092 97% 39065-54-8 
457 1-(4-fluorophenyl)piperazine 180.2247 97% 2252-63-3 
458 [5-(2-furyl)thien-2-yl]methanol 180.2262 97% 868755-65-1 
459 (5-thien-2-yl-1H-pyrazol-3-yl)methanol 180.2302 97% 852228-02-5 
460 1-[(4-methylphenyl)thio]acetone 180.2698 97% 1200-13-1 
461 benzene-1,3-diamine dihydrochloride 181.065 97% 541-69-5 
462 [5-(2-thienyl)-3-isoxazolyl]methanol 181.2143 97% 194491-44-6 
463 methyl 6H-thieno[2,3-b]pyrrole-5-carboxylate 181.2143 97% 118465-49-9 
464 4-methyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid 181.2143 97% 841222-62-6 
465 2-(benzylthio)acetic acid 182.242 97% 103-46-8 
466 methyl 2-(phenylthio)acetate 182.242 97% 17277-58-6 
467 (1,3-dimethyl-1H-thieno[2,3-c]pyrazol-5-yl)methanol 182.246 97% 423769-75-9 
468 3-piperidinyl(1-pyrrolidinyl)methanone 182.2652 97% 35090-94-9 
469 4-piperidinyl(1-pyrrolidinyl)methanone 182.2652 97% 35090-95-0 
471 5-amino-2-(1H-pyrrol-1-yl)benzonitrile 183.2131 97% 106981-51-5 
472 2-(phenylthio)ethanethioamide 183.2981 97% 59865-82-6 
473 4-chloro-2-methylacetanilide 183.637 95% 5202-86-8 
474 methyl 1,3-thiazolane-2-carboxylate hydrochloride 183.658 97% 33305-08-7 
475 2-(1H-imidazol-4-yl)ethylamine dihydrochloride 184.0689 97% 56-92-8 
476 (6-fluoro-4H-1,3-benzodioxin-8-yl)methanol 184.1651 97% 306934-89-4 
477 2-amino-5-phenyl-3-furonitrile 184.1972 95% 14742-32-6 
478 4-oxo-4-(2-thienyl)butanoic acid 184.2142 97% 4653-08-1 
479 thieno[3,2-b]thiophene-2-carboxylic acid 184.2386 97% 1723-27-9 
481 1,3-dimethoxy-2-(methylthio)benzene 184.2578 97% 33617-67-3 
482 5-(2-thienyl)tetrahydrothiophen-3-one 184.2822 97% 108372-48-1 
484 methyl 3-chloro-4-methylbenzoate 184.6211 97% 56525-63-4 
486 4-chloro-5-methylthieno[2,3-d]pyrimidine 184.6495 97% 43088-67-1 
487 2,2-dimethyl-2H-chromene-6-carbonitrile 185.2249 97% 33143-29-2 
488 (4-pyrid-4-ylphenyl)methanol 185.2249 97% 217192-22-8 
489 (4-pyrid-3-ylphenyl)methanol 185.2249 97% 217189-04-3 
490 (4-pyrid-2-ylphenyl)methanol 185.2249 97% 98061-39-3 
491 (3-pyrid-4-ylphenyl)methanol 185.2249 97% 85553-55-5 
492 (6-phenyl-3-pyridinyl)methanol 185.225 97% 4634-09-7 
493 3-(2-methylpyrimidin-4-yl)aniline 185.2289 97% 175201-90-8 
494 ethyl 2-(2-methyl-1,3-thiazol-4-yl)acetate 185.2459 95% 37128-24-8 
495 
N-(2,3-dihydrothieno[3,4-b][1,4]dioxin-5-ylmethyl)-N-
methylamine 185.2459 95% 859851-03-9 
496 2,3-dihydrobenzo[b]furan-5-ylmethylamine hydrochloride 185.6528 97% 55745-74-9 
497 4-isopropyl-3-methylaniline hydrochloride 185.6964 97% 4534-11-6 
498 6-methyl-4-(trifluoromethyl)nicotinonitrile 186.135 97% 13600-49-2 
499 2-(trifluoromethyl)-1H-benzo[d]imidazole 186.1355 97% 312-73-2 
500 4-amino-2-(trifluoromethyl)benzonitrile 186.1355 95% 654-70-6 
502 4-phenoxyphenol 186.209 97% 831-82-3 
503 1-[4-(1H-imidazol-1-yl)phenyl]-1-ethanone 186.213 97% 10041-06-2 
504 (3-pyrimidin-5-ylphenyl)methanol 186.213 97% 852180-75-7 
505 (4-pyrimidin-5-ylphenyl)methanol 186.213 97% 198084-13-8 
506 3-(pyridin-2-yloxy)aniline 186.213 97% 86556-09-4 
507 6-phenoxy-3-pyridinamine 186.213 95% 25194-67-6 
508 5-chloro-2-methoxybenzoic acid 186.5933 97% 3438-16-2 
509 2-(trifluoromethoxy)benzonitrile 187.1196 97% 63968-85-4 
510 2-methyl-6-quinolinecarboxylic acid 187.197 97% 635-80-3 
511 3-(1H-pyrrol-1-yl)benzoic acid 187.1971 97% 61471-45-2 
512 4-(1H-pyrrol-1-yl)benzoic acid 187.1971 97% 22106-33-8 
513 2-(1H-pyrrol-1-yl)benzoic acid 187.1971 97% 10333-68-3 
514 methyl isoquinoline-3-carboxylate 187.1971 97% 27104-73-0 
Continued 
 	  	  	  	  	  	  	  	  	  	  	  	  	   308	  
 
 
 
 
Library number Chemical Name Molecular Weight Purity CAS Number 
515 methyl quinoline-6-carboxylate 187.1971 97% 38896-30-9 
516 6,7,8,9-tetrahydrodibenzo[b,d]furan-2-amine 187.2407 97% 38084-44-5 
517 3-piperidin-1-ylpyridine-2-carbonitrile 187.2447 97% 780802-33-7 
518 4-Piperazin-1-yl-benzonitrile 187.2447 97% 68104-63-2 
519 2-(2-chloro-4-fluorophenyl)acetamide 187.6003 97% 306937-35-9 
520 2-(2-furyl)benzoic acid 188.1812 97% 331942-47-3 
521 (2-methyl-5-phenyl-3-furyl)methanol 188.2248 97% 111787-91-8 
522 (5-methyl-2-phenyl-3-furyl)methanol 188.2248 95% 183210-33-5 
523 (5-methyl-1-phenyl-1H-pyrazol-4-yl)methanol 188.2288 97% 153863-35-5 
524 (1-methyl-3-phenyl-1H-pyrazol-5-yl)methanol 188.2288 97% 864068-97-3 
525 (1-methyl-5-phenyl-1H-pyrazol-3-yl)methanol 188.2288 97% 124344-98-5 
526 (1-benzyl-1H-imidazol-2-yl)methanol 188.2288 95% 5376-10-3 
527 [3-(1H-imidazol-1-ylmethyl)phenyl]methanol 188.2288 97% 151055-79-7 
528 [4-(1H-imidazol-1-ylmethyl)phenyl]methanol 188.2288 97% 103573-92-8 
529 [4-(1H-pyrazol-1-ylmethyl)phenyl]methanol 188.2288 97% 160388-55-6 
530 (1-methyl-5-phenyl-1H-pyrazol-4-yl)methanol 188.2288 97% 499785-47-6 
531 methyl 2-chloro-4-fluorobenzoate 188.5844 97% 85953-29-3 
532 2-(trifluoromethyl)benzamide 189.1354 97% 360-64-5 
533 3-(1H-indol-3-yl)propanoic acid 189.2129 97% 830-96-6 
534 (5-methyl-3-phenyl-4-isoxazolyl)methanol 189.2129 97% 18718-79-1 
535 N1-(1-oxo-2,3-dihydro-1H-inden-5-yl)acetamide 189.2129 97% 58161-35-6 
537 2,3-dimethyl-1H-indole-5-carboxylic acid 189.2129 97% 14844-73-6 
539 4-(trifluoromethyl)benzoic acid 190.1195 97% 455-24-3 
540 (5-phenoxy-2-furyl)methanol 190.197 97% 51551-74-7 
541 7-methyl-2,3-dihydro-1H-inden-4-yl acetate 190.2406 97% 175136-12-6 
542 4-[2-(dimethylamino)ethoxy]benzonitrile 190.2446 97% 24197-95-3 
543 (2-thien-2-ylphenyl)methanol 190.265 97% 773872-97-2 
544 (4-thien-2-ylphenyl)methanol 190.265 97% 81443-44-9 
545 (4-thien-3-ylphenyl)methanol 190.265 97% 160278-20-6 
546 3-(2-methyl-1,3-thiazol-4-yl)aniline 190.269 97% 89250-34-0 
547 4-(2-methyl-1,3-thiazol-4-yl)phenylamine 190.269 97% 25021-49-2 
548 1-benzylpiperidin-4-amine 190.2882 97% 50541-93-0 
549 1-(2,3-dimethylphenyl)piperazine 190.2882 97% 1013-22-5 
550 [3-(1-pyrrolidinylmethyl)phenyl]methanamine 190.2882 97% 91271-78-2 
551 methyl 3-chloro-4-methylthiophene-2-carboxylate 190.6493 97% 175137-11-8 
552 
8-methyl-8-azabicyclo[3.2.1]octan-3-one oxime 
hydrochloride 190.6725 97% 212079-30-6 
553 4-(trifluoromethyl)nicotinic acid 191.1076 97% 158063-66-2 
554 2-(1-methylhydrazino)-4-(trifluoromethyl)pyridine 191.1552 97% 208720-09-6 
555 isoquinoline-3-carboxylic acid hydrate 191.19 97% 6624-49-3 
556 [5-(2-pyridinyl)-2-thienyl]methanol 191.2531 97% 197899-76-6 
557 (2-phenyl-1,3-thiazol-4-yl)methanol 191.2531 97% 23780-13-4 
558 2H-chromene-3-carbothioamide 191.2531 97% 423768-57-4 
559 [4-(pyrrolidin-1-ylmethyl)phenyl]methanol 191.2723 97% 91271-60-2 
560 4-(2-methoxyphenyl)piperidine 191.2723 97% 58333-75-8 
561 2-(4-methylpiperazin-1-yl)aniline 191.2763 97% 180605-36-1 
562 4-(4-methylpiperazino)aniline 191.2763 97% 16153-81-4 
563 [4-(trifluoromethoxy)phenyl]methanol 192.1353 97% 1736-74-9 
564 2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carboxylic acid 192.2128 97% 42327-95-7 
565 4-(2-amino-1,3-thiazol-4-yl)phenol 192.2412 97% 57634-55-6 
566 (2-pyridin-3-yl-1,3-thiazol-4-yl)methanol 192.2412 97% 138745-99-0 
567 4-(morpholinomethyl)aniline 192.26 95% 51013-67-3 
568 (2-piperidinopyrid-4-yl)methanol 192.2604 97% 888070-04-0 
569 (Piperidino-3-pyridinyl)methanol 192.2604 97% 690631-99-3 
570 2-(morpholin-4-ylmethyl)aniline 192.2604 97% 95539-61-0 
571 2-morpholinobenzylamine 192.2604 97% 204078-48-8 
572 (2-piperidino-3-pyridinyl)methanol 192.2604 97% 690632-84-9 
574 3-(phenylthio)thiophene 192.3052 97% 16718-11-9 
575 5-chloro-4-methoxythiophene-3-carboxylic acid 192.6215 97% 133659-14-0 
576 2,4-difluorobenzenesulfonamide 193.173 95% 13656-60-5 
577 3-(1H-pyrrol-1-yl)thiophene-2-carboxylic acid 193.2253 97% 74772-17-1 
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578 (4-morpholin-4-yl-phenyl)-methanol 193.2445 95% 280556-71-0 
579 (3-morpholinophenyl)methanol 193.2445 97% 145127-38-4 
580 (2-morpholinophenyl)methanol 193.2445 97% 465514-33-4 
581 
2-amino-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-
carbonitrile 193.2729 97% 37578-06-6 
582 3-(4-chlorophenyl)-1H-pyrazol-5-amine 193.6362 97% 78583-81-0 
583 5-methyl-2-(trifluoromethyl)-3-furoic acid 194.1075 97% 17515-74-1 
584 4-[(trifluoromethyl)thio]phenol 194.1755 97% 461-84-7 
585 ethyl 3-(4-hydroxyphenyl)propanoate 194.2286 95% 23795-02-0 
586 (1-methyl-5-thien-2-yl-1H-pyrazol-3-yl)methanol 194.257 97% 879896-47-6 
587 (1-methyl-3-thien-2-yl-1H-pyrazol-5-yl)methanol 194.257 97% 879896-49-8 
588 2-(1-adamantyl)acetic acid 194.2722 97% 4942-47-6 
589 1-(5-chlorobenzo[b]furan-2-yl)ethan-1-one 194.6163 97% 1646-32-8 
590 1-(2,5-dichloro-3-thienyl)ethan-1-one 195.0686 97% 36157-40-1 
591 2-phenoxybenzonitrile 195.2201 95% 6476-32-0 
592 2,3-dihydro-1,4-benzodioxine-5-carbothioamide 195.2411 95% 690632-23-6 
593 {2-[2-(dimethylamino)ethoxy]phenyl}methanol 195.2603 97% 59115-26-3 
594 ethyl 4-ethyl-3,5-dimethyl-1H-pyrrole-2-carboxylate 195.2603 97% 2199-47-5 
596 4-(pyridin-2-yloxy)benzonitrile 196.2082 97% 270260-33-8 
597 3-hydroxyadamantane-1-carboxylic acid 196.2444 97% 42711-75-1 
598 2,2'-bithien-5-ylmethanol 196.2932 97% 3515-30-8 
599 [2-(2-thienyl)-1,3-thiazol-4-yl]methylamine 196.2972 97% 321309-35-7 
600 5H-chromeno[2,3-b]pyridin-5-one 197.1923 97% 6537-46-8 
601 (3-aminophenyl)(phenyl)methanone 197.2359 97% 2835-78-1 
602 4,5-dichloroisothiazole-3-carboxylic acid 198.0289 97% 131947-13-2 
603 N1-(4-pyridyl)benzamide 198.224 97% 5221-44-3 
604 1-[4-(methylsulfonyl)phenyl]ethan-1-one 198.241 97% 10297-73-1 
605 N-methyl-N-(3-pyridin-4-ylbenzyl)amine 198.2676 97% 852180-67-7 
606 N-methyl-N-(3-pyridin-3-ylbenzyl)amine 198.2676 97% 852180-72-4 
607 N-methyl-N-(4-pyridin-2-ylbenzyl)amine 198.2676 97% 869901-08-6 
608 (5-chloro-1-benzothiophen-3-yl)methanol 198.6723 97% 306934-93-0 
609 6-chloro-3,4-dihydro-2H-1-benzothiin-4-one 198.6723 97% 13735-12-1 
610 6-phenylnicotinic acid 199.208 95% 29051-44-3 
611 3-pyrid-2-ylbenzoic acid 199.2081 97% 4467-07-6 
612 4-pyrid-3-ylbenzoic acid 199.2081 97% 4385-75-5 
613 2-pyrid-3-ylbenzoic acid 199.2081 97% 134363-45-4 
614 3-pyrid-4-ylbenzoic acid 199.2081 97% 4385-78-8 
615 5-phenylnicotinic acid 199.2081 95% 10177-12-5 
616 3-(phenoxymethyl)aniline 199.2517 97% 93189-16-3 
617 ethyl 2-amino-4,5-dimethylthiophene-3-carboxylate 199.2727 97% 4815-24-1 
618 (5-morpholinothien-2-yl)methanol 199.2727 97% 910036-90-7 
619 tert-butyl N-(3-thienyl)carbamate 199.2727 97% 19228-91-2 
620 tert-butyl N-(2-thienyl)carbamate 199.2727 95% 56267-50-6 
621 (2-phenoxyphenyl)methanol 200.2358 97% 13807-84-6 
622 (4-phenoxyphenyl)methanol 200.2358 97% 2215-78-3 
623 (4-methyl-2-phenyl-5-pyrimidinyl)methanol 200.2398 95% 342405-27-0 
624 3-(benzyloxy)pyridin-2-amine 200.24 97% 24016-03-3 
625 4-(2-methyl-1,3-thiazol-4-yl)benzonitrile 200.2642 97% 127406-79-5 
626 1,3-benzothiazol-2-ylmethylamine hydrochloride 200.6921 97% 29198-41-2 
628 methyl 2-(1H-pyrrol-1-yl)benzoate 201.2239 97% 10333-67-2 
629 [4-(pyrid-2-yloxy)phenyl]methanol 201.2239 97% 194017-70-4 
630 [3-(pyrid-2-yloxy)phenyl]methanol 201.2239 97% 869901-22-4 
631 
N-methyl-N-[(1-methyl-3-phenyl-1H-pyrazol-5-
yl)methyl]amine 201.2715 97% 864068-98-4 
632 3-Aminomethylbenzoic acid methyl ester hydrochloride 201.6518 95% 17841-68-8 
633 2-(3-chlorophenoxy)ethanethioamide 201.6762 95% 35370-95-7 
634 2-{[5-(trifluoromethyl)-2-pyridyl]oxy}acetonitrile 202.135 97% 680593-95-7 
635 5-methyl-2-phenyl-3-furoic acid 202.208 97% 64354-50-3 
636 (3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methanol 202.2556 97% 58789-53-0 
637 N-methyl-N-[(5-methyl-3-phenylisoxazol-4-yl)methyl]amine 202.2556 97% 857283-57-9 
638 2-morpholino-2-phenylacetonitrile 202.256 97% 15190-10-0 
639 6-phenyl-2,3-dihydroimidazo[2,1-b][1,3]thiazole 202.28 95% 4335-28-8 
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641 2-[(4-chlorophenyl)thio]acetic acid 202.66 97% 3405-88-7 
643 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethan-1-ol 203.2397 97% 103788-65-4 
644 N1-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide 203.2397 97% 88611-67-0 
645 4-(tetrahydropyran-4-yloxy)benzonitrile 203.2397 97% 884507-34-0 
646 N-methyl-N-(2-thien-2-ylbenzyl)amine 203.3077 97% 852180-66-6 
648 4-(3-thienyl)benzoic acid 204.2482 97% 29886-64-4 
649 5-phenylthiophene-2-carboxylic acid 204.2482 95% 19163-24-7 
650 3-thien-3-ylbenzoic acid 204.2482 97% 20608-89-3 
651 2-piperidinobenzamide 204.2714 97% 3430-40-8 
653 N-methyl-3-(1,3-thiazol-2-yl)benzylamine 204.2958 97% 892501-89-2 
654 N-methyl-4-(1,3-thiazol-2-yl)benzylamine 204.2958 97% 886851-31-6 
655 3-piperidin-1-ylmethyl benzylamine 204.315 97% 91271-80-6 
656 N-methyl-N-(3-piperidin-1-ylbenzyl)amine 204.315 97% 859850-65-0 
657 N-methyl-N-(4-piperidin-1-ylbenzyl)amine 204.315 97% 852180-55-3 
658 [4-(piperidinomethyl)phenyl]methylamine 204.315 97% 91271-81-7 
659 2-(3,4-dichlorophenyl)acetic acid 205.0394 97% 5807-30-7 
660 6-fluoro-2-methyl-4-quinolinecarboxylic acid 205.1872 97% 716-03-0 
661 5-(2-pyridyl)thiophene-2-carboxylic acid 205.2363 97% 119082-97-2 
662 4-(1,3-thiazol-2-yl)benzoic acid 205.2363 97% 266369-49-7 
663 3-piperidinobenzoic acid 205.2555 97% 77940-94-4 
664 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 205.2555 97% 4721-98-6 
665 4-(pyrrolidin-1-ylmethyl)benzoic acid 205.2555 97% 159691-25-5 
666 (2-methyl-4-phenyl-1,3-thiazol-5-yl)methanol 205.2799 97% 857284-12-9 
667 [4-(2-methyl-1,3-thiazol-4-yl)phenyl]methanol 205.2799 97% 857283-96-6 
668 2-thiomorpholinoisonicotinonitrile 205.2839 97% 884507-30-6 
669 [4-(piperidin-1-ylmethyl)phenyl]methanol 205.2991 95% 91271-62-4 
670 2-[(4-methylpiperazin-1-yl)methyl]aniline 205.3031 97% 19577-84-5 
671 N-methyl-N-[(2-piperidin-1-ylpyridin-4-yl)methyl]amine 205.3031 97% 879896-58-9 
672 ethyl 2-chloro-4-methyl-1,3-thiazole-5-carboxylate 205.6642 97% 7238-62-2 
Continued 
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Arenavirus NP protein-protein interactions.  
List of Mass Spectrometry-identified protein hits for the TCRV, JUNV and 
MACV NP from A549, BHK and Huh7 cells. The protein-hits are added from the 
individual pulldown experiments to a comprehensive list of protein hits in no 
particular order. Indicated is next to the protein name from the MASCOT server, 
the Pubmed accession code, the molecular weight of the protein, protein group 
(function), the virus species the protein interacted with and the cell line the 
interaction was detected. Virus species: J – Junin virus, M – Machupo virus, T – 
Tacaribe virus; cell line: A - A549, B – BHK21, H – Huh7. 	  
# Identified Proteins Accession Number 
Molecular 
Weight Protein Group  
Virus 
species 
Cell 
line 
1 myosin-9  gi|12667788 227 kDa cytoskeleton J, M, T A, B, H 
2 40S ribosomal protein S15a  gi|14165469 (+1) 15 kDa translation J, M, T A, B, H 
3 clathrin heavy chain 1  gi|27806689 (+5) 192 kDa protein transport J, M, T A, B, H 
4 tubulin, beta 6 class V  gi|71043680 50 kDa cytoskeleton J, M, T A, B, H 
5 ATP synthase beta subunit  gi|1374715 (+9) 51 kDa enzyme J, M, T A, B, H 
6 40S ribosomal protein S3a  gi|254553321 (+6) 30 kDa translation J, M, T A, B, H 
7 Rpl7a protein  gi|30410942 (+14) 30 kDa translation J, M, T A, B, H 
8 unnamed protein product  gi|12846587 (+24) 15 kDa translation J, M, T A, B, H 
9 Ribosomal protein, large, P0  gi|12654583 (+4) 34 kDa translation J, M, T A, B, H 
10 ribosomal protein, partial gi|337518 (+1) 22 kDa translation J, M, T A, B, H 
11 DNA damage-binding protein 1  gi|148529014 (+8) 127 kDa repair J, M, T A, B, H 
12 60S ribosomal protein L4  gi|16579885 (+2) 48 kDa translation J, M, T A, B, H 
13 tubulin beta-3 chain  gi|12963615 (+1) 50 kDa cytoskeleton J, M, T A, B, H 
14 40S ribosomal protein S8  gi|4506743 24 kDa translation J, M, T A, B, H 
15 ribosomal protein L3, partial  gi|337580 (+1) 45 kDa translation J, M, T A, B, H 
16 unnamed protein product  gi|12846200 (+8) 28 kDa translation J, M, T A, B, H 
17 60S ribosomal protein L6  gi|16753227 (+4) 33 kDa translation J, M, T A, B, H 
18 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1  gi|16877071 (+2) 33 kDa energy J, M, T A, B, H 
19 Plectin gi|14195008 509 kDa cytoskeleton J, M, T A, B 
20 60S ribosomal protein L18  gi|4506607 (+1) 22 kDa translation J, M, T A, H 
21 RNA helicase II/Gu protein gi|11890755 (+3) 80 kDa antiviral J, M, T A, B, H 
22 ADP/ATP translocase 2  gi|22094075 (+3) 33 kDa apoptosis J, M, T A, B, H 
23 unnamed protein product  gi|12835827 (+28) 25 kDa translation J, M, T A, B, H 
24 tubulin beta-2B chain  gi|21746161 (+1) 50 kDa cytoskeleton J, M, T A, B, H 
25 unnamed protein product  gi|12836870 (+4) 19 kDa translation J, M, T A, B, H 
26 40S ribosomal protein S10  gi|13399310 (+3) 19 kDa translation J, M, T A, B, H 
27 Rig homolog  gi|262391 (+2) 16 kDa / J, M, T A, B, H 
28 ATP synthase subunit O, mitochondrial precursor  gi|4502303 (+1) 23 kDa energy J, M, T A, H 
29 60S ribosomal protein L7  gi|15431301 29 kDa translation J, M, T A, B, H 
30 cytoplasmic dynein 1 heavy chain 1  gi|33350932 532 kDa motor protein J, M, T A, B, H 
31 eukaryotic initiation factor 4A-I  gi|197099748 (+12) 46 kDa translation J, M, T A, B, H 
32 nucleolin  gi|189306 (+5) 76 kDa transcription J, M, T A, B, H 
33 RanBP7/importin 7  gi|11342591 (+3) 120 kDa transport J, M, T A, B, H 
34 trifunctional enzyme subunit beta, mitochondrial precursor gi|4504327 (+1) 51 kDa metabolic process J, M, T A, H 
35 Chain E, Architecture Of Mammalian Fatty Acid Synthase gi|93279106 24 kDa metabolic process J, M, T A, B, H 
36 60S ribosomal protein L27a gi|31560517 (+4) 17 kDa translation J, M, T A, B, H 
37 keratin 10  gi|623409 57 kDa cytoskeleton J, M, T A, B, H 
38 DNA mismatch repair protein Msh2  gi|4557761 105 kDa repair J, M, T A, B, H 
39 60S ribosomal protein L36  gi|16117794 (+5) 12 kDa translation J, M, T A, B, H 
40 eIF-3 p110 subunit  gi|1931584 (+1) 105 kDa translation J, M, T A, B, H 
 	  	  	  	  	  	  	  	  	  	  	  	  	   312	  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
# Identified Proteins Accession Number 
Molecular 
Weight Protein Group  
Virus 
species 
Cell 
line 
41 60S ribosomal protein L35  gi|13385044 (+3) 15 kDa translation J, M, T A, B, H 
42 unnamed protein product  gi|12844972 (+8) 19 kDa RNA transport J, M, T A, B, H 
43 gamma-tubulin  gi|183703 (+5) 51 kDa cytoskeleton J, M, T A, B, H 
44 unnamed protein product  gi|12846287 (+3) 24 kDa translation J, M, T A, B, H 
45 heterogeneous nuclear ribonucleoprotein Q isoform 1  gi|114145493 (+15) 70 kDa mRNA processing J, M, T A, B, H 
46 sarcoplasmic/endoplasmic reticulum calcium ATPase 2 isoform b  gi|24638454 (+1) 115 kDa ion transport J, M, T A, B, H 
47 BBC1  gi|29383 24 kDa translation J, M, T A, H 
48 60S ribosomal protein L10  gi|13592053 (+7) 25 kDa translation J, M, T A, H 
49 phosphate carrier protein, mitochondrial precursor  gi|197099438 (+6) 40 kDa transport J, M, T A, B, H 
50 60S ribosomal protein L13a  gi|197099650 (+4) 24 kDa translation J, M, T A, B, H 
51 DNA dependent protein kinase catalytic subunit  gi|13606056 (+1) 466 kDa antiviral J, M, T A, H 
52 60S ribosomal protein L21  gi|18104948 (+17) 19 kDa translation J, M, T A, B, H 
53 nucleophosmin isoform 1  gi|10835063 (+16) 33 kDa proliferation J, M, T A, B, H 
54 nucleosome assembly protein 1-like 1  gi|197103012 (+2) 45 kDa proliferation J, M, T A, B, H 
55 eukaryotic translation initiation factor 3, subunit 10 (theta)  gi|149040541 (+3) 163 kDa translation J, M, T A, B, H 
56 heat shock protein beta-1  gi|4504517 (+1) 23 kDa stress response J, M, T A, H 
57 KIAA1398 protein  gi|14133249 (+1) 170 kDa transport J, M, T H 
58 Myosin IC  gi|45751608 (+1) 118 kDa cytoskeleton J, M, T A 
59 nuclease-sensitive element-binding protein 1  gi|130488167 (+19) 36 kDa RNA processing J, M, T A, B, H 
60 60S ribosomal protein L32  gi|4506635 (+9) 16 kDa translation J, M, T A, B, H 
61 myosin light polypeptide 6  gi|155369650 (+15) 17 kDa cytoskeleton J, M, T A, B, H 
62 hRlf beta subunit (p102 protein)  gi|1552242 (+3) 91 kDa DNA replication J, M, T A, B, H 
63 ribosomal protein L19  gi|198643 (+5) 23 kDa translation J, M, T A, H 
64 Syndecan 1  gi|14250612 (+4) 33 kDa inflammation J, M, T H 
65 myb-binding protein 1A isoform 2  gi|157694492 (+2) 149 kDa cell cycle J, M, T A, B, H 
66 Ribosomal protein L17  gi|42542645 (+1) 21 kDa translation J, M, T A, H 
67 filamin-A  gi|125347376 (+4) 280 kDa cytoskeleton J, M, T A, B 
68 unnamed protein product  gi|12846904 (+14) 33 kDa translation J, M, T A, B, H 
69 glypican-1 precursor  gi|167001141 (+1) 62 kDa metabolic process J, M, T A 
70 trifunctional enzyme subunit alpha, mitochondrial precursor  gi|20127408 (+1) 83 kDa metabolic process J, M, T A, H 
71 heterogeneous nuclear ribonucleoproteins C1/C2-like isoform 2  gi|109082737 (+17) 28 kDa RNA transport J, M, T A, B, H 
72 60S ribosomal protein L18a  gi|11415026 (+2) 21 kDa translation J, M, T A, B, H 
73 unconventional myosin-Ib isoform 1  gi|194328685 (+1) 132 kDa cytoskeleton J, M, T A, H 
74 C-1-tetrahydrofolate synthase, cytoplasmic gi|115206 (+2) 102 kDa metabolic process J, M, T A, H 
75 leucine-zipper protein FKSG13  gi|11034809 (+7) 43 kDa transcription J, M, T A, B 
76 polypyrimidine tract-binding protein 1 isoform 1  gi|116517301 (+27) 59 kDa RNA processing J, M, T A, B 
77 KIAA0788 protein  gi|20521660 (+3) 232 kDa RNA processing J, M, T A, H 
78 serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform  gi|16758910 (+13) 52 kDa cell cycle J, M, T A, B, H 
79 ribosomal protein L14  gi|17932938 (+1) 24 kDa translation J, M, T A, B, H 
80 dnaJ homolog subfamily A member 2  gi|5031741 (+1) 46 kDa stress response J, M, T A, B, H 
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# Identified Proteins Accession Number 
Molecular 
Weight Protein Group  
Virus 
species 
Cell 
line 
81 unnamed protein product gi|12849707 (+3) 25 kDa translation J, M, T A, B, H 
82 Similar to ribophorin I, partial  gi|14124942 (+4) 65 kDa metabolic process J, M, T A, B, H 
83 Fatty acid synthase  gi|38648667 (+4) 273 kDa metabolic process J, M, T A, H 
84 mlrq-like protein, partial  gi|1401252 (+6) 9 kDa transport J, M, T A, B 
85 Ndufs2 protein, partial gi|13278096 (+4) 53 kDa oxidative stress J, M, T B 
86 Dhx30 protein, partial  gi|13278588 (+8) 104 kDa helicase J, M, T A, B, H 
87 rRNA 2'-O-methyltransferase fibrillarin  gi|12056465 (+11) 34 kDa RNA processing J, M, T A, B, H 
88 fatty acid-binding protein, epidermal  gi|4557581 15 kDa metabolic process M H 
89 Putative ribosomal RNA methyltransferase NOP2 gi|146289861 (+2) 89 kDa translation J, M, T A, B, H 
90 regulator of nonsense transcripts 1-like  gi|109504000 (+5) 123 kDa DNA replication J, M, T B, H 
91 leucine-rich PPR motif-containing protein, mitochondrial precursor gi|31621305 (+2) 158 kDa translation J, M, T A, B, H 
92 importin 4  gi|18700635 (+2) 119 kDa transport J, M, T A, H 
93 nucleolar protein 58-like  gi|109100610 (+12) 60 kDa / J, M, T A, B 
94 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial precursor  gi|4758788 (+2) 30 kDa metabolic process J, M, T A, B, H 
95 DNA topoisomerase 2-alpha  gi|19913406 (+2) 174 kDa apoptosis J, M, T A, H 
96 Karyopherin alpha 2 (RAG cohort 1, importin alpha 1)  gi|13543657 (+4) 58 kDa antiviral J, M, T A, H 
97 M2-type pyruvate kinase  gi|189998 (+5) 58 kDa apoptosis J, M, T A, H 
98 prelamin-A/C isoform prelamin A precursor  gi|27436946 (+4) 74 kDa apoptosis J, M, T A, B, H 
99 Long-chain-fatty-acid--CoA ligase 3 gi|108935948 (+4) 80 kDa metabolic process J, M, T H 
100 glyceraldehyde-3-phosphate dehydrogenase  gi|89573925 24 kDa metabolic process J, M, T B 
101 Chain A, P93a Variant Of Bovine Pancreatic Ribonuclease A gi|157829693 (+10) 14 kDa / J, M B 
102 unnamed protein product  gi|12835698 (+6) 14 kDa / J, M, T A, B, H 
103 exportin-1  gi|4507943 (+1) 123 kDa transport J, M, T A, B, H 
104 mitochondrial import receptor subunit TOM20 homolog  gi|7657257 16 kDa transport J, M A, B, H 
105 adenine phosphoribosyltransferase isoform a  gi|4502171 20 kDa metabolic process J, M, T A, H 
106 glutathione S-transferase A4  gi|4504173 (+1) 26 kDa metabolic process J, M, T A, H 
107 Ras GTPase-activating-like protein IQGAP1 gi|13959396 (+4) 189 kDa vesicle assembly J, M, T A, B 
108 amphiglycan  gi|28680 (+1) 22 kDa metabolic process J, M, T H 
109 protein S100-A16  gi|115497862 (+2) 12 kDa ion transport J, M, T B 
110 NADH dehydrogenase (ubiquinone) Fe-S protein 7, isoform CRA_a  gi|149034568 (+1) 23 kDa energy J, M, T B 
111 ribosomal protein L22 like 1-like  gi|109468809 (+2) 14 kDa translation J, M, T B 
112 ruvB-like 2  gi|6755382 (+1) 51 kDa helicase J, M, T B 
113 eukaryotic translation initiation factor 4G I  gi|21634449 (+6) 176 kDa translation J, M, T B 
114 programmed cell death 6 variant  gi|62898293 (+1) 22 kDa apoptosis J, M, T A, B 
115 interleukin enhancer-binding factor 2  gi|13385872 (+2) 43 kDa antiviral J, M, T A, B, H 
116 nucleic acid binding factor pRM10  gi|4378711 34 kDa / J, M, T A, B 
117 hypothetical protein gi|12052826 (+6) 22 kDa transport J, M, T A, H 
118 Sodium/potassium-transporting ATPase subunit alpha-1 gi|114373 (+14) 113 kDa metabolic process J, M, T A, B, H 
119 ribosomal L1 domain-containing protein 1  gi|118498359 (+6) 55 kDa translation J, M, T A, H 
120 glutamyl-prolyl-tRNA synthetase  gi|148681120 (+2) 165 kDa transcription J, M, T B, H 
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# Identified Proteins Accession Number 
Molecular 
Weight Protein Group  
Virus 
species 
Cell 
line 
121 unnamed protein product  gi|12840425 (+5) 33 kDa transport J, M, T B 
122 non-muscle myosin B  gi|641958 (+4) 229 kDa cytoskeleton J, M, T H 
123 Nucleolin gi|128842 (+1) 77 kDa transcription J, M B 
124 Chain A, Solution Structure Of Calmodulin-Like Skin Protein C Terminal Domain gi|109157166 (+4) 8 kDa transport M H 
125 Ribosomal protein L8  gi|15082586 (+4) 28 kDa cytoskeleton J, M, T A, B 
126 glyceraldehyde-3-phosphate dehydrogenase gi|31645 36 kDa metabolic process J, M, T B, H 
127 60S ribosomal protein L37a-like, partial  gi|149628763 (+6) 10 kDa translation J, M, T A, B 
128 hypothetical protein  gi|31873336 (+4) 142 kDa translation J, M, T A, H 
129 ADP-ribosylation factor-like protein 2  gi|13928996 (+8) 21 kDa GTPase J, M, T B 
130 cancer-related nucleoside-triphosphatase  gi|14150100 (+1) 21 kDa RNA processing J, M, T A 
131 serine (or cysteine) peptidase inhibitor, clade H, member 1, isoform CRA_a  gi|148684430 (+11) 45 kDa proteolysis J, M, T B 
132 ATP synthase subunit O, mitochondrial precursor  gi|20070412 (+3) 23 kDa transport J, M, T B 
133 bacterial MutS homolog  gi|1840467 (+4) 153 kDa repair J, M, T A 
134 protein S100-A4 gi|4506765 12 kDa NF-kB J, M, T A, B 
135 KIAA0219  gi|20521848 (+1) 293 kDa translation M, T A, H 
136 peptidyl-prolyl cis-trans isomerase A  gi|10863927 (+3) 18 kDa viral replication M H 
137 filaggrin  gi|60097902 435 kDa development M H 
138 caspase-14 precursor  gi|6912286 28 kDa apoptosis M H 
139 Importin9 isoform 2  gi|15186758 (+8) 116 kDa transport J, M, T A, B, H 
140 putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 isoform 2  gi|110835723 (+18) 91 kDa RNA processing J, M A, B, H 
141 enhancer of rudimentary homolog  gi|4758302 (+4) 12 kDa cell cycle J, M, T A, B, H 
142 Small nuclear ribonucleoprotein D3  gi|15079335 (+1) 14 kDa RNA processing J, M, T B, H 
143 Galactokinase gi|11132435 (+6) 42 kDa metabolic process J, M, T B 
144 scg  gi|1669535 (+5) 97 kDa / J, M A, B, H 
145 chromatin-specific transcription elongation factor, 140 kDa subunit  gi|15637171 (+7) 120 kDa repair M, T A, B 
146 apoptosis-inducing factor  gi|14279176 (+2) 66 kDa apoptosis J, M, T B 
147 TKT protein  gi|14250367 (+10) 43 kDa metabolic process J, M, T A, H 
148 unnamed protein product  gi|12844560 (+4) 13 kDa energy J, M, T B 
149 ADP-ribosylation factor-like protein 1  gi|11693150 (+6) 20 kDa GTPase M, T A, B 
150 class V beta tubulin  gi|350538479 50 kDa cytoskeleton M, T B 
151 PRO1512  gi|11493522 (+5) 34 kDa / J, M, T A 
152 unnamed protein product  gi|1334284 (+15) 58 kDa cytokines J, M A, H 
153 plakophilin-1 isoform 2  gi|114571758 (+3) 83 kDa / M H 
154 
Human Muscle L-Lactate Dehydrogenase M Chain, Ternary Complex With Nadh 
And Oxamate gi|13786849 (+4) 37 kDa / M H 
155 serpin B5  gi|167860126 (+2) 42 kDa morphogenesis M H 
156 unnamed protein product gi|26353870 65 kDa apoptosis J, M, T A, B 
157 unknown gi|3283893 (+7) 26 kDa / J, M, T A, B 
158 Eif3b protein  gi|13938120 (+7) 75 kDa translation T A, B, H 
159 mCG120681  gi|148698365 (+5) 16 kDa / J, M, T B 
160 heat shock protein 90 alpha gi|12082136 (+7) 83 kDa stress response J, M A, H 
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# Identified Proteins Accession Number 
Molecula
r Weight Protein Group  
Virus 
species 
Cell 
line 
161 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 3 isoform 
b  gi|77157788 (+1) 20 kDa translation J, M, T B 
162 pre-mRNA-processing-splicing factor 8  gi|115583687 (+4) 274 kDa RNA processing J, M, T A, H 
163 Chain C, Architecture Of Mammalian Fatty Acid Synthase gi|93279104 38 kDa metabolic process M, T B 
164 enolase 1, (alpha)  gi|307219254 (+5) 47 kDa metabolic process M H 
165 fructose-bisphosphate aldolase A isoform 1  gi|109128138 (+21) 75 kDa metabolic process M H 
166 
Chain A, Phosphorylation Independent Interactions Between 14-3-3 And Exoenzyme 
S gi|161172138 (+6) 26 kDa / M H 
167 unnamed protein product  gi|12833012 (+7) 38 kDa translation M, T A, B, H 
168 dual specificity protein phosphatase 23  gi|56786144 (+1) 17 kDa metabolic process J, M, T A 
169 histone H2A type 1-A  gi|25092737 (+3) 14 kDa DNA binding M, T A, B 
170 nucleolar protein 56  gi|126090932 (+8) 64 kDa biogenesis J, T A, B 
171 carbamoyl-phosphate synthase [ammonia], mitochondrial isoform b precursor  gi|21361331 (+8) 165 kDa metabolic process J, M, T A 
172 aldehyde dehydrogenase  gi|1263008 (+1) 57 kDa metabolic process J, M, T A 
173 myb-binding protein 1a  gi|19070182 (+3) 152 kDa various J, M, T B 
174 E3 ubiquitin-protein ligase NEDD4 isoform 1  gi|114520609 (+12) 104 kDa transport J, M B 
175 paraneoplastic antigen Ma2  gi|11464969 (+3) 42 kDa apoptosis J, M A 
176 eukaryotic translation initiation factor 3, subunit 7 zeta, 66/67kDa, isoform CRA_b  gi|119580514 (+11) 64 kDa translation M, T B 
177 HKDC1 protein, partial  gi|15214423 75 kDa metabolic process J, M A 
178 
Chain A, Crystal Structure Of The Calmodulin-Like Protein (Hclp) From Human 
Epithelial Cells gi|21465435 (+1) 17 kDa transport M H 
179 reticulocalbin-2 isoform 1  gi|114658293 (+2) 39 kDa / T H 
180 phosphoglycerate kinase 1 gi|197099640 (+4) 45 kDa metabolic process M H 
181 triosephosphate isomerase 1  gi|146741412 (+7) 27 kDa metabolic process M H 
182 premature ovarian failure, 1B, isoform CRA_b  gi|119618967 (+2) 68 kDa actin binding M H 
183 hCG1744472  gi|119573745 (+2) 66 kDa / M H 
184 peroxiredoxin-2  gi|197100696 (+3) 19 kDa metabolic process M H 
185 pre-rRNA-processing protein TSR1 homolog gi|197101928 (+4) 92 kDa RNA processing J, T A 
186 eukaryotic translation initiation factor 6-like, partial  gi|109094726 (+14) 22 kDa translation J, T H 
187 unconventional myosin-Ie  gi|27465533 (+4) 127 kDa cytoskeleton M, T A 
188 60S ribosomal protein L9  gi|14149647 (+12) 22 kDa translation M, T A 
189 glycosyl-phosphatidyl-inositol-anchored protein p137-like  gi|37723349 (+22) 74 kDa morphogenesis M A, B 
190 unnamed protein product  gi|10435327 (+12) 42 kDa metabolic process J, T H 
191 39S ribosomal protein L17, mitochondrial  gi|11596859 (+3) 20 kDa translation M, T A 
192 protein UXT  gi|55741553 18 kDa transcription J, M B 
193 pyruvate carboxylase, mitochondrial precursor  gi|106049292 (+10) 130 kDa metabolic process M, T H 
194 Ribosomal RNA processing 12 homolog  gi|15215317 (+3) 144 kDa translation M A 
195 HEAT repeat containing 1  gi|55959427 (+1) 233 kDa / M A 
196 AP-2 complex subunit beta  gi|115497346 (+19) 106 kDa transport M B 
197 non-specific cytotoxic cell receptor protein 1 homolog gi|109124651 (+3) 31 kDa / M H 
198 histidine ammonia-lyase isoform 1  gi|109098268 (+3) 73 kDa metabolic process M H 
199 nucleolar protein 16 isoform 3  gi|148747209 (+2) 21 kDa / T A 
200 transitional endoplasmic reticulum ATPase  gi|17865351 (+19) 89 kDa apoptosis M H 
201 e3 ubiquitin-protein ligase TRIM32 isoform 1 gi|109110460 (+8) 72 kDa / T H 
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Construct Primers 
pLou3-
TCRV NP 
5’-CGTGCAGAATTCATGGCTCAATCCAAGGAAGTGCCAAGCTTCAG-3’ 
5’-CGTAATGCGGCCGCCAGTGCACAGTGAGGTTC-3’ 
pLou3-
TCRV NP 
D386A 
5’-CACTATTTGGTTGGCCATCGAGGGACCTCCTAC-3’ 
5’-GAGGTCCCTCGATGGCCAACCAAATAGTGTTGGAG-3’ 
pSUMO-
JUNV NP 
5’-CGTGCAGAATTCATGGCACACTCCAAGGAGGTTCCAAG-3’ 
5’-CGTGCAGTCGACCTATTACAGTGCATAGGCTGCCTTCGGG-3’ 
pSUMO-
JUNV NP 
D380A 
5’-CACCCTTTGGCTCGCCATTGAAGGACCAGCCAC-3’ 
5’-CTGGTCCTTCAATGGCGAGCCAAAGGGTGTTGGTG-3’ 
 pSUMO-
MACV NP 
5’-CGTGCAGCCATGGCTCACTCCAAGGAAATTCCCAG-3’ 
5’-CGTGCAGAATTCCTATTACAGTGCAAAGGCTGCCTTGGG-3’ 
pSUMO-
MACV NP 
D380A 
5’-CTAATACACTGTGGCTTGCCATTGAAGGGCCTCCAAC-3’ 
5’-GCCCTTCAATGGCAAGCCACAGTGTATTAGTGGGGTC-3’ 
pGEX-
TCRV NP 
5’-CGTGCAGAATTCCCACCCCCTGAGCTCCTGGGGGGACCGATGGCTCAAT 
CCAAGGAAGTGCCAAGCTTCAG-3’ 
5’-CGTAATGCGGCCGCCAGTGCACAGTGAGGTTC-3’ 
pGEX-
TCRV NP 
1-229 
5’-CGTGCAGAATTCATGGCTCAATCCAAGGAAGTGCCAAGCTTCAG-3’ 
5’-CGTAATGCGGCCGCTTCTTTGGTTATAATTTGCAGACACTCATGG-3’ 
pGEX-
TCRV NP 
230-333 
5’-GCATTCAGAATTCGAAGAGAGTTCAATTAACATTTCAGG-3’ 
5’-CGTAATGCGGCCGCCAGATCTACGCTCGTGTTGTC-3’ 
pGEX-
TCRV NP 
364-570 
5’-GCATTCAGAATTCGAGGGGCAAGAACTAATAGTCAG-3’ 
5’-CGTAATGCGGCCGCCAGTGCACAGTGAGGTTC-3’ 
pGEX-
TCRV 
NPmut1 
5’-GAGAGTTCAATTAACATTGCAGCTGCCGCCCTCAGTCTGTTGGC-3’ 
5’-GCCAACAGACTGAGGGCGGCAGCTGCAATGTTAATTGAAC-3’ 
pGEX-
TCRV 
NPmut2 
5’-GCAGGAGCCTCCATCCTTGCTGCTGCTGCCGCGGCGGCGACAATCAGAG 
TGAG-3’ 
5’-CGGGACTCACTCTGATTGTCGCCGCCGCGGCAGCAGCAGCAAGGATGGA 
GGC-3’ 
pGEX-
TCRV 
NPmut3 
 
5’-GATCAAAAACACCTTACAAGTCGCGGCAGCGGAGGCTGCGGCTATTGAC 
GACAGACCTGGAAG-3’ 
5’-CAGGTCTGTCGTCAATAGCCGCAGCCTCCGCTGCGCGACTTGTAAGGT 
G-3’ 
pGEX-
JUNV NP 
5’-CGTGCAGAATTCCCACCCCCTGAGCTCCTGGGGGGACCGATGGCACACT 
CCAAGGAGGTTCCAAGCTTTAG-3’ 
5’-CGTGCAGTCGACCTATTACAGTGCATAGGCTGCCTTCGGG-3’ 
pGEX-
MACV NP 
5’-CGTGCAGAATTCCCACCCCCTGAGCTCCTGGGGGGACCGATGGCTCACT 
CCAAGGAAATTCCCAGCTTTCG-3’ 
5’-CGTGCAGAATTCCTATTACAGTGCAAAGGCTGCCTTGGG-3’ 
pGEX-AIF 5’-GCACGCGAATTCATGTTCCGGTGTGGAGGCCTGGCGGCG-3’ 
5’-GCACGCGCGGCCGCTCAGTCTTCATCGAATGTTGAATAGTTTGGC-3’ 
Primer list.  
List of primers used to clone plasmid vectors generated in this study. Indicated 
are the constructs generated and the primers used for DNA amplification by PCR 
followed by restriction enzyme digest to insert into plasmid backbones. Forward 
as well as reverse primers are written in 5’ – 3’ directionality. 	  
 	  	  	  	  	  	  	  	  	  	  	  	  	   317	  
pGEX-
AIFΔ103 
5’-GCACGCGATTCCCCAGAAGAGAAACAGAGAAGAGC-3’ 
5’-GCACGCGCGGCCGCTCAGTCTTCATCGAATGTTGAATAGTTTGGC-3’ 
pGEX-
AIFΔ262 
5’-GCATACGAATTCACTCCAAGAAGTCTGTCTGCC-3’ 
5’-GCACGCGCGGCCGCTCAGTCTTCATCGAATGTTGAATAGTTTGGC-3’ 
pGEX-
AIFΔ350 
5’-GCACGCGAATTCATGGAAAAAGTCAGACGAGAGGGGGTTAAG-3’ 
5’-GCACGCGCGGCCGCTCAGTCTTCATCGAATGTTGAATAGTTTGGC-3’ 
pGEX-
AIFΔ479 
5’-GCACGCGAATTCATGTTCTGGAGTGATTTGGGCC-3’ 
5’-GCACGCGCGGCCGCTCAGTCTTCATCGAATGTTGAATAGTTTGGC-3’ 
pTVT7R-
TCRV Lseg 
 
5’-AAATTTGGATCCCCGGTGCGCGGGTCGGCATGGCATC-3’ 
5’-AAATTTGGATCCACTGTGCGTATAGTGAGTCGTATTAATTTCGCGGG-3’ 
5’-ATACGACTCACTATACGCACAGTGGATCCTAGGCGGC-3’ 
5’-CGCACAGTGGATCCTAGGCGGCACTTG-3’ 
5’-GGCGGCACTTGACCATGGATG-3’ 
5’-ATGTGTGATGAGATGACAACTTGGCTGG-3’ 
5’-CCAGCCAAGTTGTCATCTCATCACACAT-3’ 
5’-GCAGCGTTGCACAATGTGAAATGC-3’ 
5’-GCATTTCACATTGTGCAACGCTGC-3’ 
5’-CTCACCCAATTCAATCTGACCATC-3’ 
5’-GATCCTAGGCGTTACGTGCACTC-3’ 
5’-CGCACCGGGGATCCTAGGCGTTAC-3’ 
5’-GTACCATGCCGACCCGCGCACCGGGGATCCTAGGCGTTAC-3’ 
pTVT7R-
TCRV Sseg 
 
5’-ATACGACTCACTATAGCACAGTGGATCCTAGGCAAATTG -3’ 
5’-GAGCACACCTGGCACAGCATCCTC-3’ 
5’-GTGCCAGGTGTGCTCAGTTATGTC-3’ 
5’-CATTGGTTTCCCAACTCATGAACAC-3’ 
5’-GTTGGGAAACCAATGAGGTGCAAG-3’ 
5’-GTACCATGCCGACCCGGCATTTCTTGTCCATATTTGC-3’ 
pdl-AIF 5’-GCATACACTAGTATGTTCCGGTGTGGAGGCCTGG-3’ 
5’-GCATACCATATGTCAGTCTTCATGAATGTTGAATAG-3’ 
pLKO-AIF 
 
5’-GATCCGAACTGGTATCCGATCAGAGATTCAAGAGATCTCTGATCGGATA 
CCAGTTCTTTTTCTAGAG-3’ 
5’-AATTCTCTAGAAAAAGAACTGGTATCCGATCAGAGATCTCTTGAATCTC 
TGATCGGATACCAGTTCG-3’ 
pLKO-
CypA 
 
5’-GATCCGTTCCTGCTTTCACAGAATTTTCAAGAGAAATTCTGTGAAAGCA 
GGAACTTTTTCTAGAG-3’ 
5’-AATTCTCTAGAAAAAGTTCCTGCTTTCACAGAATTTCTCTTGAAAATTCT 
GTGAAAGCAGGAACG-3’ 
exonuclease 
substrate 
5’-rCrCrGrUrGrUrArUrArGrCrUrCrCrArCrCrUrGrUrUrGrUrCrU-3’ 
5’-rArGrArCrArArCrArGrGrUrGrGrArGrCrUrArUrArCrArCrGrG-3’ 
pTVT7R lin 5’-TATAGTGAGTCGTATTAATTTGGC-3’ 
5’-GGGTCGGCATGGCATCTCCACCTC-3’ 
pTVT7RΔB
amHI 
5’-GATGGCTAAGGGAGAGCTCGGATTCGGCTGCTAACAAAGCC-3’ 
5’-GGCTTTGTTAGCAGCCGAATCCGAGCTCTCCCTTAGCCATC-3’ 
 
 
